chair
yamamoto
japank
arimura
japan
plenari
lectur
belong
coreceptor
famili
neg
regul
immun
respons
upon
interact
ligand
mice
develop
variou
autoimmun
diseas
depend
genet
background
balbc
background
mice
develop
autoimmun
dilat
cardiomyopathi
dcm
hightit
autoantibodi
kda
cardiac
antigen
recent
identifi
kda
antigen
cardiac
troponin
ctni
show
deregul
product
antictni
autoantibodi
main
caus
dcm
mice
recent
analyz
function
dcm
mice
known
play
pivot
role
remov
inhibit
autoreact
b
cell
dcm
mice
affect
disrupt
howev
mice
develop
autoimmun
hydronephrosi
concomit
product
autoantibodi
urothelium
massiv
inflamm
observ
around
pelvi
kidney
junction
uret
bladder
consid
caus
occlus
subsequ
develop
hydronephrosi
mice
develop
hydronephrosi
similar
frequenc
mice
wherea
mice
show
autoimmun
symptom
therefor
autoimmun
urotheli
cell
seem
control
primarili
exagger
defici
observ
suggest
collabor
role
regul
autoimmun
urinari
tract
heart
may
help
understand
multigen
natur
autoimmun
diseas
research
institut
microbi
diseas
osaka
univers
exploratori
research
advanc
technolog
erato
japan
scienc
technolog
agenc
suita
japan
mammalian
tolllik
receptor
play
critic
role
detect
invad
pathogen
well
trigger
subsequ
inflammatori
immun
respons
individu
tlr
recogn
differ
microbi
compon
adaptor
essenti
respons
tlr
ligand
except
ligand
involv
induct
inflammatori
cytokin
activ
irak
addit
signal
possess
pathway
activ
anoth
adapt
molecul
trif
trifdepend
pathway
activ
result
induct
type
interferon
plasmacytoid
dendrit
cell
pdc
rapidli
produc
ifn
alpha
respons
viral
infect
respons
imidazoquinolin
srna
cpg
dna
ifn
alpha
induct
pdc
involv
format
complex
consist
act
kinas
besid
tlr
recent
find
shown
presenc
cytosol
detector
system
invad
pathogen
two
dexdh
box
rna
helicas
retino
acid
induc
proteini
rigi
melanoma
differentiationassoci
gene
involv
antivir
respons
recogn
drna
cytoplasm
rigi
recogn
distinct
rna
virus
identifi
novel
molecul
name
bridg
recent
gener
knockout
mice
shown
essenti
role
rigi
depend
signal
pathway
symposium
discuss
recent
progress
tlrdepend
independ
recognit
viral
infect
compar
autoimmun
cell
b
cell
much
less
attent
paid
onto
role
nk
cell
multipl
sclerosi
ms
although
specul
could
explain
limit
understand
nk
cell
biolog
time
ago
possibl
due
controversi
literatur
howev
nk
cell
major
sourc
regulatori
cytokin
would
function
polar
toward
involv
pathogenesi
autoimmun
diseas
like
ms
thought
like
fact
recent
work
laboratori
show
nk
cell
peripher
blood
ms
remark
alter
regard
cytokin
secret
profil
surfac
phenotyp
takahashi
et
al
jci
takahashi
et
al
brain
initi
key
observ
nk
cell
remiss
ms
would
exhibit
properti
cell
similar
cell
chang
like
protect
ms
interpret
adapt
chang
maintain
state
remiss
analysi
support
idea
also
convinc
us
peripher
nk
cell
window
diseas
statu
ms
exampl
recent
found
higher
express
nk
cell
predict
occurr
relaps
within
month
wherea
absenc
nk
cell
would
defin
stabl
remiss
aranami
et
al
submit
term
mechan
nk
cell
would
mirror
diseas
statu
present
hypothet
model
discuss
implic
futur
direct
research
heat
shock
autoimmun
irun
r
cohen
depart
immunolog
weizmann
institut
scienc
rehovot
israel
heat
shock
protein
hsp
initi
identifi
famili
stressinduc
protein
character
chaperon
activ
howev
later
identifi
selfantigen
recogn
host
cell
autoantibodi
mani
autoimmun
diseas
recent
role
hsp
endogen
activ
innat
immun
system
unveil
shall
discuss
relev
regul
inflamm
autoimmun
diseas
initi
resolv
inflamm
proinflammatori
activ
deriv
innat
activ
macrophag
dendrit
cell
microgramml
concentr
requir
antiinflammatori
activ
result
signal
function
epitop
complex
mhcii
express
activ
effector
cell
complex
activ
antiergotyp
regulatori
cell
innat
activ
via
antigenpres
b
cell
secret
polar
respond
cell
toward
nanogramsml
suffic
act
costimul
treg
enhanc
abil
rel
low
concentr
treg
downregul
target
cell
detect
inhibit
target
tcell
prolifer
secret
antiinflammatori
effect
b
cell
account
success
downregul
autoimmun
diseas
human
mous
type
diabet
mellitu
rat
adjuv
arthriti
peptid
current
phase
trial
newonset
human
diabet
migrat
studi
suggest
event
earli
life
prime
genet
suscept
individu
ms
later
life
also
differ
viral
infect
associ
exacerb
ms
howev
singl
viru
identifi
caus
agent
ms
develop
model
infect
mice
viru
molecular
mimicri
prime
mice
later
diseas
induc
differ
viru
young
femal
sjlj
mice
infect
recombin
vaccinia
viru
vv
encod
myelin
proteolipid
protein
plp
infect
recombin
vv
plp
clear
mice
clinic
sign
experiment
autoimmun
encephalomyel
eae
vv
plp
prime
mice
challeng
murin
cytomegaloviru
mice
develop
exacerb
eae
data
indic
virus
molecular
mimicri
could
prime
genet
suscept
anim
diseas
earli
life
induc
differ
viru
later
life
data
could
also
explain
singl
agent
isol
caus
ms
agent
data
indic
infect
need
occur
within
cn
event
take
place
work
support
nih
mechan
immunemedi
demyelin
cn
jp
antel
md
capac
immun
mediat
mechan
mediat
demyelin
within
cn
recogn
sinc
descript
case
acut
dissemin
encephalomyel
adem
follow
introduct
neural
tissu
contain
pasteur
rabi
vaccin
subsequ
develop
anim
model
experiment
autoimmun
encephalomyel
eae
disord
indic
requir
autoreact
cell
initi
inflammatori
respons
within
cn
immun
cell
molecul
actual
mediat
injuri
myelin
cell
origin
oligodendrocyt
olg
like
extend
beyond
inflamm
initi
cell
includ
constitu
adapt
innat
immun
system
select
neural
target
injuri
could
reflect
properti
immun
effector
andor
target
cell
select
immun
effector
would
includ
olgmyelin
specif
mhc
class
restrict
cell
antibodi
injuri
mediat
member
tumor
necrosi
factor
tnf
superfamili
fa
trail
tnf
provid
exampl
targetconf
select
depend
express
requisit
receptor
chronic
inflammatori
environ
contribut
enhanc
product
effector
molecul
upregul
receptor
environ
also
enhanc
express
molecular
partner
ligand
involv
non
mhc
restrict
cytotox
respons
mediat
innat
immun
cell
nk
cell
cell
even
induc
molecul
cell
neuroprotect
strategi
direct
immuneneur
molecul
directli
involv
injuri
process
modul
cn
environ
regul
express
activ
neuropatholog
multipl
sclerosi
h
lassmann
multipl
sclerosi
ms
initi
defin
chronic
inflammatori
diseas
central
nervou
system
give
rise
focal
demyelin
plaqu
white
matter
although
demyelin
plaqu
diagnost
hallmark
patholog
diseas
much
complex
focal
white
matter
plaqu
highli
heterogen
regard
immunopatholog
profil
pattern
tissu
destruct
capac
repair
heterogen
part
stage
depend
part
reflect
true
divers
patient
patient
subgroup
addit
patholog
alter
restrict
focal
white
matter
plaqu
cn
affect
global
sens
particularli
case
patient
primari
secondari
progress
ms
patient
extens
demyelin
also
found
cerebr
cortex
deep
brain
stem
nuclei
furthermor
massiv
diffus
axon
injuri
damag
normal
appear
white
matter
associ
persist
inflamm
tcell
bcell
plasma
cell
well
global
diffus
microglia
activ
part
spectrum
patholog
alter
within
ms
brain
far
detect
magnet
reson
imag
addit
pathogenesi
divers
compon
ms
patholog
appar
differ
complex
patholog
ms
suggest
therapeut
strategi
tailor
cope
stage
patient
depend
variabl
intens
crosstalk
muscl
immun
cell
muscl
cell
express
mani
immunolog
import
molecul
includ
mhc
costimulatori
molecul
furthermor
muscl
cell
secret
mani
cytokin
chemokin
cell
adhes
molecul
well
receptor
innat
immun
system
convers
element
immun
system
affect
muscl
cell
properti
therefor
muscl
cell
consid
activ
modul
rather
passiv
target
immun
reaction
relev
immunopathogenesi
differ
inflammatori
myopathi
polymyos
inclus
bodi
myositi
clonal
expand
cell
invad
muscl
fiber
express
mhc
class
antigen
caus
antigen
yet
defin
recent
howev
becom
possibl
reviv
put
pathogen
autoimmun
cell
frozen
specimen
human
muscl
biopsi
tissu
use
spectratyp
clonal
expand
cell
receptor
tcr
identifi
muscl
section
patient
inflammatori
myopathi
put
pathogen
cell
isol
lasermicrodissect
coexpress
pair
tcr
alphaand
betachain
identifi
multiplex
pcr
protocol
allow
concomit
amplif
chain
singl
cell
pair
tcr
alphaand
betachain
function
express
thybridoma
cell
use
search
target
antigen
ref
hohlfeld
engel
immunol
today
wiendl
hohlfeld
kieseier
trend
immunol
dalaka
hohlfeld
lancet
immun
mediat
neuropathi
peripher
nerv
target
aberr
immun
respons
number
acut
chronic
neuropathi
includ
guillainbarr
syndrom
cidp
paraproteinem
neuropathi
vasculit
paraneoplast
neuropathi
local
immun
circuitri
made
endoneuri
macrophag
schwann
cell
pn
separ
system
immun
compart
blood
bloodnerv
barrier
howev
absent
defici
proxim
distal
part
therefor
immun
cell
antibodi
mediat
readili
access
neural
structur
principl
normal
immun
reactiv
nerv
respons
infect
danger
signal
review
concept
illustr
refer
guillainbarr
syndrom
cidp
predominantli
myelin
sheath
attack
disturb
immun
glycolipid
antibodi
implic
dysfunct
structur
damag
gb
variant
wherea
myelin
protein
identifi
number
patient
cidp
target
autoantigen
concept
molecular
mimicri
elabor
depth
gb
often
anted
infect
campylobact
jejuni
cytomegaloviru
molecular
structur
contain
lp
fraction
present
review
eae
variant
regard
usabl
model
human
ms
discuss
new
transgen
model
repres
mechan
determin
spontan
initi
cours
cn
autoimmun
distribut
lesion
within
cn
cellular
composit
inflammatori
infiltr
shall
review
aspect
earli
inflammatori
phase
ms
plaqu
gener
particular
concern
dynam
immun
cell
invas
central
nervou
system
cn
regulatori
function
nkt
cell
protect
autoimmun
diseas
develop
masaru
taniguchi
ryusuk
nakagawa
satoshi
kojo
hiroshi
watarai
riken
research
center
allergi
immunolog
yokohama
japan
nkt
cell
produc
larg
amount
time
thu
mediat
dual
function
activ
includ
protect
regulatori
function
nkt
cell
vivo
activ
singl
inject
splenic
dc
undergo
rapid
matur
acquir
potenti
produc
high
induc
respons
contrast
repeat
activ
nkt
cell
keep
produc
stop
produc
result
gener
regulatori
dc
produc
high
low
fact
nkt
cell
absenc
keep
maintain
regulatori
activ
dc
produc
long
time
least
day
also
gener
regulatori
cell
high
low
product
regulatori
dc
due
upregul
phosphoryl
extracellular
signalregul
kinas
augment
product
induc
suppress
activ
respect
experiment
allerg
encephalomyel
eae
induc
eae
develop
significantli
suppress
gener
regulatori
cell
induc
transfer
myelin
oligodendrocyt
glycoproteinpuls
dc
obtain
repeat
find
indic
nkt
cell
play
import
role
induc
regulatori
cell
suppress
eae
develop
sachiko
miyak
depart
immunolog
nation
institut
neurosci
ncnp
japan
invari
nkt
cell
uniqu
lymphocyt
subset
implic
varieti
immunoregul
nkt
cell
inhibit
diseas
autoimmun
diseas
model
experiment
autoimmun
encephalomyel
eae
type
diabet
wherea
exacerb
diseas
model
arthriti
allerg
airway
inflamm
even
though
role
nkt
cell
pathogenesi
reciproc
model
activ
nkt
cell
synthet
glycolipid
ligand
suppress
diseas
och
sphingosin
truncat
deriv
stimul
nkt
cell
select
produc
cytokin
prevent
autoimmun
diseas
model
deriv
suppress
antibodyinduc
arthriti
allerg
airway
inflamm
result
highlight
therapeut
potenti
target
nkt
cell
treatment
diseas
recent
invari
cell
receptor
express
cell
popul
emerg
second
invari
nkt
cell
popul
nkt
cell
howev
unidentifi
role
autoimmun
demonstr
overexpress
adopt
transfer
nkt
cell
inhibit
eae
convers
mice
lack
nkt
cell
exhibit
exacerb
diseas
mechan
nkt
cellmedi
suppress
diseas
also
discuss
mucos
associ
invari
cell
evolutionarili
conserv
cell
subset
restrict
lantz
b
l
duban
b
cruzmoura
b
e
treiner
c
laboratoir
dimmunologi
institut
curi
pari
franc
b
inserm
pari
franc
c
inserm
amien
franc
two
cell
subset
display
conserv
invari
repertoir
among
speci
nkt
cell
recent
discov
mucos
associ
invari
mait
cell
express
highli
conserv
chain
respect
recogn
relat
ligand
respect
human
mous
mait
cell
highli
abund
cattl
blood
human
blood
gut
less
mous
gut
select
b
cell
thymic
epithelium
restrict
strikingli
phylogenet
conserv
mhc
class
ib
molecul
tap
ii
chain
independ
depend
upon
commens
microbi
flora
absent
germ
free
mice
secret
high
level
cytokin
function
mait
cell
unknown
high
conserv
chain
mhc
ligand
speci
suggest
import
one
gut
epitheli
homeostasi
control
class
immun
respons
gut
altern
mait
cell
could
involv
defens
ubiquit
pathogen
importantli
accumul
mait
cell
found
lesion
multipl
sclerosi
ms
patient
well
nerv
biopsi
sampl
chronic
inflammatori
demyelin
polyneuropathi
cidp
patient
respons
self
lipid
autoimmun
diseas
experiment
immunolog
depart
research
univers
hospit
basel
switzerland
recognit
self
essenti
repertoir
select
immun
regul
autoimmun
may
consequ
infect
repres
escap
strategi
adopt
pathogen
also
incit
autoimmun
immun
respons
self
lipid
antigen
novel
mechan
may
contribut
autoimmun
diseas
cell
recognit
self
lipid
influenc
repertoir
immunogen
self
lipid
rule
lipid
present
isoform
regul
lipid
metabol
modif
occur
lipid
structur
ontogeni
synthesi
differ
organ
inflamm
may
lead
gener
highli
immunogen
self
lipid
effici
activ
autoreact
cell
bacteri
infect
may
also
dramat
effect
lipid
metabol
lipid
antigen
present
illustr
enhanc
de
novo
synthesi
immunogen
self
lipid
infect
cell
thu
becom
stimulatori
self
lipidreact
cell
mechan
regul
cell
respons
self
lipid
discuss
context
autoimmun
respons
multipl
sclerosi
admixtur
multipl
sclerosi
suscept
locu
chromosom
refin
mb
interv
africanamerican
popul
hla
haplotyp
wellvalid
genet
risk
ms
howev
recent
publish
genomewid
admixtur
scan
identifi
second
locu
associ
suscept
ms
africanamerican
patient
lod
score
degre
european
ancestri
patient
chromosom
locu
rise
genomewid
baselin
suggest
presenc
risk
allel
european
origin
region
control
subject
show
signific
differ
level
european
ancestri
locu
expand
collect
africanamerican
subject
ms
studi
subject
use
admixtur
map
strategi
also
perform
finemap
analys
compar
affect
subject
africanamerican
control
subject
associ
suscept
ms
primari
outcom
studi
addit
subject
marker
publish
dataset
improv
maxim
associ
lod
score
refin
locu
mb
mb
segment
effort
ongo
refin
locu
addit
affect
subject
marker
current
genotyp
rapidli
refin
locat
second
ms
suscept
allel
gene
lie
current
interv
mb
find
risk
allel
particularli
inform
africanamerican
patient
ms
may
identifi
new
molecul
pathway
involv
pathophysiolog
ms
work
may
therefor
gener
new
target
therapi
may
broadli
applic
patient
ms
whole
genom
associ
screen
multipl
sclerosi
da
compston
behalf
intern
multipl
sclerosi
genet
consortium
imsgc
earli
candid
gene
studi
quickli
identifi
import
extend
human
leukocyt
antigen
hla
haplotyp
confer
suscept
multipl
sclerosi
subsequ
whole
genom
linkag
screen
fail
conclus
identifi
suscept
factor
result
recent
highdens
linkag
screen
indic
nonhla
loci
exert
modest
effect
individu
requir
test
associ
larg
dataset
identifi
statist
confid
result
human
genom
variat
project
confirm
linkag
disequilibrium
ld
correl
close
map
loci
highli
variabl
common
featur
human
genom
one
often
consid
consequ
ld
possibl
effect
screen
nearli
common
variat
human
genom
type
proport
polymorph
especi
type
marker
care
chosen
captur
much
avail
variat
possibl
eg
tag
technolog
requir
undertak
indirect
whole
genom
associ
screen
realiti
indirect
associ
screen
multipl
sclerosi
intern
multipl
sclerosi
genet
consortium
imsgc
genotyp
affymetrix
chip
trio
famili
affect
intern
symposium
alzheim
diseas
neurodegener
immun
alzheim
diseas
ad
agerel
progress
neurodegen
disord
character
memori
loss
sever
cognit
declin
clinic
featur
manifest
morpholog
excess
accumul
extracellular
amyloid
abeta
brain
parenchyma
particularli
hippocampu
cerebr
cortex
lead
neuron
loss
addit
aggreg
abeta
form
neurit
plaqu
brain
becom
toxic
trigger
chronic
glial
activ
therebi
interfer
normal
brain
function
investig
immun
system
involv
diseas
base
new
emerg
characterist
three
biolog
system
autoimmun
brainimmun
interact
neurogenesi
data
demonstr
abeta
specif
cell
induc
ad
specif
magnitud
respons
depend
primarili
hladr
allel
limit
express
brain
observ
normal
brain
age
essenti
promot
migrat
abeta
reactiv
cell
parenchym
tissu
hippocampu
subsequ
interact
local
antigen
present
cell
contrast
injuri
effect
induc
chronic
innat
immun
mechan
involv
ad
tcellmedi
immunomodul
may
support
tissu
recoveri
regul
glial
activ
differenti
clearanc
abeta
neuron
surviv
translat
result
safe
immunotherapeut
approach
discuss
mucos
immunotherapi
alzheim
diseas
viral
vector
h
hara
inou
b
hasegawa
b
yonemitsu
c
nabeshima
tabira
nation
center
geriatr
gerontolog
obu
japan
b
dnavec
corpor
tsukuba
japan
c
kyushu
univers
fukuoka
japan
nagoya
univers
nagoya
japan
background
alzheim
diseas
character
progress
loss
cognit
function
due
deposit
central
nervou
system
base
amyloid
cascad
theori
mani
report
indic
immunotherapi
effect
treatment
alzheim
diseas
develop
mucos
immunotherapi
alzheim
diseas
nasal
administr
recombin
sendaiviru
vector
express
method
old
app
transgen
mous
nasal
administ
recombin
sendaiviru
vector
express
week
treatment
mice
sacrif
investig
amyloid
burden
brain
immunohistochemistri
elisa
result
serum
antibodi
level
elev
four
week
treatment
immunohistochemistri
mous
brain
tissu
show
extracellular
amyloid
deposit
clearli
decreas
compar
nontreat
mous
amount
measur
elisa
also
decreas
solubl
insolubl
fraction
brain
tissu
inflamm
lymphocyt
infiltr
recogn
organ
includ
brain
conclus
nasal
administr
recombin
sendaiviru
vector
express
advantag
cellular
immun
respons
elicit
antibodi
product
induc
furthermor
adjuv
requir
new
mucos
immunotherapi
induc
strong
immun
reaction
reduc
side
effect
enceph
found
peptid
vaccin
antibodi
independ
clearanc
abeta
mous
model
alzheim
diseas
activ
microglia
via
nasal
vaccin
method
ageand
sexmatch
litterm
mice
receiv
weekli
nasal
treatment
protollin
proteosomebas
adjuv
use
human
influenza
vaccin
plu
glatiram
acet
ga
approv
drug
ms
begin
age
month
treat
month
result
found
signific
reduct
amyloid
fibril
ga
protollin
treat
mice
versu
control
p
reduct
solubl
insolubl
form
p
measur
elisa
elev
total
serum
level
treat
anim
exhibit
toxic
measur
bodi
weight
eat
habit
tail
tone
mobil
clearanc
also
observ
nasal
protollin
alon
direct
intrahippocamp
inject
protollin
activ
microglia
reduc
plaqu
also
found
reduct
astrocytosi
follow
nasal
vaccin
ga
protollin
protollin
alon
previous
report
nasal
vaccin
ga
protollin
decreas
plaqu
month
old
app
tg
mice
vaccin
anim
develop
activ
microglia
cell
coloc
fibril
extent
microgli
activ
correl
decreas
fibril
jci
jci
studi
chronic
treatment
month
observ
differ
microgli
activ
suggest
clear
downregul
microgli
activ
conclus
result
demonstr
antibodyindepend
therapeut
approach
treatment
ad
target
microgli
cell
also
effect
without
toxic
given
chronic
young
mice
prevent
microglia
doubleedg
sword
motor
neuron
injuri
sh
appel
js
henkel
dr
beer
q
xiao
w
zhao
methodist
neurolog
institut
houston
usa
immuneinflammatori
factor
implic
pathogenesi
motoneuron
degener
amyotroph
later
sclerosi
presenc
spinal
cord
tissu
activ
microglia
dendrit
cell
igg
deposit
lymphocyt
infiltr
mark
increas
chemokin
involv
immun
cell
recruit
transgen
mice
overexpress
mutant
human
superoxid
dismutas
provid
use
model
investig
mechan
motoneuron
injuri
mice
activ
microglia
increas
present
prior
onset
weak
dendrit
cell
subsequ
appear
defin
potenti
role
microglia
diseas
pathogenesi
use
mous
model
unabl
develop
myeloid
cell
lymphoid
cell
bone
marrow
transplant
mice
result
donorderiv
microglia
spinal
cord
parenchyma
transplant
bone
marrow
alon
induc
diseas
howev
mice
express
motor
neuron
transplant
wild
type
donor
cell
greater
motoneuron
preserv
prolong
diseas
durat
surviv
compar
mice
receiv
donor
cell
vitro
studi
confirm
wildtyp
microglia
less
neurotox
microglia
transplant
mice
bone
marrow
lack
receptor
remov
neuroprotect
effect
wildtyp
microglia
express
mice
lack
function
tand
bcell
diseas
progress
actual
acceler
studi
suggest
cn
parenchym
microglia
neuroprotect
toxic
specif
effect
modul
commun
peripher
immun
cell
neuroinflamm
noncel
autonom
death
motor
neuron
al
primari
characterist
amyotroph
later
sclerosi
al
prematur
death
motor
neuron
inherit
form
caus
mutat
superoxid
dismutas
toxic
noncel
autonom
requir
mutant
act
within
motor
neuron
neighbor
astrocyt
microglia
silenc
mutant
express
select
within
motor
neuron
slow
diseas
onset
littl
effect
progress
reduc
mutant
synthesi
microglia
select
gene
excis
littl
effect
diseas
onset
strikingli
extend
surviv
onset
demonstr
damag
microglia
play
essenti
role
diseas
progress
use
primari
motor
neuron
microgli
cell
condit
medium
mutant
microgli
cell
produc
neurotox
mutant
express
motor
neuron
exploit
find
gene
therapi
develop
target
almost
gene
use
continu
infus
deliv
antisens
oligonucleotid
neuron
nonneuron
neighbor
throughout
nervou
system
oligonucleotid
infus
promot
catalyt
degrad
mrna
encod
mutant
slow
diseas
progress
thu
antisens
oligonucleotid
therapi
effect
mean
treat
neurodegen
diseas
includ
al
alzheim
parkinson
huntington
appropri
target
gene
identifi
phenotyp
divers
microglia
macrophag
sever
find
reveal
treatment
certain
cytokin
confront
microbi
agent
exposur
tumor
materi
apoptot
cell
trigger
macrophag
acquir
distinct
reactiv
phenotyp
phenotyp
therebi
defin
singl
releas
product
receptor
express
compris
time
coordin
often
even
reciproc
induct
pattern
mediat
cellular
commun
profil
effector
molecul
eg
cytokin
metabol
extracellular
matrixmodel
enzym
surfac
structur
phagocytosi
antigen
present
adapt
execut
behavior
come
function
consequ
includ
opposit
effect
inflamm
skew
type
immun
respons
orient
either
defens
repair
although
microglia
cn
tissu
macrophag
equival
challeng
virtual
neuropatholog
scenario
less
known
concern
phenotyp
divers
dynam
associ
molecular
characterist
function
consequ
conceiv
cell
also
choos
rather
variabl
respons
option
adequ
cope
exogen
endogen
threat
decid
recruit
adapt
immun
support
yet
microglia
macrophag
noncn
origin
may
differ
reactiv
profil
impos
specif
biochem
milieu
structur
vulner
control
defenc
mechan
neural
tissu
notabl
distinct
reactiv
phenotyp
may
occur
altern
develop
interchang
stagespecif
activ
process
highli
organ
contextdetermin
situationadapt
switch
antiinflammatori
messeng
product
time
recruit
vs
declin
immun
infiltr
phagocytot
clearanc
tissu
rebuild
attempt
could
element
open
usual
selflimit
mostli
effici
program
protect
restor
find
support
view
discuss
neurotox
microglia
mechan
potenti
therapeut
strategi
akio
suzumura
depart
neuroimmunolog
riem
nagoya
univers
nagoya
japan
accumul
activ
microglia
observ
around
degener
neuron
cell
may
play
critic
role
neurotox
neuroprotect
shown
recent
toxic
agent
activ
microglia
glutam
disturb
mitochondri
respiratori
chain
caus
neuron
dysfunct
glutam
activ
microglia
differenti
contribut
neuron
damag
neurodegen
diseas
howev
clinic
trial
block
factor
fail
seriou
advers
effect
show
stimul
extens
microgli
glutam
releas
caus
excitoneurotox
activ
glutaminas
addit
glutam
releas
microglia
hemichannel
gap
junction
glutam
transport
either
hemichannel
blocker
glutaminas
inhibitor
effect
suppress
microgli
glutam
releas
subsequ
neuron
cell
death
uniqu
mechan
microgli
glutam
releas
give
us
new
strategi
neurodegen
diseas
without
perturb
physiolog
signal
glutam
role
immun
neurodegener
autoimmun
encephalomyel
mani
year
multipl
sclerosi
ms
thought
result
autoimmun
attack
central
nervou
system
cn
experiment
autoimmun
encephalomyel
eae
autoimmun
model
ms
greatli
influenc
develop
immunotherapeut
paradigm
aim
treat
ms
despit
limit
success
inhibit
relaps
diseas
poor
translat
anim
studi
clinic
progress
ms
larg
unrespons
immunotherapi
howev
becom
increasingli
recogn
neurodegen
element
respons
diseas
progress
ms
axon
loss
increas
increas
number
neurolog
attack
result
develop
perman
residu
paresi
activ
clinic
diseas
ms
eae
associ
mononuclear
cell
infiltr
cn
infiltr
demyelin
axon
loss
inhibit
inflamm
one
rout
neuroprotect
relaps
diseas
inhibit
suffici
earli
diseas
cours
slow
rate
atrophi
cn
axon
loss
readili
appar
eae
recent
shown
ms
howev
immunotherapi
initi
late
chronicrelaps
diseas
cours
whilst
relaps
diseas
still
elimin
use
antigenspecif
toler
induct
appear
slow
deterior
mobil
increas
neurolog
sign
ongo
axon
damag
auto
immuneindepend
therefor
appear
case
ms
suffici
damag
accumul
inhibit
auto
immun
via
neuroimmunolog
approach
may
insuffici
control
progress
diseas
element
protect
effect
mucos
toler
eselectin
memori
impair
white
matter
injuri
rat
model
vascular
dementia
hideaki
wakita
b
john
hallenbeck
depart
vascular
dementia
research
nation
institut
longev
scienc
nation
center
geriatr
gerontolog
obu
citi
japan
b
stroke
branch
nation
institut
neurolog
disord
stroke
nation
institut
health
bethesda
md
usa
subcort
ischem
form
vascular
dementia
common
type
vascular
dementia
one
major
caus
cognit
declin
elderli
peopl
ischem
white
matter
lesion
characterist
patholog
chang
subcort
ischem
vascular
dementia
ischem
white
matter
lesion
impair
memori
function
report
rat
chronic
cerebr
hypoperfus
use
model
investig
effect
mucos
toler
eselectin
white
matter
damag
memori
impair
wistar
rat
subject
perman
occlus
common
carotid
arteri
mucos
toler
induc
repetit
intranas
administr
eselectin
control
group
receiv
pb
rarefact
white
matter
evalu
luxol
fast
blue
stain
activ
vessel
examin
immunohistochemistri
tumor
necrosi
factor
tnf
eselectin
memori
impair
evalu
object
recognit
tmaze
spontan
altern
tmaze
memori
retent
test
mucos
toler
eselectin
potent
protect
effect
white
matter
rarefact
addit
mucos
toler
eselectin
suppress
effect
activ
brain
vessel
mucos
toler
eselectin
also
protect
memori
impair
result
indic
mucos
toler
eselectin
suppress
vessel
activ
support
local
immunolog
inflammatori
process
protect
ischem
white
matter
damag
result
provid
new
therapeut
strategi
use
mucos
toler
eselectin
subcort
ischem
vascular
dementia
immun
regul
neural
stem
cell
program
eae
brigham
women
hospit
harvard
medic
school
boston
usa
multipl
sclerosi
character
progress
patholog
alter
remyelin
capac
neural
stem
cell
oligodendrocyt
progenitor
gener
myelin
oligodendrocyt
develop
normal
adult
turnov
endogen
progenitor
cell
ms
appear
fail
chronic
progress
respons
endogen
cell
eae
appear
limit
hypothes
inflammatori
mediat
may
act
upon
genet
program
nsc
initi
process
repair
chronic
phase
inflammatori
mediat
may
decreas
intrins
properti
nsc
result
failur
repair
nsc
express
immunerel
gene
includ
chemokin
cytokin
receptor
shown
molecul
chemokin
permiss
repair
function
nsc
injuri
eae
lesion
express
signal
molecul
neural
stem
cell
yet
lack
neurogenesi
lack
oligodendrogenesi
chronic
phase
lack
function
correl
microglia
activ
vivo
vitro
order
identifi
potenti
mechan
focus
molecular
biolog
candid
gene
may
mediat
interact
present
data
regard
molecular
effect
prototyp
cytokin
molecular
program
nsc
conclus
identifi
molecular
mechan
respons
nsc
injuri
eae
help
increas
efficaci
exogen
nsc
transplant
increas
activ
intrins
properti
endogen
stem
cell
model
multipl
sclerosi
neural
stem
cell
transplant
cell
replac
vs
bystand
neuroprotect
g
martino
recent
evid
challeng
sole
view
neural
stemprecursor
cell
npc
achiev
therapeut
efficaci
exclus
cellreplac
mechan
fact
npc
may
also
promot
central
nervou
system
cn
repair
intrins
neuroprotect
abil
mainli
exert
undifferenti
cell
releas
site
tissu
damag
milieu
neuroprotect
molecul
tempor
spatial
orchestr
environment
need
milieu
contain
molecul
immunomodulatori
substanc
neurotroph
growth
factor
stem
cell
regul
constitut
express
npc
maintain
tissu
homeostasi
develop
adulthood
intrins
natur
pleiotrop
redund
molecul
well
constitut
express
differ
type
stem
cell
mesenchym
haematopoiet
stem
cell
may
repres
stem
cell
signatur
might
also
reconcil
data
show
sourc
somat
stem
cell
mesenchym
stem
cell
haematopoiet
stem
cell
low
potenti
neural
tran
differenti
may
effici
promot
cn
repair
thu
cell
plastic
also
view
capac
somat
stem
cell
adapt
fate
function
specif
environment
need
aris
result
patholog
conditionsthi
notion
therapeut
plastic
abil
transplant
npc
protect
brain
sever
type
injuri
use
differ
andor
multifacet
bystand
strategi
signific
import
futur
stem
cellbas
therapeut
approach
tcell
base
therapi
oper
synergi
adult
neural
stem
cell
neuron
surviv
renew
implic
alzheim
diseas
depart
neurobiolog
weizmann
institut
scienc
rehovot
israel
michalschwartz
weizmannacil
sever
year
ago
propos
contrari
prevail
wisdom
mainten
repair
central
nervou
system
cn
need
assist
immun
system
innat
adapt
immun
known
implic
patholog
inflammatori
noninflammatori
neurodegen
diseas
multipl
sclerosi
first
instanc
alzheim
diseas
second
question
aros
condit
immun
activ
oper
part
repair
process
thu
need
boost
becom
part
patholog
henc
requir
modul
earli
find
led
us
formul
concept
protect
autoimmun
accord
concept
cell
recogn
cnsrelat
autoantigen
autoimmun
cell
protect
neural
tissu
induc
neural
cell
renew
endogen
stem
cell
local
provid
growth
factor
caus
microglia
adopt
support
phenotyp
use
anim
model
alzheim
diseas
demonstr
tcellbas
vaccin
weak
agonist
autoantigen
shift
default
microgli
phenotyp
toward
one
enabl
microglia
engulf
aggreg
produc
growth
factor
lead
arrest
diseas
progress
induct
function
rescu
tissu
repair
even
neurogenesi
similar
cellbas
approach
shown
group
applic
acut
brain
injuri
stroke
neurodegen
condit
studi
argu
favor
autoimmun
physiolog
system
defens
mainten
neurodegen
diseas
agerel
cognit
loss
result
least
part
age
immun
system
depart
pharmacolog
experiment
neurosci
univers
nebraska
medic
center
omaha
nebraska
usa
recent
result
obtain
rodent
suggest
cell
import
role
sever
aspect
neuron
plastic
hippocamp
neurogenesi
spatial
learn
memori
cognit
perform
test
learn
memori
task
impair
immunedefici
mice
compar
wildtyp
counterpart
superior
perform
wild
type
mice
correl
activ
gfapposit
astrocyt
hippocampu
restor
cell
pool
immun
defici
mice
result
improv
cognit
abil
also
accompani
signific
increas
gfap
posit
cell
hippocampi
vitro
result
provid
evid
astrocyt
major
nonneuron
cell
activ
particip
neuron
network
activ
cell
possess
phenotyp
support
neuron
function
establish
neuron
network
therefor
cellmedi
improv
cognit
function
might
encount
least
part
enhanc
neuron
plastic
support
astrocyt
result
interact
cell
base
hypothesi
boost
cell
respons
immun
synthet
glatiram
acet
give
rise
cell
partial
recognit
brainspecif
antigen
immun
significantli
improv
perform
wild
type
mice
cognit
task
find
suggest
declin
immun
activ
known
associ
sever
mental
neurodegen
disord
schizophrenia
alzheim
diseas
might
account
least
part
cognit
dysfunct
observ
patient
new
understand
could
lead
identif
new
therapeut
target
develop
new
therapeut
approach
demyelin
lesion
plaqu
multipl
sclerosi
ms
distinct
histolog
featur
reflect
stage
evolut
identifi
key
molecul
involv
differ
stage
lesion
progress
perform
proteom
profil
three
type
ms
plaqu
use
mass
spectrometri
bioinformat
fresh
frozen
autopsi
brain
sampl
six
ms
patient
agematch
control
classifi
acut
plaqu
ap
character
presenc
inflammatori
cell
ongo
demyelin
chronic
activ
plaqu
cap
character
chronic
demyelin
astrogliosi
activ
rim
chronic
plaqu
cp
character
lack
inflammatori
cell
dens
astrogliosi
sampl
plaqu
isol
laser
captur
microdissect
global
protein
identif
carri
sdspage
ingel
proteas
digest
liquid
chromatographi
mass
spectrometri
identifi
protein
analyz
bioinformat
softwar
sequest
interact
intersect
empai
identif
uniqu
protein
quantit
total
protein
identifi
analysi
reveal
protein
uniqu
ap
n
cap
n
cp
n
protein
common
three
type
n
protein
associ
activ
inflamm
uniqu
chronic
lesion
final
assign
protein
complex
uniqu
type
plaqu
may
biolog
import
result
provid
first
comprehens
inform
global
protein
express
ms
plaqu
enhanc
understand
molecular
pathogenesi
ms
lesion
identifi
potenti
key
molecul
involv
diseas
progress
offer
possibl
therapeut
target
endogen
neuroprotect
mechan
multipl
sclerosi
zei
u
graunman
aj
steck
w
b
n
schaerenwiem
neurobiolog
depart
research
univers
hospit
basel
pharmacent
switzerland
b
institut
neuropatholog
georgaugustunivers
germani
ms
chronic
inflammatori
diseas
cn
lead
focal
destruct
myelin
howev
earliest
chang
lead
lesion
format
known
recent
microarray
analysi
normalappear
white
matter
nawm
reveal
upregul
number
function
relat
gene
known
involv
endogen
neuroprotect
well
mainten
cellular
homeostasi
brain
patholog
result
introduc
novel
concept
molecular
pathogenesi
ms
ischem
precondit
import
mechan
neuroprotect
question
aris
alter
occur
earli
stage
ms
consequ
long
diseas
progress
biopsi
tissu
routin
embed
paraffin
therefor
establish
protocol
success
isol
total
rna
allow
quantit
rtpcr
analysi
detect
low
abund
gene
ongo
studi
character
nawm
needl
biopsi
old
femal
patient
immunopatholog
examin
reveal
patholog
agreement
pattern
iii
lesion
classif
lucchinetti
isol
total
rna
nawm
tissu
sampl
patient
perform
qrtpcr
strikingli
could
detect
high
no
express
level
nawm
biopsi
much
less
evid
nawm
postmortem
tissu
base
data
believ
alter
reflect
earli
chang
ms
specul
depend
regul
endogen
neuroprotect
mechan
lesion
format
might
either
prevent
sustain
hormon
effect
autoimmun
diseas
cc
whitacr
mcclain
tl
papenfuss
nn
gatson
n
damico
ie
gienapp
f
song
shawler
ohio
state
univers
columbu
ohio
usa
women
multipl
sclerosi
ms
experi
decreas
relaps
rate
late
pregnanc
flare
diseas
month
postpartum
examin
effect
pregnanc
experiment
autoimmun
encephalomyel
eae
sjl
mous
impact
pregnanc
ongo
diseas
pregnant
anim
show
reduc
incid
eae
decreas
clinic
sever
mice
induc
eae
postpartum
period
show
sever
diseas
strike
result
mice
becam
pregnant
acut
diseas
period
show
complet
protect
mid
late
pregnanc
cell
protect
mice
produc
less
nonpregn
control
cell
increas
mice
immun
pregnanc
primari
sourc
cell
explor
role
dendrit
cell
dc
mediat
pregnancyinduc
protect
eae
mice
immun
late
pregnanc
found
signific
increas
costimulatori
molecul
express
dc
similar
increas
costimulatori
molecul
note
dc
mice
treat
estriol
pregnanc
estrogen
transfer
dc
estrioltr
mice
protect
recipi
eae
result
suggest
pregnanc
immunoregulatori
environ
promot
dc
upregul
neg
costimulatori
molecul
product
support
nih
ai
nation
ms
societi
intric
interfac
immun
metabol
regul
role
leptin
pathogenesi
multipl
sclerosi
istituto
di
endocrinologia
e
oncologia
sperimental
consiglio
nazional
dell
ricerch
via
pansini
napoli
itali
email
gmatares
napolicom
last
year
seri
molecul
known
play
function
metabol
function
also
shown
play
import
role
regul
immun
respons
context
adipocytederiv
hormon
leptin
shown
regul
immun
respons
normal
well
patholog
condit
specif
shown
condit
reduc
leptin
product
ie
genet
leptin
defici
anorexia
nervosa
malnutrit
associ
increas
suscept
infect
convers
immunemedi
disord
autoimmun
disord
associ
increas
secret
leptin
product
proinflammatori
pathogen
cytokin
leptin
could
repres
miss
link
immun
respons
metabol
function
nutrit
statu
inde
recent
leptindefici
mice
shown
resist
seri
experimentallyinduc
autoimmun
disord
includ
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
normal
wildtyp
mice
show
increas
secret
leptin
serum
upon
eae
induct
brain
inflammatori
infiltr
stain
posit
leptin
final
leptin
neutral
antileptin
antibodi
improv
eae
cours
progress
profoundli
alter
intracellular
signal
myelinreact
cell
data
suggest
leptin
consid
major
link
immun
metabol
regul
strategi
aim
interf
leptin
axi
could
repres
innov
therapeut
tool
autoimmun
disord
dual
role
sympathet
nervou
system
chronic
inflamm
laboratori
neuroendocrinoimmunolog
depart
intern
medicin
univers
hospit
regensburg
germani
present
demonstr
dual
proand
antiinflammatori
role
sn
sn
inflammatori
joint
diseas
via
distinct
adrenoceptor
dual
role
sn
depend
involv
compart
time
distinct
effector
mechan
inflammatori
process
avail
respect
adrenoceptor
target
cell
intric
shift
betato
alphaadrenerg
signal
progress
cours
inflammatori
diseas
betato
alphaadrenerg
shift
critic
point
dual
role
sn
inflamm
underli
chang
immun
effector
mechan
process
diseas
progress
also
behavior
sympathet
nerv
fiber
inflam
tissu
nerv
fiber
loss
accompani
rel
lack
antiinflammatori
glucocorticoid
relat
inflamm
quintess
earli
stage
inflammatori
joint
diseas
sn
play
predomin
proinflammatori
role
wherea
late
stage
diseas
sn
probabl
exert
antiinflammatori
effect
sinc
patient
rheumatoid
arthriti
often
present
chronic
phase
diseas
support
antiinflammatori
sympathet
pathway
promis
therapeut
option
chronic
inflammatori
diseas
experiment
stroke
caus
earli
immun
activ
follow
system
immunosuppress
oregon
health
scienc
univers
portland
usa
induct
stroke
produc
local
ischemia
brain
damag
also
profound
effect
peripher
immun
respons
gener
hypothesi
focal
cerebr
ischemia
alter
immunocyt
function
braintospleen
signal
via
sympathet
nervou
system
observ
initi
rapid
intrasplen
activ
immunocyt
includ
tlymphocyt
tcell
appear
releas
poststrok
spleen
within
hour
home
brain
secret
cytokin
amplifi
periinfarct
inflamm
subsequ
loss
immun
compet
character
splenic
atrophi
increas
splenocyt
apoptosi
accompani
reduc
cell
prolifer
secret
inflammatori
cytokin
chang
produc
drastic
reduct
b
cell
number
novel
increas
regulatori
tcell
increas
percentag
nonapoptot
macrophag
monocyt
immunosuppress
respons
brain
injuri
may
account
reduct
inflammatori
factor
stroke
affect
brain
also
potenti
could
curtail
protect
immun
respons
peripheri
find
provid
new
evid
support
content
damag
brain
caus
cerebr
ischemia
produc
immunosuppress
caus
cell
death
well
increas
presenc
treg
cell
net
effect
stroke
survivor
would
enhanc
risk
crippl
system
infect
septicemia
clinic
characterist
pathophysiolog
biopsi
neuromuscular
junction
japanes
musk
antibodyposit
myasthen
patient
investig
uniqu
suscept
extraocular
muscl
eom
myasthenia
gravi
mg
led
novel
insight
diseas
neuromuscular
transmiss
reason
suscept
multipl
base
molecular
physiolog
properti
eom
requir
ocular
motor
system
natur
autoimmun
patholog
even
minor
eom
weak
suffici
misalign
visual
axe
produc
dramat
symptom
propriocept
feedback
limit
overcom
deficit
eom
neuromuscular
junction
subject
high
neuron
stimul
would
make
suscept
fatigu
eom
synaps
structur
featur
would
make
suscept
neuromuscular
blockad
secondari
synapt
fold
simplifi
certain
fiber
contract
tonic
fashion
compromis
transmiss
would
lead
reduct
contract
forc
combin
featur
high
neuron
stimul
junction
featur
make
transmiss
failur
like
suggest
neuromuscular
junction
behav
like
central
nervou
system
synaps
eom
junction
lower
level
intrins
complement
regulatori
factor
would
make
prone
damag
acetylcholin
receptor
achr
antibodi
among
ocular
mg
patient
serum
achr
antibodi
level
low
would
support
concept
eom
junction
suscept
antibodi
injuri
junction
specif
inhibit
complement
system
could
particular
util
treatment
ocular
myasthenia
improv
understand
eom
suscept
mg
may
continu
provid
insight
mg
pathogenesi
neuromuscular
transmiss
mechan
autoimmunis
hard
studi
especi
human
focuss
hyperplast
neoplast
chang
mg
thymu
patient
earlyonset
mg
eomg
age
thymoma
pathogen
antibodi
nativ
muscl
acetylcholin
receptor
achr
autoantibodi
yet
detect
standard
assay
achr
musk
patient
typic
generalis
mg
antiachr
despit
mild
thymic
hyperplasia
eomg
patient
infiltr
tcell
area
germin
centr
gc
compress
hyperplast
medullari
thymic
epitheli
cell
mtec
mtec
express
hlaclass
ii
unfold
achr
subunit
could
prime
helper
tcell
th
achr
abnorm
adjac
profession
lymphoid
tissu
hypothesis
prime
th
evok
earli
autoantibodi
attack
nearbi
thymic
myoid
cell
express
intact
achrwhich
frequent
label
activ
even
complement
compon
similar
label
antiachr
patient
suggest
belong
eomg
spectrum
autoantibodi
diversifi
gc
recognis
nativ
achr
includ
fetal
isoform
express
myoid
cell
thymoma
neoplasm
tec
express
isol
achr
subunit
addit
antiachr
patient
high
titr
neutralis
antibodi
subtyp
diagnosi
latter
increas
thymoma
recur
metastasis
also
produc
spontan
matur
plasma
cell
thymoma
impli
stimul
cell
type
attempt
identifi
summaris
antibodi
presynapt
receptor
act
synapt
plastic
myasthenia
takamori
k
otsuka
myasthenia
gravi
mg
acetylcholin
ach
releas
nerv
termin
upregul
synapt
transmiss
postsynapt
impair
antiacetylcholin
receptor
achr
antibodi
mechan
synapt
plastic
act
via
intratermin
second
messeng
depend
cytoplasm
free
ca
depend
compon
caus
via
regulatori
effect
presynapt
voltageg
ca
channel
vgcc
independ
membran
depolar
presynapt
ca
influx
trigger
via
phospholipas
c
activ
phosphatidylinositid
pi
pathway
affect
intracellular
ca
store
focus
attent
onto
two
mechan
one
membraneassoci
ca
influx
channel
transient
receptor
potenti
classic
activ
pathway
includ
brainderiv
neurotroph
factor
receptor
tyrosin
kinas
b
gproteincoupl
muscarin
achr
machr
effici
pqtype
vgccmediat
ca
influx
via
pi
pathway
differ
manner
physiolog
associ
trpcmediat
ca
influx
via
activ
diacylglycerol
forti
mg
patient
posit
neg
antiachr
antibodi
studi
antibodi
peptid
bone
marrow
stromal
cell
msc
capabl
specif
condit
differenti
variou
cell
type
demonstr
highli
effici
specif
induct
schwann
cell
peripher
glial
cell
neuron
skelet
muscl
cell
rat
human
msc
schwann
cell
constitut
peripher
nervou
system
known
support
axon
elong
msc
treat
betamercaptoethanol
follow
retino
acid
ra
cytokin
express
marker
schwann
cell
cell
promot
axon
regener
result
function
recoveri
transplant
spinal
cord
injuri
model
neuron
induct
could
achiev
nicd
transfect
follow
trophic
factor
administr
bfgf
cntf
forskolin
msc
express
marker
relat
neural
stem
cell
transfect
nicd
subsequ
administr
trophic
factor
induc
postmitot
neuron
without
differenti
glial
cell
induc
cell
show
action
potenti
compat
characterist
function
neuron
treatment
neuron
gdnf
increas
proport
dopamineproduc
cell
transplant
neuron
show
improv
rat
model
parkinson
diseas
highli
effici
skelet
muscl
induct
could
also
achiev
administr
combin
cytokin
follow
nicd
transfect
induc
cell
differenti
muscl
fiber
upon
transplant
degener
muscl
sinc
induc
cell
contain
satellitelik
cell
contribut
subsequ
regener
upon
repetit
damag
without
addit
transplant
cell
msc
differenti
system
may
contribut
substanti
major
advanc
toward
eventu
cellbas
therapi
neurodegen
muscl
degen
diseas
clearanc
tissu
debri
myeloid
cell
promot
recoveri
experiment
autoimmun
encephalomyel
kazuya
takahashi
marco
prinz
harald
neumann
neural
regener
unit
institut
reconstruct
neurobiolog
univers
bonn
life
brain
center
hertiefound
sigmundfreudstr
bonn
germani
depart
neuropatholog
univers
hospit
germani
background
inflamm
success
prevent
multipl
sclerosi
tissu
repair
still
major
challeng
therapi
bone
marrow
bloodderiv
hematopoiet
myeloid
precursor
suitabl
access
sourc
cellbas
repair
therapi
effici
remov
apoptot
cell
cellular
debri
without
inflamm
degen
central
nervou
system
cn
diseas
essenti
repair
injur
tissu
diseas
recoveri
method
bone
marrowderiv
myeloid
precursor
expand
cultur
lentivir
transduc
microgli
innat
immun
receptor
trigger
receptor
express
myeloid
myeloid
cell
intraven
appli
mice
afflict
experiment
autoimmun
encephalomyel
eae
result
myeloid
precursor
show
increas
phagocyt
activ
antiinflammatori
cytokin
product
stimul
intraven
applic
myeloid
cell
peak
eae
led
signific
amelior
clinic
symptom
reduct
axon
damag
prevent
demyelin
myeloid
cell
migrat
inflammatori
spinal
cord
lesion
within
hour
iv
applic
local
creat
antiinflammatori
cytokin
milieu
within
spinal
cord
express
myeloid
cell
resolv
inflamm
remov
cellular
debri
creat
milieu
support
repair
injur
tissu
conclus
data
demonstr
involv
tissu
debri
clearanc
resolut
inflamm
eae
furthermor
identifi
novel
target
therapi
inflammatori
autoimmun
brain
diseas
neuroimmunolog
group
depart
neurolog
heinrich
heineunivers
germani
multipl
sclerosi
ms
chronic
diseas
cn
character
inflamm
demyelin
axon
injuri
although
etiolog
ms
still
unknown
mani
find
point
central
role
immun
system
pathogenesi
diseas
occurr
local
antibodi
synthesi
csf
demonstr
presenc
oligoclon
band
intrathec
igg
product
still
diagnost
laboratori
marker
ms
paradox
howev
b
cell
neglect
ms
research
decad
owe
dispens
role
eae
lack
suitabl
technolog
recent
impact
ms
pathogenesi
thoroughli
studi
b
cell
ms
lesion
csf
compris
domin
clonotyp
contain
replac
mutat
bcell
receptor
gene
compat
antigendriven
select
process
bcell
clonotyp
found
csf
cours
diseas
impli
period
recruit
persist
cn
compart
model
compat
csf
paramet
immunoglobulin
predominantli
releas
csf
lesion
ms
patient
bcell
cytokin
baff
also
detect
ms
lesion
plasma
blast
plasma
cellstermin
differenti
b
cell
usual
found
acut
infecti
diseasescan
identifi
csf
compart
ms
patient
number
correl
local
igg
synthesi
also
extent
cn
inflamm
although
find
strongli
support
role
humor
immun
respons
ms
specif
function
respons
remain
determin
immunomodul
statin
potenti
role
ms
therapi
depart
neurolog
program
immunolog
univers
california
san
francisco
san
francisco
ca
usa
statin
wide
prescrib
cholesterol
reduct
immunomodulatori
properti
may
benefici
treatment
ms
mediat
autoimmun
diseas
data
indic
immunomodul
statin
occur
cholesterolindepend
manner
recent
connect
isoprenoid
intermedi
mevalon
pathway
signal
pathway
cell
differenti
vivo
deplet
isoprenoid
intermedi
geranylgeranylpyrophosph
ggpp
farnesylpp
oral
atorvastatin
inhibit
respons
decreas
geranylgeranyl
rhoa
farnesyl
ra
plasma
membran
associ
reduc
phosphoryl
erk
reduc
dna
bind
cotarget
cfo
recent
data
indic
oral
atorvastatin
rosuvastatin
highli
potent
induc
differenti
inhibit
erk
signal
howev
oral
simvastatin
inhibit
cell
prolifer
less
effect
induc
modul
individu
differ
may
import
choos
statin
test
human
autoimmun
condit
base
primarili
upon
benefici
immun
modul
atorvastatin
eae
conduct
multicent
random
placebocontrol
studi
determin
whether
oral
atorvastin
mg
reduc
risk
convers
clinic
definit
ms
patient
experienc
clinic
isol
syndrom
ci
trial
fund
immun
toler
network
itn
nih
activ
recruit
patient
ralf
gold
shinyoung
na
fred
thoma
institut
ms
research
univers
germani
institut
virolog
immunobiolog
univers
germani
regulatori
cell
reg
cell
play
key
role
control
autoimmun
inflamm
therefor
therapeut
agent
capabl
elev
number
andor
increas
effector
function
cell
subset
highli
desir
previou
report
show
superagonist
monoclon
antibodi
specif
expand
activ
reg
cell
vivo
singl
intraven
administr
low
dose
superagonist
either
da
rat
lewi
rat
suffer
experiment
autoimmun
encephalomyel
eae
prove
highli
efficaci
experi
novel
spontan
mous
eae
mediat
cell
treat
reg
cell
transgen
mice
express
model
antigen
ovalbumin
ova
oligodendrocyt
odc
tcell
transgen
ovaspecif
tcell
receptor
tcr
caus
fulmin
eae
spontan
develop
sever
eae
mainli
affect
cerebellum
brainstem
suggest
name
charcot
mous
specif
phenotyp
transfer
polyclon
reg
cell
activ
novel
mous
superagonist
monoclon
antibodi
protect
anim
lethal
eae
surviv
mice
transfer
regulatori
tcell
found
affect
region
cn
brain
spinal
cord
data
indic
polyclon
reg
cell
therapeut
efficaci
mediat
rodent
eae
immun
irradi
autolog
autoreact
cell
cell
vaccin
shown
induc
regulatori
cell
respons
patient
multipl
sclerosi
ms
regulatori
cell
reactiv
thought
contribut
suppress
deplet
circul
myelinreact
cell
use
vaccin
characterist
regulatori
mechan
antiidiotyp
cell
regulatori
cell
induc
cell
vaccin
review
emphasi
newli
character
regulatori
cell
pna
regulatori
cell
line
gener
patient
ms
receiv
immun
irradi
autolog
myelin
basic
protein
mbp
reactiv
cell
regulatori
cell
line
mark
inhibit
autolog
mbpreactiv
cell
display
two
distinct
pattern
distinguish
express
transcript
factor
cytokin
profil
major
cell
line
high
express
secret
compar
pattern
characterist
low
express
predomin
product
regulatori
cell
line
pattern
express
react
activ
autolog
cell
rest
cell
irrespect
antigen
specif
target
cell
evid
recogn
preferenti
synthet
peptid
correspond
residu
receptor
alphachain
cell
vaccin
correl
increas
express
cell
reactiv
peptid
find
import
implic
understand
role
regulatori
cell
respons
induc
cell
vaccin
innat
signal
cn
glial
respons
medic
biotechnolog
center
univers
southern
denmark
odens
denmark
signal
central
nervou
system
cn
immun
system
contribut
patholog
inflammatori
demyelin
diseas
multipl
sclerosi
studi
innat
signal
glial
respons
exogenouslyand
endogenouslyderiv
present
describ
activ
glial
cell
mous
brain
respons
axon
injuri
cuprizon
demyelin
cytokineexpress
adenoviru
glial
activ
respons
experiment
stimuli
initi
independ
immun
involv
result
chemokin
cytokin
secret
injuryinduc
microgli
tolllik
signal
act
upstream
onswitch
glial
cytokin
chemokin
respons
microgli
prolif
expans
wherea
injuryor
cuprizon
demyelinationinduc
glial
cytokin
chemokin
appear
suffici
entri
macrophag
cell
cn
leukocyt
entri
respons
transgen
adenovir
interferon
gammainduc
chemokin
product
requir
addit
signal
provid
recognit
pathogenderiv
innat
trigger
pertussi
toxin
glial
crosstalk
mediat
cytokin
characterist
intracellular
signal
activ
microglia
macrophag
show
antigenpres
cell
surfac
phenotyp
activ
cell
cultur
howev
cell
enter
cn
absenc
deliber
immun
requir
signal
addit
chemokin
cytokin
function
activ
find
identifi
complex
signal
event
must
combin
immun
patholog
cn
tolllik
receptor
astrocyt
mediat
neuroprotect
respons
activ
endogen
protein
agonist
tolllik
receptor
tlr
express
varieti
cell
type
function
sensor
microbi
structur
endotoxin
peptidoglycan
nucleic
acid
respons
molecul
tlr
gener
activ
proinflammatori
host
defens
respons
human
astrocyt
express
limit
repertoir
tlr
found
cell
surfac
particular
appear
special
astrocyt
sinc
strongli
preferenti
upregul
respons
varieti
stimuli
includ
cytokin
oxid
stress
tlr
agonist
gene
profil
respons
astrocyt
activ
reveal
power
respons
domin
antiinflammatori
cytokin
neuroprotect
molecul
remyelin
signal
sever
chemokin
function
test
confirm
abil
collect
astrocyt
product
enhanc
surviv
neuron
organotyp
human
brain
slice
cultur
given
appar
tissu
repair
function
surfaceexpos
astrocyt
examin
possibl
presenc
endogen
agonist
central
nervou
system
inde
genomescal
screen
brain
tumorderiv
cdna
bank
reveal
protein
preferenti
express
human
cn
activ
respons
astrocyt
detail
protein
possibl
role
control
cn
inflamm
repair
present
discuss
dendrit
cell
lymphoid
microenviron
inflam
cn
francesca
aloisi
barbara
serafini
roberta
magliozzi
abhilash
vora
richard
reynold
depart
cell
biolog
neurosci
istituto
superior
di
rome
itali
depart
cellular
molecular
neurosci
imperi
colleg
london
london
uk
chronic
inflammatori
diseas
autoimmun
infecti
diseas
associ
repeat
recruit
persist
immun
cell
target
tissu
evid
accumul
even
within
immun
privileg
site
central
nervou
system
cn
chronic
inflamm
lead
organ
lymphoid
microenviron
may
contribut
sustain
local
immun
respons
microbi
self
antigen
dendrit
cell
dc
recruit
inflam
cn
thought
play
key
role
process
multipl
sclerosi
anim
model
eae
perivascular
space
inflam
blood
vessel
white
matter
preferenti
site
dendrit
cell
accumul
take
myelin
compon
interact
cnsinfiltr
lymphocyt
inflam
mening
provid
even
support
environ
gener
ectop
lymphoidlik
tissu
myeloid
plasmacytoid
dc
detect
bcell
follicl
follicular
dendrit
cell
fdc
develop
substanti
proport
patient
secondari
progress
ms
fdc
mesenchym
origin
central
role
select
memori
b
cell
germin
center
reaction
remark
develop
ectop
lymphoid
tissu
ms
associ
extens
cortic
demyelin
aggress
clinic
cours
propos
seed
brain
lymphocyt
antigen
present
cell
organ
lymphoidlik
structur
exacerb
inflammatori
process
consequ
increas
avail
pathogen
presum
autoreact
lymphocyt
product
prevent
erad
lymphoid
microenviron
nest
within
cn
consid
import
goal
therapeut
intervent
innat
immun
bone
marrow
stem
cell
brain
diseas
repair
receptor
tlr
cytokin
chemokin
protein
complement
system
circumventricular
organ
structur
devoid
bloodbrain
barrier
diffus
progress
microglia
across
brain
parenchyma
may
lead
adapt
immun
respons
cerebr
innat
immun
like
essenti
player
etiolog
inflammatori
cn
disord
result
infect
well
assum
immun
etiolog
hand
molecul
innat
immun
found
trigger
product
neurotroph
factor
promot
neurorepair
remyelin
respons
brain
injuri
trauma
toxininduc
demyelin
excit
new
data
also
present
regard
role
newli
recruit
microglia
bone
marrow
stem
cell
cn
diseas
alzheim
diseas
ad
diseas
character
deposit
aggreg
betaamyloid
form
amyloid
plaqu
senil
plaqu
compos
microglia
infiltr
core
amyloid
bodi
cell
differ
origin
deriv
bone
marrow
stem
cell
abil
elimin
plaqu
inhibit
process
found
aggrav
diseas
data
provid
novel
insight
develop
new
therapeut
strategi
use
bone
marrow
stem
cell
vehicl
gene
therapi
elimin
toxic
senil
plaqu
work
subject
current
fund
canadian
institut
health
research
cihr
go
solo
need
friend
gangliosid
lipid
cluster
form
novel
antigen
determin
gb
kinki
univeristi
school
medicin
osaka
japan
antigangliosid
antibodi
titer
frequent
elev
acut
phase
sera
patient
syndrom
gb
use
diagnost
marker
well
possibl
pathogenet
factor
gb
antibodi
assay
usual
perform
elisa
purifi
gangliosid
use
antigen
howev
gangliosid
present
plasma
membran
coloc
phospholipid
gangliosid
form
lipid
raft
pay
attent
effect
lipid
molecul
recent
perform
elisa
use
mixtur
antigen
compos
gangliosid
phospholipid
result
sera
higher
antibodi
titer
mixtur
sever
phospholipid
phosphatid
acid
alon
contrast
phospholipid
provid
signific
enhanc
antibodi
titer
sphingomyelin
provid
decreas
activ
antibodi
next
use
mixtur
antigen
compos
two
differ
gangliosid
found
gb
sera
antibodi
specif
gangliosid
complex
gsc
conform
epitop
form
two
gangliosid
antigscposit
gb
featur
anteced
gastrointestin
infect
lower
cranial
nerv
deficit
among
antigsc
antibodi
andor
antibodi
associ
sever
disabl
requir
mechan
ventil
may
predictor
sever
gb
consid
cluster
antigen
epitop
determin
pathogenet
role
antigangliosid
antibodi
gb
gene
campylobact
polymorph
direct
clinic
featur
gb
n
yuki
gangliosid
mimicri
campylobact
jejuni
lipooligosaccharid
lo
caus
syndrom
gb
loss
synthes
campylobact
sialyltransferas
cstii
nacetylgalactosaminyltransferas
cgta
galactosyltransferas
cgtb
c
jejuni
group
sever
lo
locu
class
base
organ
lo
biosynthesi
gene
isol
gb
patient
belong
class
contain
cgta
b
cstii
gene
essenti
biosynthesi
gangliosidelik
lo
identifi
c
jejuni
gene
respons
develop
gb
cstii
consist
amino
acid
fiftyfirst
amino
acid
determin
enzymat
activ
cstii
make
loss
wherea
cstii
make
lo
neuropath
strain
cstii
express
epitop
wherea
strain
cstii
express
epitop
patient
infect
cstii
strain
antibodi
patient
show
limb
weak
patient
infect
cstii
strain
antibodi
patient
show
ophthalmoplegia
ataxia
summari
cstii
strain
make
loss
induc
product
antibodi
patient
develop
limb
weak
cstii
strain
make
lo
induc
product
antibodi
patient
develop
ophthalmoplegia
ataxia
word
cstii
polymorph
determin
clinic
present
gb
fisher
syndrom
propos
new
paradigm
microbi
genet
polymorph
determin
clinic
present
human
autoimmun
diseas
model
gb
man
mous
patholog
inform
pathogenesi
incid
onset
rapid
lead
total
paralysi
within
h
patient
left
sever
disabl
dead
repres
major
social
econom
burden
recent
clinicalserolog
studi
identifi
serum
antigangliosid
antibodi
gb
case
chronic
neuropathi
gangliosid
sialic
acidcontain
glycosphingolipid
highli
enrich
nervou
system
antibodi
characteris
motor
axon
form
gb
antibodi
characteris
miller
fisher
syndrom
mf
murin
model
shown
antigangliosid
antibodi
target
gangliosid
neuron
glial
membran
includ
motor
nerv
termin
morpholog
dens
antibodi
complement
deposit
found
synapt
cleft
perisynapt
schwann
cell
psc
alongsid
loss
neurofila
destruct
nerv
termin
psc
death
manipul
gangliosid
level
synthas
synthas
nullmut
enhanc
attenu
diseas
termin
attack
complex
complement
critic
develop
acut
neural
injuri
allow
calcium
ingress
activ
calpain
degrad
nerv
termin
calcium
deplet
calpain
inhibit
protect
cytoskeleton
degrad
human
immunoglobulin
therapi
also
protect
nerv
injuri
antiidiotyp
effect
inhibit
complement
activ
also
abl
attenu
injuri
studi
show
nerv
termin
gangliosid
act
target
human
diseaseassoci
autoantibodi
site
provid
use
model
system
test
new
pathogenesi
paradigm
therapeut
strategi
regul
myelin
basic
proteinspecif
cell
respons
vivo
loss
toler
myelinspecif
cell
believ
contribut
pathogenesi
multipl
sclerosi
previou
studi
show
cell
specif
myelin
basic
protein
mbp
highli
immunogen
mbp
epitop
mice
larg
toler
clonal
delet
thymu
howev
development
regul
express
mbp
allow
cell
escap
central
toler
young
mice
littl
mbp
synthes
defin
peripher
toler
mechan
prevent
cell
mediat
autoimmun
later
life
encount
mbp
peripheri
regulatori
cell
essenti
prevent
cell
mediat
autoimmun
regulatori
cell
prevent
prolifer
expans
traffick
mbpspecif
cell
transfer
wildtyp
mice
instead
cytokin
product
mbpspecif
cell
strongli
suppress
suppress
cytokin
protect
autoimmun
abrog
endogen
antigenpres
cell
apc
activ
first
week
transfer
mbpspecif
cell
recipi
interestingli
activ
apc
thirti
day
transfer
mbpspecif
cell
longer
trigger
autoimmun
instead
mbpspecif
cell
persist
peripheri
wildtyp
mice
respond
stimulu
suppress
cytokin
respons
toler
phenotyp
mbpspecif
cell
persist
wildtyp
mice
depend
cell
intrins
host
factor
repres
termin
differenti
state
retransf
regul
mbpspecif
cell
celldefici
recipi
caus
autoimmun
diseas
natur
regul
cn
autoimmun
diseas
institut
immunolog
infect
research
univers
edinburgh
king
build
edinburgh
uk
uk
develop
new
therapeut
autoimmun
disord
benefit
understand
natur
regulatori
mechan
promot
resolut
diseas
mind
notabl
multipl
sclerosi
ms
often
follow
benign
relaps
remit
cours
investig
regul
mous
model
msexperiment
autoimmun
encephalomyel
eae
diseas
mice
peak
second
week
immun
cn
autoantigen
peptid
recoveri
phase
follow
correl
specif
accumul
cell
within
cn
cnsderiv
treg
preferenti
produc
express
anerg
act
potent
suppressor
respond
cell
vitro
transfer
vivo
acceler
recoveri
eae
recipi
mice
deplet
exacerb
diseas
delay
recoveri
moreov
deplet
recoveri
also
render
mice
fulli
suscept
reinduct
eae
data
present
relat
origin
mode
action
specif
cn
treg
cell
data
highlight
key
role
treg
natur
recoveri
ongo
inflammatori
autoimmun
diseas
subsequ
resist
effect
appear
within
target
organ
thu
real
potenti
tregdirect
therapi
boost
natur
regul
activ
autoimmun
diseas
human
natur
treg
compos
two
function
distinct
subset
cell
base
express
mhc
class
ii
ex
vivo
c
baecherallan
c
ashley
c
costantino
g
beriou
h
hafler
harvard
medic
school
brigham
women
hospit
boston
usa
natur
high
regulatori
treg
popul
isol
patient
multipl
sclerosi
ms
shown
decreas
suppress
abil
compar
treg
isol
healthi
donor
subsequ
found
high
treg
popul
consist
two
function
distinct
suppress
subset
identifi
direct
ex
vivo
express
hla
class
ii
hla
dr
studi
treg
express
hla
dr
dr
treg
exhibit
strong
swift
suppress
dr
neg
treg
induc
delay
inhibit
accompani
suppress
increas
cytokin
dr
dr
neg
treg
also
exhibit
strike
differ
product
util
dr
dr
neg
treg
express
high
level
exhibit
strong
cell
contactdepend
suppress
dr
neg
treg
also
suppress
via
product
produc
dr
treg
contrast
dr
treg
express
highest
level
target
cell
product
inhibit
dr
treg
regulatori
function
result
increas
cocultur
prolifer
whether
inhibit
dr
treg
suppress
occur
reduc
suppress
abil
dr
treg
increas
resist
respond
cell
suppress
investig
addit
studi
also
underway
assess
activ
sensit
individu
dr
dr
neg
treg
subset
isol
patient
ms
elucid
mechan
defici
suppress
total
treg
popul
isol
patient
ms
regulatori
cell
selftoler
autoimmun
diseas
natur
occur
regulatori
cell
treg
activ
engag
mainten
immunolog
selftoler
immunoregul
specif
express
transcript
factor
master
control
molecul
develop
function
although
sever
cell
surfac
molecul
report
tregspecif
marker
gitr
glucocorticoidinduc
tnf
receptor
familyrel
geneprotein
also
express
activ
cell
deriv
cell
identifi
tregspecif
molecul
control
perform
dna
microarray
analysi
found
sever
gene
includ
helio
specif
express
natur
treg
discuss
role
gene
product
natur
treg
control
express
molecular
mechan
cell
migrat
across
bbb
vivo
theodor
kocher
institut
univers
bern
bern
switzerland
multipl
sclerosi
anim
model
experiment
autoimmun
encephalomyel
eae
inflammatori
cell
migrat
across
endotheli
bloodbrain
barrier
bbb
gain
access
central
nervou
system
cn
well
establish
activ
involv
leukocyt
recruit
across
bbb
contrast
involv
selectin
lselectin
eand
pselectin
respect
carbohydr
ligand
process
controversi
discuss
demonstr
antibodi
direct
eand
pselectin
major
leukocyt
ligand
interfer
recruit
inflammatori
cell
across
bbb
develop
clinic
eae
extend
studi
demonstr
lack
eand
pselectin
epselectindefici
mice
lack
lselectin
lselectindefici
mice
prevent
leukocyt
migrat
across
bbb
develop
clinic
eae
taken
togeth
find
suggest
selectin
requir
leukocyt
recruit
across
bbb
eae
point
predomin
role
process
find
discuss
light
potenti
risk
versu
benefit
therapi
multipl
sclerosi
transmigr
human
monocyt
across
blood
brain
barrier
induc
differenti
dendrit
cell
univers
montreal
neuroimmunolog
laboratori
chumnotredam
hospit
montreal
quebec
canada
bloodbrain
barrier
bbb
play
import
role
regul
transmigr
immun
cell
central
nervou
system
cn
disrupt
bbb
traffick
autoreact
cell
antigen
present
cell
cn
seen
import
earli
event
lesion
develop
multipl
sclerosi
ms
howev
date
still
much
controversi
surround
presenc
recruit
dendrit
cell
dc
within
human
brain
elect
demonstr
human
peripher
blood
monocyt
cross
bbb
differenti
dclike
phenotyp
use
vitro
model
transhuman
brain
endotheli
cell
hbec
migrat
identifi
chemokin
main
chemoattract
monocyt
migrat
across
bbb
demonstr
presenc
hbec
inflammatori
process
lead
differenti
monocyt
immatur
hladr
low
low
low
neg
matur
hladr
high
high
high
dcsign
high
high
dc
phenotyp
dc
capac
initi
cell
immun
respons
immunohistochemistri
studi
perform
brain
section
ms
patient
also
reveal
presenc
high
hladr
high
high
dcsign
high
express
cell
acut
lesion
final
show
vitro
differenti
monocyt
dc
inhibit
block
hbec
product
gmcsf
tgf
beta
data
support
notion
uniqu
popul
immatur
matur
dc
aris
migrat
peripher
blood
monocyt
across
human
bbb
concert
action
tgf
beta
gmcsf
reactiv
oxygen
speci
induc
alter
bloodbrain
barrier
integr
elga
de
vri
gerti
schreibelt
gij
kooij
j
hendrik
christien
dijkstra
eric
ronken
multipl
sclerosi
ms
migrat
monocyt
across
bloodbrain
barrier
bbb
crucial
step
format
lesion
central
nervou
system
cn
enter
cn
monocyt
cross
bbb
reactiv
oxygen
speci
ro
play
essenti
role
previous
show
anim
model
ms
experiment
allerg
encephalomyel
eae
antioxid
lipoic
acid
la
flavonoid
luteolin
suppress
develop
clinic
sign
prevent
new
relaps
coupl
reduc
cellular
infiltr
axon
damag
oxid
stress
recent
data
demonstr
monocyt
adhes
cultur
brain
endothelium
induc
product
ro
monocyt
within
minut
monocyt
adhes
model
bbb
vitro
lead
enhanc
permeabl
exogen
administ
ro
specif
activ
signal
pathway
kinas
within
brain
endothelium
subsequ
induc
cytoskeleton
tight
junction
chang
use
life
cell
imag
techniqu
abl
visual
superoxid
time
induc
bundl
factin
alter
integr
tight
junction
besid
modul
effect
integr
brain
endothelium
superoxid
also
induc
specif
alter
brain
endotheli
gene
protein
express
reveal
upregul
marker
oxid
stress
inflamm
result
indic
antioxid
may
suitabl
new
therapi
ms
limit
cellular
infiltr
brain
also
stabil
bbb
resist
inflammatori
attack
chemokin
bbb
function
also
caus
bbb
open
induc
interendotheli
junction
protein
redistribut
endotheli
actin
cytoskeleton
rearrang
effect
bbb
integr
mediat
least
two
distinct
signal
pathway
rhogtpas
rhoa
pkc
examin
reveal
endocytot
intern
transmembran
tight
junction
protein
occludin
stimul
import
disassembl
complex
endotheli
tight
junction
well
paracellular
rout
format
howev
fate
intern
protein
recycl
back
plasma
membran
collect
data
provid
new
inform
underli
mechan
chemokin
induc
bbb
disrupt
relev
multipl
diseas
state
hope
provid
insight
method
prevent
disrupt
effect
statin
lymphocyt
migrat
across
bloodbrain
barrier
j
greenwood
lymphocyt
adhes
brain
endotheli
cell
ec
known
initi
number
signal
cascad
physiolog
signific
remain
poorli
defin
howev
signal
gener
engag
cn
ec
surfac
adhes
molecul
unidentifi
gprotein
coupl
receptor
shown
essenti
success
lymphocyt
transendotheli
migrat
identif
key
compon
ec
pathway
rais
possibl
target
pharmacolog
intervent
may
provid
us
novel
antiinflammatori
strategi
treatment
diseas
multipl
sclerosi
ms
effici
transduct
mediat
signal
respons
cn
ec
subsequ
transendotheli
migrat
tlymphocyt
critic
depend
activ
small
gtpase
rho
pharmacolog
inhibit
rho
protein
achiev
prevent
posttransl
prenyl
inhibit
cholesterol
synthesi
pathway
provid
isoprenoid
pyrophosph
explor
effect
statin
potent
inhibitor
enzym
hmgcoa
reductas
rate
limit
step
cholesterol
synthesi
upon
signal
pathway
transendotheli
lymphocyt
migrat
vitro
neuroinflammatori
diseas
vivo
shown
statin
treatment
cn
ec
inhibit
lymphocyt
migrat
attenu
experiment
cn
autoimmun
diseas
data
present
support
pleiotrop
action
statin
potenti
use
treat
ms
identif
novel
cytokin
produc
encephalitogen
cell
induc
divis
neuroimmunolog
univers
zurich
winterthur
strass
switzerland
tissuedirect
autoimmun
diseas
wide
held
mediat
conduct
selfreact
h
cell
other
previous
shown
neither
geneexpress
serv
reliabl
marker
encephalopathogen
contrast
apcderiv
cytokin
shown
absolut
critic
induct
autoimmun
diseas
becom
increasingli
evid
support
expans
distinct
lineag
cell
produc
th
cell
appear
play
major
role
autoimmun
inflamm
use
high
densiti
transcriptom
could
identifi
addit
gene
specif
induc
memori
cell
discov
relat
cytokin
whose
express
profil
ident
diseas
associ
express
correl
exquisit
point
toward
major
role
illdescrib
cytokin
inflammatori
diseas
taken
togeth
molecul
help
defin
encephalopathogen
phenotyp
autoaggress
effector
h
cell
context
neuroimmun
diseas
chemokin
nervou
system
beyond
chemoattract
neuroinflamm
research
center
cleveland
clinic
cleveland
oh
usa
inflamm
central
nervou
system
cn
entail
activ
resid
microglia
recruit
hematogen
leukocyt
thu
defin
inflamm
accompani
neurolog
disord
includ
multipl
sclerosi
ms
stroke
neoplasia
trauma
dementia
well
alzheim
diseas
primari
neurodegener
chemokin
compris
famili
peptid
act
g
proteincoupl
receptor
gpcr
regul
leukocyt
migrat
throughout
tissu
exquisit
specif
flexibl
fashion
initi
studi
ask
chemokin
chemokin
receptor
govern
inflammatori
cell
recruit
cn
immunemedi
virusinduc
inflamm
recent
becom
clear
cn
complement
constitut
chemokin
support
development
neurophysiolog
function
well
regul
activ
microglia
gpcr
serv
drug
target
result
implic
understand
treatment
diseas
neurologist
support
us
nation
institut
health
nation
multipl
sclerosi
societi
usa
charl
dana
foundat
robert
packard
center
al
research
nanci
davi
center
without
wall
transfer
toler
modifi
dendrit
cell
experiment
autoimmun
encephalomyel
brigham
women
hospit
harvard
medic
school
boston
usa
dendrit
cell
potent
antigen
present
cell
apc
mediat
toler
immun
depend
state
matur
exvivo
incub
dc
mog
peptid
alter
biolog
function
cell
render
tolerogen
exvivo
modifi
dc
characterist
immatur
dc
decreas
express
mhc
ii
cytokin
product
show
molecul
express
dc
requir
tolerogen
effect
fcgamma
receptor
mechan
protect
independ
indoleamin
tolerogen
dc
exhibit
decreas
express
surfac
mhc
ii
molecul
cytokin
product
interestingli
protect
eae
transfer
apc
cell
origin
recipi
conclus
exvivo
exposur
dc
toler
regimen
may
provid
novel
therapeut
option
fewer
system
side
effect
autoimmun
diseas
transcript
regul
immun
axi
cn
autoimmun
inflamm
h
novel
cell
subset
driven
potent
proinflammatori
activ
suffici
differenti
cell
produc
cell
requir
expans
surviv
proencephalitogen
function
hypothesi
h
distinct
cell
lineag
predict
andor
must
promot
express
transcript
regul
control
immun
repertoir
immun
axi
use
affymetrix
geneexpress
analysi
found
number
h
cellspecif
novel
gene
encod
put
protein
potenti
dna
bind
activ
genet
deplet
experi
confirm
one
dna
bind
protein
orphan
nuclear
receptorlik
factor
necessari
differenti
function
h
cell
mice
lack
orphan
nuclear
receptor
eae
resist
defici
h
develop
identif
transcript
regul
provid
evid
h
distinct
cell
lineag
uniqu
role
immun
implic
find
immun
axi
regul
cn
autoimmun
inflamm
discuss
interest
defin
role
viral
infect
autoimmun
present
discuss
follow
aspect
earlier
studi
shown
viral
infect
enhanc
abrog
ongo
autoimmun
process
outcom
depend
time
infect
relat
autoimmun
process
natur
viru
molecular
mimicri
occur
enhanc
expect
contrast
strong
crossreact
lead
apoptosi
autoreact
lymphocyt
demis
prevent
autoimmun
viral
infect
essenti
creat
inflammatori
milieu
precipit
autoimmun
diabet
occur
ifngamma
mhc
class
upregul
islet
discuss
find
precipit
autoimmun
without
viral
infect
target
organ
much
difficult
illustr
natur
safeguard
prevent
accident
induct
autoreact
process
induct
treg
occur
viral
autoantigen
data
indic
efficaci
treg
induct
viru
infect
depend
epitop
present
gener
virallyinduc
treg
poorer
abil
prevent
autoimmun
treg
induc
autoantigen
autoantigen
specif
treg
use
immunotherapi
act
bystand
suppressor
novel
mechanist
insight
present
discuss
innat
adapt
immun
requir
induct
cn
autoimmun
via
virusinduc
molecular
mimicri
share
amino
acid
mous
hepat
viru
papainlik
proteinas
mhv
share
amino
acid
plp
develop
earlyonset
demyelin
diseas
mediat
plp
specif
cell
rel
import
innat
immun
signal
diseas
induct
found
diseas
induc
mimic
deliv
genet
engin
tmev
immun
synthet
peptid
mimic
cfa
prolin
secondari
mhc
class
ii
contact
residu
requir
effect
crossreact
addit
nativ
mhv
sequenc
increas
abil
crossactiv
plp
specif
autoreact
cell
substitut
prolin
hi
mimic
peptid
opposit
effect
earli
onset
demyelin
diseas
plp
specif
crossreact
respons
also
induc
infect
virus
engin
express
residu
entir
encompass
h
influenza
mhv
epitop
indic
mimic
capabl
process
endogen
flank
residu
result
thu
describ
structur
requir
autoreact
cell
activ
potenti
plp
mimic
peptid
provid
support
infectioninduc
molecular
mimicri
pathogenesi
autoimmun
diseas
innat
immun
mechan
promot
develop
effector
regulatori
lineag
eae
experiment
autoimmun
encephalomyel
previous
shown
viral
infect
provok
autoimmun
interact
innat
adapt
immun
respons
epitop
express
crossreact
self
antigen
trigger
expans
autoreact
cell
consequ
autoimmun
diseas
second
set
interact
innat
immun
system
also
play
essenti
role
effect
expans
pathogen
cell
summar
recent
experiment
analysi
interact
virus
innat
immun
system
regul
develop
autoimmun
diseas
eae
experiment
autoimmun
encephalomyel
find
suggest
express
innat
mediat
osteopontin
opn
dendrit
cell
subset
regul
treg
develop
may
play
key
role
develop
eae
molecular
mimicri
autoimmun
infect
mw
cunningham
c
j
cox
e
swedo
b
ca
kirvan
univers
oklahoma
health
scienc
center
oklahoma
citi
ok
usa
b
nation
institut
mental
health
bethesda
md
usa
molecular
mimicri
central
theme
autoimmun
sequela
follow
group
streptococc
infect
human
immun
respons
group
streptococc
bacterium
direct
host
tissu
lead
major
manifest
rheumat
fever
includ
rheumat
heart
diseas
sydenham
chorea
sydenham
chorea
movement
disord
major
neurolog
manifest
acut
rheumat
fever
human
monoclon
antibodi
deriv
sydenham
chorea
use
investig
molecular
mechan
immun
pathogenesi
human
chorea
monoclon
antibodi
demonstr
specif
streptococc
membran
group
streptococc
carbohydr
epitop
nacetylbetadglucosamin
well
brain
antigen
lysogangliosid
surfac
neuron
cell
cultur
monoclon
autoantibodi
mab
acut
sera
igg
cerebrospin
fluid
igg
recogn
lysogangliosid
intracellular
protein
tubulin
identifi
kd
protein
n
termin
sequenc
mreivhlq
nucleotid
sequenc
analysi
vh
vl
gene
chorea
mab
reveal
sequenc
homolog
v
gene
encod
antitubulin
antibodi
nucleotid
sequenc
reactiv
chorea
mab
distinctli
differ
mab
deriv
rheumat
heart
diseas
reactiv
mab
caudat
putamen
tissu
block
lysogangliosid
mix
neuron
cell
chorea
mab
acut
chorea
serum
igg
csf
igg
demonstr
antibodymedi
cell
signal
neuron
cell
activ
calciumcalmodulin
depend
protein
kinas
ii
activ
tritiat
dopamin
releas
summari
data
suggest
mimicri
antibodymedi
cell
signal
mechan
brain
promot
dopamin
releas
chorea
human
effect
stress
immun
function
good
bad
beauti
stanford
univers
school
medicin
stanford
california
usa
stress
known
suppress
immun
increas
suscept
infect
cancer
paradox
stress
exacerb
autoimmun
diseas
like
multipl
sclerosi
suggest
stress
may
also
enhanc
immun
respons
therefor
import
elucid
condit
mechan
mediat
bidirect
effect
stress
immun
function
shown
acut
stress
experienc
primari
antigen
exposur
increas
memori
cell
format
induc
longlast
increas
immun
intern
immunolog
american
j
physiolog
acut
stress
experienc
antigen
reexposur
enhanc
secondari
immun
respons
j
immunolog
stressinduc
chang
leukocyt
distribut
pna
epinephrin
corticosteron
pna
system
mediat
gammainterferon
one
local
mediat
pna
immunoenhanc
contrast
chronic
stress
immunosuppress
bbi
exampl
chronic
stress
increas
suscept
skin
cancer
suppress
type
cytokin
protect
cell
increas
suppressor
cell
number
j
nation
cancer
institut
suggest
adapt
function
stress
respons
promot
surviv
ie
stress
hormon
prepar
cardiovascular
musculoskelet
immun
system
oncom
challeng
eg
attack
detect
brain
howev
stress
exacerb
diseas
immunoenhanc
direct
innocu
self
antigen
immunosuppress
dysregul
occur
chronic
stress
view
ubiquit
natur
stress
signific
immunoprotect
immunopatholog
effect
import
elucid
mechan
mediat
stressimmun
interact
meaning
translat
find
bench
bedsid
support
dana
foundat
prenat
influenc
develop
immun
cl
coe
g
r
lubach
harlow
center
biolog
psycholog
univers
wisconsin
madison
wi
usa
background
prenat
earli
rear
environ
play
critic
role
initi
normal
ontogeni
consequ
matern
disturb
affect
matur
trajectori
fetu
chronic
affect
function
postpartum
like
brain
immatur
immun
system
design
learn
environ
includ
mani
aspect
matern
care
method
pregnanc
condit
rhesu
monkey
manipul
includ
psycholog
disturb
gravid
femal
administr
dexamethason
viral
infect
impact
infant
behavior
immun
brain
develop
assess
result
matern
stress
antenat
corticosteroid
influenza
exposur
significantli
affect
neurolog
develop
offspr
evinc
immatur
neuromotor
reflex
birth
greater
emotion
first
year
life
smaller
hippocampu
juvenil
smaller
hippocamp
size
associ
lower
neurogenesi
alter
pituitaryadren
activ
immun
alter
also
evid
includ
reduc
capac
neonat
lymphocyt
recogn
self
antigen
decreas
prolif
respons
lower
cytokin
product
cultur
cell
sever
mediat
pathway
identifi
includ
predisposit
iron
defici
anemia
fastgrow
infant
addit
prenat
stress
infant
establish
differ
profil
gut
microbiota
lower
level
protect
lactobacilli
bifidobacteria
conclus
advers
event
fetal
life
affect
health
postpartum
impact
brain
immun
system
vulner
point
chang
regulatori
set
point
addit
matern
cortisol
disturb
micronutri
transmiss
establish
abnorm
profil
gut
bacteria
identifi
import
factor
mechan
interferoninduc
depress
involv
hippocamp
neurogenesi
kanba
n
kaneko
b
k
kudo
c
k
takemoto
h
wati
depart
neuropsychiatri
kyushu
univers
fukuoka
japan
b
keio
univers
c
tokyo
univers
yamanashi
univers
therapeut
use
human
interferonalpha
known
caus
variou
neuropsychiatr
side
effect
particular
depress
occur
patient
frequent
interrupt
treatment
treat
anim
also
show
depressionlik
behavior
howev
mechan
underli
depress
caus
remain
defin
recent
decreas
adult
hippocamp
neurogenesi
reveal
possibl
neuropatholog
mechan
depress
neurogenesi
known
regul
variou
cytokin
therefor
investig
effect
subchron
treatment
iukgday
neurogenesi
adult
rat
dentat
gyru
dg
dose
correspond
clinic
dose
shown
induc
depress
behavior
rodent
without
reduc
voluntari
activ
immedi
oneweek
treatment
brdulabel
prolifer
cell
decreas
dg
detect
effect
cell
differenti
matur
granul
cell
three
week
treatment
treatment
major
proinflammatori
cytokin
increas
hippocampu
coadministr
receptor
antagonist
complet
block
suppress
cell
prolifer
dg
result
demonstr
suppress
cell
prolifer
cell
differenti
dg
play
essenti
role
suppress
decreas
cell
prolifer
caus
may
partli
respons
induc
depress
stress
immun
cancer
incid
noriyuki
kawamura
toshio
ishikawa
norito
kawakami
b
nation
center
neurolog
psychiatri
japan
b
tokyo
univers
japan
chronic
stressor
depress
symptom
associ
suppress
cellular
humor
immun
recent
low
nk
cell
activ
shown
associ
increas
cancer
risk
addit
report
critic
life
event
depress
symptom
risk
factor
cancer
incid
thu
one
hypothes
stressor
andor
stress
symptom
one
major
risk
factor
via
stressinduc
immunosuppress
start
epidemiolog
cohort
studi
order
elucid
relationship
stress
immun
cancer
follow
approv
ethic
aspect
studi
institut
review
board
administ
questionnair
worker
age
year
old
work
compani
manufactur
motor
vehicl
part
collect
blood
sampl
respond
gave
written
inform
consent
inform
questionnair
includ
gender
birth
date
lifestyl
habit
marit
statu
educ
famili
histori
cancer
past
current
histori
diseas
job
stress
baselin
measur
lymphocyt
subpopul
particip
wherea
cytokin
nk
cytotox
assay
particip
randomli
select
total
subject
accord
followup
data
found
depress
symptom
associ
increas
cancer
incid
lower
nk
cell
activ
lower
cytokin
product
indic
relev
hypothesi
loss
axon
na
k
atpas
chronic
lesion
multipl
sclerosi
christin
fowler
elizabeth
ayoung
graham
kidd
ansi
chang
bruce
trapp
depart
neurosci
cleveland
clinic
cleveland
oh
usa
neurodegener
major
caus
perman
neurolog
disabl
individu
demyelin
diseas
multipl
sclerosi
continu
irrevers
neurolog
declin
occur
latter
stage
ms
thought
result
degener
chronic
demyelin
axon
molecular
mechan
respons
degener
dysfunct
chronic
demyelin
axon
poorli
understood
one
propos
mechan
involv
dysfunct
na
k
atpas
essenti
nerv
transmiss
studi
determin
distribut
na
k
atpas
subunit
normal
human
white
matter
demyelin
lesion
multipl
sclerosi
na
k
atpas
subunit
detect
internod
axolemma
absent
nodal
axolemma
myelin
fiber
adult
human
brain
follow
demyelin
three
subunit
initi
detect
demyelin
axolemma
contract
demyelin
axon
chronic
inact
lesion
multipl
sclerosi
contain
littl
na
k
atpas
immunoreact
result
chronic
demyelin
axon
exchang
axoplasm
na
extracellular
k
axolemma
remain
depolar
state
incap
nerv
transmiss
propos
loss
axon
na
k
atpas
major
contributor
axon
degener
continu
neurolog
declin
multipl
sclerosi
patient
oligodendrocyt
schwann
cell
support
axon
function
surviv
independ
role
myelin
implic
multipl
sclerosi
oligodendrocyt
schwann
cell
well
known
common
function
facilit
rapid
impuls
propag
nervou
system
enwrap
axon
myelin
experiment
genet
data
suggest
addit
function
ensheath
glia
may
even
preced
myelin
evolutionari
term
relev
diseas
previous
shown
null
mutat
two
glial
gene
impair
function
myelin
cn
caus
progress
axon
degener
absenc
inflamm
griffith
et
al
scienc
lappesiefk
et
al
nat
genet
axon
loss
preced
swell
slow
retrograd
transport
edgar
et
al
jcb
underli
caus
understood
recent
proteom
analysi
myelin
membran
purifi
brain
plp
null
mutant
reveal
virtual
absenc
nad
depend
regulatori
enzym
jansen
et
al
unpublish
suggest
oligodendrocyt
function
coupl
energi
state
white
matter
support
find
extens
axon
loss
demyelin
condit
mous
mutant
lack
function
peroxisom
known
role
fatti
acid
surprisingli
oligodendrocytespecif
loss
share
mani
patholog
featur
human
xlink
ald
includ
invas
band
tcell
brain
kassmann
et
al
unpublish
novel
mous
mutant
prove
experiment
glial
peroxisom
import
axon
mainten
primari
oligodendrocyt
defect
suffici
caus
secondari
inflammatori
respons
find
relev
etiolog
multipl
sclerosi
mechan
promot
axon
regener
vivo
mari
filbin
biolog
depart
hunter
colleg
park
avenu
new
york
ny
usa
one
major
impedi
axon
regener
injuri
inhibitor
myelin
three
myelin
inhibitor
identifi
nogoa
mag
omgp
one
approach
overcom
inhibitor
encourag
regener
chang
intrins
state
axon
longer
recogn
molecul
inhibitori
shown
neuron
camp
level
elev
either
artifici
analogu
db
camp
prime
neuron
varieti
neurotrophin
ngf
bdnf
exposur
inhibitor
mag
myelin
gener
longer
inhibit
axon
growth
furthermor
also
shown
longrecogn
abil
spinal
dorsal
column
axon
regener
peripher
branch
neuron
lesion
beforehand
consequ
transient
increas
endogen
camp
level
drg
cell
bodi
importantli
inject
db
camp
directli
drg
absenc
condit
lesion
suffici
induc
regener
subsequ
lesion
dorsal
column
axon
camp
effect
transcript
depend
identifi
differ
gene
upregul
respons
either
elev
camp
condit
lesion
protein
block
inhibit
myelin
current
test
abil
promot
regener
vivo
cambridg
centr
brain
repair
univers
cambridg
cambridg
oe
uk
remyelin
process
new
myelin
sheath
restor
demyelin
axon
repres
one
compel
exampl
adult
multipot
progenitor
cell
contribut
regener
injur
cn
process
occur
remark
effici
clinic
diseas
multipl
sclerosi
experiment
model
reveal
impress
abil
adult
cn
repair
howev
inconsist
remyelin
multipl
sclerosi
loss
axon
integr
result
failur
make
enhanc
remyelin
import
therapeut
object
identifi
potenti
target
depend
detail
understand
cellular
molecular
mechan
remyelin
talk
review
natur
cell
cell
respond
demyelin
gener
new
oligodendrocyt
identifi
current
area
uncertainti
address
role
adult
cn
stem
progenitor
cell
intrins
factor
regul
precursor
differenti
environ
favour
remyelin
gener
introduc
concept
matrix
signal
event
critic
success
complet
remyelin
genet
neuroimmunolog
disord
olsson
georg
eber
b
neuroimmunolog
unit
karolinska
hospit
stockholm
sweden
b
univers
oxford
uk
solid
evid
role
gene
regul
ms
deciph
may
allow
definit
mechan
central
diseas
therebi
precis
select
therapi
mhchla
complex
well
establish
risk
gene
region
studi
experiment
autoimmun
encephalomyel
eae
shown
allel
specif
diseas
protect
promot
action
class
class
ii
gene
possibl
convey
critic
peptidemhc
molecul
interact
similar
data
accumul
human
ms
well
linkag
analys
fail
show
nonhla
region
paradigm
gener
use
justifi
genom
search
may
incorrect
effect
individu
locu
would
small
inde
exampl
discret
nonmhc
gene
suggest
proven
influenc
display
odd
ratio
order
pkrca
mhciita
interest
whole
genom
snp
type
associ
analysi
larg
casecontrol
materi
assur
approach
fruit
gene
map
eae
may
reveal
gene
andor
mechan
share
speci
option
experiment
studi
function
collect
around
quatit
trait
loci
qtl
describ
differ
rodent
cross
upon
fine
dissect
often
resolv
two
five
subqtl
show
linkag
peak
mostli
depend
one
gene
extrapol
number
gene
potenti
role
ms
approach
hundr
experiment
qtl
fine
dissect
albeit
cumbersom
definit
diseas
relev
variant
gene
result
first
posit
gene
start
appear
literatur
western
countri
frequenc
case
opticospin
os
multipl
sclerosi
ms
ms
case
lack
oligoclon
immunoglobulin
g
band
ocb
cerebrospin
fluid
low
databas
patient
ms
possibl
ms
identifi
patient
ocbneg
ms
patient
osm
osm
defin
broadli
clinic
evid
involv
optic
nerv
brainstem
spinal
cord
without
clinic
radiolog
evid
diseas
cerebrum
cerebellum
carriag
rate
hla
class
ii
allel
fring
phenotyp
compar
rate
clinic
paraclin
typic
ms
hla
genotyp
perform
subset
patient
well
healthi
control
carriag
associ
ocbneg
ms
odd
ratio
confid
interv
ci
highresolut
genotyp
uncov
highli
signific
riskconf
associ
allel
ocbneg
ms
ci
frequenc
slightli
yet
nonsignificantli
higher
osm
convent
ms
japan
sardinia
also
common
ms
patient
without
ocb
patient
ocb
yet
japan
elev
ocbneg
ms
conclus
sweden
fring
phenotyp
osm
uniqu
associ
allel
ocbneg
ms
howev
appear
immunogenet
distinct
ocbposit
ms
multipl
sclerosi
ms
chronic
inflammatori
diseas
cn
complex
diseas
ms
like
result
problem
network
interact
sever
gene
environment
factor
consist
locu
observ
popul
numer
genom
screen
also
provid
evid
ms
locu
sixtythre
finnish
ms
famili
ascertain
identifi
suscept
gene
within
previous
establish
region
flank
segment
duplic
complex
genom
structur
may
predispos
copynumb
structur
variat
initi
associ
implic
prkca
analyz
finnish
canadian
ms
famili
util
dens
snp
set
origin
prkca
associ
replic
independ
finnish
ms
famili
p
flank
snp
show
associ
canadian
popul
p
snp
haplotyp
analysi
reveal
two
allel
variant
prkca
overrepres
finnish
canadian
ms
case
odd
ratio
analysi
ms
famili
sweden
denmark
norway
suggest
role
finnish
risk
haplotyp
ms
suscept
also
scandinavian
popul
transcript
level
prkca
correl
copi
number
risk
allel
finnish
ceph
individu
european
origin
initi
express
analysi
result
impli
involv
prkca
etiolog
ms
moreov
function
prkca
signal
transduct
pathway
alter
bloodbrain
barrier
permeabl
support
role
chronic
inflamm
cn
myelin
destruct
protect
influenc
multipl
sclerosi
hlaa
implic
two
step
model
pathogenesi
multipl
sclerosi
ms
tradit
thought
tcell
mediat
diseas
associ
howev
twostep
model
recent
propos
fries
implic
cell
begin
ms
tcell
chronic
phase
diseas
model
suggest
hlaclass
may
also
contribut
ms
alreadi
describ
hlaa
hlaa
aim
studi
investig
role
hlaa
hlaa
allel
diseas
suscept
sever
portugues
ms
popul
studi
unrel
patient
clinic
definit
ms
accord
mcdonald
criteria
attend
outpati
neurolog
clinic
hgsa
healthi
control
north
portug
evalu
diseas
sever
patient
divid
group
benign
ms
edss
year
onset
nonbenign
ms
edss
stage
aggress
ms
edss
year
onset
hlaa
frequenc
similar
patient
control
hlaa
neg
associ
ms
vs
p
differ
even
higher
neg
individu
vs
p
diseas
sever
consid
associ
observ
benign
group
vs
p
result
accord
fogdellhahn
establish
hlaa
allel
protect
genet
marker
ms
portugues
popul
observ
support
fries
model
ms
highlight
import
hlaclass
tcell
function
role
diseas
outcom
work
support
serono
portug
chromosom
mediat
resist
experiment
autoimmun
encephalomyel
type
diabet
suscept
region
locat
chromosom
introgress
dna
strain
onto
nod
background
protect
also
experiment
autoimmun
encephalomyel
eae
studi
region
diseas
suscept
congen
mice
entir
locu
subcongen
line
defin
portion
region
gener
previou
studi
show
proxim
contain
ico
enhanc
eae
sever
regul
ico
express
product
compar
nodderiv
cell
cell
eaeresist
congen
mice
produc
lower
amount
higher
amount
cytokin
cytokin
alter
may
respons
diseas
protect
eaeresist
congen
mice
genet
element
present
region
diseas
resist
character
ident
gene
caus
eae
resist
requir
develop
addit
congen
strain
reduc
size
subregion
therebi
number
candid
gene
one
encod
cell
inhibitori
molecul
whether
polymorph
impart
genet
resist
affect
differenti
studi
evid
ychromosom
influenc
experiment
allerg
encephalomyel
femal
mice
experiment
allerg
encephalomyel
eae
autoimmun
model
multipl
sclerosi
complex
diseas
influenc
genet
intrins
environment
factor
studi
question
whether
parentoforigin
effect
influenc
eae
use
reciproc
intercross
progeni
gener
eae
suscept
sjlj
eae
resist
sgmcdj
b
mice
eae
suscept
sever
found
differ
femal
bs
bs
intercross
mice
compar
femal
three
birth
cross
bs
sb
sb
sb
sb
bs
fact
trait
femal
mice
resembl
male
sibl
masculin
associ
transmiss
sjlj
ychromosom
increas
sex
ratio
relat
studi
use
ychromosom
substitut
strain
demonstr
ychromosom
influenc
eae
male
femal
mice
diseas
cours
mog
specif
immun
respons
femal
resembl
male
litterm
importantli
first
experiment
evid
demonstr
exist
ychromosom
polymorph
capabl
modifi
autoimmun
diseas
suscept
male
femal
develop
cn
chemokin
receptor
control
posit
oligodendrocyt
precursor
arrest
migrat
essenti
form
normal
cerebellar
cytoarchitectur
regul
prolifer
migrat
cerebellar
granul
cell
healthi
adult
brain
certain
chemokin
like
astrocyt
endotheli
cell
neuron
display
neuron
deriv
shed
regul
state
activ
microglia
product
chemokin
insid
cn
astrocyt
microglia
induc
autoimmun
inflamm
infect
also
neurotrauma
chemokin
product
stimul
via
cell
deriv
cytokin
via
innat
immun
role
chemokin
cn
infect
indic
observ
human
subject
lossoffunct
mutat
higher
risk
develop
enceph
infect
west
nile
viru
eae
model
ms
inflammatori
cytokin
also
homeostat
chemokin
involv
lesion
format
crucial
role
chemokin
neuroinflamm
provid
possibl
develop
novel
chemokinedirect
therapeut
strategi
chemokin
key
molecul
autoimmun
myasthenia
gravi
meraouna
g
cizeronclairac
r
le
pans
j
bismuth
f
truffault
c
tallaksen
berrihaknin
cnrsumr
ipsc
le
plessisrobinson
franc
sonia
berrih
ccmlupsudfr
depart
neurolog
ullev
univers
hospit
oslo
norway
myasthenia
gravi
mg
associ
ectop
germin
centr
thymu
thymectomi
glucocorticoid
main
treatment
induc
oper
risk
side
effect
respect
aim
studi
propos
new
therapi
effici
mg
hypothes
molecul
dysregul
mg
thymu
normal
glucocorticoid
may
play
key
role
thymic
pathogenesi
use
gene
chip
analysi
identifi
gene
compli
criteria
remark
b
cell
chemoattract
express
increas
thymu
sera
glucocorticoid
untreat
patient
decreas
respons
treatment
correl
clinic
improv
normal
b
cell
activ
chemoattract
thymic
extract
glucocorticoid
untreat
patient
effect
inhibit
antibodi
thymu
preferenti
produc
epitheli
cell
overproduc
epitheli
cell
mg
patient
altogeth
result
suggest
high
product
epitheli
cell
could
respons
germin
centr
format
mg
thymu
furthermor
show
gene
main
target
corticotherapi
thu
new
therapi
target
could
interest
mg
autoimmun
diseas
character
ectop
germin
centr
format
role
ligand
herp
simplex
viru
type
infect
investig
wild
type
wt
defici
defici
mice
infect
plaqu
form
unitscornea
assess
viru
titer
well
host
respons
infect
trigemin
ganglion
tg
brain
stem
bs
acut
infect
day
post
infect
pi
titer
recov
tg
bs
mice
log
higher
comparison
wt
mice
day
pi
likewis
signific
loss
thymocyt
mice
follow
infect
rel
two
group
correl
chang
corticosteron
level
rather
incid
detect
viru
within
thymu
bone
marrow
progenitor
cell
commit
notic
modifi
strong
chang
toward
myeloid
away
lymphoid
progenitor
evalu
cell
infiltr
tg
bs
infect
mice
mice
possess
cell
tg
compar
wt
mice
day
pi
contrast
mice
possess
cell
bs
compar
wt
mice
day
pi
absolut
number
nk
cell
reduc
tg
bs
mice
compar
wt
mice
collect
result
indic
dispar
rel
clinic
signific
neurotrop
viru
infect
differenti
effect
decoy
chemokin
gene
therapi
acut
biphas
chronic
autoimmun
encephalomyel
implic
pathomechan
lesion
format
ilkwon
park
kuniko
kohyama
mie
nakajima
yoh
matsumoto
depart
molecular
neuropatholog
tokyo
metropolitan
institut
neurosci
tokyo
japan
multipl
sclerosi
anim
model
experiment
autoimmun
encephalomyel
eae
exhibit
sever
clinic
subtyp
relapsingremit
secondari
progress
form
although
clinic
sign
similar
among
diseas
subtyp
becom
evid
lesion
format
central
nervou
system
cn
may
take
place
differ
mechan
present
studi
induc
three
differ
type
eae
ie
acut
biphas
chronic
eae
rat
examin
effect
decoy
chemokin
gene
therapi
inhibit
migrat
macrophag
interestingli
demonstr
clinic
cours
acut
eae
affect
wherea
chronic
eae
complet
suppress
treatment
furthermor
relaps
first
attack
biphas
eae
inhibit
gene
administr
histopatholog
examin
reveal
number
infiltr
macrophag
reduc
stage
three
type
eae
real
time
pcr
analysi
show
level
cytokin
chemokin
mrna
parallel
macrophag
behavior
cn
find
suggest
acut
eae
first
attack
biphas
eae
antimacrophag
therapi
almost
ineffect
pathogen
cell
play
critic
role
contrast
relaps
biphas
eae
chronic
eae
thought
produc
mainli
macrophag
thu
mechan
lesion
format
uniform
immunotherapi
perform
basi
inform
pathomechan
lesion
format
autoimmun
diseas
modul
innat
rhythm
networkdriven
gabamedi
giant
depolar
potenti
develop
nervou
system
kasiyanov
htamamura
n
fujii
h
xiong
univers
nebraska
medic
center
omaha
usa
tokyo
medic
dental
univers
tokyo
japan
kyoto
univers
kyoto
japan
chemoattract
stromal
cellderiv
alpha
receptor
cxc
chemokin
receptor
play
import
role
format
hippocamp
circuitri
synapt
plastic
addit
involv
brain
inflammatori
process
understand
role
might
play
hippocamp
circuitri
develop
studi
effect
natur
ligand
receptor
networkdriven
gabamedi
giant
depolar
potenti
gdp
immatur
rat
hippocamp
neuron
use
wholecel
patch
clamp
techniqu
demonstr
downregul
gdp
fire
frequenc
neuron
without
signific
chang
neuron
passiv
membran
properti
suggest
site
action
interneuron
andor
glial
cell
instead
record
neuron
per
se
downregul
gdp
fire
block
receptor
antagonist
applic
alon
enhanc
gdp
fire
frequenc
indic
involv
endogen
modul
gdp
activ
taken
togeth
result
show
exogen
endogen
modul
gdp
fire
via
receptor
develop
hippocampu
gdp
innat
rhythm
networkdriven
gabamedi
synapt
event
modul
gdp
may
contribut
neuron
develop
earli
life
support
nih
grant
role
aminoglycosid
ototox
recent
studi
demonstr
accumul
macrophag
cochlea
follow
acoust
trauma
druginduc
ototox
distinct
clinicallyrelev
caus
sensorineur
hear
loss
unknown
whether
inflammatori
cell
play
role
ototox
injuri
studi
design
investig
role
play
hear
loss
hair
cell
death
aminoglycosid
exposur
mice
age
week
expos
mgkg
kanamycin
intraperiton
ip
deliv
twice
daili
day
hear
threshold
record
day
final
dose
kanamycin
age
week
cochlea
harvest
histolog
analysi
hear
threshold
mice
profoundli
elev
compar
either
wild
type
mice
addit
hair
cell
damag
greatest
mice
compar
wild
type
heterozyg
litterm
neither
hair
cell
number
hear
threshold
abnorm
control
mice
expos
aminoglycosid
data
indic
protect
role
aminoglycosid
ototox
possibl
act
cochlear
macrophag
reduc
hair
cell
death
lessen
hear
impair
last
year
dramat
reevalu
type
cellular
immun
respons
occur
within
central
nervou
system
cn
better
part
last
centuri
cn
believ
immunolog
inert
immunolog
separ
peripher
immun
system
view
primarili
tissu
postmitot
cell
highli
vulner
onslaught
activ
immun
cell
immun
cell
infiltr
cn
view
element
protect
cn
immunemedi
harm
presenc
intact
bloodbrain
barrier
bbb
absenc
fulli
immunolog
popul
compet
tissu
macrophag
current
data
indic
cn
immunolog
compet
activ
interact
peripher
immun
system
inflamm
also
recogn
promin
featur
mani
classic
neurodegen
disord
even
absenc
substanti
infiltr
peripher
immun
cell
furthermor
stark
contrast
older
view
neuroinflamm
realiz
neuroprotect
well
neurotox
aspect
discuss
new
class
receptor
trem
tlt
potenti
trigger
modifi
glial
inflammatori
respons
identif
solubl
endogen
agonist
tolllik
receptor
human
astrocyt
genomescal
function
screen
glial
cell
deriv
protein
human
astrocyt
express
limit
repertoir
tolllik
receptor
tlr
famili
member
includ
express
cell
surfac
recent
data
indic
tlr
astrocyt
play
role
host
defens
also
tissu
repair
respons
prompt
us
examin
possibl
endogen
tlr
agonist
could
express
human
central
nervou
system
regul
appar
dual
astrocyt
function
trauma
inflamm
develop
high
throughput
genomescal
function
screen
method
identifi
endogen
tlr
agonist
method
base
pool
transfect
brainderiv
gene
eukaryot
cell
evalu
function
effect
translat
protein
primari
human
astrocyt
releas
use
readout
sinc
cytokin
highli
produc
astrocyt
upon
activ
via
tlr
use
strategi
identifi
altern
splice
variant
solubl
use
panel
tlr
transfect
cell
found
solubl
induc
releas
transfect
cell
transfect
cell
data
indic
apart
wellknown
abil
act
coreceptor
tlrdepend
signal
peptidoglycan
lp
solubl
also
act
direct
agonist
current
explor
function
effect
solubl
human
primari
astrocyt
genomescal
screen
method
use
identifi
protein
base
function
properti
previous
report
tolllik
receptor
tlr
ligat
tailor
activ
profil
human
microglia
particular
induc
product
ifnbeta
function
consequ
adapt
immun
respons
downstream
tlrmediat
polar
remain
undefin
human
cell
compar
capac
adult
human
microglia
activ
vitro
ligand
regul
cell
respons
specif
test
abil
ligand
poli
inosin
poli
cytidyl
acid
lipopolysaccharid
induc
matur
microglia
term
mhc
costimulatori
molecul
express
use
flow
cytometri
prolifer
interferongamma
secret
allogen
lymphocyt
determin
follow
cultur
microglia
preactiv
via
h
found
tlr
signal
increas
microgli
mhc
class
ii
surfac
express
downstream
tlrmediat
activ
adult
microglia
result
signific
increas
overal
cell
prolifer
ligat
microglia
led
signific
boost
secret
cell
tlrsignal
thu
lead
matur
human
microglia
antigen
present
cell
activ
specif
bridg
innat
adapt
immun
respons
drive
cell
polar
critic
role
tolllik
receptor
nerv
injuryinduc
spinal
cord
glial
cell
activ
pain
hypersensit
activ
spinal
cord
glial
cell
implic
develop
neuropath
pain
upon
peripher
nerv
injuri
molecular
entiti
activ
glial
cell
howev
elucid
address
lack
inform
primari
spinal
cord
glial
cell
stimul
variou
molecul
put
releas
upon
peripher
nerv
injuri
spinal
cord
dorsal
horn
vitro
data
indic
spinal
cord
glial
cell
rel
unrespons
stimul
glutam
substanc
p
atp
lysophosphatid
acid
lpa
fractalkin
interestingli
necrot
neuron
cell
extract
nnce
howev
induc
signific
upregul
ino
gene
implic
develop
neuropath
pain
studi
use
primari
glial
cell
isol
knockout
mice
indic
nnce
activ
glial
cell
via
addit
behavior
studi
use
knockout
mice
demonstr
express
requir
induct
mechan
allodynia
thermal
hyperalgesia
due
spinal
nerv
axotomi
nerv
injuryinduc
spinal
cord
microglia
astrocyt
activ
reduc
knockout
mice
similarli
nerv
injuryinduc
proinflammatori
gene
express
spinal
cord
also
reduc
knockout
mice
data
demonstr
play
critic
role
nerv
injuryinduc
spinal
cord
glial
cell
activ
subsequ
pain
hypersensit
addit
data
impli
endogen
agonist
releas
damag
sensori
neuron
may
activ
spinal
cord
glial
cell
via
therebi
induc
neuropath
pain
microgli
activ
correl
decreas
express
cerebr
cortex
infect
patient
neuroprotect
role
microglia
aid
encephalopathi
izumo
xing
hq
kuboda
r
hayakawa
h
b
gelpi
e
b
budka
h
b
center
chronic
viral
diseas
kagoshima
univers
kagoshima
japan
b
institut
neurolog
vienna
univers
vienna
austria
pathogenesi
aid
encephalopathi
discuss
correl
microgli
activ
infiltr
macrophag
glutam
primarili
express
astrocyt
keep
extracellular
glutam
concentr
low
brain
take
glutam
prevent
neuron
excitotox
cell
death
gray
gra
report
microglia
brain
macrophag
express
neuroprotect
role
aid
encephalopathi
order
clarifi
precis
role
microglia
aid
encephalopathi
examin
autopsi
brain
twenti
patient
infect
immunohistochemistri
demonstr
decreas
express
diffus
activ
microglia
express
activ
microglia
frontal
cortex
express
detect
glial
nodul
diffus
activ
microglia
cortic
chang
neither
correl
sever
hiv
enceph
presenc
cell
quantit
analysi
express
microgli
activ
demonstr
number
activ
microglia
increas
case
area
express
declin
case
signific
neg
correl
area
express
number
activ
microglia
p
among
case
decreas
express
data
indic
activ
microglia
occur
accord
reduct
express
astrocyt
cerebr
cortex
aid
patient
express
activ
microglia
suggest
compensatori
effect
prevent
neuron
glutam
neurotox
trkb
physiolog
express
astrocyt
upregul
multipl
sclerosi
lesion
neurotrophin
play
fundament
role
regul
prolifer
differenti
neuron
exert
action
receptor
differ
trk
receptor
littl
known
potenti
effect
glia
cell
publish
data
indic
astrocyt
express
neurotrophin
receptor
ntr
mainli
activ
neoplast
transform
aim
present
studi
analys
ntr
profil
human
astrocyt
vitro
situ
normal
multipl
sclerosi
ms
brain
sampl
molecular
analys
show
rest
foetal
astrocyt
transcrib
mrna
trkb
trkc
trka
trkb
trkc
isoform
analys
real
time
pcr
mainli
truncat
isoform
detect
rest
astrocyt
fac
analysi
demonstr
protein
express
trkb
trkc
exposur
cell
ifngamma
enhanc
level
mrna
protein
level
wherea
trkb
trkc
unchang
immunofluoresc
show
membran
stain
three
receptor
furthermor
immunohistochem
analysi
show
constitut
express
trkb
situ
astrocyt
normal
brain
specimen
enhanc
level
within
ms
lesion
togeth
data
suggest
role
neurotrophin
regul
glia
cell
reactiv
workshop
gene
therapi
immunotherapi
brain
tumor
abstract
gene
therapi
immunotherapi
brain
tumor
kyogo
itoh
b
joseph
c
glorioso
b
immunolog
kurum
univers
school
medicin
japan
b
molecular
genet
biochemistri
univers
pittsburgh
medic
center
usa
develop
new
treatment
modal
need
improv
prognosi
brain
tumor
recent
progress
basic
clinic
research
field
neuron
oncolog
suggest
gene
therapi
immunotherapi
could
promis
featur
new
treatment
modal
workshop
take
five
distinguish
present
relat
gene
therapi
immunotherapi
brain
tumor
first
present
report
new
find
gliomainfiltr
dendrit
cell
second
one
show
invas
promot
effect
microglia
glioblastoma
cell
suppress
cyclosporin
third
paper
present
find
support
paradigm
express
low
grade
glioma
inactiv
tumorinfiltr
cell
turn
result
promot
tumor
cell
prolifer
invas
use
cell
clone
establish
glioblastoma
tissu
last
two
paper
report
new
data
relat
gene
therapi
fourth
paper
show
new
find
hsv
vectormedi
codeliveri
mutant
ikba
hsv
thymidin
kinas
glioblastoma
last
present
indic
suicid
gene
therapi
use
hightit
retroviru
vector
cytotox
cancer
stem
cell
deriv
malign
glioma
hope
activ
discuss
five
distinguish
present
better
understand
potenti
develop
clinic
effect
treatment
modal
glioblastoma
multiform
hsv
gene
vector
treatment
chronic
pain
cancer
herp
simplex
viru
promis
vehicl
deliveri
gene
nervou
system
laboratori
exploit
replic
defect
vector
treatment
peripher
nerv
diseas
includ
chronic
pain
peripher
neuropathi
treatment
central
nervou
system
diseas
includ
cancer
parkinson
diseas
experi
present
describ
current
vector
engin
applic
specif
studi
relat
treatment
chronic
pain
use
enkephalin
gene
vector
addit
given
interest
use
oncolyt
hsv
vector
treatment
cancer
describ
new
vector
reli
mutat
affect
viru
attenu
vector
highli
improv
profil
safeti
efficaci
brain
tumor
therapi
object
although
mani
mechan
respons
aggress
behavior
glioblastoma
role
system
immunsuppress
tumor
appear
critic
compon
pathogenesi
dendrit
cell
dc
play
critic
role
orchestr
antitumor
immun
previou
work
implic
defect
andor
impair
maturationmigr
dc
critic
defect
immun
respons
cancer
aim
studi
identifi
character
glioma
infiltr
dc
immunohistochemistri
ihc
fac
function
assay
method
ihc
perform
glioma
use
dcspecif
antibodi
infiltr
mononuclear
cell
popul
deriv
six
tumor
evalu
threecolorfac
analysi
addit
stimulatori
capac
monocytederiv
dc
tumor
patient
compar
control
allogen
mlr
level
product
assess
elisa
result
dc
found
present
high
grade
glioma
low
number
mainli
immatur
state
origin
gliomaderiv
dc
mainli
myeloid
cell
stimulatori
capac
strongli
reduc
allogen
mlr
interestingli
capac
monocytederiv
dc
patient
also
reduc
albeit
statist
signific
control
conclus
taken
togeth
result
suggest
inhibit
dc
developmentfunct
repres
addit
mechan
glioma
escap
immun
recognit
invas
promot
effect
microglia
glioblastoma
cell
inhibit
cyclosporin
tumor
cell
seem
recruit
stromal
inflammatori
cell
tumor
site
transform
tumorsupport
cell
invas
glioma
cell
brain
tissu
hallmark
glioblastoma
contribut
failur
current
therapeut
treatment
activ
microglia
abund
brain
tumor
may
support
tumor
growth
invas
howev
defens
function
microgli
cell
glioma
compromis
tumor
eg
impair
surfac
express
mhc
class
ii
immunesuppress
microglia
may
still
display
tumorpromot
activ
found
cyclosporin
csa
affect
growth
glioma
cell
vitro
inhibit
signal
pathway
essenti
tumor
prolifer
invas
work
demonstr
migrat
egfptransfect
glioblastoma
cell
organotyp
brain
slice
significantli
inhibit
csa
inhibitori
effect
lost
glioblastoma
cell
inject
microgliadeplet
brain
slice
vitro
studi
demonstr
microgliaderiv
factor
increas
glioma
invas
matrigel
assay
associ
activ
signal
pathway
csa
abolish
invas
promot
effect
microglia
hand
gliomaderiv
solubl
factor
induc
morpholog
transform
microglia
ameboid
microglia
activ
mapk
signal
although
product
proinflammatori
factor
nitric
oxid
observ
found
csa
may
interfer
gliomaassoci
microglia
stimul
turn
rest
state
find
csa
may
impair
invas
growth
glioma
cell
clinic
relev
concentr
provid
novel
therapeut
strategi
pathway
human
glioma
pathogenesi
approxim
patient
die
year
unit
state
gbm
two
welldocu
aspect
human
malign
glioma
highli
invas
immun
direct
ineffect
hypothes
glioma
express
regul
aspect
glioma
pathogenesi
express
peripher
human
tumor
favor
clinic
prognosi
appear
limit
tumor
cell
metastasisinvas
thu
one
predict
glioma
express
limit
tumor
cell
prolifer
andor
invas
inde
found
sirnamedi
reduct
primari
gbm
cell
line
enhanc
tumor
cell
prolifer
moreov
cultur
cell
line
express
higher
level
highgrad
versu
lowgrad
glioma
reduc
tumor
cell
express
addit
quantit
rtpcr
analysi
level
express
gbm
tumor
cell
versu
reactiv
astrocyt
indic
gbm
tumor
cell
express
lower
level
situ
hand
recent
identifi
ligand
shown
kill
cell
end
clone
cell
infiltr
gbm
found
exposur
recombin
inhibit
secret
activ
cell
block
monoclon
antibodi
collect
data
suggest
paradigm
express
lowgrad
glioma
inactiv
infiltr
cell
increas
stage
malign
downmodul
glioma
promot
tumor
cell
prolifer
invas
combin
gene
therapi
glioblastoma
involv
herp
simplex
viru
hsv
vectormedi
codeliveri
mutant
hsv
thymidin
kinas
glioblastoma
improv
effect
hsv
thymidin
kinaseganciclovir
hsvtkgcv
suicid
gene
therapi
replic
defect
hsv
vector
express
hsvtk
mutant
form
inhibitor
develop
human
glioblastoma
cell
dimer
alreadi
transloc
nucleu
without
receptordepend
signal
follow
infect
nuclear
transloc
mg
cell
significantli
inhibit
activ
increas
compar
cell
cytotox
mg
cell
investig
colorimetr
mtt
assay
moi
infect
kill
cell
compar
kill
infect
presenc
gcv
number
increas
surviv
nude
mice
implant
brain
tumor
cell
markedli
prolong
intratumor
inject
gcv
administr
surviv
gcv
group
significantli
longer
p
wilcoxon
test
control
group
pb
pb
gcv
result
suggest
express
may
safe
enhanc
replicationdefect
hsvbase
suicid
gene
therapi
vitro
vivo
efficaci
suicid
gene
therapi
use
hightit
retroviru
vector
cancer
stem
cell
deriv
malign
glioma
yawata
k
c
park
toyonaga
chihara
n
masahira
k
ikenaka
b
k
shimizu
depart
neurosugeri
kochi
medic
school
nankoku
japan
b
divis
neurobiolog
bioinformat
nation
institut
physiolog
scienc
okazaki
japan
despit
mani
effort
develop
effect
therapi
outcom
malign
glioma
remain
poor
gene
therapi
diseas
use
retrovir
vector
attract
viru
infect
mitot
cell
establish
packag
cell
line
produc
hightit
retroviru
express
suicid
gene
hsvtk
concentr
viru
titer
high
cfuml
low
speed
centrifug
use
retrovir
vector
mous
glioma
model
cure
complet
administr
ganciclovir
gcv
recent
sever
investig
identifi
small
popul
cancer
stem
cell
brain
tumor
tissu
cell
line
cancer
stem
cell
form
sphere
maintain
selfrenew
capac
tumorigenec
multipl
drug
resist
exist
cancer
stem
cell
thought
caus
recurr
tumor
treatment
chemotherapi
radiotherapi
surgic
resect
therefor
investig
therapeut
efficaci
suicid
gene
therapi
cancer
stem
cell
deriv
glioma
cell
high
transduct
rate
gap
junction
mediat
bystand
effect
allow
kill
nontransduc
cell
enhanc
efficaci
suicid
gene
therapi
lower
effici
transduct
retroviru
vector
express
connexin
compon
gap
junction
observ
cancer
stem
cell
result
suggest
nontransduc
cancer
stem
cell
kill
via
bystand
effect
gain
insight
bystand
effect
cancer
stem
cell
current
perform
immunohistochemistri
studi
mous
glioma
model
studi
undertaken
speaker
laboratori
shown
distinct
popul
regulatori
cell
induc
inject
solubl
peptid
peptid
treatment
led
gener
regulatori
pit
reg
cell
anerg
fail
produc
respond
antigen
secret
cell
predominantli
anerg
state
revers
addit
vitro
pit
reg
cell
abl
suppress
prolifer
product
cell
vivo
suppress
abrog
neutralis
deplet
cell
affect
suppress
properti
pit
reg
cell
furthermor
pit
reg
cell
could
gener
mice
spontan
gener
regulatori
cell
result
suggest
natur
induc
regulatori
cell
fall
distinct
subset
distinct
recent
confirm
demonstr
pit
reg
cell
express
member
forkheadwing
helix
famili
transcript
factor
control
differenti
natur
reg
cell
recent
work
led
identif
novel
set
gene
upregul
cell
render
toler
peptid
therapi
gene
control
cell
divis
andor
cytokin
product
therebi
control
toler
clarif
mechan
control
antigenspecif
toler
lead
develop
safer
effect
vaccin
treatment
allerg
autoimmun
diseas
new
model
experiment
autoimmun
encephalomyel
eae
mediat
memori
cell
differenti
function
costimulatori
pathway
regul
autoreact
memori
cell
vivo
w
elyaman
p
vijay
k
kuchroo
moham
h
sayegh
b
samia
j
khouri
center
neurolog
diseas
brigham
women
hospit
boston
usa
b
transplant
center
brigham
women
hospit
children
hospit
boston
usa
limit
mani
experiment
model
autoimmun
diseas
focu
target
prevent
diseas
therapi
earli
diseas
trigger
cell
memori
cell
less
depend
posit
costimulatori
signal
cell
also
less
suscept
toler
induct
import
clinic
goal
develop
strategi
suppress
function
chronic
activ
memori
cell
develop
new
model
eae
induc
antigenspecif
memori
cell
gener
mice
immun
mog
day
prior
transfer
memori
cell
induc
sever
eae
effector
cell
clinic
patholog
cell
memori
cell
recipi
prolifer
respons
mog
secret
higher
level
compar
recipi
recent
gener
effector
cell
percentag
cell
affect
indic
differ
clinic
diseas
due
differenti
expans
regulatori
cell
effector
cellmedi
eae
suppress
aggrav
antiicosl
treatment
contrast
memori
cellmedi
diseas
suppress
icosl
blockad
effect
shift
cytokin
balanc
toward
increas
reduc
secret
observ
effector
cell
recipi
treatment
icosl
blockad
result
similar
shift
memori
cell
recipi
data
suggest
presenc
specif
mechan
diseas
mediat
memori
cell
indic
differenti
role
costimulatori
pathway
regul
effector
versu
memori
cell
differenti
regul
axe
might
account
discrep
suscept
toward
experiment
autoimmun
encephalomyel
albino
oxford
dark
agouti
rat
previous
shown
albino
oxford
ao
rat
resist
induct
experiment
autoimmun
encephalomyel
eae
studi
compar
product
cytokin
presum
role
pathogenesi
eae
name
interferon
interleukin
il
ao
rat
eae
suscept
dark
agouti
da
rat
end
drain
poplit
lymph
node
cell
dlnc
collect
day
postimmun
spinal
cord
homogen
carbonyl
iron
adjuv
cell
stimul
concanavalin
cona
specif
antigen
myelin
basic
protein
mbp
product
cytokin
measur
mrna
protein
level
use
rtpcr
elisa
respect
dlnc
da
rat
express
higher
level
mrna
produc
ao
rat
sinc
potent
induc
synthesi
respect
analyz
mrna
express
subunit
common
interestingli
express
similarli
cytokin
higher
da
anim
ao
rat
express
mrna
nevertheless
da
rat
made
protein
well
taken
togeth
data
suggest
differenti
regul
axe
particular
induct
phase
eae
could
respons
discrep
suscept
eae
two
strain
engag
requir
develop
autoimmun
gutcher
e
urich
prinz
b
b
becher
univers
hospit
zurich
zurich
switzerland
b
univers
germani
consid
vital
cofactor
togeth
polar
h
cell
h
cell
long
suspect
major
pathogen
cell
popul
autoimmun
diseas
rheumatoid
arthriti
multipl
sclerosi
howev
other
could
recent
firmli
establish
anim
model
ra
ms
diseas
promot
factor
h
polar
cell
prerequisit
diseas
develop
therefor
want
determin
role
anoth
h
cytokin
name
receptor
context
eae
line
find
found
mice
fulli
suscept
eae
induc
immun
mog
peptid
surprisingli
howev
discov
mice
defici
eaeresist
suggest
presenc
altern
ligand
encephalitogen
properti
could
establish
loss
lesion
accessori
leukocyt
lymphocyt
directli
demonstr
signal
promot
gener
cell
consid
major
pathogen
popul
eae
well
autoimmun
diseas
result
establish
h
develop
dispens
eae
pathogenesi
signal
yet
unidentifi
ligand
absolut
essenti
gener
encephalitogen
h
cell
antibodi
nativ
myelin
oligodendrocyt
glycoprotein
critic
sever
chronic
experiment
autoimmun
encephalomyel
demyelin
mice
marmoset
n
heijman
jagessar
p
smith
myelin
oligodendrocyt
glycoprotein
mog
power
encephalitogen
experiment
autoimmun
demyelin
howev
use
mog
peptid
recombin
protein
repres
part
protein
fail
address
possibl
pathogen
role
fulllength
myelinderiv
protein
express
posttransl
modif
immunis
central
nervou
system
cn
tissu
wildtyp
wt
mogdefici
mog
mice
demonstr
mog
myelin
necessari
develop
chronic
demyelin
experiment
autoimmun
encephalomyel
eae
mice
marmoset
sinc
myelin
wt
mice
induc
chronic
eae
mog
myelin
induc
mild
selflimit
monophas
diseas
follow
immunis
anim
develop
tcell
respons
recombin
mous
mog
rmmog
indic
mog
releas
myelin
antigen
lack
chronic
diseas
follow
immunis
mog
myelin
indic
respons
pathogen
antibodi
wt
mog
myelin
immunis
anim
recognis
rmmog
mog
transfect
fibroblast
cell
line
mog
peptid
anim
antibodi
myelin
basic
protein
oligodendrocyt
specif
protein
proteolipid
protein
galactocerebrosid
observ
correl
diseas
sever
data
indic
conform
form
mog
crucial
gener
pathogen
antibodi
glycosyl
mog
protein
requir
antibodi
recognit
data
reveal
immunis
posttransl
modifi
form
mog
myelin
promot
chronic
autoimmun
demyelin
neurolog
diseas
probabl
due
pathogen
antibodi
unmodifi
protein
rather
linear
epitop
cell
real
time
imag
autoreact
effector
cell
cn
lesion
autoimmun
encephalomyel
experiment
autoimmun
encephalomyel
eae
induc
brain
antigenspecif
cell
upon
transfer
healthi
recipi
cell
induc
massiv
cn
inflamm
sever
paralyt
diseas
use
twophoton
microscopi
visual
behavior
retrovir
label
mbpspecif
cell
cn
lewi
rat
differ
phase
clinic
eae
imag
intact
anim
acut
spinal
cord
slice
enabl
us
track
autoreact
effector
cell
mening
perivasular
area
well
deep
within
cn
parenchyma
report
two
major
find
effector
cell
redistribut
cours
eae
primari
clinic
phase
day
cell
transfer
effector
cell
restrict
perivascular
locat
begin
day
transfer
howev
spread
mening
penetr
deepli
cn
parenchyma
motil
behavior
profoundli
chang
cours
eae
cell
perivascular
cuff
move
predominantli
along
vessel
wall
cell
within
cn
parenchyma
move
seemingli
nondirect
cell
display
two
distinct
motil
pattern
motil
cell
rapidli
move
compact
white
matter
stationari
cell
attach
move
around
fix
anchor
point
ratio
two
fraction
chang
significantli
time
wherea
earli
eae
number
motil
cell
exceed
one
stationari
cell
ratio
becam
invert
late
eae
last
decad
wit
unpreced
progress
therapi
multipl
sclerosi
ms
despit
obviou
benefit
clinic
outcom
new
therapi
extens
test
autoimmun
concept
ms
although
evid
autoimmun
mechan
ms
larg
indirect
proof
achiev
demonstr
therapi
base
correct
immun
deviat
abl
restor
neurolog
function
drug
current
use
ms
address
aim
interferon
beta
glatiram
two
wide
use
immunomodul
drug
ms
effect
reduc
diseas
activ
mean
autoimmun
concept
challeng
immun
mechan
ms
requir
addit
point
intercept
clinic
heterogen
ms
may
impli
sever
independ
mechan
exist
might
need
separ
target
regard
use
nonantigen
specif
immun
therapi
aim
common
pathway
gener
immun
respons
might
overcom
difficulti
relat
claim
heterogen
ms
howev
recent
histori
side
effect
induc
natalizumab
shown
antigen
nonspecif
therapi
culmin
sever
loss
immun
surveil
therefor
select
immun
therapi
base
upon
antigen
reactiv
specificallydefin
cell
subpopul
effector
immun
mediat
may
offer
promis
addit
point
complex
ms
therapi
rais
demonstr
neurodegener
brain
atrophi
repres
import
patholog
event
diseas
current
sever
immunerel
molecul
test
clinic
trial
ms
near
futur
becom
knowledg
correct
immun
respons
differ
level
influenc
cours
diseas
immun
surveil
central
nervou
system
multipl
sclerosi
patient
treat
natalizumab
object
evalu
whether
treatment
multipl
sclerosi
ms
patient
natalizumab
antibodi
interfer
immun
surveil
cerebrospin
fluid
csf
peripher
blood
pb
background
natalizumab
therapi
recent
associ
develop
progress
multifoc
leukoencephalopathi
pml
demyelin
disord
cn
caus
jc
viru
jcv
infect
designmethod
cell
number
cellular
phenotyp
csf
pb
analyz
flow
cytometri
ms
patient
treat
natalizumab
untreat
ms
patient
patient
neurolog
diseas
ond
hivinfect
patient
jcv
dna
csf
pb
patient
cohort
quantifi
kinet
pcr
result
csf
total
leukocyt
count
cell
b
cell
plasma
cell
significantli
lower
natalizumabtr
ms
patient
compar
ond
patient
untreat
ms
patient
natalizumab
therapi
decreas
ratio
csf
level
similar
hivinfect
patient
jcv
dna
detect
natalizumabtr
patient
six
month
cessat
therapi
low
lymphocyt
count
csf
persist
wherea
ratio
normal
patient
highest
total
leukocyt
cell
count
csf
experienc
clinic
relaps
interpret
data
suggest
low
csf
ratio
natalizumabtr
patient
may
confer
increas
risk
develop
pml
success
therapi
multipl
sclerosi
ms
target
highaffin
receptor
reveal
regulatori
role
bright
nk
cell
cell
respons
human
administr
daclizumab
human
monoclon
antibodi
direct
receptor
strongli
reduc
brain
inflamm
multipl
sclerosi
ms
patient
purpos
studi
elucid
mechan
action
daclizumab
ms
percentag
absolut
number
immun
cell
track
exvivo
flow
cytometri
function
assay
includ
flowcytometri
base
prolifer
intracellular
cytokin
product
transwel
cellsurviv
assay
chromiumreleas
cytotox
assay
contrari
expect
daclizumab
treatment
lead
mild
function
blockad
cell
major
candid
ms
pathogenesi
instead
daclizumab
therapi
associ
gradual
declin
circul
cell
signific
expans
bright
natur
killer
nk
cell
vivo
effect
correl
highli
treatment
respons
vitro
studi
show
nk
cell
inhibit
cell
surviv
activ
pbmc
cultur
contactdepend
mechan
moreov
bright
nk
cell
isol
daclizumabtr
patient
directli
cytotox
activ
rest
autolog
cell
perforindepend
manner
posit
correl
expans
bright
nk
cell
contract
cell
number
individu
patient
vivo
provid
support
evid
nkcell
mediat
neg
immunoregul
activ
cell
daclizumab
therapi
data
support
exist
immunoregulatori
pathway
wherein
activ
bright
nk
cell
inhibit
cell
surviv
immunoregul
potenti
import
treatment
autoimmun
diseas
transplant
reject
toward
modif
tumor
immun
increas
apoptot
elimin
activ
tcell
follow
treatment
multipl
sclerosi
multipl
sclerosi
ms
believ
autoimmun
diseas
aberr
immun
respons
lead
demyelin
loss
oligodendrocyt
acut
axon
transect
suggest
mechan
breakdown
immun
selftoler
includ
impair
hi
function
dysregul
apoptot
elimin
autoreact
tcell
monoclon
antibodi
induc
tcell
lymphopaenia
reduc
ms
relaps
rate
flow
cytometri
investig
effect
apoptot
death
tcell
emerg
lymphopaen
environ
observ
signific
increas
spontan
tcell
death
antifa
induc
tcell
death
respect
pancaspas
inhibit
larg
revers
confirm
cell
death
predominantli
apoptot
increas
tcell
death
also
observ
follow
stimul
myelin
basic
protein
mbp
specif
antigen
follow
treatment
howev
stimul
mbp
recal
antigen
led
reduct
cell
death
day
compar
unstimul
cell
expos
neoantigen
keyhol
limpet
haemocyanin
effect
disappear
day
impli
factor
releas
earli
memori
respons
peripher
blood
mononuclear
cell
extract
lymphopaen
environ
protect
apoptosi
mechan
lead
alter
apoptot
state
tcell
alter
respons
mbp
follow
discuss
elimin
activ
tcell
import
immun
homeostasi
avoid
immunopatholog
find
suggest
efficaci
may
part
due
increas
apoptot
elimin
activ
tcell
frequenc
regulatori
cell
treg
peripher
blood
multipl
sclerosi
comparison
studi
identifi
treg
high
cell
multipl
sclerosi
ms
assum
result
breakdown
peripher
toler
sinc
regulatori
cell
treg
play
role
maintain
peripher
toler
import
determin
dysregul
treg
contribut
onset
andor
progress
ms
although
previou
studi
identifi
human
treg
high
cell
activ
cell
also
express
molecul
specif
assess
frequenc
treg
analyz
express
cell
method
pbmc
obtain
consent
patient
ms
healthi
control
hc
among
patient
enrol
patient
receiv
ifnbeta
therapi
cell
stain
antihuman
antihuman
pe
fitc
intracellularli
express
molecul
determin
facscalibur
result
cell
divid
low
high
fraction
hc
sampl
averag
high
express
consider
number
cell
also
found
among
low
contrast
nontreg
constitut
high
five
patient
ifnbeta
therapi
one
receiv
ifnbeta
therapi
proport
treg
cell
mspb
significantli
decreas
compar
hcpb
vs
p
ttest
interestingli
ifnbeta
therapi
significantli
increas
treg
frequenc
mspb
averag
p
ttest
discuss
show
decreas
frequenc
circul
treg
ms
note
ifnbeta
may
partial
revers
deficit
treg
ms
prognost
relev
antimyelin
antibodi
progress
multipl
sclerosi
first
demyelin
event
result
benefit
trial
patient
clinic
isol
syndrom
ci
high
risk
progress
clinic
definit
multipl
sclerosi
cdm
howev
individu
prognosi
unpredict
berger
et
al
report
significantli
increas
risk
convers
cdm
patient
antibodi
myelin
oligodendrocyt
glycoprotein
mog
myelin
basic
protein
mbp
nejm
betaferon
r
newli
emerg
multipl
sclerosi
initi
treatment
studi
benefit
total
patient
ci
least
two
clinic
silent
brain
mri
lesion
investig
multicentr
doubleblind
trial
patient
randomis
n
placebo
n
treat
month
cdm
diagnos
regular
visit
schedul
collect
data
neurolog
disabl
mri
treatment
studi
month
measur
serum
antimog
antimbp
antibodi
baselin
western
blot
month
placebo
patient
reach
cdm
correspondingli
reach
mcdonald
ms
data
relat
antibodi
convers
cdm
mcdonald
ms
present
analys
allow
evalu
clinic
relev
antimogmbp
antibodi
test
repres
ci
popul
thoroughli
character
clinic
mri
set
clinic
trial
autoimmun
glycolipid
implic
pathogenesi
sever
neuropath
syndrom
associ
igm
monoclon
gammopathi
follow
exposur
bacteria
campylobact
jejuni
cj
crossreact
lipopolysaccharid
lp
great
deal
learn
antiglycolipid
antibodi
rel
littl
known
role
tcell
associ
neuropathi
system
transfer
igg
igm
antibodi
without
tcell
demonstr
caus
neurolog
dysfunct
experiment
adult
anim
igm
might
requir
presenc
tcell
reactiv
anoth
nerv
antigen
exert
effect
inflammatori
tcell
could
provid
chemotact
factor
activ
monoclon
bcell
facilit
igm
penetr
blood
nerv
barrier
expos
cryptic
glycolipid
antigen
creat
proinflammatori
environ
amplifi
respons
high
titer
igg
antigangliosid
antibodi
close
associ
variant
guillainbarr
syndrom
antibodi
tcell
depend
isotyp
tcell
might
addit
damag
nerv
via
tcell
depend
effector
mechan
lp
activ
bcell
via
tcell
independ
mechan
develop
tcell
respons
follow
cj
infect
unexplain
howev
pathway
lipid
antigen
present
recent
link
gb
cidp
cj
lp
present
tcell
via
pathway
might
also
induc
tcell
depend
antiglycolipid
respons
role
tcell
mediat
antigen
present
warrant
investig
object
campylobact
jejuni
c
jejuni
recogn
anteced
caus
guillainbarr
syndrom
gb
recent
identifi
character
ironbind
protein
dp
c
jejuni
cdp
aim
studi
determin
whether
cdp
contribut
pathogenesi
gb
method
tri
evalu
effect
exposur
cdp
nerv
conduct
intraneur
inject
bind
studi
cdp
rat
neuron
tissu
perform
furthermor
evalu
cluster
sodium
channel
node
ranvier
direct
effect
cdp
sodium
channel
use
wholecel
patchclamp
method
result
found
cdp
neither
pb
heatdenatur
cdp
inject
rat
sciatic
nerv
significantli
decreas
proximalcompound
muscl
action
potenti
cmap
motor
conduct
veloc
chang
significantli
b
cdp
bind
node
ranvier
outer
surfac
myelin
sheath
c
cdp
inject
sciatic
nerv
immunostain
sodium
channel
markedli
decreas
node
ranvier
cdp
direct
effect
sodium
channel
rat
hippocamp
neuron
conclus
cdp
direct
neurotox
mediat
downregul
sodium
channel
node
ranvier
mechan
may
contribut
axon
damag
gb
preced
c
jejuni
infect
campylobact
jejuni
cell
bodi
antigen
induc
experiment
autoimmun
neuriti
cs
koh
miyoshi
k
oana
k
nakayama
ehara
kyogashima
b
shin
c
shinshu
univers
matsumoto
japan
b
aichi
cancer
center
research
institut
nagoya
japan
c
cheju
nation
univers
jeju
south
korea
etiolog
syndrom
gb
still
remain
elus
gb
current
view
group
syndrom
sever
distinct
subtyp
patient
gb
develop
syndrom
infect
gramneg
bacterium
campylobact
jejuni
c
jejuni
lead
caus
acut
gastroenter
human
recognit
c
jejuni
infect
frequent
anteced
event
gb
rais
mani
question
specif
diseas
mechan
involv
experiment
autoimmun
neuriti
ean
consid
vivo
model
gb
howev
anim
model
ean
induc
c
jejuni
cell
bodi
antigen
report
new
form
ean
success
induc
first
time
anim
use
c
jejuni
cell
bodi
antigen
c
jejuni
penner
serotyp
isol
patient
gb
cultur
ean
could
induc
bear
anim
lewi
rat
sjlj
mice
mice
induc
bear
anim
mice
singl
sensit
c
jejuni
cell
bodi
antigen
complet
freund
adjuv
anim
ean
develop
limp
tail
paraparesi
histolog
inflammatori
cell
infiltr
observ
sciatic
nerv
especi
perineurium
cauda
equin
immunohistolog
studi
show
infiltr
cell
marker
macrophag
posit
taken
togeth
find
suggest
immun
respons
may
play
import
role
pathogenesi
new
form
ean
use
c
jejuni
cell
bodi
antigen
effect
rhokinas
inhibitor
fasudil
experiment
autoimmun
neuriti
objectivemethod
studi
potenti
role
rhokinas
inhibitor
fasudil
cours
ean
experiment
autoimmun
neuriti
induc
ean
lewi
rat
use
peptid
prevent
group
pb
n
fasudil
mgkgday
n
rat
immun
pb
fasudil
deliv
via
alzet
minipump
start
day
postimmun
day
splenocyt
harvest
cultur
assess
incorpor
h
thymidin
prolifer
assay
cytokin
assay
also
done
weight
clinic
score
record
daili
treatment
group
divid
two
control
pb
n
fasudil
mgkgday
n
respect
fasudil
start
onset
clinic
sign
day
deliv
continu
also
via
alzet
miniosmot
pump
day
result
prevent
studi
incid
ean
pb
group
fasudil
significantli
differ
use
fisher
exact
test
p
mean
clinic
score
also
significantli
lower
fasudilprevent
group
pb
group
use
mannwhitney
utest
p
day
day
p
valu
ean
prolifer
assay
day
also
show
significantli
higher
h
thymidin
incorpor
pb
group
fasudilprevent
group
cultur
supernat
also
show
higher
level
pb
group
well
higher
ratio
also
pb
treatment
studi
mean
clinic
score
also
significantli
lower
fasudiltreat
group
pb
group
day
postimmun
p
valu
conclus
fasudil
hydrochlorid
show
promis
effect
promot
probabl
hasten
neurolog
recoveri
cours
ean
readthrough
acetylcholinesteras
facilit
inflamm
associ
neuropathi
antisens
suppress
manner
inflammatori
factor
penetr
disrupt
bloodnerv
barrier
may
play
common
pathophysiolog
role
variou
neuropathi
disrupt
bloodnerv
barrier
concomit
induct
system
inflamm
lipopolysaccharid
lp
administr
caus
transient
conduct
block
rat
lp
administr
lead
proteolyt
cleavag
stressinduc
readthrough
acetylcholinesteras
variant
acher
accumul
distinct
cleavabl
ctermin
peptid
arp
therefor
examin
involv
acher
arp
inflammationassoci
nerv
conduct
impair
dissoci
rat
splenocyt
react
vitro
campylobact
jejuni
cj
e
coli
lp
cellfre
reactiv
splenocyt
medium
inject
intraneuron
rat
sciatic
nerv
medium
untreat
splenocyt
serv
control
compound
muscl
action
potenti
record
intrins
foot
muscl
follow
stimul
proximaland
distal
inject
site
record
proximaltodist
amplitud
ratio
pdr
calcul
repres
conduct
effici
nerv
segment
includ
inject
site
collect
analys
acher
mrna
identifi
situ
hybrid
within
cytoplasm
schwann
cell
bodi
myelin
sheath
immunohistochemistri
identifi
arp
within
cytoplasm
schwann
cell
addit
within
axon
intraneur
inject
reactiv
splenocyt
medium
induc
transient
pdr
reduct
accompani
arp
accumul
intraneur
inject
synthet
arp
induc
similar
reduct
pdr
furthermor
system
treatment
antisens
oligonucleotid
suppress
acher
express
attenu
conduct
block
format
follow
intraneur
reactiv
splenocyt
medium
inject
thu
acher
arp
may
play
key
role
inflammationassoci
neuropathi
might
emerg
novel
treatment
neuropathi
role
membran
attack
complex
mac
complement
compon
defici
lewi
rat
role
antibodi
deposit
complement
activ
especi
role
membran
attack
complex
mac
mediat
injuri
experiment
allerg
neuriti
ean
thought
critic
previou
studi
examin
cours
activ
experiment
allerg
encephalomyel
eae
strain
pvg
rat
total
defici
compon
complement
thu
unabl
assembl
mac
rat
develop
less
sever
eae
compar
pvgc
rat
follow
immun
myelin
basic
protein
mbp
howev
role
complement
demyelin
could
examin
eae
model
limit
central
nervou
system
demyelin
furthermor
pvg
rat
suscept
either
activ
passiv
ean
therefor
backcross
onto
lewi
rat
ean
suscept
train
gener
congen
lewi
rat
defici
unabl
form
mac
otherwis
rat
healthi
immunolog
ident
normal
lewi
rat
strain
congen
lewi
rat
allow
us
directli
examin
role
mac
ean
studi
shown
suscept
ean
lower
diseas
sever
compar
wild
type
lewi
rat
similarli
level
demyelin
significantli
less
wild
type
lewi
result
suggest
although
mac
role
demyelin
overal
pathogenesi
diseas
essenti
sole
factor
process
role
autoantibodi
central
nervou
system
cn
diseas
multipl
sclerosi
clear
increas
evid
specif
autoantibodi
neuron
protein
marker
paraneoplast
nonparaneoplast
neurolog
diseas
onconeur
antibodi
usual
measur
indirect
immunohistochemistri
immunofluoresc
also
measur
commerci
immunoblot
test
antibodi
hu
yo
ri
mata
amphiphysin
tr
highli
diseas
specif
often
found
high
titer
usual
indic
presenc
particular
tumour
eg
small
cell
lung
cancer
ovarian
etc
howev
mani
unansw
question
concern
relev
instanc
onconeur
antibodi
thought
pathogen
associ
diseas
like
caus
cytotox
cell
whether
control
specif
regulatori
cell
one
question
need
answer
also
sever
nonparaneoplast
condit
potenti
caus
antibodi
voltageg
potassium
channel
antibodi
associ
usual
nonparaneoplast
peripher
cn
disord
like
pathogen
although
prove
cn
disord
glutam
receptor
antibodi
activ
receptor
mimic
excess
glutam
lead
neuron
loss
enolas
antibodi
identifi
sever
diseas
hashimoto
retinopathi
may
induc
calcium
releas
intern
store
addit
number
antibodi
techniqu
employ
identifi
specif
serum
csf
prove
use
futur
autoantibodi
aminotermin
alphaenolas
hashimoto
encephalopathi
yoneda
fujii
ito
h
nakagawa
kuriyama
univers
fukui
fukui
japan
background
hashimoto
encephalopathi
autoimmun
encephalopathi
distinct
myxoedema
encephalopathi
associ
hashimoto
thyroid
ht
present
variou
neuropsychiatr
featur
detect
antithyroid
antibodi
patient
sera
help
suffici
diagnosi
high
preval
normal
popul
recent
report
autoantibodi
amino
nh
termin
region
alphaenolas
nae
use
diagnost
marker
method
perform
immunoblot
analys
patient
serum
recombin
nae
investig
preval
antina
autoantibodi
sera
patient
examin
clinic
featur
laboratori
mri
find
result
patient
ht
show
encephalopathi
presenc
antithyroid
antibodi
steroidrespons
demonstr
high
preval
antina
autoantibodi
sera
compar
low
preval
ht
without
encephalopathi
p
absenc
autoimmun
condit
conscious
disturb
seizur
cognit
impair
eeg
abnorm
common
patient
antina
autoantibodi
show
good
steroidrespons
high
preval
abnorm
eeg
conclus
studi
demonstr
high
preval
serum
antina
autoantibodi
patient
antina
autoantibodi
emphas
instead
antithyroid
antibodi
use
serolog
diagnost
marker
includ
diagnost
criteria
examin
pathogen
antienolas
antibodi
paraneoplast
autoimmun
retinopathi
thimmappa
anekonda
landon
karren
richard
g
weleb
grazyna
adamu
neurolog
scienc
institut
casey
eye
institut
oregon
health
scienc
univers
portland
oregon
usa
antienolas
autoantibodi
associ
retin
degener
patient
autoimmun
paraneoplast
retinopathi
patient
usual
suffer
slow
progress
central
vision
loss
central
cone
dysfunct
show
signific
reduct
electroretinogram
consider
interest
examin
relationship
antienolas
antibodi
retin
degener
sinc
role
pathogen
retinopathi
fulli
understood
character
patient
sera
antienolas
reactiv
use
western
blot
elisa
investig
perform
accord
guidelin
declar
helsinki
inform
consent
obtain
time
blood
collect
five
epitop
enolas
protein
determin
major
epitop
locat
within
amino
acid
sequenc
normal
sera
without
antienolas
reactiv
react
enolas
peptid
propos
block
enolas
function
antienolas
antibodi
may
lead
deplet
cellular
atp
subsequ
increas
intracellular
calcium
final
cell
death
previous
shown
antienolas
antibodi
inhibit
enolas
function
vitro
studi
found
antienolas
antibodi
significantli
reduc
cytosol
atp
retin
neuron
grown
antienolas
antibodi
addit
measur
level
intracellular
calcium
retin
cell
treat
patient
antienolas
igg
found
igg
potent
induc
intracellular
calcium
increas
normal
igg
induc
intracellular
calcium
reduc
cytosol
atp
use
calcium
blocker
glycolyt
inhibit
antienolas
antibodi
led
sudden
releas
endoplasmicstor
ca
conclus
result
strongli
suggest
antienolas
antibodi
potenti
role
pathogen
retin
degener
deregul
glucos
metabol
retin
cell
work
support
grant
nih
ffb
rpb
glutam
receptor
antibodi
induc
brain
damag
neurobehavior
dysfunct
autoimmun
epilepsi
neuropsychiatr
sle
weizmann
institut
scienc
rehovot
israel
decad
document
massiv
brain
patholog
caus
numer
human
anim
neuron
injuriesdiseas
excess
glutam
time
glutamatereceptor
autoantibodi
come
longer
ignor
grow
increment
evid
show
two
type
glutamatereceptor
autoantibodi
antiampa
subtyp
antinmda
autoantibodi
present
serum
andor
csf
patient
epilepsi
sle
stroke
highli
pathogen
cn
virtu
kill
neuron
glia
induc
variou
neurobehavior
impair
evok
augment
epilepsi
importantli
sharp
contrast
block
autoantibodi
play
pathogen
role
mostal
autoimmun
diseas
glutamatereceptor
antibodi
activ
antibodi
activ
antigen
key
neurotransmitt
receptor
glutamatereceptor
antibodi
mimic
glutam
excess
glutam
activ
ionotrop
glutamatereceptor
trigger
ion
current
kill
neuron
lead
cn
damag
dysfunct
herein
wish
summar
vivo
vitro
evid
human
rabbit
rat
mice
reveal
lab
presenc
glutamatereceptor
autoantibodi
patient
epilepsi
sle
pathogen
activ
uniqu
mechan
action
strikingli
autoimmunemedi
brain
damag
caus
glutamatereceptor
autoantibodi
differ
everi
aspect
occur
ms
date
studi
human
autoimmunemedi
cn
patholog
recommend
glutamatereceptor
antibodi
consid
onward
genuin
caus
autoimmunemedi
brain
damag
unrecogn
underestim
thu
far
develop
mean
arrest
monoclon
oligoclonalityor
unravel
secret
oligoclon
band
resurrect
expand
csf
plasma
clone
recombin
human
monoclon
antibodi
neuroborreliosi
chronic
inflammatori
diseas
central
nervou
system
caus
tickborn
spirochet
borrelia
burgdorferii
bb
neuroborreliosi
chronic
cn
infect
oligoclon
csf
immunoglobulinswhich
detect
call
oligoclon
ig
band
ocb
isoelectr
focusingar
direct
caus
infecti
agent
specif
diseas
relev
ocb
chronic
inflammatori
diseas
cn
multipl
sclerosi
still
unknown
establish
experiment
system
identifi
antigen
specif
ocb
product
oligoclon
expand
csf
plasma
cell
start
singl
cell
rt
pcr
individu
csf
plasma
cell
identifi
expand
clone
express
heavi
light
ig
chain
gene
recombin
human
monoclon
antibodi
mab
eukaryot
express
system
use
immunoprecipit
bb
lysat
subsequ
maldi
analysi
could
identifi
antigen
specif
deriv
mab
direct
antigen
bb
could
show
affin
patient
deriv
human
mab
time
higher
nativ
bb
lysat
denatur
recombin
result
demonstr
one
hand
valid
experiment
system
resurrect
origin
antigen
specif
expand
csf
plasma
cell
clone
instrument
elucid
antigen
specif
ocb
ms
relat
diseas
hand
result
impli
ocb
may
direct
conform
depend
epitop
might
escap
identif
current
popular
approach
use
recombin
antigen
express
librari
cerebrospin
fluid
proteom
profil
predict
cognit
impair
infect
hispan
women
associ
cognit
impair
diagnosi
exclus
search
opportunist
infect
malign
elimin
thu
search
diseas
biomark
remain
time
relev
step
toward
achiev
goal
integr
proteom
platform
combin
surfac
enhanc
laser
desorpt
ioniz
time
flight
selditof
reversephas
high
perform
liquid
chromatographi
rphplc
one
dimension
sdspage
electrophoresi
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
employ
determin
link
cerebrospin
fluid
csf
profil
cognit
impair
csf
collect
puerto
rican
hispan
women
fraction
rphplc
nine
differenti
express
protein
peak
detect
csf
fraction
selditof
electrophoresi
lc
msm
studi
identifi
common
protein
among
protein
preferenti
identifi
cognit
impair
subject
famili
al
mutant
cu
zn
superoxid
dismutas
msod
mw
lymphocyt
cytosol
protein
lplastin
mw
migrat
inhibitori
factorrel
protein
mif
mw
mw
vgf
nerv
growth
factor
vgf
mw
western
blot
examin
confirm
preferenti
protein
express
sod
cognit
impair
subject
puerto
rican
north
american
cohort
studi
highlight
util
proteom
platform
profil
toward
uncov
uniqu
biomark
cognit
impair
support
grant
nihnind
nihncrrrcmi
selditof
beckman
instrument
experiment
autoimmun
encephalomyel
eae
anim
model
human
diseas
multipl
sclerosi
ms
eae
thought
mediat
cell
secret
proinflammatori
cytokin
lymphotoxin
although
cell
secret
also
thought
play
role
diseas
pathogenesi
given
central
role
diseas
pathogenesi
cell
repres
excel
target
regul
potenti
therapi
interest
pathway
regul
develop
inflamm
inflammatori
central
nervou
system
cn
diseas
eae
shown
silenc
tbet
transcript
factor
import
cell
differenti
suppress
eae
develop
also
investig
member
nuclear
hormon
receptor
superfamili
peroxisom
prolifer
activ
receptor
ppar
abil
regul
cn
inflamm
use
chromatin
immunoprecipit
assay
show
bind
regulatori
region
gene
promot
secret
cytokin
use
agonist
gemfibrozil
demonstr
receptordepend
increas
inhibit
tbet
data
suggest
target
transcript
regul
cell
differenti
could
success
therapeut
strategi
immunemedi
cn
inflammatori
diseas
object
investig
whether
experiment
autoimmun
encephalomyel
eae
protect
atorvastatin
requir
differenti
background
prevent
revers
eae
current
test
multipl
sclerosi
treatment
sever
eae
studi
report
differenti
myelin
reactiv
cell
treatment
upregul
signal
control
differenti
order
elucid
clinic
signific
atmedi
differenti
evalu
attreat
mice
method
mice
fed
oral
mgkgd
start
either
day
prior
immun
mog
eae
establish
mice
treat
eae
prevent
evalu
prolifer
cytokin
secret
mog
cell
cell
report
mice
differenti
cell
distinguish
fac
rest
cell
stimul
presenc
result
treatment
could
effect
prevent
revers
eae
mice
compar
treatment
effect
wildtyp
mice
mog
prolifer
secret
ifng
tnfa
reduc
cell
attreat
mice
vitro
inhibit
prolifer
cell
dosedepend
manner
conclus
data
indic
prevent
revers
eae
independ
differenti
mechan
besid
differenti
includ
inhibitori
effect
cell
prolifer
differenti
report
significantli
contribut
therapeut
effect
eae
oral
administr
antibodi
suppress
mog
induc
autoimmun
encephalomyel
eae
nod
mice
nod
mice
r
maron
tamvacaki
hl
weiner
center
neurolog
diseas
brigham
women
hospit
harvard
medic
school
boston
usa
one
major
goal
immunotherapi
autoimmun
diseas
multipl
sclerosi
ms
induct
regulatori
cell
found
feed
antibodi
suppress
plp
induc
eae
sjl
mice
via
induct
regulatori
cell
function
depend
fashion
natur
medicin
press
investig
effect
oral
mog
induc
eae
nod
mice
develop
relapsingremit
follow
progress
cours
occur
ms
sjl
mice
oral
suppress
mog
induc
eae
nod
mice
studi
oral
nod
mice
nod
mice
develop
sever
eae
exacerb
diseas
pattern
amelior
oral
anti
nod
mice
develop
mild
relaps
diseas
exacerb
oral
wild
type
nod
mice
fed
show
decreas
secret
increas
compar
control
igg
nod
mice
secret
increas
decreas
wherea
nod
mice
decreas
increas
oral
effect
mog
specif
secret
either
nod
nod
mice
result
demonstr
eae
diseas
pattern
nod
mice
affect
defici
ifn
inabl
oral
suppress
eae
appear
link
inabl
induc
regul
mice
therapeut
effect
mous
superagonist
murin
eae
activ
preexist
regulatori
cell
f
f
elia
b
schill
b
r
gold
institut
multipl
sclerosi
research
germani
b
institut
virolog
immunbiolog
germani
regulatori
cell
treg
cell
crucial
control
autoimmun
inflamm
previous
could
show
rat
specif
superagonist
monoclon
antibodi
abl
activ
expand
treg
vivo
consid
major
mechan
capabl
amelior
eae
lewi
rat
model
present
studi
demonstr
new
analog
superagonist
antibodi
specif
mous
significantli
delay
diseas
onset
reduc
diseas
sever
moginduc
eae
mice
administr
mab
amelior
eae
prevent
therapeut
set
treg
cell
deplet
vivo
superagonist
administr
protect
effect
abolish
demonstr
import
cell
mechanist
link
protect
effect
superagonist
case
deplet
treg
incomplet
howev
superagonist
restor
treg
compart
within
day
normal
level
indic
potenc
treg
activ
expans
vivo
adopt
transfer
experi
use
lymphocyt
either
gfp
transgen
mice
label
cfse
reveal
expans
treg
compart
due
convers
cell
treg
cell
rather
result
rapid
prolifer
preexist
treg
result
show
even
condit
partial
deplet
treg
compart
associ
human
autoimmun
diseas
superagonist
therapi
prevent
diseas
activ
expand
regulatori
cell
modul
notch
signal
affect
encephalitogen
potenti
autoreact
cell
background
notch
regul
differenti
mani
cell
type
includ
cell
interact
distinct
notch
receptor
ligand
jag
deltalik
effect
peripher
cell
respons
object
studi
examin
effect
notch
pathway
manipul
prolifer
cytokin
profil
encephalitogen
potenti
autoreact
cell
method
lymph
node
cell
lnc
isol
sjlj
mice
preimmun
plp
cultur
gammasecretas
inhibitor
gsi
antibodi
neutral
distinct
notch
receptor
elisa
cfse
prolifer
assay
use
order
measur
cytokin
product
prolifer
lymphocyt
popul
respect
level
notch
protein
express
notch
gene
assess
immunoblot
realtim
pcr
respect
cultur
lnc
transfer
via
tail
vein
normal
sjlj
mice
order
induc
experiment
autoimmun
encephalomy
eae
clinic
cours
eae
group
mice
observ
histopatholog
brain
spinal
cord
perform
result
gsi
treatment
decreas
express
four
notch
gene
reduc
product
plpstimul
autoreact
cell
gsitreat
lymph
node
cell
induc
milder
diseas
control
lnc
histopatholog
brain
spinal
cord
gsitreat
mice
show
diminish
inflamm
block
experi
product
markedli
decreas
ab
treatment
affect
select
inhibit
conclus
modul
notch
signal
autoreact
cell
affect
encephalitogen
potenti
notch
may
promis
therapeut
target
autoimmun
diseas
includ
ms
role
tbet
regul
inflamm
cn
petra
craven
ann
r
gock
sara
c
northrop
lihong
ben
rehana
z
hussain
michael
k
rack
ami
lovettrack
univers
texa
southwestern
medic
center
depart
neurolog
center
immunolog
usa
group
recent
shown
suppress
transcript
factor
tbet
tbox
express
cell
intraven
administ
sirna
direct
tbet
prevent
onset
experiment
autoimmun
encephalomyel
eae
sinc
eae
immunemedi
demyelin
diseas
central
nervou
system
serv
anim
model
multipl
sclerosi
would
appropri
determin
whether
silenc
tbet
use
sirna
mice
ongo
eae
would
benefici
sirnatbet
sirnanonsens
sirnan
administ
intraven
timepoint
mice
develop
eae
adopt
transfer
encephalitogen
cell
splenocyt
isol
mice
treat
sirna
tbet
produc
less
reduc
express
mice
treat
sirnan
express
affect
examin
gene
may
transactiv
tbet
vivo
chromatin
immunoprecipit
assay
perform
tbet
bound
promot
promot
engag
cell
result
secret
express
cn
sirnatbet
mice
decreas
examin
immun
cell
present
cn
mice
multiparamet
flow
cytometri
indic
may
produc
cn
cell
percentag
cell
abl
releas
reduc
mice
treat
sirna
tbet
data
indic
amelior
ongo
eae
via
suppress
tbet
may
result
antiinflammatori
environ
cn
due
decreas
express
reduc
secret
longstand
interest
b
cell
respons
may
contribut
patholog
neurolog
diseas
tradit
premis
contribut
relat
potenti
b
cell
produc
autopathogen
antibodi
target
autoantibodi
continu
import
therapeut
approach
particularli
disord
role
antibodi
well
establish
myasthenia
gravi
condit
multipl
sclerosi
role
circul
antibodi
less
clear
though
patholog
studi
continu
implic
cnsreactiv
antibodi
well
b
cell
within
cn
compart
recent
new
insight
fundament
properti
b
cell
suggest
cell
may
contribut
antibodyindepend
fashion
normal
immun
respons
well
context
immun
mediat
diseas
session
associ
poster
consid
role
humor
immun
respons
well
antibodyindepend
b
cell
involv
sever
neurolog
disord
also
cover
consider
role
therapeut
mechan
action
exist
therapi
ivig
well
emerg
approach
b
cell
target
select
diseasespecif
antiigg
fraction
isol
pool
human
igg
ivig
suppress
experiment
myastehenia
gravi
eamg
intraven
immunoglobulin
ivig
administr
benefici
use
recent
year
treatment
varieti
autoimmun
diseas
includ
myasthenia
gravi
howev
mechan
action
ivig
treatment
fraction
respons
therapeut
effect
autoimmun
diseas
still
establish
studi
therapeut
effect
ivig
administr
experiment
autoimmun
myasthenia
gravi
eamg
rat
model
myasthenia
gravi
show
ivig
treatment
could
success
prevent
induct
eamg
immunosuppress
ongo
diseas
mechan
ivig
modul
eamg
involv
suppress
cell
b
cell
prolifer
probabl
act
via
regulatori
cell
establish
optim
condit
eamg
suppress
ivig
administr
employ
model
attempt
isol
specif
suppress
fraction
ivig
prepar
identifi
therapeut
activ
demonstr
chromatographi
human
ivig
immobil
rat
antiachr
igg
isol
rat
eamg
result
complet
deplet
suppress
activ
ivig
moreov
elut
immunoglobulin
fraction
adsorb
onto
antiachr
antibodi
compris
less
ivig
prepar
retain
immunosuppress
activ
ivig
studi
support
notion
therapeut
effect
ivig
mediat
antigenspecif
antiimmunoglobulin
activ
antiidiotyp
activ
present
pool
human
immunoglobulin
rais
possibl
diseasespecif
antiidiotyp
activ
fraction
ivig
becom
preferenti
reagent
therapeut
purpos
object
cidp
improv
intraven
immunoglobulin
ivig
treatment
patient
need
intermitt
ivig
maintain
improv
studi
aim
identifi
factor
especi
relat
longterm
treatment
prognosi
method
data
collect
cidp
patient
known
erasmu
medic
center
treat
ivig
follow
least
month
clinic
laboratori
paramet
analyz
possibl
relat
improv
rankin
scale
result
male
femal
follow
period
rang
month
year
median
year
patient
receiv
addit
treatment
reduc
amount
ivig
patient
improv
ivig
patient
need
least
cours
suggest
improv
due
spontan
remiss
improv
relat
relaps
past
patient
improv
progress
weak
treatment
discrep
weak
arm
leg
mean
time
ivig
treatment
remiss
year
median
year
patient
sensorymotor
disturb
p
hr
rel
short
durat
weak
p
hr
higher
chanc
reach
remiss
discontinu
ivig
need
ivig
period
year
maximum
year
sever
sideeffect
seen
conclus
patient
need
ivig
long
period
time
patient
prognost
factor
indic
necess
longterm
treatment
may
consideredespeci
due
high
cost
ivigto
switch
treatment
earli
stage
diseas
chang
axon
excit
follow
intraven
immunoglobulin
infus
patient
dysimmun
demyelin
neuropathi
boerio
delphin
creang
alain
hogrel
jeanyv
lefaucheur
jeanpasc
servic
de
physiologi
explor
fonctionnel
chu
henri
mondor
franc
servic
de
neurologi
chu
henri
mondor
franc
institut
de
myologi
gh
pari
franc
background
dysimmun
demyelin
neuropathi
associ
chang
nerv
excit
result
alter
axon
membran
properti
object
investig
effect
intraven
immunoglobulin
ivig
nerv
excit
patient
multifoc
motor
neuropathi
conduct
block
mmn
chronic
inflammatori
demyelin
polyneuropathi
cidp
method
patient
mmn
cidp
evalu
ivig
gkgday
consecut
day
absolut
arp
rel
refractori
period
rrp
durat
percentag
refractori
ms
supernorm
ms
interstimuli
interv
determin
stimulusrespons
sr
strengthdur
sd
curv
establish
activitydepend
hyperpolaris
induc
voluntari
contract
apprais
percentag
conduct
block
affect
territori
result
ivig
patient
longer
refractori
smaller
supernorm
healthi
subject
ivig
increas
refractori
vs
p
prolong
rrp
vs
ms
p
modifi
arp
durat
supernorm
sd
time
constant
decreas
vs
p
rheobas
sr
curv
slope
remain
unchang
ivig
reduc
percentag
activitydepend
conduct
block
p
conclus
electrophysiolog
studi
provid
addit
inform
usual
conduct
studi
refractori
prolong
consist
chang
na
conduct
nodal
membran
properti
suggest
reduct
intraaxon
na
accumul
decreas
occurr
hyperpolaris
reduct
percentag
conduct
block
traduc
improv
na
k
atpas
pump
function
greater
conduct
studi
reveal
potenti
protect
effect
ivig
improv
conduct
across
conduct
block
cidp
mmn
object
examin
whether
novel
b
cell
regulatori
cytokin
network
influenc
local
environ
patient
ms
control
modul
target
therapeut
method
circul
b
cell
purifi
untreat
ms
patient
poser
criteria
match
healthi
control
stimul
b
cell
receptor
engag
follow
stimul
modul
b
cell
respons
local
cell
environ
assess
addit
b
cell
prolifer
thymidin
incorpor
lt
elisa
subsequ
measur
result
b
cell
prolifer
differ
ms
control
stimul
condit
addit
gener
enhanc
b
cell
cytokin
product
expect
differ
product
ms
control
upon
addit
ms
patient
b
cell
produc
significantli
lt
compar
control
b
cell
product
differ
interestingli
follow
mitoxantron
therapi
ms
patient
addit
ms
b
cell
stimul
associ
significantli
less
lt
induct
compar
baselin
data
conclus
activ
ms
patient
b
cell
may
abnorm
enhanc
proinflammatori
environ
increas
releas
lt
therapi
mitoxantron
appear
revers
abnorm
pattern
suggest
differ
b
cell
popul
may
contribut
distinct
cytokin
local
inflammatori
environ
insight
pertin
given
grow
interest
b
cell
role
ms
lipid
microdomainmedi
signal
implic
antimog
mediat
demyelin
diseas
antibodi
myelin
compon
routin
detect
multipl
sclerosi
ms
patient
find
antibodi
crosslink
oligodendrocyt
ol
myelin
protein
mog
mag
result
rapid
repartit
glycosphingolipidcholesterol
microdomain
lipid
raft
small
nm
membran
entiti
protein
upon
ligandor
antibodymedi
crosslink
coalesc
function
signal
transduct
activ
center
high
cholesterolglycosphingolipid
content
olsmyelin
suggest
raft
contribut
function
physiolog
follow
b
raftdepend
phosphorylationdephosphoryl
specif
protein
downstream
event
case
mog
c
dramat
rapid
loss
myelinlik
membran
immun
mice
either
rat
human
mog
produc
compar
antimog
elisa
titer
howev
human
mog
yield
b
cell
depend
eae
encephalitogen
prime
b
cell
defici
mice
substitut
ser
human
mog
rat
mog
elimin
b
cell
requir
nonpathogen
igg
bind
recombin
mous
mog
deglycosyl
mog
myelin
pathogen
igg
bind
glycosyl
mog
purifi
igg
human
mog
bind
live
rodent
ol
cultur
crosslink
induc
repartit
mog
lipid
raft
dramat
chang
cell
morpholog
data
provid
strong
link
vivo
vitro
observ
regard
demyelin
diseas
suggest
biochem
mechan
antimoginduc
demyelin
suggest
vitro
tool
determin
autoimmun
ab
pathogen
ms
kim
pfeiffer
taylor
et
al
marta
et
al
schafer
et
al
marta
et
al
marta
et
al
cm
nhr
sp
workshop
studi
neuroimmun
pharmacolog
studi
grow
interdisciplin
neuroimmun
pharmacolog
r
donaho
j
roger
b
univers
utah
salt
lake
citi
ut
usa
b
templ
univers
philadelphia
pa
usa
neuroimmun
pharmacolog
new
interdisciplinari
area
research
repres
societi
neuroimmun
pharmacolog
symposium
studi
neuroimmun
pharmacolog
repres
broad
interest
new
interdisciplin
data
effect
opiat
monkey
model
aid
show
statist
meaning
evid
opiat
modul
aid
diseas
progress
data
consider
implic
opiat
addict
infect
data
also
present
show
mu
opiatereceptor
ligand
induc
desensit
chemokin
receptor
macrophag
via
phoshoryl
protein
kinasec
fundament
data
import
role
opiat
neuroimmun
function
hivaid
similarli
signal
transduct
mechan
involv
stimul
lymphocyt
deltaopioid
tcell
surfac
receptor
present
elabor
opioid
interact
directli
cell
immun
system
basic
molecular
level
human
immunereconstitut
mous
model
also
use
show
antihiv
drug
indinavir
deliv
effect
via
nanoparticl
packag
bonemarrow
deriv
macrophag
drug
carrier
novel
model
offer
new
approach
new
hope
treatment
hivaid
final
structur
mri
magnet
reson
spectroscopi
positron
emiss
tomographi
studi
use
human
show
neurolog
chang
subject
also
use
cocain
methamphetamin
studi
reveal
drugspecif
neurolog
chang
associ
neurobehavior
motor
cognit
function
patient
studi
combin
data
show
promis
neuroimmun
pharmacolog
advanc
understand
major
medic
problem
mean
resolut
crosstalk
mu
opioid
receptor
mediat
protein
kinas
c
zeta
center
substanc
abus
research
fel
institut
cancer
research
molecular
biolog
templ
univers
school
medicin
philadelphia
pa
usa
previous
laboratori
shown
heterolog
desensit
induc
upon
activ
mu
opioid
receptor
mor
present
studi
examin
signal
event
mediat
inactiv
pretreat
enkephalin
damgo
morselect
agonist
cell
line
stablytransfect
mor
human
monocytederiv
macrophag
treat
damgo
use
variou
assay
coimmunoprecipit
western
blot
analys
show
associ
damgo
induc
phosphoryl
phosphoinositidedepend
kinas
known
activ
addit
damgo
augment
kinas
activ
observ
upon
immunoprecipit
induc
phosphoryl
cell
transfect
sirna
show
signific
inhibit
kinas
activ
associ
studi
desensit
led
inhibit
calcium
mobil
decreas
chemotact
respons
use
pseudosubstr
inhibitor
revers
result
overal
data
suggest
damgoinduc
desensit
lead
phosphoryl
mediat
effect
work
support
nida
grant
opiat
use
report
retard
advanc
aid
progress
detect
effect
human
clinic
monkey
sivmodel
studi
contribut
equivoc
small
pilot
monkey
studi
laboratori
suggest
opiatedepend
retard
aid
progress
result
nearli
followup
studi
confirm
origin
observ
male
rhesu
macaqu
around
yr
age
adapt
period
singlecag
hold
environ
psycholog
enrich
baselin
data
collect
follow
introduct
opiatedepend
paradigm
daili
apart
scim
inject
morphin
sulphat
mgkgmonkey
nineteen
monkey
receiv
opiat
receiv
equival
weightbyvolum
inject
salin
control
two
week
initi
inject
monkey
inject
iv
tcid
progress
infect
diseas
follow
yr
thereaft
morphin
retard
progress
aid
overal
p
v
larg
select
monkey
progress
rel
rapidli
aid
opiatedepend
also
alter
cerebr
spinal
inflamm
retard
diseas
progress
correspond
abil
opiat
revers
neg
correl
typic
seen
viral
load
increas
time
conjunct
tcell
loss
data
repres
solid
evid
date
opiat
alter
aid
progress
view
conflict
data
opiat
exacerb
aid
progress
current
understand
issu
support
prior
conjectur
influenc
opiat
aid
conditionalb
depend
variabl
drugdepend
viral
immun
state
possibl
relat
influenc
factor
stress
find
conclus
support
need
thorough
understand
opiat
affect
aid
progress
drugabus
popul
opioid
modul
array
function
respons
tcell
includ
prolifer
cytokin
product
chemotaxi
express
human
immunodefici
hiv
howev
signal
pathway
mediat
effect
opioid
larg
unknown
recent
observ
delta
opioid
ligand
exert
dual
effect
specif
tcell
signal
cascad
opioid
stimul
wherea
opioid
pretreat
attenu
signal
respons
anoth
agent
exampl
brief
exposur
min
specif
delta
opioid
agonist
ie
dadl
dosedepend
induc
phosphoryl
cjun
activ
phosphoinositid
protein
kinas
b
akt
mitogenactiv
protein
kinas
mapk
cjun
kinas
jnk
moreov
dadl
stimul
phosphoryl
activ
transcript
implic
cytokin
gene
transcript
associ
jnk
contrast
direct
activ
signal
pretreat
dadl
inhibit
akt
phosphoryl
induc
stromal
cellderiv
pretreat
highli
purifi
human
peripher
blood
tcell
dadl
h
significantli
reduc
akt
phosphoryl
approxim
n
contrast
dadl
fail
stimul
phosphoryl
mapk
affect
erk
phosphoryl
recent
studi
also
demonstr
morphin
inhibit
akt
phosphoryl
stimul
togeth
studi
demonstr
endogen
exogen
opioid
exert
direct
indirect
modulatori
effect
signal
cascad
depend
pharmacokinet
immun
antivir
respons
nanoparticl
indinavir
murin
model
enceph
howard
e
gendelman
md
center
neurovirolog
neurodegen
disord
nebraska
medic
center
omaha
ne
phone
fax
email
hegendel
unmcedu
abstract
introduct
highli
activ
antiretrovir
therapi
human
immunodefici
viru
infect
revolution
pharmacolog
manag
human
diseas
nonetheless
complex
dose
regimen
cost
untoward
side
effect
limit
bio
distribut
variabl
drug
pharmacokinet
pattern
affect
longterm
use
notabl
clinic
efficaci
within
nervou
system
posit
nanotechnologyderiv
cell
base
system
may
overcom
limit
first
step
toward
test
idea
develop
nanoparticl
indinavir
npidv
formul
packag
bonemarrowderivedmacrophag
bmm
drug
carrier
drug
distribut
diseas
outcom
assess
immun
compet
nonobes
diabet
sever
combin
immunodefici
mice
nodscid
reconstitut
human
peripher
blood
lymphocyt
model
npidv
contain
within
bmm
adopt
transfer
mice
singl
administr
singl
photon
emiss
comput
tomographi
histolog
demonstr
robust
lung
liver
spleen
bmm
distribut
tissu
sera
idv
level
nmml
week
observ
npidvbmm
administ
viruschalleng
immunodefici
human
mice
show
reduc
number
virusinfect
cell
plasma
lymph
node
spleen
liver
lung
number
cell
restor
npidvbmm
administr
nodscid
mice
activ
enceph
show
robust
deliveri
npidv
affect
brain
subregion
conclud
singl
dose
npidv
use
bmm
carrier
bioavail
effect
warrant
consider
human
test
basal
ganglia
abnorm
hiv
patient
chronic
psychostimul
drug
user
l
chang
ernst
univers
hawaii
honolulu
usa
varieti
vivo
physiolog
neuroimag
techniqu
quantit
assess
brain
injuri
associ
hiv
andor
substanc
abus
structur
mri
demonstr
atrophi
caudat
putamen
subject
infect
hiv
enlarg
striatal
volum
chronic
psychostimul
abus
methamphetamin
cocain
etc
henc
hiv
psychostimul
use
opposit
effect
brain
volum
convers
magnet
reson
spectroscopi
mr
show
metabolit
abnorm
addit
hiv
patient
methamphetamin
user
spectroscop
abnorm
includ
decreas
neuron
marker
nacetylaspar
elev
glial
marker
myoinositol
promin
basal
ganglia
frontal
cortex
sinc
psychomotor
slow
attent
deficit
major
featur
hiv
dementia
psychostimul
abus
dopamin
dysfunct
postul
dopaminerg
termin
synaps
highest
densiti
basal
ganglia
region
positron
emiss
tomographi
studi
cocain
inde
illustr
lower
dopamin
transport
hiv
patient
dementia
well
individu
chronic
methamphetamin
depend
compar
seroneg
nondrug
user
correl
cognit
perform
dopamin
transport
level
document
function
consequ
dopaminerg
deficit
find
suggest
methamphetamin
cocain
abus
exacerb
brain
injuri
hiv
patient
therefor
dopamin
augment
might
benefici
treatment
hiv
dementia
collect
find
neuroimag
studi
provid
insight
pathophysiolog
mechan
hivassoci
brain
injuri
drug
abus
might
lead
new
therapeut
approach
acknowledg
studi
resourc
support
nih
nind
nimh
nida
ncrr
depart
energi
ondcp
cholinerg
antiinflammatori
pathway
recent
discov
vagu
nerv
control
peripher
innat
immun
respons
mechan
employ
treatment
inflammatori
disord
nat
rev
dd
electr
stimul
vagu
nerv
attenu
system
inflamm
experiment
sepsi
inhibit
product
proinflammatori
cytokin
spleen
mechan
depend
common
celiac
branch
vagu
nerv
stimul
fail
attenu
endotoxininduc
serum
tnf
level
splenectom
anim
acetylcholin
princip
neurotransmitt
vagu
nerv
inhibit
endotoxininduc
tnf
releas
human
macrophag
mechan
depend
acetylcholin
receptor
vivo
vagu
nerv
stimul
reduc
splenic
tnf
protein
mrna
level
wildtyp
mice
mice
nicotin
select
cholinerg
agonist
abolish
releas
dosedepend
manner
effici
inhibitor
macrophag
vivo
treatment
nicotin
attenu
serum
level
prevent
lethal
endotoxemia
improv
surviv
establish
polymicrobi
periton
even
treatment
start
appear
clinic
sign
sepsi
nicotin
alreadi
use
clinic
trial
inflammatori
disord
ulcer
coliti
clinic
potenti
limit
collater
toxic
similar
develop
select
agonist
adrenerg
receptor
select
nicotin
agonist
may
repres
promis
pharmacolog
strategi
infecti
inflammatori
diseas
research
support
faculti
award
program
nslijh
nigm
darpa
three
broad
question
driven
research
immun
respons
first
persist
individu
host
particular
role
immun
respons
control
limit
viral
persist
second
peopl
develop
consequ
diseas
hamtsp
leukaemia
wherea
major
remain
asymptomat
carrier
viru
differ
outcom
infect
due
primarili
variat
host
variat
viru
third
inflammatori
lesion
hamtsp
initi
maintain
inflamm
halt
evid
immun
respons
summar
recent
work
host
viral
genet
dna
express
microarray
tcell
function
cell
biolog
evid
favour
two
main
conclus
first
effici
person
cytotox
tlymphocyt
ctl
respons
play
domin
role
determin
person
provir
load
risk
associ
inflammatori
diseas
second
persist
transcript
activ
spread
directli
lymphocyt
special
cellcel
contact
known
virolog
synaps
recent
infer
persist
transcrib
rest
entir
evid
vitro
experi
howev
new
evid
quantif
lymphocyt
turnov
vivo
strongli
support
view
persist
transcript
conclus
implic
therapeut
approach
inflammatori
diseas
syndrom
adult
tcell
leukaemia
immun
respons
persist
viral
infect
central
nervou
system
cn
involv
herp
simplex
viru
hsv
restrict
mice
follow
mucos
inocul
hsv
suscept
strain
mice
develop
recurr
multifoc
cn
demyelin
preced
spread
viru
lip
peripher
nervou
system
cn
contrast
mice
develop
cn
demyelin
viral
access
cn
restrict
object
studi
identifi
immun
mechan
restrict
hsv
entri
cn
mice
control
along
mice
deplet
immun
cell
subset
knock
ko
mice
lip
inocul
hsv
strain
viral
titer
lip
trigemin
ganglia
tg
brain
determin
serial
studi
hsv
restrict
lip
tg
control
mice
treat
either
monoclon
antibodi
mab
mab
mab
combin
mab
viru
also
restrict
lip
tg
j
dlablea
j
ko
mice
hsv
spread
throughout
cn
j
mice
associ
signific
mortal
contrast
viru
spread
throughout
cn
j
mice
infect
limit
first
day
post
infect
pi
thu
tcell
nknkt
cell
tcell
tcell
limit
hsv
infect
lip
tg
restrict
spread
viru
cn
contrast
viru
spread
throughout
brain
j
mice
tcell
nknkt
cell
affect
without
signific
mortal
suggest
interact
innat
adapt
immun
requir
restrict
spread
hsv
cn
vivo
select
tcell
receptor
junction
region
sequenc
human
tcell
lymphotrop
viru
type
envelop
peptid
complex
associ
myelopathytrop
spastic
paraparesi
hamtsp
human
tcell
lymphotrop
viru
type
associ
myelopathytrop
spastic
paraparesi
hamtsp
neurolog
diseas
observ
infect
individu
previous
report
associ
suscept
hamtsp
two
independ
htlvi
infect
cohort
southern
japan
kagoshima
northeastern
iran
mashhad
wherea
envelop
cell
restrict
character
role
restrict
env
specif
cell
chronic
infect
exploit
tetramer
mhcpeptid
complex
along
magnet
cell
sort
purifi
envelop
cell
directli
peripher
blood
lymphocyt
two
posit
hamtsp
patient
rtpcr
spectratyp
sequenc
analysi
tcr
reveal
junction
sequenc
deriv
two
unrel
hamtsp
patient
share
ident
amino
acid
motif
region
data
provid
strong
evid
sever
differ
cell
bear
distinct
tcr
stimul
complex
prolifer
vivo
ie
select
certain
tcr
gene
sequenc
exert
vivo
mhcpeptid
complex
safeti
efficaci
patient
myelopathi
ham
object
postmarket
surveil
studi
undertaken
investig
safeti
efficaci
ham
routin
treatment
condit
method
total
case
medic
institut
regist
survey
far
case
evalu
safeti
efficaci
efficaci
evalu
rate
base
clinic
symptom
ham
result
rate
respons
treatment
rate
improv
fair
week
factor
significantli
affect
efficaci
week
initi
osam
motor
disabl
score
omd
therapi
durat
stage
ill
sustain
improv
omd
least
month
stop
observ
patient
total
advers
drug
reaction
adr
occur
patient
seriou
incid
adr
higher
previous
report
control
trial
although
specif
adr
occur
patient
ham
conclus
result
indic
treatment
effect
least
patient
incipi
stage
ham
though
incid
adr
rather
high
longterm
administr
may
advantag
maintain
improv
condit
treatment
thu
suitabl
protocol
administr
ham
need
defin
futur
enter
brain
stay
brain
neuroaid
complic
hiv
infect
affect
hiv
individu
trigger
earli
presenc
viru
brain
siv
infect
rhesu
macaqu
parallel
human
hiv
infect
includ
develop
cn
diseas
neurophysiolog
alter
allow
recognit
earli
sign
cn
dysfunct
analysi
alter
immunecel
brain
correl
cn
dysfunct
show
remark
increas
highli
activ
memori
ctl
infect
brain
specif
cell
investig
found
brain
ctl
recogn
immunodomin
epitop
tat
gag
monkey
mhc
haplotyp
blood
csf
tatspecif
cell
peak
acut
phase
becom
undetect
thereaft
howev
brain
cell
remain
larg
proport
accumul
ctl
hypothes
virusspecif
cell
enter
brain
acut
phase
maintain
chronic
stage
dpi
enrich
tat
gagspecif
cell
brain
alreadi
observ
suggest
earli
entri
factor
favor
surviv
examin
undetect
increas
fold
sivinfect
brain
vitro
effici
support
surviv
increas
cycl
cell
express
memori
marker
result
suggest
brain
environ
support
surviv
sivspecif
bystand
memori
ctl
taken
togeth
increas
level
infect
brain
favor
activ
proinflammatori
virusspecif
ctl
enter
brain
acut
phase
persist
potenti
particip
develop
inflammatori
patholog
axon
transport
toxic
lectin
pn
target
inflammatori
demyelin
lesion
site
wallerian
degener
cn
theiler
viru
infect
lesion
develop
axon
insid
myelin
outsid
tsunoda
tanaka
saijoh
b
e
doyl
e
j
terri
r
fujinami
depart
neurolog
neurobiolog
anatomi
b
univers
utah
school
medicin
salt
lake
citi
utah
usa
theiler
murin
encephalomyel
viru
tmev
infect
anim
model
multipl
sclerosi
ms
axon
injuri
preced
inflammatori
demyelin
distribut
axon
injuri
earli
phase
correspond
region
subsequ
demyelin
occur
chronic
phase
hypothes
axon
injuri
recruit
inflammatori
cell
site
wallerian
degener
lead
demyelin
scenario
lesion
develop
axon
insid
myelin
outsid
insideout
model
establish
method
induct
wallerian
degener
central
nervou
system
cn
approach
use
toxic
lectin
ricinu
communi
agglutinin
rca
lead
bloodbrain
barrier
breakdown
lectin
inject
sciatic
nerv
transport
axon
lead
death
dorsal
root
ganglion
cell
wallerian
degener
posterior
funiculu
spinal
cord
use
microinject
system
inject
lectin
sciatic
nerv
sjlj
mice
week
tmev
infect
neuropatholog
examin
week
lectin
inject
control
mice
receiv
tmev
lectin
inflammatori
demyelin
lesion
anterior
later
funiculi
contrast
lectininject
infect
mice
lesion
anterior
later
funiculi
well
posterior
funiculu
lesion
present
ipsilater
inject
side
found
differ
antitmev
lymphoprolif
respons
group
suggest
axon
injuri
could
contribut
recruit
inflammatori
cell
cn
alter
local
microenviron
activ
microglia
recent
studi
show
neural
precursor
cell
npc
attenu
experiment
autoimmun
encephalomyel
eae
intracerebroventricular
intraven
iv
inject
npc
therapi
eae
associ
decreas
brain
inflamm
tissu
injuri
studi
mechan
iv
inject
npc
inhibit
myelin
oligodendrocyt
glycoprotein
mog
induc
eae
mice
iv
npc
therapi
day
post
eae
induct
attenu
clinic
cours
eae
reduc
brain
inflamm
tissu
injuri
microscop
analysi
reveal
npc
enter
brain
detect
lymph
node
spleen
direct
interact
npc
lymph
node
cell
lnc
examin
vitro
cocultur
experi
show
neurospher
attenu
significantli
prolifer
eaederiv
tcell
respons
mog
well
tcell
respons
nonspecif
activ
cona
neurospher
also
inhibit
moginduc
product
proinflammatori
cytokin
lnc
analysi
cfse
emiss
descent
express
dna
content
annexinv
express
indic
npc
block
tcell
activ
prolifer
rather
induc
lnc
death
final
examin
relev
npclnc
interact
vivo
util
proteolipid
plp
induc
transfer
eae
model
sjlj
mice
transfer
lnc
deriv
npctreat
plpimmun
mice
recipi
caus
significantli
milder
diseas
transfer
lnc
nontreat
mice
indic
npc
therapi
reduc
encephalitogen
lnc
find
suggest
peripher
immunosuppress
effect
ivinject
npc
nonspecif
inhibitori
effect
activ
prolifer
lymphocyt
lymph
node
neural
stemprecursor
cell
npc
transplant
experiment
autoimmun
encephalomyel
mice
unravel
molecular
base
npcdepend
immunomodul
transplant
undifferenti
adult
neural
stemprecursor
cell
anpc
promot
longlast
neuroprotect
experiment
multipl
sclerosi
remyelin
injur
central
nervou
system
csn
axon
well
immunomodulatori
function
system
transplant
anpc
enter
brain
spinal
cord
select
reach
inflam
cn
areasth
atyp
perivascular
nich
major
stem
cell
regul
focal
expressedand
surviv
vivo
day
transplant
explor
immunomodulatori
properti
adult
neural
precursor
cell
anpc
mice
experiment
autoimmun
encephalomyel
eae
intraven
iv
inject
syngen
anpc
mice
relapsingremit
form
diseas
sjl
femal
mice
immun
subcutan
proteolipid
protein
plp
iv
inject
syngen
anpc
onset
diseas
transplant
anpc
accumul
persist
day
transplant
within
major
secondari
lymphoid
organ
whereagainmajor
stem
cell
regul
eg
fgfii
notch
bmp
etc
dynam
eg
day
immun
express
protein
mrna
level
vitro
experi
show
anpc
effici
inhibit
antigenspecif
prolifer
cocultur
plpreactiv
encephalitogen
cell
preliminari
data
show
systemicallyinject
anpc
may
surviv
vivo
even
long
period
time
protect
chronic
cn
inflamm
owe
capabl
exert
immunomodulatori
function
within
canon
central
eg
cn
well
noncanon
peripher
eg
lymph
node
site
accumul
stem
cell
surviv
factor
ectop
express
respons
inflamm
mesenchym
stem
cell
treat
relapsingremit
experiment
autoimmun
encephalomyel
dual
effect
inflamm
tissu
damag
gerdoni
e
gallo
b
casazza
pedemont
e
musio
mancardi
gl
pedotti
r
uccelli
mesenchym
stem
cell
msc
subset
adult
stem
cell
deriv
bone
marrow
stroma
repres
appeal
tool
regen
medicin
recent
studi
demonstr
msc
modul
immun
respons
support
util
treatment
autoimmun
thu
sought
verifi
whether
msc
cure
mice
affect
experiment
autoimmun
encephalomyel
induc
peptid
proteolipid
protein
plp
myelin
antigen
capabl
induc
potent
pathogen
b
cell
respons
msc
treat
mice
show
significantli
milder
diseas
fewer
relaps
compar
control
vivo
plp
specif
antibodi
titr
antigenspecif
cell
respons
significantli
lower
msc
treat
mice
adopt
transfer
encephalitogen
plp
sensit
precondit
msc
induc
milder
diseas
compar
control
msc
treat
encephalitogen
cell
show
decreas
product
prolifer
upon
antigen
recal
thu
consid
anerg
upon
iv
inject
green
fluoresc
protein
gfp
label
msc
detect
insid
lymph
node
earli
upon
inject
insid
inflam
cn
later
stage
msc
inject
result
decreas
number
inflammatori
infiltr
reduc
demyelin
apoptot
neural
cell
consequ
spare
axon
oligodendrocyt
contrast
evid
gfp
label
neural
cell
detect
thu
support
hypothesi
transdifferenti
overal
propos
msc
may
dual
function
may
effect
treatment
ms
autoimmun
diseas
cn
degener
neural
cell
follow
inflamm
bone
marrow
bm
deriv
mesenchym
stromal
stem
cell
msc
differenti
certain
circumst
cell
variou
tissu
aim
studi
investig
abil
bmmsc
migrat
cn
inflam
tissu
differenti
cell
neuralgli
lineag
chronicea
model
evalu
whether
cell
exert
benefici
clinic
effect
msc
obtain
gfptransgen
mice
cell
cultur
combin
growth
factor
check
differenti
properti
msc
inject
intraventricularli
icv
mice
chronicea
initi
phase
diseas
anim
follow
clinic
least
two
month
vitro
msc
show
abil
differenti
cell
neural
gliallik
morpholog
stain
gfap
nestin
cultur
msc
show
immunomodulatori
properti
significantli
downregul
lymphocyt
prolifer
myelin
antigen
vivo
icv
inject
msc
suppress
clinic
mortal
vs
control
mean
maxim
score
vs
histopatholog
manifest
chronicea
induc
signific
neuroprotect
axon
unaffect
treat
anim
vs
control
msc
migrat
inflam
lesion
found
present
immunohistolog
characterist
neuron
glial
cell
result
indic
autolog
bm
provid
sourc
stem
cell
downregul
clinicopatholog
sign
chronicea
carri
neuroprotect
potenti
treatment
protocol
may
applic
diseas
like
multipl
sclerosi
inject
human
neurospher
amelior
nonhuman
primat
model
multipl
sclerosi
transplant
human
foetal
npc
nonhuman
primat
experiment
autoimmun
encephalomyel
eae
eae
induc
marmoset
follow
subcutan
administr
recombin
human
myelinoligodendrocyt
glycoprotein
mog
complet
freund
adjuv
order
detect
also
sub
clinic
eae
immun
monkey
underw
serial
everi
week
immun
brain
magnet
reson
mr
clinic
subclin
diseas
onset
marmoset
inject
either
intraven
iv
n
intrathec
ie
cerebrospin
fluid
csf
n
remain
six
monkey
use
shamtreat
control
npc
vitro
prelabel
insert
green
fluoresc
protein
gfp
gene
gener
lentiviralbas
infect
marmoset
receiv
daili
intramuscular
cyclosporin
mgkg
treatment
time
diseas
onset
clinic
score
weight
daili
monitor
along
daylong
follow
period
eae
monkey
transplant
iv
well
ic
hfnpc
show
amelior
eae
mean
cumul
daili
score
ii
relaps
per
day
followup
iii
eaerel
death
iv
cumul
surviv
reduct
demyelin
axon
loss
observ
transplant
marmoset
histopatholog
great
major
transplant
cell
accumul
within
chronicallyinflam
cn
persist
time
around
inflam
cn
perivascular
area
without
display
major
featur
termin
differenti
result
critic
propedeut
import
envisag
futur
use
hfnpc
safe
efficaci
neuroprotect
therapi
ms
cellular
molecular
analysi
svzresid
neural
stem
cell
mice
affect
chronic
experiment
autoimmun
encephalomyel
eae
author
contribut
equal
work
adopt
multidisciplinari
approach
analys
kynet
subventricular
zone
svz
resid
neural
stemprecursor
cell
npc
chronic
experiment
autoimmun
encephalomyel
eae
mice
adult
femal
mice
immun
myelinoligodendrocyt
glycoprotein
mog
combin
vivo
situ
ex
vivo
analys
perform
differ
timepoint
immun
fastand
slowcycl
svzresid
npc
studi
intraperiton
inject
puls
iddubrdu
prior
sacrif
orient
mitot
cleavag
endogen
divid
npc
name
measur
sub
fraction
npc
undergo
asymmetr
vs
symmetr
cell
divis
also
studi
earli
eg
day
immun
increas
brdu
incorpor
svzresid
glial
neuron
progenitor
reveal
confoc
microscopi
parallel
vitro
data
show
progress
impair
clonal
effici
within
neurospher
cell
line
establish
eae
mice
start
dpi
peak
dpi
slowli
insuffici
recov
later
time
point
differ
sphere
size
vitro
growth
rate
found
group
preliminari
result
show
increas
cell
prolifer
within
svz
neurogen
nich
parallel
strike
quantit
impair
endogen
neural
stem
cell
compart
studi
aim
identif
cellular
molecular
pathway
involv
reactivationreprogram
cell
type
trigger
lesion
may
help
solv
andor
improv
contribut
endogen
npc
repair
mechan
adenosin
releas
site
inflamm
tissu
damag
activ
adenosin
receptor
mani
report
adenosin
receptormedi
effect
neuroprotect
howev
adenosin
may
also
aggrav
neuron
injuri
promot
inflamm
recent
demonstr
antiinflammatori
function
foami
macrophag
multipl
sclerosi
ms
lesion
hypothes
express
adenosin
receptor
alter
cell
therebi
affect
function
therefor
determin
mrna
express
level
adenosin
receptor
human
myelinladen
macrophag
vitro
ms
lesion
receptor
mrna
express
significantli
downregul
foami
macrophag
compar
control
macrophag
lp
strongli
induc
mrna
express
control
foami
macrophag
contrast
lp
synergist
downregul
receptor
mrna
foami
macrophag
compar
control
macrophag
assess
whether
potent
mrna
regul
also
occur
ms
express
level
determin
ms
brain
brain
tissu
nondement
control
receptor
mrna
significantli
upregul
ms
brain
express
correl
lesion
activ
immunohistochemistri
reveal
cell
express
receptor
ms
brain
data
demonstr
adenosin
receptor
express
ms
brain
foami
macrophag
vitro
strongli
regul
alter
balanc
express
level
differ
adenosin
receptor
like
influenc
function
respons
adenosin
unravel
function
immunemodulatori
receptor
allow
better
understand
endogen
neuroprotect
mechan
may
therebi
open
new
road
diseas
intervent
orphan
nuclear
receptor
overexpress
peripher
blood
lymphocyt
multipl
sclerosi
yoshimitsu
doi
shinji
oki
junichi
satoh
toshimasa
aranami
sachiko
miyak
takashi
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
tokyo
japan
object
studi
role
subfamili
nuclear
receptor
immunopathogenesi
multipl
sclerosi
ms
background
nurrel
nerv
growth
factorinduc
geneb
ngfib
neuronrel
orphan
transcript
factor
steroidthyroid
receptor
superfamili
rapidli
induc
exposur
growth
factor
cytokin
suggest
biolog
role
cell
growth
differenti
apoptosi
pei
et
al
jbc
one
transcript
target
osteopontin
opn
lammi
et
al
mol
endocrinol
analyz
cdna
microarray
found
upregul
cell
ms
patient
compar
healthi
control
cn
subject
satoh
et
al
neurobiol
di
howev
activ
role
transcript
target
ms
remain
unknown
method
opn
mrna
level
quantit
analyz
cdna
cell
untreat
activ
ms
patient
cn
subject
realtim
pcr
result
significantli
upregul
ms
cell
level
correl
opn
conclus
quantit
realtim
rtpcr
confirm
upregul
ms
cell
although
specif
transcript
target
cell
remain
unknown
might
play
role
immunopathogenet
mechan
ms
patient
genom
evid
subtyp
multipl
sclerosi
presenc
viral
respons
signatur
subpopul
patient
despit
epidemiolog
support
hypothesi
presenc
physiolog
signific
viral
infect
ms
still
unclear
studi
analyz
whole
blood
gene
express
profil
patient
relaps
remit
rr
ms
age
sex
match
healthi
control
compar
analysi
identifi
stereotyp
gene
express
program
appear
reflect
viru
respons
program
peripher
blood
cell
patient
rrm
subsequ
analysi
reveal
viru
respons
program
characterist
approxim
half
rrm
patient
thu
transcript
signatur
peripher
blood
cell
defin
subpopul
rrm
patient
exhibit
evid
link
virus
ms
mechan
respons
local
lesion
multipl
sclerosi
ms
current
unknown
investig
perform
hladr
hladq
type
examin
tcell
reactiv
myelin
protein
patient
ms
immunomodulatori
therapi
healthi
subject
patient
diseas
central
nervou
system
cn
found
ms
patient
brainstem
cerebellar
lesion
determin
clinic
assess
andor
magnet
reson
imag
increas
circul
tcell
reactiv
immunodomin
region
myelin
proteolipid
protein
compar
ms
patient
without
brainstem
cerebellar
lesion
healthi
subject
patient
cn
diseas
p
also
found
ms
patient
brainstem
cerebellar
lesion
carri
allel
wherea
patient
without
brainstem
cerebellar
lesion
carri
allel
p
furthermor
ms
patient
carri
allel
increas
tcell
reactiv
plp
compar
ms
patient
carri
hla
allel
p
interestingli
k
mice
immun
plp
also
develop
inflammatori
demyelin
lesion
predominantli
brainstem
cerebellum
result
indic
tcell
reactiv
plp
drive
develop
brainstem
cerebellar
lesion
ms
patient
carri
allel
therapi
alter
peptid
ligand
base
plp
might
prevent
develop
brainstem
cerebellar
lesion
system
biolog
approach
immun
system
network
reveal
function
differ
health
multipl
sclerosi
p
villoslada
r
palacio
j
n
velez
j
sepulcr
background
function
knowledg
properti
gene
network
control
biolog
function
might
critic
understand
complex
diseas
multipl
sclerosi
ms
aim
model
gene
network
control
tcell
activationdifferentiationsuppress
process
critic
develop
ms
assess
function
properti
health
autoimmun
method
model
network
critic
immun
system
gene
use
scientif
text
mine
experiment
data
healthi
control
patient
ms
obtain
realtim
pcr
use
bayesian
approach
compar
function
differ
network
health
autoimmun
use
kullbackleibl
kl
diverg
pair
node
result
found
network
link
geneinteract
alreadi
known
expect
non
previous
describ
valid
link
expect
new
one
found
signific
differ
control
ms
network
mainli
regulatori
proinflammatori
pathway
addit
identifi
effect
interferon
beta
therapi
network
mainli
interact
conclus
result
indic
assess
properti
immun
gene
network
use
system
biolog
approach
reveal
signific
chang
autoimmun
provid
insight
effect
immunomodulatori
therapi
object
character
tcell
infiltr
vivo
expand
clonotyp
deriv
ms
lesion
background
oligoclon
expand
tlymphocyt
perpetu
inflammatori
respons
cn
myelin
antigen
studi
address
represent
ms
lesion
variou
stage
develop
antigen
specif
method
brain
spinal
cord
tissu
obtain
six
hour
post
mortem
femal
patient
aggress
relaps
remit
rr
ms
lesion
character
base
longitudin
cn
mri
last
one
day
prior
death
histopatholog
immunohistochemistri
studi
viabl
cell
six
lesion
normal
appear
white
matter
nawm
expand
vitro
studi
vivo
expand
clonotyp
tcrvb
usag
infiltr
lesion
nawm
rtpcramplifi
tcr
gene
perform
singlestrand
conform
polymorph
sscp
pattern
analysi
result
antigen
specif
mslesion
deriv
tcell
test
panel
immunodomin
myelinderiv
peptid
highest
prolif
respons
detect
plp
acut
pontin
chronic
periventricular
thorac
spine
lesion
cell
deriv
acut
lesion
exhibit
prolif
respons
six
myelin
peptid
four
recogn
chronic
thorac
three
chronic
periventricular
lesion
singlestrand
conform
polymorph
sscp
pattern
analysi
identifi
limit
number
tcrvb
chain
express
correl
vivo
expand
clonotyp
reveal
distinct
pattern
tcr
vb
famili
chain
ms
lesion
nawm
howev
present
lesion
antigen
specif
clone
correspond
vivo
expand
clonotyp
present
character
use
synthet
combinatori
peptid
librari
relev
first
studi
character
postmortem
deriv
tcell
infiltr
ms
lesion
variou
stage
develop
endotheli
cell
weibelpalad
bodi
regul
blood
brain
barrier
function
suscept
experiment
allerg
encephalomyel
pertussi
toxin
ptx
immunopotenti
adjuv
experiment
allerg
encephalomyel
eae
also
elicit
leukocytosi
alter
glucos
regul
vascular
permeabl
bloodtissu
barrier
function
sensit
vascular
endothelium
vasoact
amin
histamin
bph
mechan
underli
bph
unknown
requir
day
latenc
last
day
suggest
induct
phase
associ
storag
preform
vasoact
factor
releas
effector
phase
weibelpalad
bodi
wpb
within
endotheli
cell
ec
secretori
granul
known
releas
preform
chemokin
adhes
molecul
von
willebrand
factor
vwf
follow
exposur
histamin
mice
disrupt
vwf
allel
vwfko
ec
defici
wpb
use
evalu
role
pathway
bph
suscept
eae
signific
differ
suscept
bph
wildtyp
vwfko
mice
detect
three
day
howev
vwfko
mice
sensit
persist
longer
ld
histamin
lower
later
time
point
correspondingli
onset
eae
earlier
diseas
sever
blood
brain
barrier
bbb
permeabl
significantli
increas
vwfko
mice
compar
wildtyp
mice
increas
bbb
permeabl
vwfko
mice
due
increas
encephalitogen
tcell
activ
sinc
bbb
permeabl
significantli
greater
ptxtreat
vwfko
mice
compar
mice
receiv
encephalitogencomplet
freund
adjuv
cfa
ptx
cfa
ptx
cfa
taken
togeth
data
indic
wpb
normal
repress
bph
adjuvantinduc
alter
bbb
function
associ
activ
induc
eae
comparison
monocyt
lymphocyt
traffick
blood
retin
barrier
vivo
h
xu
manivannan
b
r
dawson
ij
crane
j
liversidg
depart
ophthalmolog
b
depart
radiolog
univers
aberdeen
scotland
uk
neural
inflamm
caus
lymphocyt
monocyt
infiltr
across
tight
junction
bloodbrain
barrier
mechan
involv
adhes
transendotheli
migrat
differ
leukocyt
subset
unclear
use
scan
laser
ophthalmoscopi
investig
traffick
monocyt
compar
cell
traffick
bloodretina
barrier
brb
neuroretina
extend
organ
brain
normal
circumst
retin
vessel
subject
high
shear
stress
leukocyt
roll
activ
cell
migrat
neuroretina
absenc
roll
adhes
molecul
critic
transendotheli
migrat
inflam
retina
reduc
shear
stress
arteriol
venul
brb
leukocyt
roll
venul
cell
monocyt
roll
similar
level
howev
primedactiv
cell
roll
higher
effici
differ
adhes
molecul
respons
roll
differ
leukocyt
subset
vivo
condit
monocyt
roll
faster
primedactiv
cell
fast
roll
appear
lselectin
depend
also
involv
roll
monocyt
cell
wherea
involv
roll
activ
leukocyt
transendotheli
migrat
crucial
cell
diapedesi
monocyt
conclus
reduc
shear
stress
requir
leukocyt
roll
brb
differ
adhes
molecul
involv
traffick
differ
leukocyt
subset
brb
serv
ligand
sever
receptor
present
surfac
immun
cell
includ
express
high
level
endotheli
cell
investig
role
adhes
traffic
inflammatori
cell
experiment
allerg
encephalomyel
eae
use
vitro
techniqu
studi
adhes
migrat
blood
flow
condit
show
virtu
abil
bind
potent
substrat
adhes
cell
macrophag
function
appear
critic
vivo
null
mice
background
complet
resist
develop
moginduc
eae
spite
abil
gener
normal
immun
respons
mog
ie
normal
prolifer
antibodi
cytokin
product
upon
rechalleng
mog
vitro
vivo
role
traffick
also
suggest
find
use
immunohistochemistri
express
constitut
high
level
perimening
blood
vessel
cn
support
histolog
flow
cytometr
analys
perform
variou
interv
postea
induct
show
virtual
complet
absenc
macrophag
inflammatori
cell
infiltr
cn
null
mice
thu
find
suggest
serv
adhes
molecul
express
blood
vessel
requir
traffic
inflammatori
cell
cn
parenchyma
small
g
protein
rhoa
control
lymphocyt
recruit
brain
vessel
induct
experiment
autoimmun
encephalomyel
recent
demonstr
domain
small
g
protein
rhoa
control
integrin
affin
rhoa
domain
control
later
mobil
cluster
cell
show
rhoa
control
modal
integrin
activ
goal
studi
determin
role
rhoa
recruit
autoreact
lymphocyt
inflam
brain
vessel
induct
experiment
autoimmun
encephalomyel
eae
method
use
trojan
peptid
abl
block
rhoa
effector
region
consist
sequenc
antennapedia
abl
transloc
cell
membran
link
domain
rhoa
intravit
microscopi
inflam
mous
brain
microcircul
induct
eae
adopt
transfer
reactiv
cell
perform
result
trojan
peptid
alter
intracellular
calcium
releas
adhes
molecul
express
distribut
prolifer
specif
cell
intravit
microscopi
studi
show
trojan
peptid
inhibit
stabl
adhes
encephalitogen
lymphocyt
inflam
brain
venul
without
affect
roll
contrast
control
peptid
ineffect
moreov
rhoa
peptid
abl
block
transfer
eae
induc
specif
cell
incid
diseas
mean
clinic
score
significantli
lower
anim
treat
rhoa
peptid
conclus
select
region
rhoa
control
autoreact
cell
migrat
inflam
brain
critic
role
induct
eae
signal
regul
leukocyt
recruit
brain
injuri
injuri
central
nervou
system
cn
provok
innat
inflammatori
reaction
engag
infiltr
leukocyt
capac
repair
andor
exacerb
tissu
damag
initi
cue
orchestr
leukocyt
entri
injur
cn
remain
poorlydefin
use
flow
cytometri
investig
whether
adaptor
protein
transmit
signal
tolllik
receptor
tlr
receptor
interleukin
il
regul
leukocyt
infiltr
stabinjur
entorhin
cortex
ec
site
axon
degener
denerv
hippocampu
previous
establish
kinet
leukocyt
entri
denerv
hippocampu
show
signific
leukocyt
entri
occur
within
h
stab
injuri
ec
wherea
cell
show
small
gradual
increas
day
macrophag
infiltr
pronounc
peak
within
h
infiltr
coincid
increas
mrna
disintegrin
metalloproteinas
adam
reduc
macrophag
infiltr
stabinjur
ec
denerv
hippocampu
day
postinjuri
abrog
cell
infiltr
denerv
hippocampu
time
reduc
cell
entri
stabinjur
ec
strongli
reduc
stabinjuri
induc
transcript
increas
sever
hundr
fold
time
peak
express
wildtyp
mice
h
stab
injuryinduc
leukocyt
recruit
gene
express
unaffect
defici
data
show
signal
import
proinflammatori
gene
express
leukocyt
recruit
cn
injuri
chemokin
receptor
thought
play
import
role
induct
autoimmun
diseas
central
nervou
system
cn
attract
immun
effector
cell
peripheri
brain
aim
studi
develop
techniqu
would
lead
loss
function
hematopoiet
cell
order
reduc
infiltr
blood
born
cell
brain
experiment
autoimmun
encephalomyel
eae
use
bone
marrow
bm
chimer
mice
demonstr
express
hematopoiet
cell
radioresist
cnsresid
cell
determin
eae
diseas
cours
moreov
find
mix
chimera
bm
mice
highli
suscept
diseas
suggest
express
b
lymphocyt
requir
eae
develop
next
gener
mutant
murin
sitedirect
mutagenesi
cell
transfect
wildtyp
stimul
ligand
monocyt
chemoattract
rapid
transient
increas
intracellular
calcium
concentr
observ
calcium
respons
complet
abolish
cotransfect
cell
wildtyp
transduct
adult
hematopoiet
stem
cell
subsequ
gener
bm
chimer
mice
use
determin
contribut
myeloid
cell
inflammatori
respons
eae
interferongamma
induc
chemokin
pertussi
toxin
synerg
promot
cell
entri
central
nervou
system
inflamm
central
nervou
system
cn
occur
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
character
increas
level
interferongamma
cytokin
normal
express
cn
investig
role
cn
use
intrathec
inject
replicationdefect
adenoviru
encod
murin
sjlj
mice
gko
result
stabl
longliv
express
elisadetect
cerebrospin
fluid
induc
express
cn
chemokin
level
compar
seen
eae
chemokin
induc
mice
lack
receptor
show
respons
control
viral
vector
induc
chemokin
express
chemokin
express
predominantli
local
mening
ependym
cell
also
seen
astrocyt
microglia
chemokin
express
lead
inflamm
howev
pertussi
toxin
given
intraperiton
mice
infect
vector
dramat
increas
number
lymphocyt
detect
cn
flow
cytometri
increas
bloodderiv
immun
cell
cn
occur
pertussi
toxin
alon
manifest
histolog
detect
inflammatori
patholog
result
show
induc
characterist
glial
chemokin
respons
insuffici
promot
inflamm
cn
chemoattract
signal
synerg
peripher
infecti
stimulu
drive
cell
entri
cn
antigen
present
capac
glial
cell
type
cn
infect
acut
cn
infect
nonleth
neurotrop
coronaviru
control
lymphocyt
perforin
mediat
cytolysi
control
viru
replic
macrophagesmicroglia
astrocyt
implic
tcrclass
interact
contrast
ifngamma
control
viru
replic
oligodendroglia
suggest
inher
resist
cytolysi
despit
effector
function
cell
retent
viru
persist
glia
result
ongo
demyelin
investig
molecular
basi
gliat
cell
interact
vivo
microglia
astrocyt
oligodendroglia
isol
infect
mice
analyz
mhc
express
mrna
encod
antigen
process
molecul
maxim
surfac
class
express
delay
astrocyt
oligodendroglia
compar
microglia
enhanc
class
express
consist
earlier
transcript
gene
associ
antigenprocess
machineri
specif
microglia
compar
oligodendroglia
furthermor
biphas
transcript
profil
observ
microglia
contrast
sharp
express
peak
oligodendroglia
coincid
maxim
cell
effector
function
oligodendroglia
also
distinct
microglia
strong
upregul
cell
inhibitori
ligand
substanti
strict
control
cell
effector
function
contrast
class
express
class
ii
upregul
extens
microglia
limit
oligodendroglia
astrocyt
summari
microglia
enhanc
earlier
potenti
present
antigen
compar
oligodendroglia
astrocyt
due
distinct
respons
type
iand
type
iiifn
nevertheless
prolong
antigen
present
capac
implic
sustain
mhc
express
glial
cell
type
may
mute
differenti
express
modulatori
molecul
immunemedi
loss
neuron
secondari
destruct
support
astrocyt
neuron
injuri
loss
increasingli
recogn
compon
patholog
multipl
sclerosi
ms
publish
data
indic
cell
mediat
neuron
damag
mhcantigenrestrict
well
mhcunrestrict
manner
spare
astrocyt
contrast
gliadirect
neurocytotox
shown
occur
vitro
innat
immunecel
cell
natur
killer
nk
cell
sought
determin
nk
cell
could
damag
human
neuron
util
nk
cell
normal
adult
blood
primari
human
neuronglia
cultur
deriv
fetal
brain
tissu
interestingli
found
although
coincub
nk
cell
neuronglia
cultur
result
detach
neuron
neuron
viabil
determin
propidium
iodid
exclus
normal
time
point
examin
contrast
underli
astrocyt
constitut
cultur
effici
kill
nk
cell
timelaps
video
microscopi
indic
nk
cell
began
target
glial
cell
within
minut
coincub
wherea
neuron
larg
ignor
h
remain
neuron
found
clump
surviv
glial
cell
determin
confoc
microscopi
data
consist
model
indirect
neuron
injuri
mediat
innat
immun
cell
neuron
loss
reflect
primari
loss
glial
trophic
substrat
support
invari
nkt
cell
promot
icosdepend
product
b
cell
regul
inflamm
model
multipl
sclerosi
j
ludov
croxford
sachiko
miyak
michio
shimamura
b
takashi
yamamura
depart
immunolog
nation
institut
neurosci
tokyo
japan
b
development
immunolog
unit
mitsubishi
kagaku
institut
tokyo
japan
recent
new
popul
nkt
cell
restrict
nonclass
mhc
class
molecul
describ
nkt
cell
express
invari
cell
receptor
nkt
howev
function
immun
unknown
human
nkt
cell
homolog
nkt
cell
detect
multipl
sclerosi
ms
inflammatori
cn
lesion
therefor
determin
role
nkt
cell
experiment
autoimmun
encephalomyel
eae
tcell
mediat
autoimmun
demyelin
diseas
cn
model
ms
contrast
human
mice
extrem
low
number
nkt
cell
therefor
use
tcr
tg
mice
cross
defici
mice
lack
nkt
cell
observ
overexpress
nkt
cell
protect
mice
eae
associ
decreas
cytokin
increas
addit
adopt
transfer
nkt
cell
wt
eae
mice
could
also
inhibit
clinic
diseas
contrast
mice
defici
nkt
cell
exhibit
exacerb
eae
cocultur
nkt
cell
b
cell
demonstr
b
cell
induc
produc
antiinflammatori
cytokin
known
inhibit
eae
product
b
cell
icosdepend
independ
studi
demonstr
nkt
cell
regulatori
function
eae
therefor
may
attract
therapeut
target
therapi
ms
autoimmun
diseas
activ
nkt
cell
novel
glycolipid
may
allow
diseasespecif
therapi
oral
session
immunemedi
patholog
neuroprotect
abstract
immunomodul
microgli
phenotyp
implic
multipl
sclerosi
alzheim
diseas
cell
renew
adult
central
nervou
system
cn
limit
block
inflammatori
brain
condit
microglia
play
major
role
cellular
immun
respons
associ
neurodegener
show
tcellderiv
cytokin
induc
microglia
becom
neuroprotect
induc
cell
renew
contrast
aggreg
induc
microglia
becom
cytotox
block
neurogenesi
oligodendrogenesi
adult
rodent
neural
stemprogenitor
cell
npc
addit
high
level
low
level
cytokin
associ
inflammatori
autoimmun
diseas
confer
rodent
microglia
phenotyp
imped
oligodendrogenesi
npc
revers
impedi
attenu
product
overcam
blockag
insulin
like
growth
factor
igf
product
rodent
acut
chronic
experiment
autoimmun
encephalomyel
inject
microglia
cerebr
spinal
fluid
result
improv
clinic
symptom
increas
oligodendrogenesi
endogen
stem
cell
pool
spinal
cord
induc
neurogenesi
dentat
gyru
spatial
associ
microglia
express
mhcii
igfi
use
doubletransgen
mice
express
mutant
human
gene
encod
amyloid
precursor
protein
mous
model
alzheim
diseas
show
modul
microglia
dendriticlik
cell
achiev
cellbas
vaccin
result
reduct
cognit
declin
elimin
plaqu
format
induct
neuron
surviv
neurogenesi
result
introduc
new
microglia
phenotyp
necessari
player
fight
neurodegen
condit
uptak
microgli
cell
proinflammatori
cytokin
nation
institut
longev
scienc
obu
japan
alzheim
diseas
ad
character
extracellular
deposit
fibrillar
brain
accompani
abund
phenotyp
activ
microglia
brain
recent
studi
show
immunotherapi
reduc
amyloid
burden
brain
ad
model
mice
antibodi
enhanc
phagocytosi
microgli
cell
igg
receptor
fcr
depend
manner
address
whether
proinflammatori
cytokin
could
influenc
antibodymedi
phagocytosi
microglia
use
aggreg
fluorescentlabel
lysosom
probe
examin
phagocytosi
fibrillar
lysosom
pathway
mous
primari
cultur
microgli
cell
murin
microgli
cell
line
presenc
absenc
antibodi
proinflammatori
cytokin
antibodi
drastic
enhanc
phagocytosi
antibodi
block
proinflammatori
cytokin
tumor
necrosi
factor
decreas
uptak
well
lyososom
vesicl
format
proinflammatori
cytokin
inhibit
uptak
induc
antibodi
howev
antibodi
treatment
presenc
proinflammatori
cytokin
caus
microgli
cell
damag
character
larg
cytoplasm
vacuol
result
show
antibodi
releas
proinflammatori
cytokineinduc
suppress
phagocytosi
microgli
cell
phagocytosi
proinflammatori
condit
lead
microgli
dysfunct
find
support
vaccinationbas
therapi
combin
antiinflammatori
therapi
clear
deposit
ad
brain
new
mechan
underli
glatiram
acet
mediat
neuroprotect
jianuo
liu
jami
lin
peter
old
jason
g
glanzer
tatiana
k
bronich
steve
caplan
yuri
persidski
howard
e
gendelman
jonathan
kipni
glatiram
acet
ga
synthet
copolym
shown
induc
neuroprotect
sever
acut
chronic
neurodegen
condit
mechan
underli
neuroprotect
activ
howev
remain
obscur
mani
studi
focus
role
cell
induc
ga
administr
particularli
gainduc
shift
profil
induc
cell
respons
sinc
ga
induc
rapid
neuroprotect
follow
brain
trauma
glutamateintox
retin
ganglion
cell
time
scale
insuffici
cell
mediat
respons
hypothes
gainduc
neuroprotect
might
cellindepend
direct
effect
ga
neuron
might
exist
address
possibl
treat
primari
human
neuron
staurosporin
presenc
absenc
ga
found
ga
significantli
increas
neuron
surviv
direct
neuroprotect
effect
ga
associ
intern
primari
neuron
cell
increas
express
bdnf
activ
moreov
ga
enter
mononuclear
phagocyt
via
induct
rhoa
pathway
caus
alter
actin
organ
increas
transmigratori
abil
monocyt
dendrit
cell
dc
blood
brain
barrier
bbb
dc
load
ga
dc
vaccin
attenu
degener
injur
optic
nerv
fiber
observ
vivo
optic
nerv
crush
injuri
model
novel
mechan
gamedi
neuroprotect
may
lead
develop
new
therapeut
regimen
variou
neurodegen
well
autoimmun
diseas
cell
play
import
role
reduct
neuron
death
stroke
model
inflamm
play
import
role
ischem
stroke
human
may
benefici
effect
stroke
previous
demonstr
reduct
infarct
size
mous
stroke
model
follow
transfer
tcell
mice
toler
myelin
oligodendrocyt
glycoprotein
mog
cell
nasal
toler
mice
effect
found
less
neuron
death
axon
damag
shown
stain
stain
follow
nasal
toler
mog
wt
anim
compar
mice
cytokin
profil
splenocyt
nasallytoler
mice
reveal
reduct
compar
non
toler
litterm
associ
increas
tgfbeta
product
elev
frequenc
lap
tcell
result
demonstr
lack
neuroprotect
observ
mice
vs
wt
mice
relat
absenc
rather
lack
toler
flow
cytometri
analysi
show
elev
frequenc
tcell
follow
nasal
treatment
wt
mice
investig
neuroprotect
role
tcell
incub
mous
neuron
cultur
cell
found
increas
neuron
cell
death
follow
oxid
stress
deplet
cultur
moreov
incub
mous
neuron
cultur
cell
togeth
antibodi
significantli
reduc
neuroprotect
effect
cell
conclus
data
suggest
cell
play
import
role
reduct
neuron
cell
death
follow
brain
ischem
injuri
epo
mediat
neuroprotect
ischem
excitotox
injuri
requir
tnfri
signal
tumour
necrosi
factor
receptor
tnfri
ligand
tnf
constitut
express
cn
neuron
upregul
brain
injuri
tnf
shown
exert
direct
neuroprotect
effect
maintain
calcium
homeostasi
decreas
glutamateinduc
current
activ
cell
protect
pathway
involv
inhibit
caspas
upregul
flicelik
inhibitori
protein
flip
l
induct
taoufik
et
al
submiss
tissu
protect
cytokin
erythropoietin
epo
receptor
epor
express
cn
neuron
express
upregul
follow
injuri
epo
exert
potent
neurotroph
properti
prevent
neuron
apoptosi
metabol
stress
cerebr
ischemia
traumat
brain
injuri
spinal
cord
injuri
kainat
induc
seizur
studi
show
tnf
tnfri
necessari
induct
epoepor
neuroprotect
pathway
follow
ischem
excitotox
injuri
use
tnfri
defici
mice
vivo
model
ischem
excitotox
injuri
perman
middl
cerebr
arteri
occlus
mcao
kainat
induc
seizur
provid
evid
tnfri
signal
necessari
epomedi
neuroprotect
show
tnf
act
specif
tnfri
induc
express
epo
epor
primari
cortic
neuron
glucos
depriv
gd
oxygen
glucos
depriv
ogd
associ
increas
activ
neuron
surviv
result
extend
understand
mechan
tnftnfrimedi
neuroprotect
provid
novel
evid
benefici
role
brain
inflamm
respons
injuri
oral
session
immunemedi
patholog
neuroprotect
immun
neurofila
light
protein
induc
spastic
paresi
axon
degener
biozzi
abh
mice
axon
damag
major
caus
irrevers
neurolog
disabl
ms
patient
axon
damag
correl
antibodi
neurofila
light
nfl
protein
major
compon
axon
cytoskeleton
possibl
pathogen
role
autoimmun
axon
antigen
nfl
far
ignor
describ
biozzi
abh
mice
immun
nfl
protein
develop
neurolog
diseas
character
primarili
spastic
paresi
concomit
axon
degener
inflamm
spinal
cord
less
sciatic
nerv
cn
macrophagesmicroglia
abund
low
number
tcell
observ
peripher
respons
splenocyt
nfl
character
product
proinflammatori
cytokin
ifngamma
tnfalpha
elev
level
circul
antibodi
recogn
rmnfl
present
serum
immunoglobulin
deposit
observ
within
neuron
cell
bodi
cn
mice
exhibit
clinic
diseas
indic
antibodi
nfl
may
pathogen
role
axon
degener
conclud
autoimmun
nfl
protein
induc
axon
degener
clinic
neurolog
diseas
mice
result
indic
autoimmun
axon
antigen
describ
ms
may
pathogen
rather
act
mere
surrog
marker
axon
degener
transgen
inactiv
astrogli
improv
function
recoveri
follow
spinal
cord
injuri
experiment
autoimmun
encephalomyel
roberta
brambilla
kim
esham
martin
oudega
andr
hurtado
scott
r
barnum
john
r
bethea
central
nervou
system
cn
transcript
factor
key
regul
inflamm
secondari
injuri
process
follow
trauma
diseas
express
gene
activ
lead
protect
detriment
effect
cn
recoveri
demonstr
genetarget
inactiv
astrogli
mice
mice
lead
dramat
improv
locomotor
recoveri
week
spinal
cord
injuri
sci
histolog
transgen
mice
exhibit
increas
white
matter
preserv
select
spare
reticulospin
corticospin
tract
parallel
mice
show
reduc
express
proinflammatori
chemokin
cytokin
chondroitinsulph
proteoglycan
form
glial
scar
similarli
demonstr
mice
recov
significantli
better
wild
type
wt
follow
experiment
autoimmun
encephalomyel
eae
model
multipl
sclerosi
transgen
mice
develop
demyelin
patholog
day
later
wt
chronic
recov
locomotor
function
almost
normal
express
proinflammatori
gene
delay
reduc
conclud
inhibit
signal
astrocyt
result
protect
effect
follow
cn
injuri
propos
pathway
new
target
develop
therapeut
strategi
treat
patholog
influenc
leukaemia
inhibitori
factor
macrophag
function
vitro
experiment
autoimmun
encephalomyel
jerom
hendrik
niel
hell
jori
vanderlocht
piet
stinissen
hasselt
univers
biomed
research
institut
school
life
scienc
transnational
universiteit
limburg
diepenbeek
belgium
chronic
disabl
diseas
multipl
sclerosi
ms
infiltr
central
nervou
system
cn
autoreact
tcell
macrophag
result
damag
glial
cell
neuron
recent
find
indic
inflammatori
cell
mere
detriment
may
also
protect
effect
previous
show
leukemia
inhibitori
factor
lif
member
neurokin
famili
neurotroph
factor
secret
cell
macrophag
protect
oligodendrocyt
induc
apoptosi
experiment
autoimmun
encephalomyel
eae
anim
model
ms
clinic
symptom
suppress
lif
treatment
demonstr
among
immun
cell
mainli
macrophag
express
neurokin
receptor
thu
neurokin
may
influenc
macrophag
function
therebi
act
immunomodulatori
therefor
investig
whether
neurokin
lif
oncostatin
affect
macrophag
function
vitro
studi
effect
myelin
phagocytosi
proinflammatori
cytokin
product
oxygen
radic
product
import
process
ms
lesion
format
current
evalu
vivo
effect
neurokin
inflammatori
respons
eae
initi
result
indic
neurokin
act
proinflammatori
antiinflammatori
depend
environ
cannabinoidmedi
immunosuppress
experiment
allerg
encephalomyel
david
baker
j
ludov
croxford
gareth
pryce
samuel
jackson
catherin
ledent
giovanni
marsicano
beat
lutz
gavin
giovannoni
roger
g
pertwe
takashi
yamamura
scientif
evid
initi
demonstr
experiment
allerg
encephalomyel
eae
model
support
previous
anecdot
evid
cannabinoid
may
benefici
symptom
control
multipl
sclerosi
natur
cannabinoid
tetrahydrocannabinol
synthet
cannabinoid
cb
receptor
agonist
also
induc
immunosuppress
eae
howev
underli
mechan
receptor
locat
subtyp
involv
cannabinoidinduc
immunosuppress
remain
unclear
demonstr
amelior
eae
cannabinoid
associ
suppress
antigeninduc
cell
prolifer
proinflammatori
interferon
gamma
tumour
necrosi
factor
cytokin
product
inhibit
mononuclear
cell
infiltr
central
nervou
system
secondli
although
leucocyt
express
cb
notabl
cb
receptor
cannabinoidmedi
immunomodul
larg
exclus
cb
receptordepend
shown
use
select
agonist
loss
cannabinoid
activ
cb
defici
anim
thirdli
use
condit
cb
knockout
mice
demonstr
major
pathway
immunosuppress
due
cb
receptor
stimul
cell
like
indirect
stimul
cb
brain
centr
high
dose
cannabinoid
induc
sed
physiolog
effect
may
clinic
achiev
relev
suggest
cannabi
use
human
like
exhibit
margin
affect
relaps
diseas
multipl
sclerosi
interact
induc
microglia
activ
regul
relaps
paralysi
central
nervou
system
autoimmun
diseas
multipl
sclerosi
ms
fibrin
deposit
tempor
spatial
correl
inflammatori
demyelin
plaqu
although
presenc
extravascular
fibrin
ogen
site
inflammatori
demyelin
ms
document
pathologist
decad
molecular
cellular
mechan
fibrin
action
cn
pathogenesi
investig
show
fibrin
signal
integrin
receptor
activ
microglia
regul
progress
sever
inflammatori
demyelin
fibrinogen
directli
activ
microglia
result
dramat
cytoskelet
rearrang
increas
phagocytosi
activ
akt
rho
inhibit
fibrin
bind
inhibitor
block
antibodi
inhibit
fibrinogeninduc
microglia
activ
phagocytosi
pharmacolog
deplet
fibrin
use
snake
venom
ancrod
remittingrelaps
experiment
autoimmun
encephalomyel
eae
result
reduc
activ
microglia
cell
effect
revers
relaps
paralysi
inhibit
interact
fibrin
knockin
mice
well
vaccin
intranas
deliveri
fibrin
peptid
attenu
inflammatori
demyelin
studi
provid
cellular
molecular
definit
role
fibrin
cn
pathogenesi
show
fibrinogenmedi
microglia
activ
regul
progress
sever
inflammatori
demyelin
sinc
block
interact
affect
inflammatori
coagul
properti
fibrin
target
fibrin
epitop
could
repres
potenti
therapeut
strategi
ms
potenti
applic
neuroinflammatori
diseas
associ
bloodbrain
barrier
disrupt
microglia
activ
support
nihnind
grant
nmss
rg
ka
nmss
postdoctor
fellowship
fg
ra
fourth
nationwid
survey
multipl
sclerosi
japan
mri
characterist
japanes
multipl
sclerosi
moreov
clinic
characterist
compar
among
osm
lescl
osm
spinal
cord
lesion
extend
vertebr
segment
usual
scl
cm
lescl
cm
usual
scl
result
frequenc
patient
met
mcdonald
mri
criteria
significantli
higher
cm
osm
vs
p
frequenc
lescl
significantli
higher
osm
cm
vs
p
regardless
whether
cm
osm
lescl
show
femal
preponder
higher
edss
higher
frequenc
paraplegia
higher
csf
cell
count
compar
usual
scl
edss
ms
subgroup
except
osm
lescl
significantli
correl
diseas
durat
regardless
whether
lescl
usual
scl
osm
show
higher
age
onset
lower
frequenc
secondari
progress
higher
frequenc
neg
brain
mri
compar
cm
conclus
locat
lesion
well
exist
lescl
import
factor
decid
clinic
featur
ms
clinic
laboratori
featur
neuromyel
optica
oligoclon
igg
band
nakamura
nakashima
sato
b
k
fujihara
itoyama
depart
neurolog
tohoku
univers
school
medicin
sendai
japan
b
depart
neurolog
kohnan
hospit
sendai
japan
object
oligoclon
igg
band
ob
celebrospin
fluid
csf
import
laboratori
find
diagnosi
multipl
sclerosi
ms
posit
ms
patient
western
countri
contrast
frequenc
ob
report
much
lower
neuromyel
optica
nmo
even
sensit
isoelectr
focus
appli
present
studi
aim
reveal
clinic
laboratori
featur
patient
nmo
posit
ob
method
retrospect
review
medic
record
total
nmo
patient
women
one
man
analyz
clinic
data
age
onset
diseas
durat
expand
disabl
statu
scale
edss
score
csf
find
cell
count
protein
concentr
igg
index
immunolog
statu
nmoigg
autoantibodi
coexist
autoimmun
diseas
patient
compar
data
obposit
patient
obneg
patient
result
found
two
case
nmo
ob
among
nmo
case
patient
also
posit
nmoigg
common
featur
long
diseas
durat
coexist
autoimmun
diseas
myasthenia
gravi
sicca
syndrom
differ
age
onset
edss
score
csf
cell
count
csf
protein
concentr
two
group
conclus
ob
mostli
neg
nmo
help
distinguish
multipl
sclerosi
posit
longstand
autoimmun
may
directli
relat
nmo
antiaquaporin
antibodi
japanes
opticospin
multipl
sclerosi
k
tanaka
tani
tanaka
b
saida
b
j
idezuka
c
k
sakimura
nishizawa
brain
research
institut
niigata
univers
niigata
japan
b
utano
nation
hospit
kyoto
japan
c
ojiya
sakura
hospit
ojiya
japan
neuromyelitica
optica
nmo
igg
whose
target
molecul
probabl
aquaporin
report
specif
marker
nmo
good
tool
distinguish
nmo
multipl
sclerosi
ms
opticospin
form
ms
osm
categor
subtyp
ms
preval
asian
countri
differ
osm
nmo
long
discuss
clarifi
argument
establish
immunofluoresc
detect
system
antibodi
use
hek
cell
examin
antibodi
sera
osm
long
spinal
cord
lesion
lcl
without
cerebr
lesion
osm
without
lcl
common
form
ms
cm
healthi
control
posit
osm
lcl
neg
form
ms
among
osm
lcl
group
women
sever
visual
disturb
howev
featur
patient
mean
age
sever
limb
truncal
disabl
exist
cerebr
lesion
differ
osm
lcl
result
osm
lcl
similar
frequenc
nmoigg
found
nmo
patient
indic
group
immunopatholog
common
could
japanes
patient
ms
fulfil
poser
criteria
mri
scan
analyz
accord
mcdonaldbarkhof
mri
criteria
patholog
studi
periventricular
lesion
opticospin
ms
osm
convent
ms
cm
case
well
studi
featur
lescl
result
frequenc
patient
met
mcdonald
barkhof
mri
criteria
periventricular
ovoid
lesion
significantli
higher
cm
osm
patient
vs
p
vs
p
frequenc
lescl
periventricular
rimlik
lesion
significantli
higher
osm
cm
vs
p
vs
p
patholog
osm
show
periventricular
rimlik
demyelin
lesion
cm
demyelin
lesion
extend
deep
white
matter
lescl
distribut
diffus
cervic
thorac
cord
mainli
involv
central
portion
cord
gadoliniumenhanc
lesion
seen
frequent
upper
thorac
cord
conclus
frequenc
asian
ms
patient
fulfil
mcdonaldbarkhof
mri
criteria
low
lescl
periventricular
rimlik
lesion
frequent
seen
osm
patient
introduct
mcdonald
criteria
ms
larg
base
featur
caucasian
patient
state
spinal
lesion
longer
vertebr
length
refer
paper
describ
lesion
found
patient
propos
criteria
neuromyel
optica
wingerchuk
et
al
long
cord
lesion
extend
vertebr
segment
lcl
spinal
import
characterist
report
frequent
brain
involv
japanes
ms
patient
lcl
lclm
method
among
patient
examin
analyz
clinic
mri
laboratori
featur
consecut
patient
lclm
averag
diseas
onset
age
year
diseas
durat
year
femal
male
ratio
result
site
clinic
manifest
first
attack
spinal
cord
optic
nerv
brainstemcerebellum
cerebrum
case
lcl
confirm
within
year
onset
cerebr
symptom
present
first
attack
later
develop
frequent
symptom
sever
mri
lesion
size
larg
brainstem
lesion
develop
requir
respir
assist
averag
recurr
number
spinal
cord
optic
nerv
cerebrum
brainstem
cerebellum
cerebrospin
fluid
igg
oligoclon
band
mostli
neg
conclus
propos
lclm
variant
ms
least
japanes
popul
lcl
occur
earli
stage
mani
later
develop
sever
brain
lesion
human
myoblast
secret
express
respons
complex
vitro
marino
f
scuderi
c
provenzano
scheller
b
stefan
rosejohn
b
emanuela
bartoccioni
institut
gener
patholog
cattolica
roma
itali
b
depart
biochemistri
zu
kiel
kiel
germani
mononuclear
cell
infiltr
character
inflammatori
reaction
autoimmun
polymyos
reject
transplant
myoblast
monocyt
recruit
follow
neutrophil
exud
regul
switch
driven
action
receptor
complex
endothelialmesotheli
cell
consist
kda
ubiquit
express
transduc
element
cytokinespecif
kda
receptor
subunit
latter
express
target
cell
hepatocyt
subset
leukocyt
releas
complex
interact
membranebound
activ
virtual
cell
bodi
mechan
call
transsign
previous
shown
human
myoblast
abl
produc
specif
object
studi
verifi
whether
complex
could
drive
human
myoblast
substain
monocyt
recruit
use
stabl
analogu
complex
stimul
human
myoblast
analyz
express
membran
solubl
monocyt
chemotact
activ
rtpcr
elisa
fac
chemotaxi
assay
found
human
myoblast
produc
signific
level
respons
could
use
transsign
increas
product
addit
bind
greatli
increas
product
find
show
muscl
cell
use
local
secret
transsign
start
autoamplif
autocrin
loop
target
monocyt
chemotaxi
leukocyt
traffick
format
gradient
modul
express
chemokin
system
muscl
polymyos
tateyama
k
fujihara
misu
onodera
itoyama
polymyos
autoimmun
disord
autoaggress
cell
import
pathogenesi
howev
mechan
underli
sustain
recruit
cell
muscl
tissu
still
unknown
ligand
chemokin
system
relat
mononuclear
cell
migrat
antigen
present
suggest
play
key
role
sever
autoimmun
disord
investig
express
frozen
muscl
polymyos
immunohistochemistri
express
mainli
mononuclear
cell
infiltr
endomysium
polymyos
endomysi
mononuclear
cell
express
doubl
immunostain
endomysi
cell
infiltr
endomysium
surround
nonnecrot
muscl
fiber
coexpress
hand
express
mainli
muscl
fiber
proxim
mononuclear
cell
endothelium
vessel
mononuclear
cell
immunoreact
found
small
number
mononuclear
cell
case
immunoreact
also
found
muscl
fiber
endothelium
vessel
rtpcr
analysi
transcript
detect
polymyos
muscl
examin
detect
five
seven
polymyos
muscl
chemokin
system
express
inflam
muscl
polymyos
may
involv
pathomechan
polymyos
molecular
interact
inflamm
degener
sporad
inclus
bodi
myositi
sibm
muscl
hallmark
sibm
inflamm
muscl
yet
unknown
whether
pathomechan
trigger
rna
sibmmuscl
n
dermatomyos
dm
n
nonmyopath
control
n
analyz
realtimepcr
express
degenerationassociatedmolecul
amyloidprecursorprotein
app
ubiquitin
inflammatori
marker
induciblenitricoxid
synthas
ino
immunohistochem
stain
confirm
proteinexpress
magneticbeadpurifi
human
myotubecultur
expos
nodonor
follow
analysi
cytokineand
chemokineexpress
realtimepcr
immunohistochemistri
sandwichelisa
measur
facsanalysi
immunohistochemistri
grayscaledensitometri
sibmmuscl
compar
control
mrna
chemokin
cytokin
significantli
upregul
half
sibmsampl
display
inosexpress
dm
upregul
chemokinemrna
remain
significantli
lower
sibm
patient
express
ino
degenerationassoci
marker
significantli
overexpress
disord
yet
sibm
app
significantli
correl
mrnalevel
chemokin
ubiquitin
cellular
infiltr
immunohistochemistri
chemokin
cytokin
coloc
sibmmyofib
wherea
dm
mainli
present
connect
tissu
capillari
inflammatori
respons
myotubecultur
similar
pattern
observ
sibmmuscl
includ
strike
inosoverexpress
exposur
nodonor
caus
intracellular
reveal
immunhistochemistri
facsanalysi
conclus
result
suggest
specif
interrelationship
degen
inflammatori
pathomechan
sibmmuscl
center
around
norel
cellstress
data
understand
sibmpatholog
may
help
better
comprehend
disord
character
cell
receptor
human
histolog
specimen
seitz
ab
h
wekerl
r
hohlfeld
ab
k
dornmair
ab
depart
neuroimmunolog
mpi
neurobiolog
martinsri
germani
b
institut
clinic
neuroimmunolog
lmu
munich
germani
describ
strategi
reviv
put
pathogen
cell
frozen
specimen
human
target
organ
cell
may
use
investig
yet
unknown
antigen
distinguish
autoaggress
irrelev
cell
focu
cytotox
effector
cell
direct
contact
target
cell
clonal
expand
detect
immunohistochemistri
cell
isol
lasermicrodissect
frozen
biopsi
specimen
polymyos
inclus
bodi
myositi
lesion
identifi
match
cell
receptor
tcr
sever
patient
recent
develop
multiplex
pcr
protocol
allow
concomit
amplif
chain
even
singl
cell
one
patient
isol
cell
express
expand
chain
cell
identifi
match
ident
domin
clone
might
indic
antigen
driven
clonal
expans
point
pathogen
relev
reconstruct
sever
pair
tcr
express
function
thybridoma
cell
present
use
reviv
autoaggress
cell
investig
target
antigen
vitro
cdna
express
combinatori
synthet
peptid
librari
protocol
applic
autoimmun
diseas
like
multipl
sclerosi
also
tumor
transplant
background
establish
definit
diagnos
inflammatori
myopathi
includ
polymyos
pm
dermatomyos
dm
inclus
bodi
myositi
ibm
accord
recent
criteria
diagnos
import
obtain
muscl
biopsi
sampl
inflamm
howev
inflammatori
chang
often
absent
tissu
obtain
convent
method
biopsi
object
examin
use
magnet
reson
imag
mri
skelet
muscl
determin
muscl
biopsi
site
make
diagnos
inflammatori
myopathi
materi
method
method
mri
orient
muscl
biopsi
momb
establish
among
case
exclud
alreadi
steroid
fulfil
criteria
bohan
peter
definit
probabl
possibl
pm
dm
subject
muscl
mri
show
posit
mri
chang
enabl
us
appli
momb
neg
mri
muscl
biopsi
perform
case
comparison
biopsi
probabl
definit
case
inflammatori
myopathi
biopsi
perform
belli
muscl
histolog
chang
muscl
biopsi
grade
semiquantit
result
appli
momb
number
sampl
inflammatori
chang
increas
significantli
convent
biopsi
specimen
show
inflamm
sampl
taken
momb
hand
case
without
signific
chang
mri
chanc
observ
inflamm
mri
neg
case
conclus
momb
significantli
improv
diagnost
valu
muscl
biopsi
inflammatori
myopathi
hand
case
without
signific
chang
muscl
mri
emerg
new
issu
method
patient
csf
specimen
group
healthi
control
hc
sampl
ms
patient
sampl
classifi
clinic
isol
syndrom
sampl
rrm
sampl
spm
sampl
ppm
sampl
studi
mean
selditof
techniqu
allow
separ
identif
size
charg
set
protein
complex
mixtur
csf
result
intens
potenti
differenti
massspectroscopi
peak
associ
specif
protein
protein
fragment
differ
ms
patient
healthi
control
signific
differ
found
ci
hc
ppm
hc
potenti
biomark
respect
despit
reduc
number
sampl
therefor
limit
statist
signific
seem
two
specif
reson
assign
da
p
da
p
protein
could
consid
promis
potenti
classifi
among
differ
ms
clinic
form
conclus
preliminari
result
obtain
initi
studi
seem
point
selditof
could
potenti
use
techniqu
appli
ms
diagnosi
adequ
identif
specif
protein
directli
csf
discrimin
biomark
extens
studi
use
selditof
need
verifi
result
obtain
far
bacteri
peptidoglycan
cofactor
multipl
sclerosi
inflammatori
activ
peptidoglycan
pg
major
bacteri
cell
wall
compound
strong
proinflammatori
capac
membran
tolllik
receptor
thought
signal
receptor
intact
pg
three
type
innat
receptor
recogn
small
pg
motif
intracellularli
name
dysregul
function
molecul
involv
sever
type
inflammatori
disord
includ
crohn
diseas
blau
syndrom
previous
propos
pg
factor
codetermin
inflammatori
activ
multipl
sclerosi
ms
present
three
line
evid
support
first
postmortem
brain
ms
patient
antigen
present
cell
apc
contain
pg
presum
result
infiltr
cell
acquir
pg
fragment
mucosa
apc
immunocompet
evidenc
express
costimulatori
molecul
cytokin
second
two
nonhuman
primat
experiment
autoimmun
encephalomyel
model
marmoset
rhesu
monkey
burden
pg
inflam
brain
correl
sever
patholog
apc
subtyp
brain
leukocyt
monkey
human
respond
pg
challeng
product
third
enceph
could
precipit
mice
ad
pg
sole
microbi
compound
incomplet
freund
adjuv
plu
encephalitogen
peptid
collect
immunopatholog
function
evid
rodent
nonhuman
primat
model
well
human
ms
support
potenti
role
pg
cofactor
ms
warrant
elucid
receptor
pathway
involv
identif
novel
biomark
multipl
sclerosi
base
humor
immun
respons
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
autoreact
b
cell
play
role
fulli
explor
complex
inform
present
within
autoantibodi
repertoir
ms
patient
appli
power
procedur
call
serolog
antigen
select
sa
identifi
antigen
recogn
humor
immun
respons
ms
sa
procedur
involv
display
cdna
express
librari
ms
brain
plaqu
filament
phage
subsequ
select
immunoglobulin
g
igg
present
serum
cerebrospin
fluid
csf
enrich
select
cdna
product
bind
igg
specif
associ
ms
altern
select
strategi
ms
patient
materi
normal
sampl
perform
use
sa
pool
csf
n
relapsingremit
rr
ms
patient
identifi
panel
differ
antigen
detail
serolog
analysi
ms
csf
control
csf
show
exclus
preferenti
reactiv
ms
patient
csf
affin
select
second
pool
csf
rrm
patient
result
identif
addit
candid
antigen
addit
select
two
pool
sera
rrm
patient
result
identif
cdna
clone
clone
current
evalu
regard
sequenc
ident
msspecif
conclus
find
demonstr
sa
use
identifi
novel
candid
antigen
ms
use
diagnost
marker
use
studi
humor
immun
respons
ms
provid
myeloid
cell
astrocyt
human
cn
contribut
persist
activ
myelin
specif
cell
implic
multipl
sclerosi
cell
promin
infiltr
cell
central
nervou
system
cn
multipl
sclerosi
ms
highli
activ
memori
cell
shown
clonal
expand
persist
cn
ms
patient
year
proinflammatori
cytokin
produc
macrophag
dendrit
cell
pivot
gener
mainten
memori
cell
higher
amount
detect
ms
patient
blood
cerebrospin
fluid
bound
cell
origin
activ
bear
cell
sought
determin
whether
local
sourc
play
role
acquisit
memori
phenotyp
myelin
specif
cell
persist
cell
cn
ms
patient
human
monocytesmacrophag
astrocyt
could
provid
local
sourc
sinc
observ
cell
express
surfac
bound
upregul
respons
proinflammatori
cytokin
myelin
specif
cell
line
cultur
presenc
acquir
memori
phenotyp
observ
presenc
cell
line
contain
high
amount
cytolyt
enzym
similar
activ
nk
cell
result
underlin
novel
potenti
role
surviv
memori
myelin
specif
cell
cn
inflammatori
diseas
ms
nk
cell
mirror
diseas
activ
multipl
sclerosi
toshimasa
aranami
sachiko
miyak
takashi
yamamura
nation
center
neurolog
psychiatri
kodaira
japan
multipl
sclerosi
ms
autoimmun
diseas
show
great
degre
varianc
diseas
activ
recent
demonstr
nk
cell
bias
produc
bia
associ
remiss
state
ms
report
upregul
nk
cell
would
character
subgroup
ms
remiss
whose
nk
cell
lack
bia
compar
group
high
group
patient
low
concern
nk
cell
express
found
bia
select
charact
low
patient
contrast
high
group
show
obviou
trend
larger
proport
hladr
cell
within
nk
cell
sinc
nk
cell
stimulatori
cytokin
found
upregul
express
nk
cell
vitro
postul
inflammatori
signal
may
play
role
induc
high
nk
cell
phenotyp
although
clinic
differ
high
low
blood
sampl
high
ms
develop
clinic
relaps
significantli
earlier
low
day
followup
data
point
interpret
high
patient
higher
risk
develop
relaps
probabl
due
loss
phenotyp
thu
nk
cell
mirror
diseas
activ
ms
may
use
diseas
biomark
background
plasmacytoid
dc
pdc
repres
subpopul
dc
exert
diverg
function
innat
adopt
immun
respons
thought
differ
dcsubtyp
may
critic
involv
pathogenesi
multipl
sclerosi
ms
materi
method
studi
assess
flow
cytometri
phenotyp
peripher
blood
dc
clinic
stabl
untreat
ms
patient
healthi
control
patient
pneumonia
use
nonspecif
inflammatori
condit
nic
vitro
function
analys
dc
isol
magnet
sort
leukapheresi
materi
cultur
trophic
factor
unmethyl
cytosinephosphateguanosin
oligodeoxynucleotid
cpgodn
use
regul
cocultur
system
result
ex
vivo
express
significantli
lower
pdc
ms
patient
control
patient
nic
vs
vs
vs
vs
respect
ms
pdc
stimul
show
impair
matur
demonstr
significantli
lower
delay
upregul
stimul
pdc
cpgodn
result
significantli
lower
ifna
secret
ms
control
ms
control
pdc
fail
upregul
prolif
respons
ifng
secret
autolog
pbmc
cocultur
system
moreov
deplet
pdc
ms
patient
control
effect
gener
regulatori
cell
conclus
find
suggest
function
abnorm
pdc
ms
patient
might
help
understand
mechan
immun
dysregul
diseas
search
reliabl
immunolog
paramet
use
assess
diseas
activ
examin
pair
blood
cerebrospin
fluid
csf
sampl
obtain
nontreat
stabl
patient
relapsingremit
multipl
sclerosi
rrm
admit
confirm
diagnosi
assess
diseas
statu
sampl
analyz
humor
immun
well
cellular
immun
use
flow
cytometr
examin
cell
determin
express
surfac
antigen
includ
thereaft
patient
follow
least
year
outpati
clinic
underw
neurolog
examin
well
gadoliniumenhanc
magnet
reson
imag
mri
scan
perform
everi
month
relaps
becam
evid
anoth
group
patient
noninflammatori
neurologicalpsychiatr
diseas
serv
control
rrm
patient
experienc
relaps
within
year
initi
examin
show
relaps
within
month
respect
patient
could
differenti
percentag
cell
csf
patient
greater
ratio
cell
csf
standard
deviat
mean
control
like
relaps
within
month
find
suggest
enumer
cell
csf
serv
reliabl
measur
diseas
statu
rrm
howev
immunolog
relev
regulatori
inflammatori
cell
requir
addit
investig
alter
tcell
homeostasi
relapsingremit
multipl
sclerosi
due
peripher
mechan
object
investig
involv
peripher
mechan
homeostasi
confirm
previou
novel
find
rrm
method
untreat
rrm
patient
mean
age
recruit
montreal
neurolog
hospit
ms
clinic
patient
clinic
definit
ms
base
mcdonald
criteria
clinic
remiss
time
blood
drawn
recruit
independ
set
mean
age
healthi
control
histori
autoimmun
diseas
lymphocyt
obtain
use
tcell
subsequ
isol
technolog
stain
pelabel
indirect
measur
homeostat
prolifer
pelabel
pelabel
measur
homeostat
surviv
analysi
perform
order
ascertain
percent
express
respect
serum
level
measur
homeostat
surviv
determin
elisa
dna
extract
remain
isol
cell
signal
joint
cell
receptor
excis
circl
sjtrecsa
surrog
marker
thymic
product
quantifi
use
realtim
pcr
result
rrm
patient
show
signific
decreas
sjtrec
level
p
express
p
express
p
conclus
observ
confirm
inde
signific
cell
homeostat
abnorm
rrm
suggest
nonthym
peripher
mechan
involv
identif
pathogen
antibodi
respons
nativ
myelin
oligodendrocyt
glycoprotein
multipl
sclerosi
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
cn
although
caus
ms
still
uncertain
mani
find
point
toward
ongo
autoimmun
respons
myelin
antigen
myelin
oligodendrocyt
glycoprotein
mog
one
potenti
diseasecaus
self
antigen
determin
serum
antibodi
respons
nativ
fulllength
mog
protein
express
human
astroglioma
cell
line
cell
base
assay
antibodi
mostli
igg
detect
serum
ms
patient
specif
bound
extracelluar
domain
mog
antibodi
direct
conform
epitop
elicit
pathogen
antibodi
respons
eae
igg
igm
antibodi
titer
nativ
mog
significantli
higher
ms
patient
group
compar
control
one
third
ms
patient
particular
primari
progress
patient
elev
antimog
antibodi
titer
autoantibodi
induc
death
mogexpress
target
cell
sera
ms
patient
antimog
antibodi
stain
white
matter
myelin
rat
brain
enhanc
demyelin
axon
damag
transfer
eae
anim
summari
identifi
first
pathogen
antibodi
may
contribut
inflammatori
cn
damag
subgroup
ms
patient
unexpect
regulatori
role
anim
model
multipl
sclerosi
innat
immun
mechan
essenti
prime
encephalitogen
cell
autoimmun
neuroinflamm
poorli
understood
investig
role
tolllik
receptor
tlr
common
tlr
adaptor
molecul
anim
model
human
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
induc
immun
myelin
oligodendrocyt
glycoprotein
mog
complet
freund
adjuv
cfa
tlror
mice
mice
eae
resist
howev
expect
attenu
diseas
due
failur
signal
presenc
pathogen
associ
molecular
pattern
pamp
mycobacteria
similarli
mice
due
failur
signal
presenc
cpg
dna
mycobacteria
instead
diseas
paradox
exacerb
mice
also
expect
inhibit
diseas
mice
due
failur
signal
presenc
mycobacteri
lipopeptid
loss
tlr
affect
diseas
sever
mice
fail
express
serum
cell
absent
investig
tlr
signal
regulatori
mdc
express
higher
cell
serum
level
severalfold
higher
wt
mice
mice
serum
level
severalfold
higher
wt
mice
data
suggest
mediat
eae
via
induct
mdc
drive
encephalitogen
cell
activ
data
indic
regulatori
role
prime
encephalitogen
cell
redefin
encephalitogen
identif
novel
pathogen
cytokin
induc
k
kreymborg
r
etzensperg
b
haak
b
becher
depart
neurolog
universitatsspitalunivers
zurich
frauenklinikstrass
zurich
switzerland
b
weatheral
institut
molecular
medicin
john
radcliff
hospit
univers
oxford
oxford
uk
tissuedirect
autoimmun
diseas
wide
held
mediat
conduct
selfreact
cell
howev
previous
shown
neither
geneexpress
serv
reliabl
marker
pathogen
furthermor
mastercytokin
interleukin
il
shown
absolut
critic
induct
autoimmun
diseas
demonstr
collageninduc
arthriti
cia
well
experiment
autoimmun
encephalomyel
eae
becom
increasingli
evid
support
expans
distinct
lineag
cell
produc
th
cell
play
major
role
autoimmun
inflamm
use
high
densiti
transcriptom
could
identifi
addit
gene
induc
discov
relat
cytokin
whose
express
profil
ident
diseas
associ
hasin
contrast
far
never
describ
context
eae
express
correl
exquisit
find
point
toward
major
role
illdescrib
cytokin
taken
togeth
molecul
help
defin
encephalopathogen
phenotyp
autoaggress
effector
cell
permit
precis
character
novel
popul
th
cell
overexpress
central
nervou
system
lead
enhanc
diseas
progress
experiment
autoimmun
encephalomyel
jinq
liu
pramod
joshi
joe
carl
xuefeng
bai
depart
patholog
ohio
state
univers
medic
center
columbu
oh
usa
experiment
autoimmun
encephalomyel
eae
experiment
model
human
diseas
multipl
sclerosi
ms
previou
studi
shown
origin
describ
costimulatori
molecul
requir
pathogenesi
eae
develop
eae
requir
express
cell
local
cell
cn
order
understand
role
express
local
cn
cell
eae
develop
gener
transgen
mice
express
cn
control
gfap
promotor
astro
mice
astro
mice
abundantli
express
astrocyt
upon
immun
astro
mice
develop
progress
diseas
compar
nontransgen
litterm
ntg
reflect
persist
eae
sign
larg
area
demyelin
axon
damag
spinal
cord
later
stage
eae
astro
mice
enhanc
eae
progress
associ
higher
express
cytokin
gene
includ
spinal
cord
astro
mice
ntg
mice
moreov
express
demyelin
associ
marker
also
increas
spinal
cord
astro
mice
compar
ntg
mice
final
adopt
transfer
cell
specif
mog
express
matur
effector
phenotyp
cn
astro
mice
ntg
mice
thu
overexpress
cn
enhanc
eae
develop
via
enhanc
costimul
encephalitogen
cell
sinc
drastic
increas
local
cell
inflammatori
cell
cn
eae
data
import
implic
target
therapi
ms
eae
anim
model
multipl
sclerosi
regulatori
cell
play
import
role
modul
eae
recoveri
studi
depend
regulatori
cell
associ
recoveri
eae
induc
follow
oral
administr
antigen
recent
oral
monoclon
antibodi
natur
medicin
press
found
surfac
express
latenc
associ
peptid
lap
mark
cell
regulatori
properti
lap
cell
increas
spleen
peripher
blood
anim
eae
recoveri
phase
initi
studi
lap
cell
lap
lap
cell
spleen
lymph
node
sjl
mice
isol
high
speed
cell
sort
anerg
stimul
presenc
apc
vitro
furthermor
two
popul
suppress
prolifer
respond
lap
lap
cell
vitro
also
found
lap
cell
produc
signific
higher
amount
compar
lap
cell
thu
addit
lap
cell
lap
cell
may
play
import
role
regul
eae
secret
increas
amount
may
play
role
eae
shown
defici
anim
wors
form
eae
secret
may
also
suggest
role
lap
cell
regulatori
cell
allergi
fucosyltransferasevii
involv
suppressor
activ
mediat
regulatori
cell
mechan
involv
regul
experiment
autoimmun
encephalomyel
eae
regulatori
cell
treg
well
understood
goal
studi
determin
role
alpha
fucosyltransferas
fuct
pselectin
glycoprotein
suppress
eae
treg
method
activ
transfer
eae
model
use
mog
peptid
perform
wt
fuctvii
fuctiv
mice
isol
treg
flow
cytometri
adhes
prolifer
assay
also
perform
result
fuctvii
mice
develop
sever
activ
eae
compar
wt
anim
moreov
encephalitogen
cell
produc
fuctvii
mice
transfer
significantli
sever
diseas
wt
cell
observ
signific
differ
express
adhes
molecul
ifngamma
product
autoreact
cell
fuctvii
defici
mice
howev
cocultur
treg
effector
cell
show
defici
fuctvii
lead
mark
decreas
suppress
capac
treg
moreov
stimul
treg
induc
increas
adhes
capac
increas
express
increas
bind
pand
eselectin
chimera
importantli
stimul
treg
display
increas
express
function
significantli
higher
suppressor
activ
conclus
data
show
fuctvii
involv
immun
suppress
mediat
treg
moginduc
eae
suggest
vitro
manipul
treg
may
lead
increas
suppressor
activ
inflammatori
diseas
immunolog
synaps
form
contact
zone
two
immun
system
cell
may
optimis
activ
congreg
signal
molecul
specialis
region
plasma
membran
howev
precis
function
remain
matter
debat
becom
clear
lglutam
major
excitatori
neurotransmitt
play
role
peripher
tissu
includ
immun
system
show
lglutam
major
excitatori
amino
acid
synapt
transmiss
nervou
system
act
immunotransmitt
immunolog
synaps
dendrit
cell
dc
potent
antigenpres
cell
contain
vesicular
compart
compet
regul
glutam
exocytosi
also
express
glutamatespecif
vesicular
vglut
transport
confer
glutamaterg
phenotyp
neuron
releas
glutam
ca
depend
exocytosi
remark
thymocyt
express
larg
repertoir
glutam
receptor
glur
mirror
neural
cell
particular
express
function
nmda
receptor
nmdar
contribut
ca
signal
lead
antigendepend
apoptosi
context
tdc
synaps
mimick
thymic
neg
select
identifi
prototyp
postsynapt
pdz
domain
protein
new
marker
immunolog
synaps
recruit
tdc
contact
zone
coloc
nmdar
cell
stimul
even
absenc
glutam
also
result
colocalis
nmdar
contact
zone
suggest
tcell
receptor
trigger
involv
recruit
function
nmdar
synaps
work
reveal
new
aspect
immunolog
synaps
function
similar
central
nervou
synaps
dcreleas
glutam
elicit
focal
respons
cell
bear
glur
glutam
therefor
consid
synapt
transmitt
act
finetun
ca
mobil
nervou
immun
system
novel
peptid
highli
express
cerebr
endotheli
cell
vitro
studi
show
peptid
regul
key
bbb
featur
includ
transendotheli
resist
permeabl
furthermor
shown
elev
eae
bbb
dysfunct
inflammatori
lesion
appar
act
primarili
calcitonin
receptorlik
receptor
crlr
combin
either
receptoractivitymodifyingprotein
ramp
main
cellular
target
neuroinflamm
uncertain
therefor
assess
receptor
express
tcell
plu
compon
cell
bbb
crlr
express
examin
use
pcr
fac
techniqu
found
activ
tcell
predominantli
express
although
also
present
signific
proport
site
membran
convers
human
endotheli
rat
astroglioma
cell
major
locat
cytoplasm
predominantli
express
physiolog
condit
crlr
present
cell
type
examin
interestingli
respons
ramp
glucocorticoid
exposur
differ
depend
cell
type
indic
could
import
role
manag
neuroinflamm
peptid
could
therefor
involv
neuroinflammatori
process
evid
human
condit
multipl
sclerosi
role
capsaicinsensit
sensori
nerv
capsaicin
receptor
endotoxininduc
airway
inflamm
hyperreact
mice
capsaicinsensit
transient
receptor
potenti
vanilloid
receptorexpress
primari
sensori
nerv
play
import
regulatori
role
pathomechan
sever
inflammatori
process
aim
present
studi
examin
role
affer
receptor
endotoxininduc
airway
inflamm
hyperreact
mice
pneumon
evok
intranas
e
coli
lipopolysaccharid
lp
enhanc
paus
penh
calcul
paramet
correl
airway
resist
measur
whole
bodi
plethysmographi
bronchoconstrict
induc
inhal
muscarin
receptor
agonist
carbachol
h
lp
histolog
score
measur
myeloperoxidas
activ
refer
granulocyt
accumul
determin
perform
lung
inactiv
capsaicinsensit
affer
resiniferatoxin
rtx
pretreat
perform
function
receptor
examin
use
genedelet
mice
destroy
capsaicinsensit
affer
rtxdesensit
markedli
enhanc
inflammatori
paramet
inhibit
hyperreact
support
concept
tachykinin
directli
contribut
bronchoconstrict
meanwhil
lack
receptor
increas
inflamm
airway
hyperrespons
specif
radioimmunoassay
use
identifi
inhibitori
mediat
releas
sensori
fibr
via
activ
prove
somatostatin
lp
increas
somatostatin
lung
plasma
mice
somatostatin
receptor
antagonist
cyclosomatostatin
aggravar
inflammatori
paramet
hyperrespons
point
function
signific
result
provid
first
evid
novel
inhibitori
mechan
mediat
somatostatin
deriv
sensori
affer
via
receptor
activ
airway
grant
otka
compartment
immun
respons
barrel
field
mous
primari
somatosensori
cortex
brain
constitut
modular
unit
group
nervou
cell
connect
process
similar
type
neural
inform
hand
previou
observ
patient
neurocysticercosi
show
immun
respons
differ
among
brain
region
thu
suggest
exist
immunolog
compart
nervou
system
whether
immun
compart
neural
modul
share
locat
function
address
explor
possibl
studi
immunolog
respons
lesion
carri
within
outsid
neural
modul
locat
primari
somatosensori
cortex
adult
mice
modul
call
barrel
repres
collect
mechanosensori
receptor
found
neural
tissu
adjac
lesion
place
outsid
barrel
field
show
intens
astrocyt
respons
mhcii
immunoreact
macrophag
activ
microglia
cell
also
express
contrast
lesion
place
insid
barrel
field
display
mhcii
immunoreact
microglia
macrophag
predominantli
border
barrel
right
next
lesion
extrem
reduc
respons
barrel
center
barrel
close
far
lesion
site
data
support
idea
neural
modul
may
also
function
immunolog
compart
observ
open
new
perspect
studi
understand
physiolog
patholog
cn
system
inflamm
impact
brain
give
rise
behaviour
chang
often
refer
sick
behaviour
symptom
thought
mainli
mediat
proinflammatori
cytokin
studi
commun
pathway
immun
system
higher
brain
function
follow
subpyrogen
inflamm
system
inflamm
induc
mice
use
model
bacteri
lipopolysaccharid
lp
viral
infect
poli
c
mgkg
chang
openfield
activ
burrow
behaviour
consumpt
glucos
solut
assess
immun
activ
studi
peripheri
brain
measur
cytokin
product
immunohistochemistri
subpyrogen
inflamm
result
chang
speciestyp
untrain
behaviour
depend
integr
hippocampu
increas
express
cytokin
observ
peripheri
select
region
brain
coincid
behaviour
chang
howev
neutral
proinflammatori
cytokin
tnfa
signific
differ
found
compar
lpsplusvehicl
treat
mice
contrast
pretreat
mice
indomethacin
complet
prevent
lp
induc
behaviour
chang
without
affect
cytokin
level
work
studi
effect
low
grade
inflamm
affect
behaviour
mice
suggest
key
role
prostaglandin
rather
cytokin
commun
chang
immun
statu
brain
studi
sponsor
bbsrc
ucb
celltech
neurogenesi
known
continu
take
place
certain
neurogen
area
adult
central
nervou
system
cn
induc
nonneurogen
area
traumat
degen
condit
introduc
cell
cnsresid
microglia
import
player
regul
adult
neurogenesi
normal
condit
immun
defici
mice
scid
nude
transgen
mice
tcell
pool
specif
irrelev
antigen
ovalbumin
exhibit
impair
hippocamp
neurogenesi
contrast
mice
major
cell
specif
recogn
cnsabund
antigen
myelin
basic
protein
show
normal
neurogenesi
cnsspecif
cell
also
found
import
spatial
learn
abil
brainderiv
neurotroph
factor
express
dentat
gyru
environment
enrich
evok
enhanc
neurogenesi
immunedefici
anim
wherea
wildtyp
anim
led
enhanc
hippocamp
neurogenesi
coupl
recruit
cell
activ
microglia
clinic
implic
find
test
use
rat
model
cerebr
ischem
insult
demonstr
tcell
base
immun
activ
follow
stroke
induc
robust
elev
neurogenesi
hippocampu
well
cerebr
cortex
result
suggest
cell
act
via
resid
antigen
present
cell
import
regul
adult
neurogenesi
physiolog
patholog
condit
immun
cell
contribut
hippocamp
plastic
agedepend
correl
local
modul
gene
express
hippocamp
neurogenesi
known
take
place
throughout
adult
life
consid
necessari
certain
type
cognit
abil
late
demonstr
peripher
immun
contribut
adult
hippocamp
neurogenesi
spatial
learningmemori
mediat
part
lymphocyt
recogn
brain
antigen
myelin
protein
investig
whether
cn
specif
cell
contribut
mainten
brain
plastic
adulthood
whether
requir
earlier
stage
well
examin
hippocamp
neurogenesi
wildtyp
mice
transgen
mice
express
tcell
receptor
recogn
ovalbumin
ova
transgen
mice
thu
bear
mainli
ova
cell
autoimmun
cell
differ
age
found
impair
neurogenesi
learn
abil
appear
alreadi
week
age
interestingli
differ
wildtyp
ova
transgen
mice
term
number
newli
form
neuron
gener
hippocampu
rel
small
infanc
increas
adulthood
decreas
older
age
also
compar
hippocamp
gene
express
wildtyp
mice
ovatransgen
mice
use
gene
express
screen
search
hippocamp
express
gene
possibl
control
immun
cell
although
ova
transgen
mice
differ
control
peripher
cell
repertoir
signific
differ
express
sever
hippocamp
gene
found
among
differenti
express
gene
found
known
involv
neurogenesi
axon
guidanc
analysi
gene
contribut
understand
adult
neurogenesi
control
role
cell
tolueneinduc
memoryrel
gene
express
mous
hippocampu
recent
demonstr
lack
matur
cell
mice
manifest
cognit
deficit
could
restor
passiv
cell
transfer
toluen
mainli
affect
central
nervou
system
caus
memori
loss
toluen
may
produc
effect
directli
inhibit
nmethyldaspart
nmda
receptor
function
subunitselect
manner
investig
possibl
involv
cell
tolueneinduc
express
memoryrel
gene
mous
hippocampu
expos
balbc
nude
mice
toluen
low
dose
ppm
air
control
ppm
toluen
well
noseonli
exposur
chamber
min
consecut
day
follow
week
week
four
hour
last
challeng
collect
hippocampu
examin
mrna
express
nmda
receptor
protein
kinas
transcript
factor
potenti
involv
memori
function
chemokin
quantit
realtim
pcr
method
data
clearli
demonstr
nmda
receptor
ca
calmodulindepend
kinas
camkiv
transcript
factor
camp
respons
elementbind
protein
mrna
express
increas
hippocampu
balbc
mice
expos
ppm
toluen
compar
air
control
immun
ovalbumin
balbc
mice
show
differ
camkiv
mrna
express
air
control
toluen
ppm
alter
observ
nude
mice
without
immun
find
indic
cell
may
play
role
memoryrel
gene
express
induc
toluen
exposur
balbc
mice
nonmhc
gene
regul
locomotor
behavior
outcom
follow
rat
spinal
cord
contus
injuri
secondari
degener
result
spinal
cord
injuri
character
inflamm
progress
loss
nervou
tissu
recent
suggest
injuryinduc
inflamm
contain
import
element
autoimmun
may
protect
detriment
order
dissect
process
genet
examin
potenti
influenc
mhc
locu
known
import
regul
autoimmun
process
wellcharacter
weightdrop
contus
model
perform
panel
inbr
strain
differ
suscept
neuroinflamm
includ
strain
aci
da
lew
pvg
well
mhc
congen
strain
strike
differ
motor
behavior
outcom
across
strain
observ
interestingli
best
outcom
demonstr
inflamm
prone
da
rat
wherea
pvg
strain
resist
inflammatori
model
display
intermedi
respons
differ
lew
strain
wild
type
three
strain
congen
differ
mhc
haplotyp
display
worst
outcom
mhc
haplotypedepend
effect
observ
intercross
experi
pvg
provid
addit
evid
domin
influenc
nonmhc
gene
conclud
outcom
follow
spinal
cord
injuri
subject
consider
genet
heterogen
howev
genet
regul
seem
depend
degre
suscept
autoimmun
neuroinflamm
particular
mhc
complex
result
provid
base
futur
studi
posit
genet
variant
regul
outcom
follow
spinal
cord
injuri
protect
role
autoimmun
reaction
neurodegen
process
caus
mptp
mice
respons
immun
system
injuri
central
nervou
system
possibl
protect
role
present
influenc
autoimmun
reaction
dopaminerg
neuron
damag
induc
mptp
male
mice
young
age
month
old
inject
mptp
mgkg
one
group
age
day
inject
induc
autoimmun
encephalomyel
eae
myelin
oligodendrocyt
glycoprotein
mog
cfa
administr
mice
receiv
mog
reveal
typic
eae
clinic
sign
tail
hind
limb
paresi
mice
mptp
caus
less
dopaminerg
system
damag
mptp
inject
mice
dopamin
level
higher
number
preserv
neuron
young
age
anim
respect
day
mptp
administr
microgli
reaction
diminish
lymphocyt
infiltr
significantli
reduc
tgf
gdnf
mrna
express
significantli
higher
mog
receiv
mice
compar
mptp
group
observ
also
shift
cell
popul
preponder
mptp
group
mog
group
inject
mice
antimog
cell
day
mptp
administr
observ
also
less
damag
dopaminerg
cell
compar
mptp
inject
mice
show
immun
enhanc
protect
toxic
damag
central
nervou
system
cell
possibl
involv
protect
mechan
induct
trophic
factor
factor
also
option
associ
autoimmun
diseas
multipl
sclerosi
suggest
vivo
detect
myelin
produc
cell
ie
main
cell
affect
ms
might
incorpor
host
cell
protein
viral
particl
replic
viru
detect
immun
system
incorpor
protein
present
immun
system
could
one
mechan
induct
autoimmun
incorpor
host
cell
protein
shown
virus
exampl
complement
protein
incorpor
hcmv
howev
puriti
viru
prepar
debat
sinc
cellular
vesicl
might
contamin
viral
prepar
purif
sucros
gradient
studi
use
isoosmot
iodixanol
gradient
purifi
tcell
cultur
gradient
peak
fraction
detect
high
level
viral
dna
realtim
pcr
express
western
blot
intact
viral
particl
electron
microscopi
purifi
viru
particl
also
abl
reinfect
cell
good
effici
low
cellular
contamin
viral
particl
contain
fraction
seen
analyz
viral
mock
prepar
sdspage
immunoblot
antihost
cell
protein
antibodi
gave
clear
band
viral
contain
fraction
compar
mock
contain
fraction
conclus
method
may
use
studi
protein
content
viral
particl
may
give
import
clue
autoimmun
induc
peripher
neuropathi
common
neurolog
complic
associ
infect
affect
onethird
individu
aid
studi
also
found
high
preval
hiv
sensori
neuropathi
hivinfect
patient
despit
administr
highli
activ
antiretrovir
therapi
studi
hivinduc
pn
diseas
establish
sivmacaqu
model
anim
develop
pn
chang
close
resembl
seen
hivinfect
individu
includ
inflamm
dorsal
root
ganglia
abund
replic
siv
macrophag
drg
neuron
loss
sural
nerv
inflamm
reduct
epiderm
nerv
fiber
densiti
distal
extrem
constitut
first
primat
model
hivinduc
peripher
neuropathi
siv
model
examin
relationship
dorsal
root
ganglia
drg
chang
sensori
nerv
function
measur
cfiber
conduct
veloc
sural
nerv
epiderm
nerv
fiber
densiti
skin
sivinfect
macaqu
uninfect
control
macaqu
sivinfect
macaqu
significantli
lower
sensori
cfiber
conduct
veloc
cv
sural
nerv
uninfect
anim
p
extent
conduct
veloc
declin
correl
strongli
extent
macrophag
infiltr
drg
p
signific
declin
densiti
epiderm
nerv
fiber
also
develop
sivinfect
macaqu
p
strongli
correl
chang
cv
find
suggest
primari
injuri
neuron
cell
bodi
drg
mediat
activ
macrophag
alter
function
properti
sensori
nerv
hivinfect
individu
efficaci
intracerebr
vaccin
pseudorabi
viru
mice
jaeho
shin
yoshihiro
sakoda
jae
hoon
kim
evalu
efficaci
intracerebr
ic
vaccin
mice
immun
formalininactiv
pseudorabi
viru
prv
either
subcutan
sc
ic
inject
plaqueform
unit
prv
introduc
hindleg
immun
nonimmun
mice
intramuscular
inject
antibodi
titer
serum
elev
boost
addit
vaccin
via
sc
ic
rout
higher
ic
vaccin
intracerebr
immun
mice
complet
protect
mortal
neurolog
sign
wherea
nonvaccin
subcutan
vaccin
mice
die
develop
neurolog
sign
ic
vaccin
effect
induc
protect
immun
respons
transneur
spread
viru
sc
vaccin
keyword
intracerebr
vaccin
transneur
spread
pseudorabi
mous
role
dendrit
cell
transmiss
induct
neuroinvas
scrapi
follow
intraven
infect
institut
anim
health
neuropathogenesi
unit
ogston
build
west
main
road
edinburgh
uk
email
claudineraymond
bbsrc
acuk
follow
peripher
scrapi
inocul
agent
accumul
follicular
dendrit
cell
fdc
lymphoid
tissu
spread
brain
absenc
fdc
diseas
suscept
reduc
tse
agent
reach
lymphoid
tissu
nervou
system
follow
exposur
known
recent
evid
suggest
possibl
role
dendrit
cell
dc
macrophag
diseasespecif
prion
protein
prp
sc
found
associ
cell
type
follow
exposur
scrapi
current
studi
util
two
intraven
infect
model
scrapi
agent
strain
determin
scrapieinfect
mononuclear
cell
mnc
especi
dc
b
cell
could
deliv
infect
directli
nervou
system
absenc
fdc
lymphoid
element
scrapieinfect
mnc
b
cell
dc
effici
transfer
infect
transfus
wildtyp
recipi
inde
diseas
incub
period
follow
transfus
scrapieinfect
dc
similar
mnc
b
cell
even
though
fewer
cell
use
howev
absenc
fdc
tnfreceptordefici
mice
abil
scrapieinfect
cell
transmit
infect
greatli
reduc
result
demonstr
strain
scrapi
effici
neuroinvas
peripheri
requir
prior
agent
replic
accumul
fdc
absenc
accumul
dc
mononuclear
cell
capabl
deliv
scrapi
agent
directli
nervou
system
via
substanti
less
effici
mechan
fund
eu
grant
regul
inflammatori
respons
staphylococcu
aureusinduc
brain
abscess
characterist
brain
abscess
local
suppur
infect
lead
substanti
damag
adjac
cn
tissu
orchestr
interplay
proand
antiinflammatori
cytokin
releas
leukocyt
well
resid
cell
central
nervou
system
crucial
effect
host
defens
limit
tissu
damag
brain
abscess
studi
regulatori
role
interleukin
il
brain
abscess
vivo
defici
mice
stereotax
infect
staphylococcu
aureusladen
agaros
bead
increas
number
intracerebr
ic
granulocyt
macrophag
cell
higher
level
tnf
ino
observ
mice
wild
type
mice
chemokin
induc
earlier
pronounc
wt
mice
togeth
promin
microvascular
haemorrhag
necrot
vascul
sever
brain
edema
markedli
increas
abscess
size
alter
led
increas
morbid
mice
nevertheless
hyperinflammatori
respons
mice
improv
bacteri
elimin
collect
data
outlin
import
role
vivo
regul
ic
host
immun
respons
experiment
aureusinduc
brain
abscess
oral
session
immunotherapi
glatiram
acet
mediat
immun
modul
driven
antigen
present
cell
cell
antigen
specif
background
ga
exert
therapeut
benefit
multipl
sclerosi
presum
induct
gaspecif
recent
report
reveal
gatreat
alter
apc
function
investig
whether
apc
effect
mediat
tcell
immunomodul
whether
gatreat
monocyt
adopt
transfer
protect
experiment
autoimmun
encephalomyel
eae
whether
tcell
crossreact
ga
myelin
antigen
requir
therapeut
effect
method
pljxsjlj
f
mice
inject
subcutan
gad
pb
prior
eae
onset
tcell
cultur
ga
intact
mbp
monocyt
gatreat
wildtyp
mice
cocultur
naiv
tcell
mbp
tcr
transgen
tg
tcr
tcr
tg
mice
gatreat
monocyt
inject
immun
mice
result
daili
ga
administr
without
adjuv
prevent
revers
eae
observ
tcell
crossreact
ga
myelin
antigen
ga
treatment
wildtyp
mice
lack
matur
tcell
induc
typeii
apc
secret
less
tnfa
apc
direct
naiv
myelinand
ovaspecif
cell
induct
regulatori
cell
treg
protect
recipi
mice
eae
conclus
therapeut
benefit
ga
eae
requir
tcell
crossreact
ga
myelin
antigen
gatreat
exert
direct
effect
apc
without
requir
tcell
gamedi
apc
immunomodul
drive
treginduct
independ
tcell
specif
suffici
adopt
transfer
eae
protect
suppress
ongo
diseas
nonhuman
primat
model
multipl
sclerosi
humanantihuman
monoclon
antibodi
share
subunit
two
cytokin
overlap
activ
induct
autoreact
therefor
potenti
target
therapi
diseas
examin
whether
ongo
diseas
nonhuman
primat
model
multipl
sclerosi
suppress
new
human
mab
human
lesion
develop
brain
white
matter
visual
character
standard
magnet
reson
imag
mri
techniqu
reflect
treatment
ms
patient
treatment
mab
initi
activ
brain
white
matter
lesion
detect
weight
imag
placebotr
control
monkey
observ
expect
progress
increas
total
lesion
volum
markedli
increas
relax
time
mri
marker
inflamm
contrast
monkey
treat
mab
chang
total
lesion
volum
relax
time
significantli
suppress
moreov
time
interv
seriou
neurolog
deficit
delay
day
day
odd
ratio
result
diseas
model
high
similar
ms
import
ongo
plan
trial
therapi
target
andor
background
interferon
beta
commonli
use
immunomodulatori
treatment
ms
administ
patient
exogen
recombin
protein
microbi
compon
induc
product
endogen
antigenpres
cell
apc
stimul
tlr
poli
c
mimic
doublestrand
rna
stimul
apc
method
femal
sjl
mice
immun
proteolipid
protein
plp
peptid
plp
treat
poli
c
pb
inject
intraperiton
induct
relaps
phase
diseas
clinic
patholog
immunolog
paramet
assess
result
treatment
poli
c
significantli
suppress
clinic
patholog
sign
eae
treatment
protocol
poli
ic
induc
significantli
increas
product
ccchemokin
spleen
cell
cultur
ex
vivo
presenc
plp
express
significantli
increas
spleen
treat
mice
neutral
either
vivo
inject
neutral
antibodi
revers
diseas
suppress
poli
c
vitro
neutral
studi
bone
marrowderiv
dendrit
cell
show
product
conclus
poli
c
treatment
suppress
eae
mechan
involv
induct
endogen
assess
strategi
treatment
ms
select
inhibitor
celecoxib
prevent
experiment
autoimmun
encephalomyer
independ
pathway
katsuichi
miyamoto
sachiko
miyak
b
susumu
kusunoki
takashi
yamamura
b
depart
neurolog
kinki
univers
osaka
japan
b
depart
immunolog
nation
institut
neurosci
ncnp
tokyo
japan
cyclooxygenas
cox
key
enzym
arachino
acid
metabol
exist
two
distinct
isoform
constitut
express
tissu
wherea
induc
express
site
inflamm
select
inhibitor
develop
use
antiinflammatori
agent
show
new
gener
inhibitor
celecoxib
inhibit
experiment
autoimmun
encephalomyel
eae
celecoxib
inhibitor
nimelsulid
prevent
myelin
oligodendrocyt
glycoprotein
mog
induc
eae
administr
oral
day
diseas
induct
celecoxib
also
suppress
sever
eae
even
initi
clinic
symptom
moreov
celecoxib
inhibit
eae
defici
mice
indic
celecoxib
inhibit
eae
manner
celecoxibtr
mice
product
mogspecif
cell
reduc
mogspecif
elev
compar
vehicletr
mice
suggest
bia
mog
reactiv
cell
vivo
infiltr
inflammatori
cell
suppress
treat
celecoxib
result
suggest
celecoxib
use
new
addit
therapeut
agent
multipl
sclerosi
prevent
experiment
autoimmun
encephalomyel
via
induct
cell
regulatori
function
transfer
esdc
express
mog
peptid
along
trail
shinya
hirata
satoru
senju
hidetak
matsuyoshi
daiki
fukuma
yasuharu
nishimura
depart
immunogenet
graduat
school
medic
scienc
kumamoto
univers
japan
previous
report
strategi
prevent
experiment
autoimmun
encephalomyel
eae
treatment
mice
genet
modifi
dendrit
cell
dc
present
myelin
oligodendrocyt
glycoprotein
mog
peptid
context
mhc
class
ii
molecul
simultan
express
tnfrelat
apoptosisinduc
ligand
trail
program
ligand
genet
modif
dc
use
recent
establish
method
gener
dc
mous
es
cell
vitro
esdc
es
cell
sequenti
transfect
express
vector
trail
mog
epitop
present
vector
subsequ
doubletransfect
es
cell
clone
induc
differenti
esdc
studi
demonstr
sever
myelin
basic
protein
mbp
induc
eae
also
reduc
esdctrailmog
prevent
effect
diminish
cell
deplet
inject
mab
mice
treatment
esdctrailmog
addit
adopt
transfer
cell
esdctrailmogtr
mice
protect
recipi
mice
mogor
mbpinduc
eae
number
cell
increas
spinal
cord
mice
treat
esdctrailmog
result
suggest
prevent
eae
treatment
esdctrailmog
mediat
least
part
mogreact
regulatori
cell
propag
esdctrailmog
treatment
organ
specif
autoimmun
diseas
genet
modifi
esdc
present
tissuespecif
selfantigen
along
trail
would
effect
even
multipl
autoantigen
recogn
autoreact
cell
mechan
epitop
spread
peripher
toler
induct
use
ecdifix
apc
treatment
eae
act
indirect
mechan
ethylcarbodiimid
ecdi
chemic
crosslink
coupl
antigen
cell
deliv
toler
signal
cell
studi
explor
mechan
ecdiantigen
ag
coupl
cell
agsp
treatment
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
agsp
toler
demonstr
induc
unrespons
autoreact
cell
present
ag
coupl
splenocyt
initi
state
anergi
toler
believ
result
direct
interact
host
cell
fix
donor
agcoupl
antigen
present
cell
apc
deliv
ag
specif
signal
ligat
host
cell
receptor
peptid
mhc
class
ii
complex
donor
apc
without
costimul
howev
mous
spinal
chord
homogen
whole
protein
peptid
function
effici
ag
induc
toler
suggest
reprocess
donor
agsp
represent
domin
epitop
host
apc
investig
mechan
agsp
toler
examin
donor
vs
host
mhc
class
ii
restrict
agsp
toler
induct
data
use
mhc
knockout
allogen
andor
syngen
deriv
donor
agsp
demonstr
mhc
restrict
necessari
agsp
toler
induct
appear
ecdiagsp
activ
undergo
apoptosi
allow
function
ag
carrier
reprocess
repres
host
apc
support
promis
use
agsp
antigen
specif
therapi
autoimmun
inflammatori
diseas
work
support
nih
grant
administr
superagonist
monoclon
antibodi
highli
effect
treatment
experiment
autoimmun
encephalomyel
eae
underli
mechan
remain
elus
use
adopt
transfer
eae
lewi
rat
model
could
show
interfer
migrat
pathogen
cell
cn
respons
great
potenc
prevent
develop
progress
eae
inhibitori
effect
achiev
within
secondari
lymphoid
organ
antibodi
uniqu
abil
expand
activ
regulatori
cell
importantli
presenc
regulatori
cell
within
cn
dispens
benefici
effect
irrespect
whether
antibodi
administ
prophylact
therapeut
overt
eae
still
regulatori
cell
preferenti
home
cn
later
time
point
diseas
initi
suggest
potenti
import
role
resolut
phase
prevent
relaps
mechan
work
found
administr
prevent
disrupt
bloodbrain
barrier
favour
secret
cytokin
abrog
product
latter
result
impair
express
major
chemokin
receptor
effector
cell
presum
account
antibodi
abil
inhibit
migrat
pathogen
cell
cn
repres
mechanist
basi
novel
therapeut
concept
believ
may
translat
clinic
practic
human
monoclon
antibodi
specif
becom
avail
oral
administr
antibodi
suppress
experiment
allerg
encephalomyel
induc
lap
regulatori
cell
background
mucos
administr
autoand
alloantigen
induc
immunolog
toler
effect
treatment
anim
model
autoimmun
inflamm
transplant
parenter
efficaci
anim
model
autoimmun
human
approv
transplant
reject
posit
result
report
new
onset
type
diabet
investig
effect
oral
anim
model
multipl
sclerosi
experiment
allerg
encephalomyel
eae
method
oral
administ
isotyp
control
antibodi
dose
rang
per
day
consecut
day
result
sjl
model
plp
induc
eae
oral
suppress
eae
given
prior
diseas
peak
optim
dose
effect
observ
worsen
diseas
plpspecif
immun
respons
show
decreas
prolifer
reduc
secret
increas
increas
lap
latenc
associ
peptid
cell
enhanc
vitro
regulatori
activ
revers
correl
dose
suppress
eae
adopt
transfer
mesenter
cell
lapdeplet
cell
suppress
eae
depend
fashion
conclus
antibodi
given
oral
immunolog
activ
mucos
surfac
oral
induc
lap
regulatori
cell
function
depend
fashion
result
identifi
novel
physiolog
mechan
induc
regulatori
cell
clinic
applic
varieti
immun
mediat
disord
glatiram
acet
copaxon
therapi
restor
regulatori
cytotox
hlaerestrict
cell
multipl
sclerosi
one
goal
success
therapeut
immun
modul
autoimmun
diseas
induct
peripher
toler
larg
part
mediat
regulatorysuppressor
cell
demonstr
novel
immunomodulatori
mechan
exogen
peptidebas
therapi
incit
hla
class
irestrict
cytotox
suppressor
tcell
respons
shown
previous
treatment
multipl
sclerosi
ms
glatiram
acet
ga
induc
differenti
upregul
gareact
tcell
respons
show
gainduc
tcell
regulatorysuppressor
natur
untreat
patient
show
overal
deficit
tcellmedi
suppress
compar
healthi
subject
ga
therapi
significantli
enhanc
suppress
abil
mediat
cell
contactdepend
mechan
tcell
gatreat
patient
healthi
subject
untreat
ms
patient
exhibit
potent
hla
class
irestrict
gaspecif
cytotox
show
gainduc
cytotox
tcell
directli
kill
tcell
gaspecif
manner
kill
enhanc
preactiv
target
tcell
depend
crosspresent
ga
hlae
thu
demonstr
ga
therapi
induc
suppressorcytotox
tcell
respons
capabl
modul
vivo
immun
respons
ongo
therapi
studi
explain
sever
prior
observ
relat
mechan
drug
also
provid
import
insight
natur
immun
interplay
underli
human
immunemedi
diseas
support
part
grant
nih
nation
ms
societi
sensit
nonisotop
assay
acetylcholin
receptor
autoantibodi
rachel
hewer
ian
matthew
shu
chen
vivienn
mcgrath
michel
evan
emma
robert
sarah
nute
jane
sander
jadwiga
furmaniak
bernard
ree
smith
fir
laboratori
rsr
ltd
parc
ty
gla
llanishen
cardiff
uk
measur
autoantibodi
acetylcholin
receptor
achr
use
assess
manag
patient
myasthenia
gravi
mg
develop
new
nonisotop
assay
achrab
provid
specif
sensit
least
high
current
isotop
assay
describ
assay
serum
sampl
preincub
mixtur
purifi
foetal
adulttyp
achr
achrab
mixtur
allow
compet
three
differ
achr
monoclon
antibodi
bind
site
achr
coat
onto
elisa
plate
well
wherea
label
biotin
use
liquid
phase
mabbiotin
bind
detect
addit
streptavidin
peroxidas
substrat
higher
concentr
achrab
test
serum
greater
inhibit
mab
bind
achr
result
reduct
final
od
achrab
detect
elisa
mg
sera
studi
whilst
posit
achrab
immunoprecipit
assay
ipa
base
achr
label
bungarotoxin
discrep
sampl
sera
posit
elisa
neg
ipa
nmoll
toxin
bound
sera
neg
elisa
whilst
posit
ipa
nmoll
toxin
bound
control
sampl
neg
achrab
ipa
also
neg
elisa
overal
result
achrab
elisa
ipa
agre
well
r
n
p
new
assay
good
precis
handl
characterist
make
suitabl
routin
use
antibodi
acetylcholin
receptor
achr
present
around
patient
typic
gener
myasthenia
gravi
variabl
proport
patient
without
achr
antibodi
antibodi
muscl
specif
kinas
musk
seri
experiment
approach
suggest
remain
achr
antibodi
neg
patient
low
affin
antibodi
achr
would
detect
standard
immunoprecipit
test
solubilis
achr
present
monomer
form
low
concentr
pm
therefor
ask
whether
could
detect
antibodi
achr
immunofluoresc
cell
express
high
densiti
cluster
achr
human
embryon
kidney
cell
hek
transfect
cdna
achr
subunit
encod
adult
achr
isoform
cotransfect
gfprapsyn
rapsyn
cytoskelet
protein
help
cluster
achr
neuromuscular
junction
cell
incub
patient
control
sera
igg
antibodi
detect
texasredantihuman
igg
control
sera
bind
appreci
achr
cluster
four
posit
control
high
achr
antibodi
nm
show
strong
igg
bind
cluster
ten
ten
sera
low
achr
antibodi
nm
show
appreci
igg
bind
cluster
ten
sera
repeatedli
neg
nm
standard
immunoprecipit
posit
igg
bind
cluster
result
show
antibodi
achr
present
half
patient
previous
thought
achr
antibodi
neg
cell
base
immunofluoresc
assay
could
prove
use
diagnost
test
myasthenia
gravi
mg
anim
model
experiment
autoimmun
mg
eamg
autoimmun
disord
acetylcholin
receptor
achr
major
autoantigen
dna
microarray
technolog
support
quantit
real
time
pcr
immunohistochemistri
flow
cytometri
use
identifi
new
potenti
drug
target
mg
delin
gene
involv
pathogenesi
diseas
chemokin
receptor
found
overexpress
lnc
muscl
eamg
rat
thymus
muscl
mg
patient
upregul
cell
mg
patient
express
sever
phosphodiesteras
pde
subtyp
upregul
lnc
muscl
eamg
rat
pentoxifyllin
ptx
gener
pde
inhibitor
suppress
progress
eamg
treatment
start
acut
chronic
stage
diseas
suppress
associ
downregul
humor
cellular
achrspecif
respons
well
downregul
specif
pde
subtyp
upregul
transcript
factor
essenti
regulatori
cell
function
data
mine
muscl
transcriptom
reveal
two
major
group
deregul
gene
common
mg
eamg
gene
link
muscl
biolog
includ
muscl
protein
regul
contract
myosin
polypeptid
myosin
bind
protein
b
gene
code
chaperon
protein
categori
includ
sever
heat
shock
protein
inflammationassoci
deregul
gene
mg
eamg
result
demonstr
power
dna
microarray
technolog
identifi
novel
gene
involv
pathogenesi
myasthenia
autoimmun
diseas
alter
express
chemokin
receptor
cell
myasthenia
gravi
patient
h
onodera
r
saito
h
tago
suzuki
itoyama
matsumura
kondo
myasthenia
gravi
mg
character
celldepend
product
antiacetylcholin
receptor
antibodi
chemokin
receptor
regul
lymphocyt
migrat
express
specif
subset
cell
name
follicular
helper
cell
tfh
key
modul
antibodi
product
b
cell
studi
frequenc
lymphocyt
peripher
blood
mg
patient
therapi
untreat
mg
patient
show
significantli
higher
frequenc
cell
peripher
blood
compar
control
group
signific
differ
percentag
cell
observ
patient
hyperplasia
group
thymoma
group
cell
frequenc
correl
diseas
sever
cell
frequenc
mg
patient
posit
autoantibodi
togeth
antiachr
antibodi
significantli
higher
antiachr
antibodi
therapi
cell
percentag
decreas
gradual
control
level
signific
invers
correl
cell
frequenc
durat
initi
mg
therapi
result
suggest
cell
play
import
role
diseas
activ
mg
mg
patient
system
abnorm
celldepend
antibodi
product
childhood
myasthenia
gravi
japan
nomura
k
hachimori
nagao
segawa
k
kimura
segawa
segawa
neurolog
clinic
children
tokyo
japan
object
age
onset
myasthenia
gravi
mg
japan
show
two
modal
pattern
highest
year
age
associ
hla
follow
young
adult
peak
clinic
characterist
treatment
long
term
prognosi
childhood
mg
present
materi
method
case
childhood
onset
mg
visit
clinic
past
year
evalu
clinic
type
divid
ocular
latent
gener
clinic
ocular
symptom
electrophysiolog
myasthen
extrem
muscl
gener
treatment
consist
anticholinesteras
steroid
thymetomi
tacrolimu
result
clinic
type
show
gener
latent
gener
ocular
acetylcholin
receptor
antibodi
achr
ab
neg
low
case
case
minimum
ocular
symptom
sequela
begin
show
elev
achr
ab
around
year
age
antimusk
antibodi
studi
case
show
neg
case
respond
steroid
less
case
need
thymectomi
steroid
show
best
effect
start
within
year
onset
onset
older
year
gener
type
often
need
thymectomi
tacrolimu
use
case
good
result
conclus
specif
immatur
genet
background
seem
play
import
role
japanes
childhood
mg
long
term
prognosi
childhood
mg
gener
good
earli
intervent
steroid
thymectomi
import
complet
remiss
tacrolimu
safe
use
switch
steroid
effect
statin
experiment
autoimmun
neuriti
kiyozuka
fujioka
kudeken
k
murata
h
ito
iwasaki
toho
univers
omori
hospit
tokyo
japan
diseasemodul
effect
statin
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
unveil
howev
effect
autoimmun
disord
peripher
nervou
system
pn
remain
unclear
investig
effect
statin
experiment
autoimmun
neuriti
ean
atorvastatin
given
oral
ean
rat
daili
entir
cours
ean
induc
femal
lewi
rat
inject
synthet
peptid
bovin
myelin
protein
cfa
ean
rat
fed
vehicl
use
control
clinic
sign
assess
daili
use
gradescor
system
cauda
equina
ce
remov
day
postimmun
dpi
histolog
ce
studi
use
frozen
section
mrna
express
ifngamma
ce
studi
use
semiquantit
rtpcr
group
develop
ean
dpi
simultan
although
atorvastatintr
rat
show
milder
sign
earlier
recoveri
mononuclear
cell
infiltr
seen
ce
atorvastatintr
rat
also
milder
control
rat
rtpcr
reveal
ifngamma
mrna
express
dpi
mrna
express
dpi
atorvastatintr
rat
decreas
compar
control
rat
eae
atorvastatin
caus
shift
cytokin
balanc
result
suppress
neurolog
deficit
data
show
ean
atorvastatin
suppress
cytokin
irrelev
cytokin
upregul
seen
eae
differ
may
reflect
differ
yet
unknown
mechan
modul
autoimmun
inflamm
cn
pn
doublestrand
rna
induc
inflammatori
gene
express
schwann
cell
sensori
neuron
death
peripher
nerv
demyelin
inflamm
peripher
nervou
system
pn
one
characterist
virusinduc
peripher
neuropathi
inflammatori
respons
schwann
cell
activ
involv
recent
tolllik
receptor
identifi
receptor
doublestrand
rna
dsrna
induc
antivir
inflammatori
respons
cell
innat
immun
system
studi
investig
express
signal
pathway
schwann
cell
constitut
express
primari
rat
schwann
cell
isc
immort
schwann
cell
line
stimul
poli
c
synthet
dsrna
induc
express
variou
inflammatori
gene
rant
ino
schwann
cell
studi
intracellular
signal
transduct
pathway
use
isc
reveal
dsrna
induc
activ
cjun
ntermin
kinas
jnk
activ
jnk
pkr
requir
dsrnamedi
ino
gene
express
howev
activ
kinas
inhibit
ino
gene
induct
process
mediat
inhibitori
effect
activ
product
induc
dsrna
caus
neuron
cell
death
cultur
dorsal
root
ganglion
drg
final
introduct
dsrna
rat
sciatic
nerv
induc
ino
gene
express
peripher
nerv
degener
vivo
taken
togeth
data
suggest
viral
rna
may
induc
inflammatori
schwann
cell
activ
peripher
nerv
damag
pn
antigangliosid
complex
antibodi
miller
fisher
syndrom
recent
report
gangliosid
complex
gsc
target
antigen
serum
antibodi
patient
syndrom
gb
antigsc
antibodi
may
associ
particular
clinic
featur
gb
miller
fisher
syndrom
mf
character
clinic
triad
ophthalmoplegia
ataxia
areflexia
presenc
serum
igg
antibodi
consid
variant
gb
purpos
studi
investig
antibodi
gsc
sera
patient
mf
investig
igg
antibodi
gsc
sera
consecut
mf
patient
use
elisa
test
gangliosid
antigen
gsc
contain
two
seven
antigen
seven
patient
igg
antibodi
gsc
contain
five
igg
antibodi
complex
two
antibodi
four
five
patient
without
sensori
symptom
antibodi
least
three
differ
specif
mfsassoci
antibodi
also
cluster
epitop
gsc
includ
may
candid
prime
target
antigen
serum
antibodi
mf
patient
mf
may
tend
escap
sensori
disturb
complex
format
bacteri
lipooligosaccharid
make
mimicri
autoantibodi
product
campylobact
jejuni
strain
class
lipooligosaccharid
lo
biosynthesi
locu
except
carri
loss
found
worldwid
associ
syndrom
gb
develop
assum
complex
format
gangliosid
epitop
make
organ
express
new
structur
result
gener
autoantibodi
differ
reactiv
antibodi
specif
gangliosid
studi
detect
igg
autoantibodi
specif
react
mixtur
gangliosid
sever
gb
patient
c
jejuni
strain
carri
loss
isol
patient
higher
titer
igg
antibodi
absorpt
studi
show
complex
antibodi
absorb
lo
furthermor
absorpt
lost
use
lo
absorb
treatment
neuraminidas
arthrobact
ureafacien
convert
structur
one
immun
class
strain
gbsrelat
carri
loss
induc
igg
antibodi
respons
well
complex
individu
find
strongli
suggest
target
structur
complex
antibodi
mimic
gangliosid
structur
differ
sugar
sequenc
could
also
direct
target
antigen
autoantibodi
gb
first
exampl
demonstr
complex
format
bacteri
structur
anoth
way
make
molecular
mimicri
autoantibodi
product
efficaci
ciclosporin
chronic
inflammatori
demyelin
polyneuropathi
patient
requir
repeat
treatment
intraven
immunoglobulin
background
primari
goal
current
therapi
use
chronic
inflammatori
demyelin
polyneuropathi
cidp
control
symptom
improv
function
abil
maintain
longterm
remiss
cidp
patient
corticosteroid
sustain
remiss
requir
repeat
treatment
intraven
immunoglobulin
ivig
object
investig
therapeut
efficaci
ciclosporin
cidp
patient
requir
repeat
ivig
evalu
basic
inform
target
sampl
size
therapeut
trial
ciclosporin
method
ciclosporin
tri
cidp
patient
corticosteroid
could
sustain
remiss
initi
dose
ciclosporin
mgkgday
plasma
trough
concentr
ngml
frequenc
symptomat
relaps
side
effect
patient
treat
ciclosporin
month
investig
result
eight
patient
respond
ciclosporin
sustain
remiss
month
gradual
prolong
remiss
interv
increas
ciclosporin
dose
show
improv
repeat
ivig
requir
except
patient
renal
function
disturb
seriou
side
effect
preliminari
favor
find
patient
treat
ciclosporin
support
target
sampl
size
ciclosporin
treatment
extend
ivig
treatment
group
patient
ciclosporin
trial
conclus
ciclosporin
effect
therapeut
agent
longterm
remiss
patient
cidp
show
sustain
improv
corticosteroid
therapi
ciclosporin
tri
patient
cidp
requir
repeat
ivig
random
parallel
group
comparison
multicent
collabor
research
attend
hospit
throughout
japan
start
soon
current
studi
use
trimethyltininduc
damag
examin
contribut
tumor
necrosi
factor
tnf
superfamili
hippocamp
dentat
granul
cell
dg
death
determin
differenti
express
tnf
receptor
relationship
glia
would
character
neuron
vulner
dg
mrna
level
qtpcr
laser
captur
materi
elev
microglia
activ
astrocyt
hypertroph
protect
ca
pyramid
layer
mrna
level
elev
astrocyt
process
thicken
reactiv
nonphagocyt
microglia
present
microglia
prolifer
dg
ca
respect
injuri
intracellular
distribut
protein
dg
shift
membran
cytoplasmicnuclear
cell
express
activ
caspas
contact
activ
microglia
ca
intracellular
distribut
shift
cell
maintain
close
contact
gfap
astrocyt
neutral
antibodi
neuroprotect
mice
null
show
damag
attenu
mice
null
either
show
exacerb
null
mice
show
signific
elev
basal
level
less
induct
tmt
compar
wildtyp
basal
mrna
level
elev
wildtyp
similar
induct
higher
basal
level
induct
mrna
occur
elev
mice
occur
lower
dose
result
suggest
sequenc
event
proinflammatori
cytokin
activ
death
receptor
microglia
phenotyp
determin
pattern
neuron
death
object
goal
determin
whether
prostanoid
receptor
contribut
excitotox
death
neuron
method
receptor
antagonist
ono
examin
neuroprotect
effect
excitotox
exposur
nmethyldaspart
nmda
test
two
prepar
primari
neuron
cultur
contain
greater
neuron
pn
mixtur
neuron
glia
result
treatment
ono
nm
inhibitor
increas
number
neuron
surviv
nmda
factor
three
pn
cultur
mix
cultur
neuroprotect
seen
concentr
ono
percent
neuron
express
mix
cultur
pn
cultur
nmda
induc
tenfold
increas
cultur
prepar
although
net
amount
fivefold
higher
mix
cultur
combin
find
indic
lack
neuroprotect
mix
cultur
antagonist
due
lack
neuron
express
due
inabl
synthes
conclus
find
indic
activ
neuron
contribut
neuron
death
influenc
nonneuron
cell
thioredoxin
inhibit
nmdainduc
neurotox
rat
retina
thioredoxin
trx
endogen
redoxactiveregul
play
cytoprotect
role
focal
ischem
excitotox
brain
damag
investig
whether
trx
modul
nmethyldaspart
nmda
induc
retin
neurotox
trx
mutant
trx
salin
inject
togeth
nmda
intravitr
rat
eye
number
retin
ganglion
cell
rgc
count
retrograd
label
analysi
evalu
retin
damag
cellular
apoptosi
retina
measur
tdtmediat
dutp
nickend
label
tunel
measur
caspas
activ
activ
mitogenactiv
protein
kinas
mapk
jnk
mapk
kinas
mkk
examin
western
blot
immunohistochemistri
protein
carbonyl
nitrosyl
lipid
peroxid
assess
evalu
antioxid
effect
trx
rgc
rescu
trx
compar
salin
evalu
retrograd
label
analysi
day
nmdainject
trx
mutant
form
prevent
nmdainduc
apoptosi
retina
measur
tunel
induct
nmda
significantli
lower
trxtreat
eye
salinetr
eye
nmdainduc
activ
jnk
h
h
markedli
suppress
rgc
trx
mutant
form
nmdainduc
increas
protein
carbonyl
nitrosyl
lipid
peroxid
also
suppress
trxtreat
eye
trx
effect
attenu
nmdainduc
retin
cell
damag
suppress
oxid
stress
inhibit
apoptot
signal
pathway
involv
cytoprotect
effect
trailinduc
death
adult
human
oligodendrocyt
mediat
jnk
mitochondri
activ
background
trail
tnfrelat
apoptosi
induc
ligand
member
tnf
famili
induc
death
mainli
tumor
cell
trail
express
autoreact
cell
induc
death
adult
human
oligodendrocyt
ligat
trailreceptor
intracellular
signal
involv
oligodendrocyt
injuri
still
unknown
method
studi
investig
involv
jnk
mitochondri
pathway
death
trail
stimul
jnk
activ
assess
use
antibodi
phosphoryl
jnk
isoform
analyz
cjun
phosphoryl
autoradiographi
role
jnk
activ
estim
use
domin
neg
construct
kinas
upstream
jnk
chang
mitochondri
membran
permeabl
assess
use
apoalert
mitochondri
membran
kit
cell
death
analyz
fac
use
annexinv
pi
stain
result
result
shown
intracellular
signal
involv
trailinduc
death
oligodendrocyt
associ
strong
sustain
activ
jnk
isoform
trail
stimul
observ
chang
mitochondri
membran
potenti
activ
occur
mitochondrium
activ
domin
neg
mutant
inhibit
trail
induc
mitochondri
membran
disrupt
oligodendrocyt
injuri
conclus
result
indic
jnk
mitochondri
activ
critic
involv
oligodendrocyt
death
induc
trail
might
import
protect
immunemedi
oligodendrocyt
demis
tumor
necrosi
factor
tnf
induc
apoptoticlik
cell
death
oligodendrocyt
cell
type
target
ms
ligat
tnf
receptor
induc
sever
signal
transduct
pathway
includ
caspas
cascad
mitochondri
deriv
factor
like
apoptosi
induc
factor
aif
howev
precis
mechan
involv
human
oligodendrocyt
hol
death
unknown
ol
prepar
human
brain
specimen
tnfinduc
hol
death
detect
flow
cytometri
annexinvfitc
pi
stain
aif
activ
assess
hol
dna
electrophoresi
nuclei
transloc
confoc
microscopi
antisens
construct
asaif
use
prevent
aif
activ
caspas
inhibitor
zvadfmk
calpain
inhibitor
zllyfmk
serin
proteas
inhibitor
tpck
cathepsin
inhibitor
zfl
use
assess
involv
ol
death
tnfinduc
death
hol
noncaspas
depend
evidenc
lack
gener
activ
subunit
lack
cleavag
fluorogen
substrat
lack
hol
death
inhibit
zvadfmk
also
calpain
serin
proteas
cathepsin
inhibitor
ineffici
prevent
hol
death
contrari
tnfinduc
hol
death
involv
aif
evidenc
characterist
aifinduc
cell
death
larg
scale
dna
fragment
aif
transloc
hol
nuclei
upon
tnf
exposur
accordingli
tnfinduc
hol
death
prevent
inhibit
aif
asaif
brain
section
within
edg
ms
lesion
oligodendrocyt
defin
antimbp
stain
show
nuclei
posit
aif
result
indic
tnfinduc
death
hol
depend
aif
inform
signific
design
strategi
protect
hol
immunemedi
demyelin
complement
complex
protect
oligodendrocyt
apoptot
cell
death
inhibit
process
upregul
flip
activ
termin
complement
cascad
involv
protein
benefici
role
oligodendrocyt
experiment
allerg
encephalomyel
anim
model
multipl
sclerosi
protect
apoptot
cell
death
previous
shown
sublyt
complex
posttransl
regul
bad
inhibit
mitochondri
pathway
apoptosi
induc
serum
depriv
present
studi
examin
possibl
involv
fa
pathway
oligodendrocyt
apoptosi
role
process
serumfre
defin
medium
oligodendrocyt
undergo
apoptosi
differenti
concomitantli
condit
found
process
increas
associ
bid
cleavag
markedli
reduc
express
cflip
l
protein
inhibitor
zietdfmk
inhibit
cell
death
associ
differenti
dosedepend
manner
exposur
induc
inhibit
activ
bid
cleavag
signific
increas
cflip
l
express
phosphatidylinositol
inhibitor
revers
effect
also
downregul
express
fasl
fa
induc
apoptosi
data
suggest
phosphatidylinositol
signal
rescu
olg
fasmedi
apoptosi
regul
process
mekerk
signal
involv
death
oligodendrogli
progenitor
cell
depart
neurolog
univers
california
davisinstitut
pediatr
regen
medicin
shriner
hospit
children
northern
california
sacramento
california
usa
oligodendrocyt
expos
variou
cytokin
inflammatori
lesion
cn
studi
focus
direct
effect
interferongamma
ifng
purifi
rat
oligodendrogli
cultur
differ
development
stage
among
three
stage
test
ifng
direct
cytotox
effect
activ
prolifer
oligodendrocyt
progenitor
much
less
immatur
oligodendrocyt
none
matur
oligodendrocyt
stage
specif
suscept
progenitor
ifnginduc
cytotox
consist
two
compon
delay
cell
cycl
transit
phase
phase
increas
cell
death
least
partli
mediat
apoptosi
suggest
progress
cell
cycl
tightli
link
toxic
mechan
far
could
determin
examin
induct
mrna
respons
ifng
function
differ
signal
transduc
activ
transcript
stat
pathway
progenitor
matur
oligodendrocyt
found
partial
inhibit
erk
pathway
one
mitogen
activ
protein
kinas
pathway
partial
revers
ifnginduc
cytotox
addit
erk
activ
quickli
downregul
differenti
progenitor
immatur
oligodendrocyt
therefor
conclud
simultan
activ
stat
pathway
ifng
erk
pathway
trophic
factor
play
role
stage
specif
ifnginduc
cytotox
oligodendrogli
progenitor
activ
akt
attenu
apoptosi
mediat
extrins
death
receptor
via
intrins
mitochondri
pathway
identifi
addit
downstream
target
akt
screen
human
protein
databas
akt
consensu
sequenc
protein
unknown
function
highli
conserv
protein
predict
contain
amino
acid
three
akt
consensu
phosphoryl
site
identifi
aris
altern
splice
kb
gene
also
encod
recent
describ
protein
mrna
predominantli
express
tissu
hematopoiet
origin
detect
matur
b
lymphocyt
macrophag
epitheli
line
primari
fibroblast
coexpress
akt
lead
kinas
depend
phosphoryl
interact
akt
explor
cellular
local
function
wild
type
mutant
lack
either
akt
phosphoryl
site
tria
mutant
nuclear
local
signal
sam
domain
express
cell
well
tria
mutant
mutant
local
nucleu
indic
akt
phosphoryl
regul
cell
local
jurkat
cell
transduc
retrovir
vector
express
wt
significantli
protect
fa
staurosporin
mediat
apoptosi
protect
requir
put
akt
phosphoryl
site
togeth
data
suggest
novel
akt
substrat
local
nucleu
cell
hematopoiet
origin
mediat
protect
fa
mediat
apoptosi
role
adenosin
receptor
neuroprotect
immunolog
respons
brain
play
crucial
role
neuropatholog
condit
nowaday
consensu
sever
inflammatori
mediat
immunoregulatori
cytokin
protect
neuron
glutamateinduc
neurotox
vitro
vivo
despit
larg
bodi
experiment
evid
fundament
mechan
underli
neuroprotect
understood
today
data
clearli
show
neuroprotect
agent
per
se
instead
enhanc
express
function
neuron
adenosin
receptor
vitro
vivo
accordingli
provid
evid
enhanc
neuron
adenosin
receptor
function
effici
protect
hippocamp
neuron
hypoxia
acut
prepar
brain
slice
facilit
neuron
surviv
excitotox
paradigm
protect
anim
chemic
induc
convuls
seizur
moreov
shown
neuroprotect
abolish
function
neuron
adenosin
receptor
block
base
data
suggest
increas
neuron
surviv
vitro
vivo
enhanc
function
neuron
adenosin
receptor
brain
major
protect
system
interferon
counteract
apoptot
cell
death
induc
tnf
primari
astrocyt
stimul
mek
although
interferon
demonstr
effect
treatment
multipl
sclerosi
ms
mechan
underli
benefici
effect
uncov
present
work
investig
abil
counteract
apoptosi
induc
treatment
primari
astrocyt
primari
monolay
cultur
rat
cortic
astrocyt
treat
differ
dose
ngml
h
absenc
presenc
ngml
apoptot
cell
death
determin
hoechst
stain
phosphoryl
akt
erk
determin
western
blot
treatment
induc
signific
increas
astrocyt
death
start
dose
ngml
effect
block
presenc
inhibitor
zietdfmk
indic
astrocyt
death
due
apoptosi
cotreat
cultur
astrocyt
significantli
reduc
cell
death
antiapoptot
effect
depend
least
partial
abil
stimul
phosphoryl
akt
activ
inhibit
mean
treatment
fail
promot
akt
phosphoryl
astrocyt
surviv
addit
also
induc
phosphoryl
erk
inhibit
mek
activ
mean
treatment
block
abil
counteract
apoptosi
view
result
tempt
specul
benefici
effect
interferon
treatment
ms
patient
may
depend
abil
prevent
astrocyt
death
support
fiss
grant
trigger
antivir
respons
astrocyt
tolllik
receptor
tlr
receptor
mediat
innat
immun
pathogen
tolllik
receptor
viral
nucleic
acid
sentinel
activ
dsrna
within
intracellular
vesicl
signal
trif
tir
domaincontain
adaptorinduc
activ
interferon
regulatori
factor
lead
product
primari
respons
delay
activ
nfkb
lead
product
proinflammatori
cytokin
chemokin
explor
spectrum
gene
induc
human
astrocyt
use
microarray
approach
dsrna
mimet
poli
c
pic
ligand
one
highli
induc
gene
protein
known
antivir
activ
express
depend
nfkb
signal
repetit
stimul
poli
c
increas
express
determin
whether
poli
c
induc
antivir
state
astrocyt
pseudotyp
hiv
viral
particl
use
poli
c
significantli
abrog
replic
wherea
also
potent
activ
astrocyt
viperin
induct
could
also
substanti
inhibit
neutral
antibodi
ifnb
could
replic
explor
role
viperin
ifnbmedi
inhibit
employ
rnai
approach
rnai
direct
viperin
scrambl
rnai
significantli
inhibit
viperin
express
also
significantli
revers
poli
c
induc
inhibit
replic
conclud
viperin
contribut
antivir
state
induc
ligat
astrocyt
support
role
astrocyt
part
innat
immun
respons
infect
cn
tolllik
receptor
profil
function
human
brain
multipl
sclerosi
tolllik
receptor
tlr
key
element
control
inflammatori
pathway
also
human
cn
previou
studi
demonstr
presenc
variou
tlr
human
microglia
astrocyt
mark
differ
howev
separ
tlr
either
type
glial
cell
microglia
rather
divers
set
tlr
express
least
found
insid
endosom
vesicl
astrocyt
hand
express
limit
set
tlr
cell
surfac
present
studi
found
upon
activ
astrocyt
display
strike
prefer
express
elev
level
genom
profil
function
data
indic
activ
astrocyt
activ
tradit
proinflammatori
respons
instead
comprehens
neuroprotect
angiogen
antiinflammatori
respons
suggest
astrocyt
may
act
repair
mediat
line
notion
recent
identifi
endogen
cn
protein
activ
astrocyt
shed
light
tlr
function
human
cn
inflamm
tlr
profil
human
brain
sampl
includ
multipl
sclerosi
lesion
vari
stage
evalu
realtim
pcr
protein
stain
techniqu
result
analys
possibl
implic
discuss
impair
cleareanc
apoptot
neuron
lack
microgli
signal
kazuya
takahashi
christian
dp
rochford
harald
neumann
neuroimmunolog
unit
european
neurosci
institut
goettingen
germani
depart
neurolog
neurobiolog
age
kanazawa
univers
graduat
school
medic
scienc
japan
institut
reconstruct
neurobiolog
univers
bonn
life
brain
center
bonn
germani
background
elimin
apoptot
neuron
without
inflamm
crucial
brain
tissu
homeostasi
molecular
mechan
firmli
establish
trigger
receptor
express
myeloid
recent
identifi
innat
immun
receptor
mutat
describ
nasuhakola
diseas
patient
analyz
microgli
function
respons
stimul
knock
method
cultur
microglia
transduc
flagtag
short
hairpin
rna
interfer
wild
type
overexpress
control
gfp
lentivir
vector
function
respons
stimul
knock
cocultur
apoptot
neuron
analyz
flow
cytometri
rtpcr
immunocytochemistri
result
stimul
increas
phagocyt
activ
neither
induc
inflammatori
mediat
upregul
surfac
marker
involv
antigen
present
furthermor
knock
microglia
show
impair
clearanc
apoptot
neuron
increas
gene
transcript
tnfalpha
overexpress
microglia
result
increas
phagocytosi
apoptot
neuron
decreas
gene
transcript
inflammatori
mediat
conclus
signal
particip
clearanc
apoptot
neuron
downregul
inflamm
maintain
immunoprivileg
cn
microenviron
primat
microglia
particularli
sensit
activ
react
activ
microglia
cn
resid
innat
immun
cell
becom
activ
upon
encount
infecti
agent
tolllik
receptor
tlr
divers
famili
receptor
recogn
pathogenassoci
molecular
pattern
drive
activ
express
cell
transform
rest
microglia
activ
apc
involv
multipl
step
outcom
determin
differenti
potenti
rest
microglia
activ
stimulu
order
studi
process
use
primari
microglia
obtain
adult
rhesu
monkey
exposur
differ
differenti
mcsf
gmcsf
regim
function
reactiv
tlrmediat
signal
determin
tlr
mrna
express
level
quantifi
type
microglia
respond
stimul
measur
product
tnfalpha
equal
import
rhesu
microglia
respons
signal
latter
contrast
murin
microglia
type
microglia
particularli
respons
stimul
howev
activ
evok
much
stronger
cytokin
respons
mcsfdifferenti
microglia
compar
gmcsfdifferenti
microglia
wherea
reaction
toward
tlr
ligand
compar
moreov
mcsfdifferenti
microglia
express
higher
mrna
level
gmcsfdifferenti
microglia
sinc
signal
activ
microglia
potent
current
screen
cn
materi
differ
origin
presenc
ofendogen
ligand
intriguingli
tlrmediat
activ
microglia
dramat
enhanc
mrna
express
level
gmcsfdifferenti
microglia
possibl
endow
cell
sensit
signal
aim
present
preliminari
data
subject
meet
releas
activin
microgli
cell
upon
stimul
bacteri
tlragonist
ebert
r
nau
u
michel
georgaugustunivers
depart
neurolog
germani
object
activin
member
transform
growth
factorbeta
famili
growth
differenti
factor
multifunct
cytokin
one
role
immun
system
inflammatori
process
neuroprotect
properti
detect
within
central
nervou
system
previous
demonstr
concentr
activin
elev
cerebrospin
fluid
csf
patient
mening
sourc
elev
activin
concentr
csf
mening
yet
discov
examin
whether
microgli
cell
releas
activin
upon
stimul
bacteri
tolllikereceptor
tlr
agonist
method
primari
mous
microgli
cell
expos
agonist
tripalmitoylsglycerylcystein
lp
lipopolysaccharid
cpg
oligonucleotid
contain
unmethyl
cytosinguanosin
motif
h
activin
concentr
cell
cultur
supernat
measur
elisa
median
minimum
maximum
result
activin
concentr
cell
cultur
supernat
detect
limit
elisa
control
group
significantli
elev
treatment
differ
tlragonist
pg
ml
lp
p
pgml
p
pgml
cpg
p
discuss
result
show
first
time
microgli
cell
releas
activin
upon
activ
bacteri
tlragonist
find
provid
evid
role
activin
innat
immun
respons
suggest
microgli
cell
sourc
elev
activin
concentr
observ
csf
bacteri
mening
previou
studi
demonstr
play
import
role
inhibit
lpsinduc
gene
express
studi
describ
lp
strong
induc
express
macrophag
microglia
occur
transcript
level
analysi
promot
indic
two
ga
element
involv
lpsinduc
transcript
macrophag
lpsinduc
express
involv
endogen
product
contribut
express
activ
block
activ
inclus
neutral
antibodi
reduc
lpsinduc
gene
express
furthermor
lp
induc
activ
mitogenactiv
protein
kinas
mapk
pathway
also
involv
lpsinduc
gene
express
result
indic
lpsinduc
mapk
activ
endogen
product
subsequ
induc
activ
play
critic
role
regul
propos
lpsinduc
express
result
neg
feedback
loop
attenu
lp
cytokineinduc
immun
inflammatori
respons
cn
heterogen
origin
reactiv
microglia
injur
rat
mous
central
nervou
system
microglia
serv
homeostat
function
normal
cn
sens
threat
modul
neuron
surviv
injur
diseas
cn
present
understand
microgli
biolog
involv
diseas
influenc
observ
exogen
bone
marrow
bm
deriv
cell
contribut
reactiv
microgliosi
mous
determin
whether
speciesdiffer
recruit
microgli
transform
bmderiv
cell
injur
cn
analyz
microgli
reaction
radiat
bm
chimer
mice
rat
subject
classic
form
experiment
manipul
known
elicit
predict
strong
microgli
reaction
minim
involv
monocyt
macrophag
found
subpopul
reactiv
bushytyp
microgli
cell
dentat
gyru
origin
transform
bmderiv
cell
entorhin
cortex
lesion
bm
chimer
mice
contrast
bm
chimer
rat
subject
global
cerebr
ischemia
display
characterist
microgli
rod
cell
transform
microgli
hyperplasia
regio
superior
hippocampu
absenc
recruit
microgli
transform
bmderiv
cell
result
provid
evid
reactiv
microglia
rat
origin
resid
microglia
mix
bmderiv
resid
origin
mous
data
emphas
import
speciesdiffer
recruit
bloodborn
microgli
precursor
brain
speciesdiffer
may
issu
consid
use
bmderiv
cell
gene
deliveri
cn
human
neurolog
disord
importantli
bm
chimer
rat
may
provid
valuabl
model
establish
condit
attract
genet
manipul
bmderiv
cell
human
cn
microarray
analysi
microglia
versu
bone
marrowderiv
macrophag
vuaillatsavarin
carin
wierinckx
ann
rey
catherin
lachuer
belin
nataf
serg
howev
molecular
basi
special
poorli
known
particular
marker
could
reliabl
discrimin
microglia
macrophag
yet
identifi
present
work
use
gene
array
analysi
compar
rna
profil
obtain
microglia
versu
bonemarrow
deriv
macrophag
bmm
microgli
cell
isol
mix
glial
cell
cultur
driven
toward
rest
state
grow
day
presenc
glial
cell
condit
medium
parallel
experi
bmm
gener
stimul
bonemarrow
deriv
myeloid
progenitor
mcsf
day
control
rna
qualiti
bioanalyz
agil
doubl
amplif
process
perform
cdna
synthesi
express
gene
assess
codelink
plateform
amersham
data
analyz
genespr
softwar
silicon
genet
valid
result
gene
interest
select
rel
level
express
evalu
realtim
rtpcr
number
immunerel
gene
identifi
includ
gene
code
mhc
class
ii
molecul
upregul
macrophag
receptor
upregul
microglia
erythropoietin
receptor
upregul
microglia
howev
also
identifi
gene
relat
immun
function
particular
sever
gene
involv
lipid
metabol
found
specif
express
microglia
character
phagocyt
activ
mous
primari
microglia
toward
apoptot
glioma
cell
microglia
ingest
variou
pathogen
well
apoptot
cell
neuron
potent
phagocyt
capac
hardli
analys
context
brain
tumour
could
serv
purpos
remov
die
also
live
tumour
cell
describ
macrophag
herein
report
quantit
studi
base
flow
cytometri
assay
qualit
studi
use
timelaps
video
microscopi
conduct
primari
cultur
microglia
deriv
three
mous
strain
three
differ
glioma
cell
line
phagocyt
capac
microglia
evalu
determin
phagocyt
rate
percent
microglia
total
popul
phagocytos
tumour
cell
within
given
time
microglia
either
balbc
vmdk
strain
phagocytos
etoposidetr
apoptot
glioma
cell
phagocyt
rate
vari
accord
strain
glioma
cell
line
use
signific
uptak
live
tumour
cell
observ
besid
known
induct
microgli
toxic
activ
lp
interferongamma
stimul
increas
phagocyt
rate
save
vmdkderiv
microglia
expect
amoeboid
microglia
present
unstimul
popul
phagocyt
wherea
upon
stimul
activ
also
observ
rodshap
cell
immun
stimul
enhanc
motil
exploratori
behaviour
stimul
microglia
kill
tumour
cell
also
phagocytos
dead
cell
present
close
vicin
altogeth
data
indic
microglia
phagocytos
apoptot
live
tumour
cell
current
work
focu
identif
receptor
ligand
mediat
microgliaglioma
cell
recognit
pathogenesi
mani
neurodegen
disord
exacerb
imbal
matrix
metalloproteinas
mmp
inhibitor
tissu
inhibitor
metalloproteinas
timp
previous
report
differenti
express
acut
versu
chronic
astrocyt
activ
brain
tissu
patient
dementia
investig
possibl
mechan
underli
chronic
downregul
neuroinflamm
use
interleukin
il
model
proinflammatori
stimulu
measur
mrna
stabil
astroglioma
cell
transcript
regul
activ
astrocyt
halflif
mrna
quantifi
use
real
time
pcr
determin
effect
stimul
stabil
transcript
promot
activ
measur
use
report
construct
transfect
astrocyt
result
demonstr
enhanc
mrna
stabil
may
lead
increas
level
follow
acut
activ
howev
chronic
downregul
like
promot
regul
loss
mrna
stabil
furthermor
proinflammatori
cytokin
includ
tumor
necrosi
factor
tnf
interferon
ifn
along
enhanc
effect
promot
regul
minimum
promot
sequenc
demonstr
strongest
downregul
promot
activ
follow
activ
transfect
astrocyt
suggest
locat
silenc
element
data
import
unravel
mechan
underli
astrocyt
respons
chronic
inflamm
broader
implic
inflammatori
diseas
involv
mmptimp
imbal
doublestrand
rna
induc
express
retino
acidinduc
genei
cultur
astrocyt
imaiuzmi
h
yoshida
k
satoh
chemokin
gener
astrocyt
may
implic
immun
reaction
central
nervou
system
retino
acidinduc
genei
rigi
cytoplasm
signal
molecul
play
role
innat
immun
viral
infect
studi
effect
doublestrand
rna
express
rigi
astrocyt
polyinosinicpolycitydyl
acid
poli
ic
authent
doublestrand
rna
mimic
viral
infect
found
induc
rigi
express
astrocyt
cell
line
poli
ic
also
induc
express
cc
type
chemokin
inhibit
rigi
express
rna
interfer
result
reduc
express
conclud
rigi
may
involv
innat
immun
viral
infect
central
nervou
system
part
regul
express
astrocyt
activ
peroxisom
proliferatoractiv
receptorgamma
decreas
monocyt
migrat
across
blood
brain
barrier
bbb
rho
depend
manner
caus
neurolog
impair
associ
migrat
virusinfect
monocyt
across
bbb
macrophag
accumul
brain
nuclear
ligandrespons
transcript
factor
known
mediat
pleiotrop
antiinflammatori
pathway
contribut
endotheli
barrier
function
remain
larg
unknown
test
effect
stimul
monocyt
migrat
across
bbb
vitro
model
primari
human
brain
microvascular
endotheli
cell
hmvec
plate
porou
membran
applic
tumor
necrosi
alpha
monocyt
chemoattract
relev
cytokin
chemokin
known
increas
infect
augment
monocyt
migrat
across
bbb
pretreat
endotheli
monolay
rosiglitazon
agonist
diminish
migrat
infect
monocyt
across
bbb
compar
untreat
control
similarli
hmvec
pretreat
increas
adhes
infect
monocyt
adhes
reduc
simultan
applic
rosiglitazon
sinc
previou
work
indic
monocytehmvec
interact
result
activ
rho
small
gtpase
test
idea
increas
monocyt
migrat
could
mediat
induc
rho
activ
agonist
prevent
effect
inde
increas
level
rhogtp
activ
form
activ
reduc
level
rhogtp
control
level
taken
togeth
result
suggest
novel
role
agonist
modul
monocyteendotheli
interact
mediat
part
rho
activ
util
agonist
approv
clinic
use
may
offer
new
therapeut
approach
prevent
bbb
dysfunct
seen
brain
infect
inhibit
leukocyt
recruit
block
seizur
epilepsi
pathogenet
link
repeat
seizur
epilepsi
complet
unknown
prevent
implement
success
therapi
goal
studi
determin
potenti
role
leukocyt
recruit
pathogenesi
epilepsi
method
epilepsi
induc
inject
mice
pilocarpin
intravit
microscopi
perform
brain
vessel
postseizur
immunofluoresc
immunohistochemistri
electron
microscopi
magnet
reson
imag
telemetri
behavior
evalu
cognit
evalu
base
enrich
openfield
reveal
also
perform
result
human
observ
granulocyt
cell
accumul
epilept
brain
next
verifi
whether
leukocyt
recruit
play
role
pathogenesi
wide
use
experiment
model
epilepsi
found
increas
permeabl
vasodilat
express
statu
epilepticu
se
repeat
seizur
electron
microscopi
magnet
reson
imag
show
granulocyt
cell
migrat
brain
postseizur
intravit
microscopi
show
blockad
integrin
inhibit
granulocyt
lymphocyt
roll
arrest
brain
vessel
therapeut
treatment
mice
mab
lead
drastic
reduct
seizur
moreov
cognit
evalu
reveal
treat
anim
present
signific
preserv
behavior
compar
epilept
mice
strikingli
prevent
administr
therapi
inhibit
induct
se
complet
block
recurr
seizur
develop
epilepsi
conclus
result
demonstr
unexpect
key
role
leukocyt
recruit
pathogenesi
epilepsi
antileukocyt
adhes
therapi
prevent
therapeut
effect
human
model
epilepsi
background
although
develop
multipl
sclerosi
ms
plaqu
mainli
driven
type
inflammatori
respons
exact
mechan
restrict
popul
lymphocyt
penetr
cn
parenchyma
still
obscur
materi
method
develop
novel
system
evalu
charact
lymphocyt
attach
intrud
beneath
human
brain
microvascular
endotheli
cell
bmec
monolay
use
analysi
confoc
laser
microscopi
lymphocyt
obtain
healthi
volunt
ms
patient
acut
stage
lymphocyt
select
seed
human
bmec
monolay
h
cell
fix
immonostain
proport
lymphocyt
repres
cell
lymphocyt
cell
attach
surfac
bmec
monolay
migrat
beneath
bmec
monolay
quantit
analyz
use
system
result
healthi
volunt
lymphocyt
migrat
beneath
bmec
monolay
significantli
domin
convers
ms
patient
acut
stage
cell
stay
surfac
monolay
migratedintrud
lymphocyt
significantli
domin
conclus
intrus
cell
cn
parenchyma
might
regul
bloodbrain
barrier
mechan
possibl
impair
acut
ms
patient
astrocyt
maintain
bloodbrain
barrier
integr
product
angiotensin
ii
wosik
k
devillersdodelet
berthelet
f
prat
bloodbrain
barrier
bbb
restrict
entranc
bloodborn
molecul
cell
central
nervou
system
cn
therebi
regul
homeostasi
astrocyt
ensheath
brain
endothelium
provid
crucial
factor
mainten
bbb
multipl
sclerosi
ms
character
breach
bbb
integr
object
studi
determin
factor
produc
astrocyt
contribut
bbb
function
integr
use
human
cnsderiv
endotheli
cell
astrocyt
demonstr
astrocyt
express
angiotensinogen
agt
produc
angiotensin
ii
human
brain
endotheli
cell
hbec
express
angiotensin
receptor
vitro
situ
addit
astrocyt
condit
media
ang
ii
receptor
agonist
hbec
cultur
induc
import
decreas
monolay
permeabl
well
specif
chang
phosphoryl
tight
junction
protein
occludin
concentr
lipid
raft
tight
junction
assembl
furthermor
effect
astrocyt
condit
media
could
block
addit
receptor
antagonist
presenc
inflammatori
cytokin
andor
astrocyt
cultur
block
abil
produc
ang
ii
addit
use
brain
section
normal
ms
patient
could
demonstr
blood
vesselproxim
human
astrocyt
normal
brain
express
agt
express
lost
around
brain
endothelium
activ
ms
lesion
conclud
studi
astrocytederiv
angiotensin
ii
act
via
receptor
necessari
bbb
integr
bioactiv
interferonbeta
mxcongen
mice
interferon
ifn
beta
first
still
lead
therapeut
intervent
shown
chang
caus
relaps
remit
multipl
sclerosi
howev
mechan
action
ifnbeta
remain
question
prevail
view
benefit
treatment
ascrib
ifnbeta
system
effect
studi
investig
permeabl
bloodbrain
barrier
bbb
ifnbeta
therebi
question
ifnbeta
potenti
effect
within
cn
relaps
clinic
type
ifninduc
mxa
gene
use
monitor
ifnbeta
treatment
use
mrna
transcript
murinecounterpart
gene
biomark
ifnbeta
treatment
mxcongen
mice
use
realtim
pcr
show
peak
level
mrna
white
blood
cell
h
subcutan
administr
human
compar
denatur
protein
constitut
level
analysi
doserespons
relationship
biodistribut
ifnbeta
show
clear
relationship
increas
level
mrna
variou
organ
includ
heart
kidney
liver
lung
spleen
final
permeabl
bbb
ifnbeta
investig
examin
level
mrna
perfus
cn
demonstr
induct
high
level
mrna
indic
ifnbeta
cross
bbb
conclus
data
support
situ
hybridis
support
warwara
larsen
foundat
diapedesi
monocyt
associ
matrix
metalloproteinas
mmp
mediat
occludin
disappear
brain
endothelium
bloodbrain
barrier
bbb
control
entri
circul
molecul
cell
brain
character
presenc
endotheli
cell
connect
tight
junction
inflammatori
cell
traffick
brain
complic
sever
neurolog
disord
conceiv
depend
mechan
regul
tight
junction
open
detail
studi
tight
junction
dynam
immun
cell
diapedesi
lack
therefor
retrovir
express
tight
junction
protein
occludin
ntermin
tag
green
fluoresc
protein
gfp
rat
brain
endotheli
cell
confoc
microscopi
analys
reveal
gfpoccludin
coloc
intracellular
tight
junction
protein
complet
absent
cell
border
lack
appos
cell
mutant
cell
retain
endotheli
properti
includ
cell
morpholog
endotheli
marker
prolifer
rate
adhes
capac
mean
live
cell
imag
studi
show
monocyt
scroll
brain
endotheli
cell
surfac
toward
cellcel
contact
induc
gap
format
associ
local
disappear
gfpoccludin
subsequ
travers
endothelium
paracellular
fashion
immunoblot
analys
indic
loss
occludin
due
protein
degrad
interestingli
occludin
contain
put
extracellular
mmp
cleavag
site
use
broad
spectrum
mmpinhibitor
show
gap
format
loss
occludin
diapedesi
inde
depend
activ
matrix
metalloproteinas
result
provid
novel
insight
mechan
leukocyt
travers
bbb
illustr
therapeut
aim
stabil
tight
junction
may
benefici
resist
neuroinflammatori
attack
highli
purifi
lipoteicho
acid
gramposit
bacteria
induc
vitro
bloodbrain
barrier
disrupt
glia
activ
role
proinflammatori
cytokin
nitric
oxid
cocultur
bovin
capillari
endotheli
cell
rat
primari
glial
cell
establish
vitro
bloodbrain
barrier
bbb
model
investig
mechan
gramposit
bacteri
cell
wall
compon
lipoteicho
acid
lta
muramyl
dipeptid
mdp
induc
injuri
bbb
structur
function
found
highli
purifi
lta
disrupt
bbb
integr
concentrationand
timedepend
manner
indirectli
glia
activ
low
transendotheli
electr
resist
teer
high
permeabl
fluorescein
isothiocyanateinulin
observ
presenc
ltaactiv
glial
cell
potenti
mdp
could
revers
glial
cell
activ
lta
higher
lta
concentr
immunocytochemistri
analysi
reveal
evid
chang
distribut
cytoskeleton
protein
factin
tight
junction
protein
occludin
claudin
lta
treatment
howev
tight
junction
associ
protein
ahnak
clearli
reveal
morpholog
alter
endotheli
cell
induc
lta
ltaactiv
glial
cell
produc
nitric
oxid
proinflammatori
cytokin
tumor
necrosi
contribut
ltainduc
bbb
disrupt
sinc
direct
treatment
endotheli
monolay
increas
bbb
permeabl
wherea
pretreat
antibodi
two
cytokin
block
lta
effect
addit
also
involv
bbb
damag
sinc
donor
diethylenetriaminenitr
oxid
adduct
increas
bloodbrain
barrier
permeabl
induc
nitric
synthas
inhibitor
w
partial
revers
ltainduc
decreas
transendotheli
electr
resist
alter
adrenomedullin
express
eae
barker
mongru
r
bolton
c
b
paul
c
c
queen
mari
univers
london
b
william
harvey
research
institut
london
c
univers
west
england
bristol
uk
loss
normal
bloodbrain
barrier
bbb
function
integr
featur
neuroinflammatori
process
human
demyelin
diseas
multipl
sclerosi
ms
adrenomedullin
act
vasodil
mani
vascular
bed
includ
cerebr
circul
vitro
work
shown
peptid
regul
bbb
characterist
includ
transendotheli
electr
resist
permeabl
pglycoprotein
pump
activ
inde
shown
inhibit
endotheli
synthesi
vasoconstrictor
furthermor
preliminari
studi
demonstr
elev
late
acut
diseas
eae
studi
fulli
examin
express
plu
assess
chang
eae
level
mrna
determin
cerebellum
medullapon
spinal
cord
lewi
rat
inocul
eae
height
diseas
earli
recoveri
rtpcr
carri
total
rna
extract
rat
tissu
tissu
examin
show
increas
acut
diseas
compar
normal
level
mrna
remain
alter
recoveri
phase
invers
relationship
seen
select
tissu
timepoint
featur
across
area
indic
chang
may
pure
aris
vascular
bed
neuroinflamm
alter
synthesi
neuroinflammatori
diseas
may
relev
multipl
sclerosi
develop
physiolog
cytokineactiv
vitro
blood
brain
barrier
studi
leukocyt
diapedesi
ex
vivo
object
develop
physiolog
cytokineactiv
vitro
bloodbrain
barrier
aivbbb
model
studi
chemokinedriven
leukocyt
migrat
neuroinflamm
method
tantigen
immort
human
brain
microvascular
endotheli
cell
thbmec
cultur
confluenc
treat
variou
concentr
h
product
marker
endotheli
activ
measur
elisa
cell
viabil
ascertain
phase
contrast
microscopi
annexin
v
immunocytochemistri
transendotheli
electr
resist
teer
measur
collagenco
insert
follow
deduct
physiolog
endotheli
activ
intercellular
adhes
molecul
icam
vascular
cell
adhes
molecul
vcam
express
studi
flow
cytometri
fibronectin
connect
segment
fn
cs
express
deduc
immunocytochemistri
result
follow
endotheli
activ
product
doubl
pgml
rest
pgml
uml
uml
athbmec
maxim
produc
without
compromis
cell
viabil
chang
teer
rest
athbmec
cm
progress
declin
resist
higher
cytokin
concentr
due
loss
cellcel
contact
secondari
apoptosisinduc
cell
retract
death
increas
increas
fn
thbmec
surfac
express
minim
express
rest
follow
physiolog
cytokin
activ
conclus
athbmec
form
physiolog
aivbbb
recapitul
vivo
cerebr
microvascular
inflammatori
milieu
model
use
accur
assess
chemokinedriven
leukocyt
transmigr
ex
vivo
mean
understand
mechan
devis
potenti
therapi
neuroinflamm
purpos
autoimmun
disord
peripher
nervou
system
pn
syndrom
chronic
inflammatori
demyelin
polyradiculoneuropathi
breakdown
bloodnerv
barrier
bnb
consid
key
step
diseas
process
bnb
also
obstacl
drug
deliveri
pn
disord
henc
import
know
cellular
properti
peripher
nerv
microvascular
endotheli
cell
pnmec
constitut
bulk
bnb
although
mani
vitro
model
bloodbrain
barrier
bbb
establish
vitro
bnb
model
report
establish
new
vitro
bnb
model
use
transgen
rat
harbor
temperaturesensit
larg
tantigen
gene
rat
investig
whether
model
poss
characterist
bnb
method
pnmec
pericyt
isol
sciatic
nerv
rat
accord
previous
describ
procedur
pnmec
identifi
follow
four
criteria
spindl
fibershap
morpholog
immunoreact
antifactor
viii
antibodi
format
tight
junction
uptak
diiacldl
pericyt
identifi
peculiar
morpholog
express
muscl
actin
result
success
isol
pnmec
pericyt
rat
cell
condit
immort
natur
pnmec
show
spindl
fibershap
morpholog
express
uptak
diiacldl
immunoreact
antifactor
viii
antibodi
barrier
properti
consequ
built
complet
vitro
bnb
model
compris
pnmec
pericyt
conclus
establish
vitro
bnb
model
rat
model
might
facilit
analys
pathophysiolog
autoimmun
diseas
pn
moreov
predict
vivo
drug
transport
pn
parenchyma
evid
differenti
chang
interendotheli
junction
murin
neurocysticerosi
depend
upon
cn
vasculatur
ji
alvarez
jm
teal
univers
texa
health
scienc
center
san
antonio
san
antonio
usa
univers
texa
san
antonio
san
antonio
usa
delic
balanc
requir
maintain
homeostasi
cn
central
nervou
system
control
bbb
blood
brain
barrier
imped
influx
compound
blood
cn
upon
injuri
eg
infect
inflamm
bbb
disrupt
compromis
cn
bbb
disrupt
repres
uniform
event
howev
group
recent
shown
murin
model
neurocysticerosi
ncc
bbb
disrupt
vari
depend
upon
anatom
sitevascular
bed
analyz
cn
studi
understand
mechan
bbb
disrupt
explor
blood
vessel
locat
leptomening
pial
vessel
brain
parenchyma
parenchym
vessel
examin
interendotheli
junction
protein
involv
integr
bbb
mice
infect
intracrani
parasit
mesocestoid
corti
sacrif
variou
time
post
infect
differ
anatom
area
infect
brain
analyz
three
color
immunofluores
util
antibodi
tight
junction
tj
adheren
junction
aj
protein
result
show
increas
permeabl
vessel
structur
alter
disappear
appar
proteolysi
particular
tj
aj
protein
extent
time
chang
differ
pial
vessel
mening
vessel
parenchyma
pial
vessel
disrupt
within
day
versu
week
parenchym
vessel
approach
potenti
mechan
express
activ
individu
matrix
metalloproteinas
mmp
evalu
situ
zymographi
differ
time
post
infect
result
indic
increas
mmp
activ
site
bbb
disrupt
exhibit
leukocyt
infiltr
moreov
time
mmp
activ
pial
parenchym
vessel
correl
differ
kinet
breakdown
vessel
thu
bbb
disrupt
homogen
process
mmp
activ
like
key
element
characteris
autoreact
lymphocyt
migrat
infiltrationa
bird
eye
view
kr
william
ek
mathey
silvestri
jv
forrest
c
linington
depart
medicin
therapeut
ophthalmolog
institut
medic
scienc
univers
aberdeen
aberdeen
scotland
uk
studi
use
central
nervou
system
cn
antigen
specif
cell
line
engin
express
gfp
dissect
migratori
pathway
activ
lymphocyt
adopt
transfer
eae
anim
model
ms
howev
studi
hinder
difficulti
identifi
initi
site
infiltr
complex
target
organ
overcom
problem
utilis
anoth
model
autoimmun
experiment
autoimmun
uveoretin
eau
target
organ
smaller
locat
lymphocyt
infiltr
easier
dissect
gener
retin
antigen
specif
gfp
express
lymphocyt
track
migrat
eye
lewi
rat
recov
cell
variou
lymphoid
organ
examin
activ
statu
characteris
infiltr
cell
eye
defin
precis
locat
entri
studi
macrophag
infiltr
antigen
present
surgic
manipul
inject
solubl
antigen
enabl
us
dissect
mechan
result
demonstr
follow
transfer
activ
gfp
lymphocyt
organ
specif
accumul
observ
two
day
transfer
cell
reappear
spleen
larg
number
nonactiv
state
day
three
cell
migrat
via
blood
still
nonactiv
start
appear
eye
strongli
express
activ
marker
activ
occur
eye
site
initi
infiltr
iri
ciliari
bodi
concurr
publish
observ
eae
demonstr
mechan
specif
particular
diseas
homeostat
chemokin
constitut
express
cn
upregul
multipl
sclerosi
lesion
correl
intrathec
igg
product
studi
focus
homeostat
chemokin
bind
direct
b
cell
matur
dendrit
cell
subset
cell
secondari
lymphoid
organ
report
normal
human
brain
transcrib
detect
tissu
lysat
display
endotheli
cell
activ
inact
ms
lesion
transcript
elev
strong
immunostain
astrocyt
blood
vessel
endotheli
cell
seen
cerebrospin
fluid
csf
relaps
remit
secondari
progress
ms
patient
elev
correl
intrathec
igg
product
ligand
detect
control
ms
csf
sampl
quantit
pcr
immunostain
show
low
level
chemokin
ms
lesion
togeth
studi
suggest
role
immunosurveil
cn
mainten
immun
cell
ms
brain
activ
multipl
sclerosi
ms
character
presenc
perivascular
inflammatori
foci
local
central
nervou
system
cn
inflammatori
cell
form
foci
migrat
blood
cn
sever
studi
confirm
chemokin
receptor
play
import
role
process
major
goal
studi
analyz
migratori
activ
subpopul
peripher
blood
mononuclear
cell
pbmc
blood
ms
patient
stimul
chemokin
moreov
impact
ms
treatment
methylprednisolon
activ
ms
mitoxantron
progress
ms
chemotact
activ
pbmc
subpopul
analyz
chemotact
activ
mononuclear
leukocyt
measur
vitro
neuroprob
chemotaxi
chamber
use
fluorimetr
reader
observ
activ
ms
treatment
vitro
chemotact
activ
lymphocyt
stimul
significantli
increas
spontan
migrat
lymphocyt
similar
studi
group
treatment
ms
methylprednisolon
mitoxantron
diminish
activ
level
observ
control
group
patient
neurolog
diseas
ond
healthi
control
hc
effect
dose
depend
observ
signific
chang
spontan
stimul
migratori
activ
monocyt
ms
patient
result
suggest
activ
ms
chemokineinduc
migratori
activ
lymphocyt
increas
activ
may
significantli
diminish
treatment
methylprednisolon
mitoxantron
object
acut
cerebr
ischaemia
induc
local
inflammatori
reaction
includ
express
chemokin
preced
relev
leukocyt
infiltr
contribut
tissu
injuri
object
studi
test
hypothesi
chemokin
potent
neutrophil
chemoattract
play
role
inflamm
earli
phase
ischaem
stroke
method
level
csf
serum
obtain
h
ischaem
stroke
patient
age
year
measur
elisa
csf
blood
sampl
tension
headach
patient
serv
control
group
neurolog
stroke
sever
estim
scandinavian
stroke
scale
sss
within
h
stroke
two
week
later
result
level
significantli
elev
csf
patient
ischaem
stroke
comparison
control
pgml
vs
pgml
pgml
vs
pgml
serum
level
studi
chemokin
differ
control
valu
csf
level
correl
significantli
neurolog
stroke
sever
within
h
two
week
onset
stroke
first
observ
conclus
result
suggest
chemokin
may
play
role
inflammatori
reaction
earli
phase
ischaem
stroke
csf
level
associ
stroke
sever
predict
valu
short
term
stroke
outcom
well
document
chemokin
play
import
role
develop
inflammatori
foci
regul
cell
traffick
within
tissu
multistep
process
occur
also
within
central
nervou
system
cn
mani
patholog
condit
present
studi
investig
role
chemokin
receptor
develop
cn
inflamm
use
previous
describ
model
local
cn
inflamm
model
inflammatori
focu
develop
deposit
bcg
bacillu
calmetteguerin
brain
parenchyma
follow
subcutan
peripher
inject
bcg
four
week
later
accumul
inflammatori
cell
around
site
bcg
deposit
follow
subsequ
myelin
damag
express
inflammatori
constitut
chemokin
well
chemokin
receptor
analyz
perform
rna
express
analysi
use
quantit
rpa
assay
local
protein
express
use
immunohistochemistri
patholog
featur
inflamm
confirm
analysi
express
mani
specif
marker
inflammatori
cell
subpopul
within
day
post
peripher
challeng
observ
increas
express
hemispher
inject
bcg
interestingli
day
post
peripher
challeng
subsequ
increas
contralater
hemispher
also
observ
similar
pattern
express
also
observ
chemokin
contralater
hemispher
increas
express
observ
week
peripher
challeng
result
confirm
chemokin
receptor
play
import
role
control
cell
traffick
cn
inflamm
astrocytespecif
overproduct
may
neuroprotect
cn
demyelin
k
omari
c
rain
depart
patholog
albert
einstein
colleg
medicin
bronx
usa
factor
respons
oligodendrocyt
surviv
featur
observ
around
earli
activ
multipl
sclerosi
ms
lesion
fulli
elucid
exist
evid
rodent
demonstr
chemokin
induc
prolifer
inhibit
chemotaxi
oligodendrocyt
precursor
cell
opc
investig
effect
cxc
chemokin
cours
central
nervou
system
cn
inflammatori
respons
gener
doubletransgen
tg
mice
overexpress
induc
control
astrocyt
specif
gene
glial
fibrillari
acid
protein
gfap
doubl
gfap
tg
singl
tg
wildtyp
wt
anim
sensit
myelin
oligodendrocyt
glycoprotein
mog
experiment
autoimmun
encephalomyel
eae
onset
clinic
sign
product
initi
intraperiton
doxycyclin
inject
preliminari
result
show
doubletg
anim
display
much
milder
clinic
diseas
histopatholog
reveal
although
inflamm
present
spinal
cord
optic
nerv
tissu
doubletg
singletg
wt
control
anim
day
postimmun
dp
demyelin
axon
patholog
wallerian
degener
wd
promin
control
mice
dpi
inflamm
demyelin
significantli
diminish
doubletg
mice
compar
control
wd
markedli
less
interestingli
rel
level
myelin
axon
patholog
remyelin
greater
doubletg
group
associ
increas
oligodendrocyt
suggest
oligodendrogli
respons
ongo
protein
express
studi
examin
inflammatori
infiltr
opc
prolifer
brdu
incorpor
within
cn
thu
preliminari
find
suggest
role
exert
neuroprotect
role
cours
eae
support
part
nmss
rg
ns
ns
ns
multipl
sclerosi
foundat
transcript
regul
astrocyt
microglia
sever
chemokin
chemokin
receptor
includ
implic
pathogenesi
multipl
sclerosi
ms
show
express
enhanc
ms
lesion
variou
diseas
stage
earlier
shown
ms
lesion
hallmark
enhanc
express
stressrespons
transcript
factor
creb
lead
enhanc
express
class
mhc
molecul
express
molecul
overlap
express
ms
lesion
therefor
investig
whether
factor
also
involv
transcript
regul
use
promot
evalu
assay
electrophoret
mobil
shift
assay
transient
transfect
determin
neither
involv
activ
promot
addit
show
factor
involv
induct
transcript
endogen
human
primari
microglia
astrocyt
determin
rtpcr
contrast
show
express
regul
campcreb
pathway
addit
data
also
suggest
epigenet
mechan
might
implic
transcript
control
taken
togeth
conclud
express
regul
sever
gener
distinct
regulatori
mechan
alter
mechan
could
account
aberr
express
ms
lesion
support
dutch
ms
research
foundat
grant
ms
differenti
chemokin
express
neuron
injuri
chemokin
discuss
involv
signal
damag
neuron
microglia
recent
shown
chemokin
upregul
neuron
cellular
injuri
vitro
vivo
biber
et
al
de
jong
et
al
attract
microglia
via
chemokin
receptor
rappert
et
al
knockout
anim
microgli
activ
injuri
almost
absent
surviv
secondari
neuron
much
higher
compar
control
rappert
et
al
neuron
also
produc
chemokin
also
ligand
microgli
rais
question
neuron
would
express
two
ligand
one
receptor
accordingli
investig
compar
express
distribut
pattern
cultur
neuron
glutam
treatment
chemokin
pack
vesicl
howev
wherea
protein
induc
neuron
damag
express
constitut
high
level
regul
neuron
damag
furthermor
releas
damag
neuron
wherea
yet
find
condit
would
induc
releas
damag
neuron
result
show
first
time
two
neuron
chemokin
act
receptor
microglia
differenti
regul
neuron
whether
involv
neuron
microglia
signal
whether
chemokin
might
induc
differ
effect
microglia
remain
establish
biber
k
et
al
object
glial
reaction
associ
upregul
induc
nitric
oxid
synthas
ino
suggest
play
import
role
inflammatori
process
neurodegen
diseas
howev
mechan
ino
induc
glial
cell
clearli
understood
clarifi
mechan
induct
focus
class
iv
semaphorin
known
enhanc
signal
b
cell
dendrit
cell
immun
system
method
express
put
receptor
primari
neural
cell
investig
rtpcr
western
blot
analysi
effect
induct
ino
investig
incub
primari
astrocyt
microglia
recombin
result
receptor
express
primari
neuron
astrocyt
microglia
lp
induc
ino
express
astrocyt
microglia
increas
incub
recombin
enhanc
also
observ
glial
cell
prepar
mice
defici
enhanc
activ
stimul
inhibit
pathway
partial
decreas
ino
express
microglia
conclus
receptor
express
neural
cell
could
exacerb
neuroinflammatori
process
enhanc
ino
express
least
part
particip
process
via
pathway
tempor
genet
pathway
thymic
select
reveal
share
regulatori
network
neuron
degener
apoptosi
given
share
requir
gener
complex
flexibl
plastic
memori
specif
brain
immun
system
might
common
first
meet
eye
recent
demonstr
lglutam
major
excitatori
amino
acid
synapt
transmiss
nervou
system
act
immunotransmitt
immunolog
synaps
form
dendrit
cell
contribut
calcium
mobil
cell
apoptosi
thymic
neg
select
explor
compar
physiolog
immun
nervou
system
combin
genomewid
express
analysi
new
bioinformat
method
identifi
function
network
involv
thymic
neg
select
use
ingenu
pathway
analysi
new
webbas
entri
tool
provid
molecular
network
high
degre
connect
gene
document
literatur
systemat
tempor
express
profil
thymocyt
tcr
transgen
mice
undergo
thymic
neg
select
gener
use
agil
oligonucleotid
microarray
level
express
probe
set
repres
around
mous
known
gene
monitor
kinet
time
point
h
period
focu
earli
time
point
h
dynam
regul
gene
identifi
use
resolv
softwar
overlaid
onto
cellular
pathway
map
ingenu
pathway
analysi
softwar
applic
gener
signific
highscor
network
includ
earli
time
point
addit
document
genet
pathway
involv
thymic
neg
select
find
provid
new
insight
regul
thymocyt
apoptosi
relat
neuron
apoptosi
neurodegener
astrocyt
regul
human
cn
inflamm
alex
kostianovski
david
e
anderson
grow
bodi
literatur
indic
resid
glial
cell
popul
modul
immun
respons
within
central
nervou
system
cn
use
primari
human
astrocyt
ex
vivo
human
monocyt
repres
microglia
report
astrocyt
modul
monocyt
activ
depend
natur
inflammatori
stimulu
monocyt
cocultur
primari
astrocyt
presenc
lp
monocyt
secret
complet
inhibit
wherea
inhibit
ligand
stimulu
data
suggest
within
human
cn
pathogenmedi
inflamm
lp
least
part
natur
inhibit
astrocyt
wherea
cellmedi
inflamm
ligand
observ
relev
regul
cellmedi
inflamm
within
cn
includ
associ
multipl
sclerosi
respons
brain
tumor
inde
use
transform
primari
malign
glioma
glioblastoma
multiforma
gbm
cell
line
found
contrast
nontransform
primari
human
astrocyt
gbm
tumor
cell
acquir
abil
suppress
monocyt
secret
respons
lp
ligand
stimul
transwel
assay
indic
solubl
cellcontact
depend
mechan
respons
tumor
cellmedi
suppress
monocyt
activ
neutral
studi
exclud
cox
molecul
associ
suppress
highthroughput
screen
strategi
plan
identifi
relev
pathway
collect
result
indic
astrocyt
inher
regulatori
capac
within
cn
respons
natur
inflammatori
stimulu
neuron
antigencontain
antigenpres
cell
cervic
lymph
node
multipl
sclerosi
patient
eae
anim
function
distinct
myelin
antigencontain
cell
multipl
sclerosi
ms
character
demyelin
neuron
damag
within
central
nervou
system
cn
transfer
cn
antigen
drain
cervic
lymph
node
cln
like
crucial
initi
modul
immun
respons
myelin
also
neuron
although
myelin
antigen
demonstr
cln
ms
patient
presenc
neuron
antigen
cln
ms
patient
yet
determin
report
presenc
neuron
antigen
cln
ms
patient
common
marmoset
monkey
rhesu
monkey
biozzi
abh
mice
eae
drain
lymph
node
lumbar
lymph
node
deep
cln
cuprizonetr
mice
exhibit
extens
cn
demyelin
littl
neuron
damag
contain
abund
myelin
antigen
neuron
antigen
neurofila
light
human
cln
cell
contain
neuron
antigen
express
apc
marker
mhc
class
ii
proinflammatori
molecul
contrast
major
cell
contain
myelin
antigen
mog
express
antiinflammatori
molecul
receptor
antagonist
mogcontain
cell
express
lymph
node
home
molecul
wherea
express
absent
cell
use
vitro
model
confirm
increas
mrna
express
human
monocytederiv
macrophag
follow
human
myelin
ingest
vitro
conclud
neuron
antigencontain
apc
present
cln
ms
eae
hypothes
specif
immunophenotyp
apc
may
caus
natur
phagocytoz
antigen
microenviron
locat
antigen
uptak
crosspresent
central
nervou
systemderiv
antigen
induc
robust
prime
cell
cervic
lymph
node
lisa
walter
matthew
l
albert
effici
antigen
present
central
nervou
system
cn
initi
induc
antigenspecif
cytotox
cell
immun
respons
remain
unclear
determin
present
antigen
brain
versu
tissu
differ
induc
cytotox
cell
respons
antigen
administ
intracerebr
ic
subcutan
sc
intraven
iv
mice
mous
splenocyt
defici
major
histocompat
complex
class
b
express
membranebound
ovalbumin
antigen
inject
monitor
respons
crosspresent
b
restrict
epitop
siinfekl
icintroduc
splenocyt
induc
higher
vivo
cell
kill
interferon
gamma
product
prolifer
administ
sc
iv
cell
prime
crosspres
ic
antigen
occur
cervic
lymph
node
requir
cell
help
addit
cell
prime
due
crosspresent
direct
present
requir
express
host
taken
togeth
data
impli
immun
respons
result
crosspresent
ic
antigen
initi
effici
therefor
like
induc
immun
prime
compar
respons
initi
elsewher
bodi
similar
tissu
antigen
crosspresent
cn
requir
express
host
presum
mediat
helperdepend
crossprim
cell
specif
cnsderiv
antigen
antigen
specif
activ
cell
resid
antigen
present
cell
brain
role
brain
antigen
present
cell
initi
cn
inflamm
compart
critic
accessori
cellt
cell
interact
take
place
prior
onset
neuroinflamm
yet
clarifi
studi
show
cell
activ
local
resid
accessori
cell
nervou
tissu
absenc
peripher
immun
organ
defin
cnsrestrict
cell
activ
prepar
brain
slice
cultur
experiment
anim
maintain
tissu
artifici
cerebr
spinal
fluid
sever
day
one
hour
prior
prepar
brain
slice
cultur
mice
inject
intracerebr
ovalbumin
antigen
ovalbuminspecif
cell
ad
cultur
cell
becom
activ
prolifer
migrat
brain
slice
contain
cognat
antigen
brain
resid
dendrit
celllik
accessori
cell
also
mobil
abl
migrat
brain
slice
presenc
inflammatori
chemokin
prolifer
antigenspecif
cell
migrat
brain
resid
accessori
cell
abrog
delet
cell
itgaxdtregfp
mice
prior
gener
brain
slice
due
transgen
express
express
cell
select
deplet
hudtr
andor
identifi
gfp
fluoresc
mice
result
suggest
antigen
present
could
take
place
local
brain
event
may
import
initi
cn
inflammatori
diseas
work
support
nation
institut
health
grant
z
fabri
metalloproteinas
control
brain
inflamm
induc
pertussi
toxin
mice
overexpress
chemokin
cn
leukocyt
accumul
spontan
perivascular
space
brain
transgen
tg
mice
overexpress
cc
chemokin
ligand
control
cnsspecif
promot
tg
mice
show
clinic
symptom
even
though
leukocyt
cross
endotheli
basement
membran
pertussi
toxin
ptx
given
intraperiton
induc
encephalopathi
weight
loss
tg
mice
use
flow
cytometri
uspioenhanc
magnet
reson
imag
immunofluoresc
stain
show
encephalopathi
involv
leukocyt
migrat
across
glia
limitan
brain
parenchyma
identifi
critic
step
induc
clinic
symptom
metalloproteinas
enzym
mp
implic
leukocyt
infiltr
cn
inflamm
unmanipul
tg
mice
elev
express
mrna
brain
ptx
induc
express
mmp
brain
tg
mice
level
microglialassoci
mp
affect
control
ptxtreat
tg
mice
ptx
also
upregul
express
proinflammatori
cytokin
mrna
tg
cn
weight
loss
parenchym
infiltr
induc
ptx
significantli
inhibit
broadspectrum
mp
inhibitor
find
mp
mediat
ptxinduc
parenchym
infiltr
chemokineoverexpress
cn
relev
pathogenesi
human
diseas
involv
cn
inflamm
multipl
sclerosi
induct
toler
alpha
bcrystallin
alpha
bcrystallin
knockout
mice
previou
data
indic
human
strong
proinflammatori
memori
tcell
respons
exist
cn
myelin
antigen
alpha
bcrystallin
qualifi
potenti
autoimmun
target
multipl
sclerosi
studi
abl
specif
toler
proinflammatori
memori
tcell
alpha
bcrystallin
anim
model
effort
made
toward
clinic
studi
sinc
contrast
human
rodent
natur
toler
self
alpha
bcrystallin
toler
studi
perform
alpha
bcrystallin
knockout
mice
highli
respons
protein
antigen
lack
form
natur
toler
alpha
bcrystallin
toleranceinduc
protocol
start
week
immun
alpha
bcrystallin
cfa
toler
induc
administ
intraven
alpha
bcrystallin
tail
vein
variou
dosetim
regiment
low
dose
induct
toler
led
almost
complet
abrog
tcell
respons
lymph
nodederiv
cell
upon
subsequ
antigen
challeng
although
limit
induct
cell
respons
detect
vitro
rechalleng
swiftli
follow
state
nonrespons
even
boost
antigen
adjuv
toler
induct
revers
toler
state
contrast
tcell
respons
increas
antibodi
respons
detect
futur
effort
made
studi
toler
induc
mechan
anergi
regulatori
tcell
role
antibodi
immatur
human
dendrit
cell
express
latencyassoci
peptid
lap
inhibit
polar
depend
fashion
multipl
sclerosi
ms
chronic
cell
mediat
inflammatori
diseas
cn
investig
role
dendrit
cell
dc
ms
cell
import
initi
immun
respons
maintain
peripher
toler
found
dc
activ
blood
ms
patient
j
immunolog
press
exact
mechan
dc
instructinginfluenc
gener
regulatori
versu
effector
cell
clear
import
immunoregulatori
molecul
implic
induct
regulatori
cell
found
present
surfac
immatur
human
dc
form
latenc
associ
peptid
lap
fac
analysi
human
exvivo
isol
dc
show
membran
bound
lap
function
import
surfac
dc
assess
neutral
recombin
lap
antibodi
neutral
result
enhanc
cell
prolifer
secret
allogen
cell
incub
exvivo
isol
human
dc
furthermor
dc
matur
stimul
lp
longer
tolerogen
observ
loss
membran
bound
lap
accompani
upmodul
hlaii
costimulatori
molecul
furthermor
initi
result
demonstr
alter
tolerogen
properti
dc
subpopul
ms
taken
togeth
result
indic
express
dc
form
lap
may
play
import
role
tolerogen
properti
immatur
dc
serv
limit
prevent
autoimmun
respons
may
abnorm
ms
cell
cell
age
mice
nishioka
r
iida
j
shimizu
section
immunolog
depart
mechan
age
nation
institut
longev
scienc
obu
japan
advanc
age
associ
signific
alter
immun
function
includ
progress
declin
function
mice
human
howev
unknown
whether
regulatorysuppress
cell
involv
declin
vitro
analys
reveal
cell
wellcharacter
natur
occur
regulatori
suppress
cell
age
mice
function
compar
young
mice
ie
anerg
suppress
though
slightli
increas
number
contrast
function
chang
whole
cell
pronounc
age
mice
separ
cell
small
subpopul
base
stain
cell
popul
rapidli
extrud
refer
lo
cell
major
age
cell
exhibit
signific
hyporespons
remain
cell
hi
cell
maintain
normal
respons
furthermor
identifi
transcript
factor
critic
confer
regulatorysuppress
function
cell
posit
suppress
cell
among
age
hyporespons
lo
cell
result
suggest
agerel
declin
cellmedi
immun
respons
ascrib
chang
cell
popul
function
augment
suppress
cell
lack
express
defin
function
immunesuppress
treg
cell
human
migrat
home
larg
control
adhes
molecul
therefor
compar
express
variou
integrin
regulatori
cell
treg
low
effector
cell
human
pbmc
strike
differ
observ
chain
highli
express
low
effector
cell
downregul
high
cell
differenti
express
pattern
evid
especi
effector
memorylik
cell
subset
loss
compens
treg
cell
express
cla
cutan
lymphocyt
antigen
treg
cell
therefor
bind
effici
claligand
eselectin
wherea
effector
cell
preferenti
adher
ligand
least
principl
invas
inflam
tissu
therefor
regul
subsetspecif
way
select
express
ligand
endotheli
barrier
notabl
high
cell
presenc
correl
appar
loss
activ
express
high
high
cell
present
pbmc
healthi
donor
minor
subset
show
margin
suppress
wherea
high
cell
effici
inhibit
prolifer
cell
thu
differenti
express
cla
allow
select
recruit
effectormemori
like
treg
trem
convent
effector
memori
cell
tem
absenc
also
use
keymark
distinguish
function
immunesuppress
treg
cell
less
activ
cell
control
product
human
nkt
cell
clone
ms
patient
follow
exogen
costimul
k
sakuishi
ab
miyak
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
tokyo
japan
b
depart
neurolog
univers
tokyo
tokyo
japan
nkt
cell
produc
cytokin
recent
nkt
cell
found
potenti
suppress
develop
experiment
allerg
encephalomyel
eae
open
possibl
therapeut
target
multipl
sclerosi
ms
howev
natur
regul
immun
respons
human
remain
larg
obscur
found
although
human
nkt
cell
clone
cocultur
antigen
present
cell
apc
produc
cytokin
ad
exogen
signific
number
clone
select
remark
produc
method
human
nkt
cell
clone
establish
stimul
fresh
pbmc
och
synthet
analogu
sort
invari
tcr
cell
nkt
cell
clone
cocultur
apc
without
recombin
cytokin
supernat
evalu
result
cocultur
apc
nkt
cell
clone
includ
ms
patient
produc
remark
amount
littl
presenc
absenc
hela
cell
well
immatur
dc
serv
good
apc
wherea
mocktransfect
hela
cell
nkt
cell
freshli
isol
balb
c
mice
similarli
show
polar
pattern
support
physiolog
implic
find
conclus
taken
togeth
play
key
role
trigger
polar
potenti
nkt
cell
respons
weak
endogen
antigen
stimul
propos
novel
depend
nkt
cell
function
immun
regul
natur
killer
cell
ligand
och
potenti
therapeut
multipl
sclerosi
mechan
ochinduc
polar
vivo
shinji
oki
takashi
yamamura
sachiko
miyak
depart
immunolog
nation
institut
neurosci
ncnp
tokyo
japan
natur
killer
nkt
cell
one
potent
immun
modul
stimul
glycolipid
ligand
massiv
product
immunoregulatori
cytokin
includ
demonstr
och
sphingosinetrunc
analogu
prevent
varieti
experiment
autoimmun
diseas
model
includ
experiment
autoimmun
encephalomyel
eae
induc
preferenti
nkt
celldepend
product
subsequ
polar
vivo
biochem
molecular
biolog
analysi
reveal
specif
featur
glycolipid
due
unstabl
captur
shortliv
stimul
nkt
cell
insuffici
effect
crel
induct
follow
lack
effect
product
intriguingli
och
induc
less
product
nkt
cell
also
natur
killer
nk
cell
anoth
major
sourc
glycolipid
administr
vivo
due
insuffici
primari
product
express
activ
nkt
cell
och
exert
margin
product
dendrit
cell
result
lower
secondari
induct
nkt
nk
cell
accordingli
avail
connect
microbi
infect
one
critic
determin
cytokin
profil
vivo
administr
och
taken
togeth
och
uniqu
properti
select
product
nkt
cell
without
induc
product
nkt
nk
cell
proper
applic
och
vivo
benefici
nkt
celltarget
therapeut
intervent
autoimmun
diseas
multipl
sclerosi
ms
recent
studi
demonstr
myelinreact
cell
would
effici
mediat
destruct
autoimmun
patholog
experiment
autoimmun
encephalomyel
eae
therefor
pathway
could
pivot
pathogenesi
multipl
sclerosi
although
much
need
learn
characterist
produc
cell
known
augment
cell
product
allow
us
address
produc
cell
might
express
receptor
interest
highli
express
within
ms
plaqu
knockout
mice
resist
eae
whole
cell
cell
purifi
healthi
donor
blood
activ
pma
ionomycin
day
cell
produc
larg
amount
popul
produc
sharp
contrast
cell
cell
produc
wherea
popul
produc
equal
notabl
cell
coexpress
minor
popul
express
alon
found
minor
fraction
main
sourc
singl
posit
cell
also
produc
much
less
fraction
conclud
identifi
cell
human
blood
cell
consist
cell
would
develop
via
lineag
distinct
lineag
role
null
cell
autoimmun
diseas
loss
express
cell
describ
good
biolog
indic
age
immun
system
increas
percentag
null
cell
also
associ
number
patholog
condit
previous
demonstr
elev
percentag
cell
blood
subset
healthi
control
hc
patient
autoimmun
diseas
howev
fraction
peopl
increas
percentag
null
cell
higher
diseas
individu
compar
hc
unravel
role
null
cell
autoimmun
diseas
function
characterist
cell
studi
intracellular
fac
stain
demonstr
larg
proport
null
cell
subset
produc
upon
stimul
major
cell
also
contain
intracellular
deposit
cytotox
molecul
addit
null
cell
could
detect
cerebrospin
fluid
ms
patient
synovi
tissu
ra
patient
studi
antigen
reactiv
null
cell
vitro
assay
develop
peripher
blood
mononuclear
cell
cultur
array
alloand
autoantigen
like
myelin
basic
protein
human
collagen
type
ii
prolifer
cytokin
product
demonstr
antigen
reactiv
assay
current
pend
null
cell
repres
cell
subset
aberr
function
capac
detect
site
tissu
damag
autoimmun
diseas
unravel
antigen
specif
null
cell
provid
insight
role
pathogenesi
autoimmun
diseas
endoplasm
reticulumresid
heat
shock
protein
innat
sensor
damag
induc
tissu
remodel
stress
bacteri
peptidoglycan
tissu
disintegr
injuri
lead
endoplasm
reticulum
er
activ
adapt
pathway
known
er
stress
respons
direct
correct
unfold
protein
activ
proteasomedepend
erassoci
degrad
misfold
protein
activ
protein
translat
modul
polypeptid
traffic
er
sinc
event
crucial
role
play
act
molecular
chaperon
also
adjuv
abl
induc
specif
immun
respons
tumour
bacteria
studi
analys
role
condit
normal
growth
induc
partial
hepatectomi
psychosoci
stress
without
tissu
lesion
treatment
bacteri
peptidoglycanmonom
pgm
pgmzn
tissu
express
protein
mrna
estim
liver
thymu
spleen
data
correl
phenotyp
cytotox
hepat
splenic
mononuclear
lymphat
cell
mnlc
syngen
thymocyt
nk
laksensit
target
procedur
induc
fast
cytoplasm
overexpress
stain
hepatocyt
follow
surfac
express
mnlc
upregul
mrna
spleen
thymu
simultan
liver
accumul
intermedi
cell
hepat
splenic
mnlc
becam
highli
cytotox
syngen
thymocyt
impli
disturb
morphostasi
may
serv
natur
adjuv
chaperon
antigen
self
peptid
immun
surveil
pathway
result
activ
autoreact
nkt
clone
morphogenet
potenti
support
grant
croatian
ministri
scienc
vivo
modul
cellular
humor
immun
respons
tetanu
toxoid
mesenchym
stem
cell
chiesa
e
traggiai
uccelli
depart
neurosci
ophthalmolog
genet
genoa
itali
institut
ggaslini
genoa
itali
murin
mesenchym
stem
cell
msc
amelior
experiment
autoimmun
encephalomyel
eae
induct
peripher
cell
toler
nevertheless
effect
msc
physiolog
immun
respons
non
self
antigen
tetanu
toxoid
tt
still
larg
unknown
thu
sought
analys
dynam
chang
humor
cellular
respons
tt
upon
msc
administr
msc
inject
intraven
balbc
mice
differ
time
point
follow
immun
tetanu
toxoid
tt
thu
analyz
differ
time
point
tt
specif
serum
antibodi
titr
tt
specif
cell
prolif
respons
peripher
blood
balbc
mice
upon
sacrific
frequenc
antigen
specif
plasma
cell
memori
b
cell
cell
analyz
bone
marrow
lymph
node
spleen
latter
extent
germin
centr
format
evalu
overal
show
vivo
administr
msc
affect
b
cell
respons
non
self
antigen
tt
lead
condit
immunodefici
result
pivot
import
due
possibl
util
msc
treatment
autoimmun
diseas
multipl
sclerosi
refold
bacteri
produc
humog
compar
pathogen
refold
humog
versu
nonrefold
humog
da
rat
wherea
da
rat
immun
nonrefold
humog
remain
perfectli
healthi
da
rat
immun
refold
humog
develop
sever
diseas
differ
mogdirect
tcell
respons
could
observ
group
contrast
mog
serum
antibodi
group
differ
capac
bind
nativ
mog
express
surfac
eukaryot
cell
measur
fac
thu
enhanc
pathogen
refold
humog
da
rat
probabl
due
presenc
conform
mog
antibodi
upon
immun
data
underscor
import
use
correctli
refold
humog
studi
mog
antibodi
respons
ms
patient
precis
role
b
cell
humor
immun
multipl
sclerosi
ms
well
experiment
autoimmun
encephalomyel
eae
remain
subject
intens
debat
intrathec
immunoglobulin
ig
product
igdeposit
inflammatori
lesion
hallmark
ms
mice
defici
b
cell
ig
shown
develop
sever
eae
hand
mice
defici
signal
entiti
activ
fcreceptor
resist
eaeinduct
resolv
appar
paradox
gener
mice
defici
b
cell
induc
eae
immun
recombin
mog
protein
mog
peptid
function
express
system
accessori
cell
cnsresid
cell
appear
vital
develop
cnsinflamm
independ
lymphocyt
data
clearli
dismiss
involv
b
cell
mediat
eae
found
inject
ab
direct
mog
drastic
worsen
eae
sever
inflamm
demyelin
mog
induc
eae
action
ab
fcr
independ
reli
entir
complement
activ
detriment
effect
mice
conclud
ab
gener
cours
mogpeptid
orprotein
induc
eae
irrelev
pathogenesi
eae
certain
condit
ab
capabl
drive
demyelin
complementdepend
fashion
induct
adapt
regulatori
cell
recoveri
eae
sensit
sjlj
mice
presenc
suppressor
epitop
within
plp
youwei
lin
sachiko
miyak
takashi
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
japan
sjlj
mice
known
develop
chronic
relaps
eae
epitop
spread
immun
although
genet
factor
employ
account
relapsingremit
cours
eae
found
immun
sjlj
mice
overlap
peptid
induc
monophas
eae
without
relaps
indic
peptid
sequenc
use
primari
immun
critic
determin
clinic
cours
wherea
immunodomin
plp
peptid
induc
crossreact
cell
immun
tend
gener
popul
compar
strikingli
mice
recoveri
phase
complet
resist
reinduct
eae
wherea
mice
fulli
suscept
eae
reinduct
furthermor
found
recoveri
eae
suppressor
cell
would
emerg
drain
lymph
node
ln
could
confer
protect
eae
upon
cell
transfer
suppress
ln
cell
popul
contain
higher
number
adapt
regulatori
cell
treg
would
coexpress
adopt
transfer
experi
show
treg
cell
induc
immun
highest
potenc
suppress
eae
vivo
result
indic
benign
natur
induc
eae
may
result
induct
strongli
suppress
treg
cell
abbrevi
eae
experiment
autoimmun
encephalomyel
plp
proteolipid
protein
paralysi
regulatori
cell
respons
chronic
autoimmun
encephalomyel
yoh
matsumoto
hiroshi
sakuma
kuniko
kohyama
mie
nakajima
ilkwon
park
elucid
pathomechan
relaps
chronic
multipl
sclerosi
examin
role
regulatori
cell
treg
anim
model
chronic
experiment
autoimmun
encephalomyel
eae
chronic
eae
induc
rat
immun
myelin
oligodendrocyt
glycoprotein
mog
result
obtain
compar
acut
eae
chronic
eae
cell
eae
lesion
central
nervou
system
cn
decreas
rapidli
begin
diseas
cell
maintain
high
level
recoveri
acut
eae
consist
find
level
mrna
cn
significantli
lower
throughout
cours
chronic
eae
recoveri
acut
eae
number
treg
level
mrna
lymphoid
organ
also
significantli
lower
chronic
eae
howev
differ
regulatori
function
individu
treg
cell
isol
diseas
cours
acut
chronic
eae
furthermor
adopt
transfer
treg
activ
mab
delay
onset
chronic
eae
one
transfer
suppress
develop
diseas
complet
two
transfer
find
suggest
impair
treg
respons
function
individu
cell
critic
develop
chronic
autoimmun
diseas
adjust
autolog
treg
transplant
natur
killer
nk
cell
exert
cytotox
effect
autoantigenspecif
encephalitogen
cell
experiment
autoimmun
encephalomyel
mechan
natur
killer
nk
cell
regulatori
role
experiment
autoimmun
encephalomyel
eae
studi
sjlj
mice
vivo
experi
show
nk
cell
deplet
monoclon
antibodi
treatment
enhanc
eae
mice
investig
mechan
cultur
proteolipid
protein
plp
peptidespecif
encephalitogen
cell
line
use
nk
cell
target
result
show
nk
cell
exert
direct
cytotox
effect
autoantigenspecif
encephalitogen
cell
furthermor
cytotox
plpspecif
encephalitogen
cn
dendrit
cell
drive
activ
selfreact
cell
recent
find
show
dc
macrophag
microglia
isol
cn
sjl
mice
proteolipid
plp
induc
relaps
experiment
autoimmun
encephalomyel
reae
induc
prolifer
naiv
hi
transgen
cell
specif
immunodomin
myelin
peptid
antigen
collect
situ
laser
sort
cn
dc
subtyp
high
puriti
peak
acut
phase
reae
demonstr
dc
induc
expans
fold
dc
dndc
dc
induc
fold
expans
respect
fold
expans
without
peptid
ad
cultur
cn
dc
driven
prolifer
mhc
class
ii
depend
level
secret
cell
highest
dc
dndc
activ
cn
dc
induc
rant
dc
dndc
cn
apc
induc
product
cultur
cell
close
associ
dc
cn
inflammatori
foci
mix
bone
marrow
chimera
bmc
mice
peak
acut
reae
dc
dc
cn
infiltr
blood
bmc
mice
cn
apc
intern
plp
cn
abund
dc
cn
correl
strongli
eae
sever
data
impli
discret
dc
popul
recruit
inflam
cn
distinct
role
drive
cell
activ
organ
work
support
grant
nation
multipl
sclerosi
societi
usa
nation
institut
health
traffic
csfcircul
dendrit
cell
experiment
autoimmun
encephalomyel
establish
dendrit
cell
dc
abl
migrat
cn
cervic
lymph
node
yet
unidentifi
pathway
show
dc
inject
csf
rat
target
bcell
follicl
cervic
lymph
node
explor
migratori
behavior
csfcircul
dc
neuroinflammatori
condit
purpos
bone
marrowderiv
myeloid
dc
label
fluoresc
marker
cfse
inject
stereotax
later
ventricl
eae
rat
rat
sacrif
day
follow
inject
brain
cervic
lymph
node
axillari
lymph
node
assess
presenc
cfselabel
cell
addit
intraventricular
inject
fluoresc
microspher
perform
order
track
endogen
csfcircul
antigen
present
cell
found
cn
inject
dc
local
mening
velum
virchowrobin
space
sever
periventricular
area
similar
result
obtain
track
endogen
mhc
class
ii
cell
fluoresc
microspher
lymph
node
cfselabel
dc
evidenc
bcell
zone
cervic
axillari
lymph
node
similarli
cell
engulf
fluoresc
microspher
detect
bcell
zone
cervic
axillari
lymph
node
final
use
western
blot
analysi
observ
igg
recov
cervic
versu
axillari
lymph
node
differ
qualit
quantit
abil
recogn
cn
antigen
altogeth
result
suggest
eae
csfcircul
dc
may
respons
develop
preponder
bcell
respons
take
place
within
cervic
lymph
node
hatter
e
davoust
n
didier
vuaillat
c
malcu
c
belin
mf
nataf
drain
without
lymphat
dendrit
cell
migrat
cerebrospin
fluid
bcell
follicul
cervic
lymph
node
blood
vaccinationinduc
autoimmun
absenc
secondari
lymphoid
tissu
greter
p
bargsten
b
becher
subcutan
sc
vaccin
deliv
antigen
ag
local
dendrit
cell
dc
subsequ
migrat
affer
lymphat
drain
lymph
node
ln
encount
lymphocyt
recogn
cognat
ag
initi
immun
experiment
autoimmun
encephalomyel
eae
serv
anim
model
multipl
sclerosi
demyelin
autoimmun
diseas
central
nervou
system
cn
eae
induc
sc
immun
myelin
antigen
myelin
oligodendrocyt
glycoprotein
mog
secondari
lymphoid
tissu
wide
held
vital
initi
adapt
immun
demonstr
alymphoplasia
ali
mice
character
complet
lack
lymph
node
ln
peyer
patch
resist
eae
induc
sc
immun
mog
howev
immunodefici
result
impact
ali
lesion
immun
lack
lymphoreticular
structur
led
excit
understand
vaccin
induc
autoimmun
cn
develop
autonom
without
dedic
immun
structur
clearli
show
b
cell
activ
requir
lymphoreticular
system
germin
center
format
cell
immun
function
independ
secondari
lymphoid
tissu
demonstr
absenc
secondari
lymphoid
tissu
liver
act
site
primari
immun
occur
inflamm
induc
tertiari
follicl
well
describ
howev
first
report
indic
vaccin
induc
fulmin
autoimmun
initi
liver
role
innat
immun
autoimmun
diseas
tolllik
receptor
agonist
trigger
autoimmun
encephalomyel
infecti
organ
may
play
role
human
autoimmun
diseas
experiment
autoimmun
encephalomyel
eae
model
multipl
sclerosi
ms
induc
lewi
rat
rat
myelin
basic
protein
mbp
peptid
complet
freund
adjuv
cfa
although
role
mycobacteria
unclear
requir
induct
eae
investig
whether
tolllik
receptor
tlr
agonist
replac
mycobacteria
adjuv
immun
rat
incomplet
adjuv
lack
mycobacteria
supplement
tlr
agonist
rat
immun
either
plu
cytosineguanin
dinucleotidecontain
oligodeoxynucleotid
cpg
agonist
plu
lipopolysaccharid
lp
agonist
develop
eae
although
cell
prolifer
secret
interferongamma
stimul
contrast
rat
immun
plu
cpg
lp
develop
clinic
eae
spleen
cell
prolifer
secret
interferongamma
respons
secret
respons
cpg
lp
suggest
tlr
agonist
promot
respons
thu
combin
cpg
lp
substitut
mycobacteria
induct
eae
conclud
combin
tlr
agonist
presenc
autoantigen
trigger
autoimmun
diseas
via
innat
immun
system
support
nih
ns
innat
immun
respons
adjuv
dictat
adapt
immun
respons
autoantigen
staykova
linar
fordham
g
bartel
w
cowden
willenborg
neurosci
research
unit
anu
medic
school
canberra
hospit
canberra
australia
da
lew
rat
known
suscept
pvg
ratsa
semisuscept
femal
develop
eae
bn
ratsa
resist
base
develop
eae
immunis
myelin
basic
protein
spinal
cord
homogen
emulsifi
complet
freund
adjuv
mbpcfa
schcfa
reexamin
eae
susceptibilityresist
rat
strain
base
knowledg
nitric
oxid
affect
gener
effector
cell
andor
transendotheli
migratori
properti
anoth
adjuv
usedcarbonyl
iron
ci
increas
system
levelsal
four
rat
strain
develop
acut
eae
signific
differ
lymph
node
spleen
percentag
lymphocyt
b
lymphocyt
nk
cell
schcfa
schci
use
signific
differ
da
lew
pvg
bn
macrophagemonocyt
number
express
costimulatori
molecul
ino
activ
cellular
composit
cn
inflammatori
infiltr
also
differ
da
lew
major
cell
lymphocyt
cell
pvg
bn
massiv
posit
experi
rat
chimera
indian
ink
load
monocyt
show
cell
da
lew
mainli
macrophag
pvg
bn
massiv
glial
cell
activ
blockad
exacerb
experiment
autoimmun
enceph
littl
known
function
central
nervou
system
cn
howev
rare
autosom
recess
condit
nasuhakola
diseas
nhd
associ
lossoffunct
mutat
brain
patholog
observ
nhd
patient
suggest
disrupt
pathway
lead
neurodegener
demyelin
axon
loss
aim
studi
determin
role
experiment
autoimmun
encephalomyel
eae
method
protein
express
investig
use
newli
produc
monoclon
antibodi
mab
mous
receptor
eae
induc
mice
mog
peptid
block
effect
mab
assess
use
cell
report
system
result
protein
express
demonstr
vitro
macrophag
microglia
dendrit
cell
report
upregul
spinal
cord
earli
inflammatori
chronic
phase
eae
also
demonstr
highli
express
microgli
cell
cn
eae
blockad
obtain
treat
mice
mab
effector
phase
eae
result
diseas
exacerb
diffus
cn
inflammatori
infiltr
demyelin
spinal
cord
conclus
data
show
critic
role
inflammatori
respons
cn
suggest
play
role
pathogenesi
autoimmun
inflammatorydemyelin
diseas
cn
type
interferon
receptor
ifnar
depend
modul
myeloid
cell
activ
determin
cours
experiment
autoimmun
encephalomyel
treatment
ms
patient
interferonb
ifnb
lead
mark
decreas
exacerb
rate
well
delay
sustain
diseas
progress
precis
mechan
benefici
effect
still
enigmat
studi
show
type
interferon
receptordefici
mice
ifnar
highli
suscept
experiment
autoimmun
diseas
eae
develop
sever
diseas
cours
increas
cn
inflamm
demyelin
lethal
sinc
ifnar
express
bodi
littl
known
actual
target
tissu
diseas
clarifi
use
creloxpmedi
gene
target
investig
cellspecif
function
ifnar
vivo
mice
specif
ifnar
delet
central
nervou
system
nestincreifnarfloxflox
reveal
differ
clinic
cours
show
compat
tissu
damag
cn
compar
wt
control
indic
type
interferon
direct
protect
impact
cn
interestingli
neither
cell
creifnarfloxflox
b
cell
creifnarfloxflox
specif
ifnar
delet
influenc
clinic
cours
cellular
composit
infiltr
cell
howev
ifnar
delet
macrophagesneutrophil
lysmcreifnarfloxflox
led
sever
diseas
enhanc
effector
phase
increas
diseas
lethal
seen
ifnar
mice
delet
ifnar
macrophag
induc
alter
mhc
class
ii
express
chang
cytokin
chemokin
product
summari
show
ifnar
trigger
specif
myeloid
cell
lymphocyt
cn
cell
crucial
immunomodulatori
effect
type
ifn
autoimmun
cn
diseas
effect
fibroblast
growth
factor
experiment
autoimmun
encephalomyel
eae
object
investig
role
eae
progress
background
fgf
potent
mitogen
glial
cell
activ
exhibit
broadspectrum
neurotroph
activ
howev
known
fgf
may
affect
eae
progress
cytokin
profil
eae
designmethod
wt
doubl
knockout
heterozygot
mice
immun
mog
emulsifi
cfa
clinic
score
assess
daili
serum
taken
day
anim
immedi
preced
euthanasia
multiplex
assay
perform
determin
serum
cytokin
level
knockout
heterozygot
result
knockout
develop
significantli
milder
clinic
symptom
compar
heterozygot
wt
mice
serum
level
kc
level
significantli
higher
knockout
heterozygot
mice
cytokin
includ
gmcsf
gcsf
rant
level
show
signific
differ
conclus
knockout
mice
develop
milder
eae
heterozygot
wt
mice
correl
serum
antiinflammatori
cytokin
level
find
suggest
cell
regul
absenc
gene
express
level
cytokin
cn
current
measur
neurotroph
factor
neuroinflamm
experiment
autoimmun
encephalomyel
condit
bdnfknock
mice
brain
deriv
neurotroph
factor
bdnf
involv
neuron
glial
develop
surviv
mainli
produc
neuron
also
leukocyt
vitro
multipl
sclerosi
ms
lesion
yet
function
relev
bdnf
express
immun
cell
autoimmun
demyelin
still
unknown
sinc
convent
bdnf
knockout
mice
die
prematur
appli
creloxp
system
gener
mice
condit
delet
bdnf
tcell
lineag
lckcre
bdnf
mice
myeloid
cell
lysmcr
bdnf
mice
mice
experiment
autoimmun
encephalomyeltit
eae
activ
induc
myelin
oligodendrocyt
glycoprotein
mog
peptid
compar
control
mice
mogea
lckcre
bdnf
mice
sever
mean
score
day
pi
vs
control
histolog
analys
chronic
diseas
phase
reveal
increas
inflammatori
infiltr
lckcre
bdnf
mice
mog
eae
lysmcr
bdnf
mice
similar
sever
chronic
phase
diseas
immun
reaction
lysmcr
bdnf
mice
attenu
decreas
interferongamma
product
reduc
inflammatori
infiltr
least
despit
less
inflamm
chronic
mogea
extent
axon
damag
differ
lysmcr
bdnf
mice
control
find
suggest
novel
role
immunecel
deriv
bdnf
immunoregul
also
underscor
import
suscept
factor
maintain
axon
integr
data
support
concept
neuroprotect
autoimmun
support
sfb
multipl
sclerosi
ms
autoimmun
demyelin
diseas
central
nervou
system
ms
predominantli
follow
relapsingremit
diseas
cours
although
minor
patient
develop
primari
progress
form
diseas
eae
wide
use
anim
model
ms
eae
follow
either
relapsingremit
rr
chronic
ch
diseas
cours
date
molecular
patholog
differ
underli
differ
form
ms
eae
fulli
understood
assess
express
soc
spinal
cord
rr
ch
eae
express
mrna
increas
earli
stage
rr
diseas
decreas
subsequ
remiss
phase
contrast
mrna
express
elev
stage
ch
diseas
express
soc
turn
proinflammatori
cytokin
signal
data
suggest
inflammatori
respons
prolong
ch
form
eae
express
soc
protein
level
assess
spinal
cord
immunohistochemistri
express
local
immun
cell
within
eae
lesion
predominantli
express
glial
cell
adjac
lesion
result
demonstr
preferenti
upregul
distinct
cell
type
cours
eae
regul
sonic
hedgehog
mediat
neural
stem
cell
differenti
experiment
autoimmun
encephalomyel
yue
wang
jaim
imitola
stine
rasmussen
samia
j
khouri
object
investig
role
sonic
hedgehog
shh
signal
neural
stem
cell
nsc
precursor
cell
differenti
effect
inflamm
experiment
autoimmun
encephalomyel
eae
signal
method
express
shh
receptor
smoothen
smo
transcript
factor
examin
spinal
cord
mice
moginduc
eae
immunohistolog
nsc
examin
realtim
pcr
western
blot
shh
shhinduc
express
effect
shh
astrocytemedi
nsc
differenti
evalu
antishh
antibodi
control
igg
treat
nscsadult
spinal
cord
astrocyt
cocultur
untreat
nsc
compar
shhmediat
differenti
vitro
result
reactiv
spinal
cord
astrocyt
upregul
shh
smo
eae
especi
around
perivascular
infiltr
area
demyelin
downregul
vitro
nsc
treat
also
downregul
nsc
differenti
neuron
astrocyt
oligodendrocyt
cocultur
adult
astrocyt
antishh
significantli
decreas
number
matur
neuron
shhmediat
nsc
differenti
significantli
inhibit
independ
cell
death
conclus
shh
import
mediat
adult
astrocyteinduc
nsc
differenti
upregul
reactiv
astrocyt
eae
howev
may
play
critic
role
inhibit
shhmediat
nsc
precursor
cell
differenti
downregul
shh
signal
molecul
eae
endogen
prion
protein
regul
inflammatori
respons
extent
cn
damag
murin
model
multipl
sclerosi
tsutsui
f
r
jirik
role
prp
c
pathogenesi
neuroinflammatori
neurodegen
diseas
remain
elus
howev
signific
number
vitro
experi
provid
evid
prp
c
neuroprotect
moreov
prp
c
express
lymphocyt
macrophag
myeloid
dendrit
cell
suggest
prp
c
might
potenti
play
critic
role
neuroinflammatori
neurodegen
diseas
determin
effect
reduc
prp
c
express
model
ms
experiment
allerg
encephalomyel
eae
homozyg
prp
c
knockout
prp
mice
litterm
wild
type
prp
control
treat
subcutan
myelin
oligodendrocyt
glycoprotein
mog
induc
eae
anim
monitor
clinic
sign
grade
daili
brain
spinal
cord
section
euthan
anim
stain
silver
prp
mice
exhibit
earlier
onset
significantli
sever
eae
phenotyp
prp
control
neurobehavior
score
eae
stain
show
mark
perivascular
infiltr
brain
silver
stain
show
number
axon
reduc
spinal
cord
prp
mice
compar
prp
control
studi
suggest
lack
prp
c
express
dysregul
eae
inflammatori
respons
might
also
render
cn
cell
suscept
injuri
elucid
role
prp
c
eae
lead
better
understand
neurodegen
diseas
pathogenesi
also
rais
possibl
alter
prion
protein
level
function
might
therapeut
benefit
critic
role
activ
signal
eae
attenu
diseas
associ
diminish
number
h
cell
cn
chander
raman
robert
c
axtel
scott
r
barnum
depart
medicin
microbiolog
univers
alabama
birmingham
birmingham
al
usa
recent
report
mice
lack
neg
regul
tcell
activ
unexpectedli
exhibit
delay
onset
decreas
sever
mogpeptid
induc
experiment
autoimmun
encephalomyel
eae
attenu
diseas
consequ
decreas
abil
activ
tcell
persist
led
discoveri
engagementdepend
prosurviv
activ
tcell
test
predict
prosurviv
activ
mediat
antiapoptot
serin
threonin
kinas
constitut
associ
gener
mice
express
unabl
bindactiv
use
transgen
knockin
approach
remark
bindingactivationdefici
mice
resist
develop
eae
resist
associ
absenc
tcell
infiltr
cn
rather
due
decreas
h
cell
coexpress
newli
describ
h
popul
tcell
develop
equal
effici
wt
defici
mice
show
tcell
defici
signal
hyperprolifer
follow
primari
stimul
howev
respond
poorli
restimul
compar
tcell
result
indic
h
like
import
pathogen
effector
popul
multipl
sclerosi
also
show
pathway
attenu
tcell
activ
cell
death
coordin
effect
activ
like
import
differenti
persist
effector
tcell
autoimmun
immun
pathogen
support
nih
lri
insun
hwang
taekyun
shin
youngheun
jee
depart
veterinari
medicin
appli
radiolog
scienc
institut
cheju
nation
univers
jeju
south
korea
develop
autoimmun
diseas
requir
coordin
express
number
immunerel
gene
mediat
mani
inflammatori
respons
key
player
regul
inflammatori
gene
express
nuclear
factorkb
nfkb
activ
phosphoryl
proteolyt
degrad
inhibitori
protein
ikb
howev
involv
nfkb
transcript
factor
variou
immunemedi
diseas
propos
direct
support
evid
still
lack
elucid
role
nfkb
phosphoikb
develop
progress
eae
investig
express
nuclear
nfkb
phosphoikb
central
nervou
system
cn
rat
experiment
autoimmun
encephalomyel
eae
western
blot
analysi
phosphoikb
express
rapidli
earli
stage
increas
significantli
peak
stage
diseas
addit
express
nfkb
increas
earli
peak
stage
follow
slight
declin
later
stage
express
nuclear
nfkb
phosphoikb
parallel
sever
eae
immunohistochem
studi
show
nfkb
phosphoikb
immunoreact
mainli
express
inflammatori
cell
macrophag
cell
glial
cell
astrocyt
microgli
cell
peak
stage
disappear
recoveri
stage
diseas
find
suggest
activ
nfkb
phosphoryl
ikb
close
associ
autoimmun
inflamm
cn
play
import
role
initi
progress
eae
antisnitrosocystein
antibodi
trigger
nitric
oxid
product
ai
boullern
sharp
l
liu
dl
feinstein
univers
illinoi
chicago
chicago
illinoi
usa
autoimmun
antibodi
respons
nitrosyl
cystein
snocysteinebsa
found
elev
plasma
multipl
sclerosi
patient
correl
clinic
activ
boullern
et
al
j
neurosci
suggest
product
nitric
oxid
trigger
autoimmun
respons
test
hypothesi
mice
immun
develop
experiment
allerg
encephalomyel
eae
monitor
antibodi
respons
product
plasma
wildtyp
null
mice
immun
myelin
oligodendrocyt
glycoprotein
peptid
mog
follow
week
later
mog
booster
treatment
antiinflammatori
ppargamma
agonist
strong
increas
observ
week
immun
lessen
lowdos
treat
mice
abolish
highdos
treat
mice
clinic
sign
increas
antibodi
respons
found
two
week
immun
correl
clinic
sign
aris
week
later
absenc
clinic
sign
antibodi
respons
null
mice
eae
show
increas
product
month
followup
antibodi
respons
reduc
half
show
opposit
fluctuat
compar
wildtyp
treatment
exacerb
antibodi
respons
clinic
sign
decreas
find
point
complex
role
ppargamma
agonist
may
promot
antibodi
respons
absenc
product
could
explain
presenc
antibodi
respons
null
mice
increas
phosphoryl
mitogenactiv
protein
kinas
eae
express
phosphospecif
phosphoryl
mitogenactiv
protein
kinas
analyz
spinal
cord
lewi
rat
experiment
autoimmun
encephalomyel
eae
western
blot
analysi
show
constitut
express
normal
spinal
cord
significantli
increas
spinal
cord
eae
peak
stage
eae
p
decreas
slightli
recoveri
stage
eae
immunohistochemistri
show
constitut
express
vascular
endotheli
cell
glial
cell
normal
rat
spinal
cord
eae
lesion
intens
immunostain
inflammatori
cell
macrophag
constitut
express
neuron
glial
cell
vascular
endotheli
cell
normal
spinal
cord
also
express
inflammatori
cell
well
increas
express
glial
cell
eae
taken
consider
postul
phosphoryl
play
import
role
pathogenesi
eae
function
role
discuss
activ
mitogenactiv
protein
kinas
experiment
autoimmun
encephalomyel
depart
veterinari
medicin
cheju
nation
univers
jeju
increas
evid
suggest
mitogenactiv
protein
map
kinas
includ
extracellular
signalregul
kinas
erk
cjun
nh
termin
protein
kinas
jnk
involv
pathogenesi
human
demyelin
diseas
anim
model
experiment
autoimmun
encephalomyel
eae
assess
involv
map
kinas
eae
express
local
phosphoryl
form
erk
perk
jnk
pjnk
analyz
eae
rat
western
blot
analysi
show
map
kinas
includ
perk
pjnk
significantli
increas
eae
lesion
peak
stage
p
slightli
declin
recoveri
stage
well
mapk
erk
kinas
upstream
activ
camp
respons
element
bind
protein
creb
downstream
transcript
factor
activ
eae
affect
spinal
cord
immunohistochemistri
show
perk
constitut
express
brain
cell
includ
astrogli
cell
show
enhanc
immunoreact
cell
eae
cell
macrophag
posit
perk
eae
lesion
pjnk
intens
immunostain
cell
eae
lesion
major
brain
cell
inflammatori
cell
posit
pcreb
eae
lesion
find
suggest
activ
map
kinas
downstream
transcript
factor
play
import
role
initi
eae
paralysi
subsequ
recoveri
function
role
mapk
discuss
delet
pten
antigenactiv
lymphocyt
reveal
potenti
role
pten
effector
popul
experiment
autoimmun
encephalomyel
eae
diseas
model
pten
phosphoinositol
phosphatas
critic
lymphocyt
ontogeni
selftoler
via
neg
regul
pathway
lie
downstream
phosphoinositid
kinas
previou
studi
use
creloxp
system
delet
pten
gene
develop
thymocyt
reveal
defect
thymic
select
cell
homeostasi
examin
function
role
pten
specif
matur
effector
lymphocyt
context
normal
preimmun
tcell
repertoir
select
system
allow
cremedi
gene
excis
occur
within
cell
subsequ
activ
system
employ
granzym
b
gene
promot
drive
express
cre
recombinas
upon
tcr
activ
use
trigger
excis
exon
flox
pten
gene
mice
homozyg
flox
allel
thu
abl
obtain
pten
delet
specif
subset
activ
lymphocyt
character
system
evalu
effici
pten
gene
delet
matur
cell
vitro
also
studi
consequ
pten
loss
model
cellmedi
immunopatholog
murin
experiment
autoimmun
encephalomyel
eae
eae
induc
inject
synthet
myelin
oligodendrocyt
glycoprotein
peptid
mog
complet
freund
adjuv
pertussi
toxin
initi
clinic
neuropatholog
character
mogimmun
granzym
b
cre
x
flox
pten
mice
indic
pten
play
critic
role
regul
sever
eae
also
timecours
diseas
exacerb
experiment
autoimmun
encephalomyel
mice
lanfen
chen
celia
f
brosnan
depart
patholog
albert
einstein
colleg
medicin
bronx
ny
usa
receptor
r
atpgat
ionotrop
receptor
propos
serv
regul
inflamm
studi
test
whether
develop
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
modifi
anim
lack
r
r
mice
clinic
patholog
sign
eae
sever
wt
mice
bone
marrow
radiat
chimera
reveal
greater
suscept
eae
detect
chimer
mice
wt
host
engraft
r
bm
cell
indic
genotyp
bm
cell
regul
diseas
suscept
vitro
spleen
lymph
node
cell
r
mice
higher
prolif
activ
less
apoptosi
respons
mog
peptid
similarli
significantli
fewer
annexin
vpi
tunel
posit
lymphocyt
found
cn
r
mice
earli
diseas
cytokin
profil
cultur
supernat
show
significantli
decreas
express
mogactiv
spleen
cell
r
mice
qpcr
protein
assay
show
protein
mrna
well
mrna
protein
significantli
reduc
spinal
cord
homogen
indoleamin
ido
product
also
decreas
spinal
cord
homogen
r
mice
data
conclud
enhanc
suscept
r
mice
eae
reflect
vigor
prolif
respons
mog
lower
level
nitric
oxid
ido
compar
wt
mice
correl
loss
apoptot
activ
lymphocyt
macrophag
phenotyp
relaps
experiment
autoimmun
encephalomyel
predict
mri
diseas
onset
macrophag
infiltr
experiment
autoimmun
encephalomyel
eae
multipl
sclerosi
ms
monitor
vivo
mri
ultrasmal
super
paramagnet
iron
oxid
uspio
nanoparticl
patholog
condit
macrophag
present
least
two
main
phenotyp
proinflammatori
macrophag
express
induc
nitric
oxid
synthas
ino
immunomodulatori
macrophag
express
arginas
use
relaps
eae
studi
macrophag
phenotyp
within
inflammatori
infiltr
clinic
onset
group
end
attack
group
ii
attack
group
iii
uspio
mri
perform
clinic
onset
repeat
anim
group
iii
anim
mri
signal
chang
consid
mri
serial
thin
section
brainstem
activ
macrophag
quantifi
anti
macrophag
anti
ino
label
use
confoc
immunofluoresc
arginas
label
axon
damag
loss
brainstem
tissu
quantifi
classic
immunohistochemistri
method
obtain
result
compar
mri
data
mri
rat
present
import
macrophag
recruit
cell
number
cell
express
ino
also
abund
mri
anim
mri
anim
regard
clinic
diseas
sever
tissu
alter
axon
loss
tissu
damag
signific
differ
mri
mri
anim
observ
phenotyp
analysi
progress
conclus
mri
perform
onset
eae
predict
presenc
inosexpress
macrophag
phenotyp
extend
nervou
tissu
lesion
inflam
cn
differ
stage
diseas
cours
magnet
reson
imag
mri
techniqu
wide
use
investig
multipl
sclerosi
ms
lesion
histopatholog
correl
mri
signal
alter
still
poorli
defin
compar
mri
histopatholog
murin
experiment
autoimmun
encephalomyel
eae
model
brainstem
lesion
induc
adopt
transfer
specif
tcell
clone
sjlj
mice
histopatholog
identifi
acut
eae
lesion
retriev
highresolut
mri
lesion
vari
respect
signal
intens
imag
two
domin
mri
lesion
pattern
could
identifi
lesion
reduc
signal
intens
mri
type
lesion
isointens
slightli
reduc
signal
intens
mri
increas
signal
intens
mri
type
b
type
lesion
character
significantli
denser
inflammatori
cell
infiltr
myelin
axon
loss
type
b
lesion
compar
analysi
reveal
lesion
cellular
myelin
loss
axon
densiti
correl
signal
intens
obtain
imag
lesion
center
perilesion
area
microglia
cell
number
ig
deposit
correl
strongli
signal
intens
mri
gddtpa
enhanc
correl
ig
deposit
mainli
took
place
area
activ
microglia
cell
summari
establish
mous
eae
model
suitabl
mr
imag
given
robust
correl
mr
signal
intens
histopatholog
chang
model
use
mri
evalu
new
therapeut
strategi
magnet
resonanceguid
evalu
diseas
burden
mice
chronic
experiment
autoimmun
encephalomyel
eae
magnet
reson
mr
may
help
preclin
studi
monitor
patholog
abnorm
brain
white
matter
investig
whether
inflammatori
demyelin
lesion
affect
brain
mice
experiment
multipl
sclerosi
ms
may
detect
monitor
natur
stori
diseas
model
human
mr
apparatu
experiment
autoimmun
encephalomyel
eae
induc
mice
use
myelinoligodendrocyt
glycoprotein
mog
complet
freund
adjuv
sex
strain
weightand
agematch
nonimmun
cfaimmun
mice
use
control
mice
n
evalu
basal
well
gadolinium
gd
contrast
enhanc
mr
imag
preclin
acuteand
chronic
phase
diseas
eg
day
immun
dpi
respect
mening
enhanc
gd
enhanc
parenchym
lesion
start
appear
earli
day
dpi
peak
activ
demyelin
lesion
record
clinic
onset
dpi
mening
enhanc
fade
time
progress
disappear
dpi
eae
mice
new
enhanc
lesion
detect
dpi
thu
indic
subclin
relaps
examin
mice
present
least
one
demyelin
lesion
cerebellum
lesion
either
corpu
callosum
extern
capsul
neuropatholog
analysi
confirm
presenc
lymphomonocyt
infiltr
mening
parenchym
gdenhanc
imag
studi
necessari
care
evalu
sensibl
specif
human
grade
mr
detect
acut
chronic
demyelin
eae
mice
infiltr
monocyt
central
nervou
system
key
event
neuroinflammatori
diseas
develop
superparamagnet
particl
iron
oxid
spio
made
magnet
reson
imag
mri
valuabl
tool
vivo
cell
track
provid
possibl
noninvas
monitor
home
inflammatori
cell
toward
site
neural
tissu
damag
aim
visual
spio
label
monocyt
enter
brain
lesion
time
compar
mr
abnorm
administr
free
label
cortic
lesion
induc
rat
photothrombosi
microvessel
day
lesion
induct
rat
receiv
intraven
either
label
free
spio
spio
label
monocyt
w
imag
sensit
iron
perform
h
h
label
inject
addit
three
rat
continu
scan
h
start
directli
administr
free
spio
rel
increas
mr
abnorm
rat
transplant
spiomonocyt
h
larger
compar
control
free
spio
treat
rat
latter
display
mr
abnorm
cover
total
lesion
area
h
imag
h
scan
show
mr
abnorm
alreadi
h
administr
free
spio
indic
leakag
spio
damag
blood
brain
barrier
result
demonstr
abl
visual
infiltr
monocyt
monitor
blood
brain
barrier
permeabl
use
spio
label
monocyt
free
spio
respect
imag
strategi
valuabl
tool
studi
dynam
pattern
monocyt
infiltr
neuroinflamm
may
contribut
develop
celldirect
therapeut
visual
effector
cell
activ
within
autoimmun
cn
lesion
solubl
antigen
treatment
f
odoardi
k
rune
c
cordiglieri
n
kawakami
h
wekerl
use
real
time
twophoton
imag
visual
effect
intraven
solubl
antigen
retrovir
label
mbpspecif
cell
acut
experiment
autoimmun
encephalomyel
eae
lesion
lewi
rat
recent
found
effector
cell
diseas
cn
show
two
distinct
motil
pattern
major
cell
move
fast
maxim
speed
appar
non
direct
compact
tissu
motil
cell
second
group
effector
cell
tether
fix
point
form
immun
synapselik
structur
stationari
cell
report
intraven
mbp
infus
profoundli
chang
cellular
locomot
pattern
veloc
effector
cell
slow
dramat
percentag
stationari
cell
increas
chang
first
observ
mening
area
start
h
inject
follow
stop
cell
within
cn
parenchyma
h
later
tether
parallel
strong
upregul
proinflammatori
cytokin
activ
marker
autoaggress
effector
cell
furthermor
h
follow
infus
mbp
clinic
eae
becam
worsen
increas
weight
loss
paralysi
result
elucid
speed
effici
antigen
recognit
vivo
add
understand
cellmedi
autoimmun
therapi
plea
proteom
biomark
research
applic
protein
twodimension
gel
electrophoresi
liquid
chromatographi
mass
spectrometri
imag
rat
experiment
autoimmun
encephalomyel
introduct
biom
research
focus
autoimmun
disord
multipl
sclerosi
ms
anim
model
experiment
autoimmun
encephalomyel
eae
one
research
topic
includ
analysi
eae
rat
brain
proteom
separ
technolog
mass
spectrometri
addit
mass
spectrometri
imag
msi
initi
set
msi
newli
develop
technolog
util
matrixassist
laser
desorpt
ionis
maldi
mass
spectrometri
profil
map
protein
present
tissu
section
goal
studi
identifi
differenti
express
protein
ultim
use
biomark
ms
method
myelin
basic
protein
mbp
immun
lewi
rat
sacrif
brain
extract
subject
twodimension
gel
electrophoresi
liquid
chromatographi
combin
tandem
mass
spectrometri
msi
cryostat
coron
section
cut
transfer
stainless
steel
maldi
target
plate
spray
matrix
spectra
kda
acquir
use
bruker
ultraflex
ii
malditoftof
instrument
result
perspect
applic
result
identif
protein
found
differenti
express
brain
eae
anim
ongo
msi
experi
includ
monitor
select
brain
protein
experiment
determin
mass
myelin
basic
protein
futur
experi
focu
identif
differenti
distribut
protein
acut
eae
well
demyelin
anim
model
differenti
express
protein
found
either
proteom
applic
valid
use
biomark
ms
immun
mice
neuron
protein
tau
induc
tauopathylik
patholog
neurolog
deficit
adtau
aggreg
neurofibrillarytangl
investig
possibl
activ
immun
mice
tau
protein
test
whether
neurodegen
diseas
induc
method
immun
mice
recombin
human
tau
protein
complet
freundsadjuv
cfa
pertussi
result
femal
anim
immun
tau
develop
neurolog
sign
limp
tail
limb
paralysi
wherea
none
cfaimmun
control
show
symptom
tauimmun
mice
detect
antitau
ab
serum
glial
activ
well
taurel
patholog
spinal
cord
lesser
extent
also
brain
find
much
promin
clinic
affect
anim
mononuclear
infiltr
axon
damag
detect
clinic
affect
tauimmun
anim
conclus
demonstr
neurodegen
diseas
induc
immun
tau
protein
best
knowledg
first
report
indic
tau
protein
immunogen
potenti
induc
neuroinflamm
neurodegener
find
may
shed
light
possibl
involv
tau
autoimmun
neurodegen
diseas
point
potenti
danger
therapeut
immun
tau
protein
antigen
confirm
contribut
lesion
distribut
clinic
sign
relaps
remit
moginduc
eae
multipl
sclerosi
ms
chronic
diseas
repeat
episod
inflammatori
demyelin
associ
increas
burden
axon
injuri
major
caus
chronic
disabl
investig
neuron
respons
axon
injuri
context
inflammatori
demyelin
develop
model
relaps
remit
moginduc
eae
lewi
rat
characteris
predict
focal
develop
lesion
cervic
spinal
cord
cerebellum
diseas
induc
immunis
refold
recombin
rat
mog
incomplet
freund
adjuv
ifa
unlik
classic
model
diseas
characteris
circl
ataxia
diseas
cours
patholog
assess
initi
episod
diseas
relaps
remiss
typic
distinct
relaps
observ
period
day
post
immunis
lesion
appear
preferenti
target
dorsal
column
cervic
spinal
cord
earli
time
point
subsequ
involv
cerebellar
region
brain
inflamm
associ
confluent
demyelin
axon
injuri
mechan
respons
select
target
specif
region
cn
unclear
preliminari
studi
indic
local
differ
recruit
activ
minim
encephalitogen
cell
respons
amplifi
high
titr
demyelin
antibodi
respons
induc
refold
mog
model
eae
use
studi
region
differ
respons
blood
brain
barrier
axon
defin
neuron
cell
popul
inflammatori
demyelin
relaps
remit
diseas
role
mhc
class
ii
express
cell
induc
eae
transgen
mice
mayo
clinic
colleg
medicin
rochest
mn
usa
mhc
class
ii
molecul
play
central
role
control
adapt
immun
respons
select
cell
repertoir
thymu
antigen
present
peripheri
inherit
suscept
autoimmun
disord
multipl
sclerosi
rheumatoid
arthriti
iddm
associ
particular
mhc
class
ii
allel
advent
hla
transgen
mice
help
us
deciph
role
particular
hla
dr
dq
class
ii
molecul
human
autoimmun
diseas
mous
express
class
ii
restrict
profession
antigen
present
cell
howev
human
class
ii
also
express
cell
unlik
mous
cell
gener
new
human
hla
class
ii
transgen
mice
express
class
ii
molecul
subset
cell
express
class
ii
cell
induc
classii
cell
present
antigen
absenc
apc
use
experiment
autoimmun
encephalomyel
eae
wellestablish
anim
model
multipl
sclerosi
test
function
signific
classii
cell
transgen
mice
suscept
induc
eae
show
cn
patholog
accompani
widespread
inflamm
demyelin
seen
human
ms
patient
suggest
role
class
ii
cell
pathogenesi
dendrit
cell
dc
profession
antigen
present
cell
activ
initi
adapt
immun
respons
control
peripher
toler
selfantigen
demonstr
particular
signal
provid
antigen
target
ctype
lectin
receptor
clr
function
uptak
receptor
glycosyl
antigen
maintain
homeostasi
induc
toler
concomit
dc
matur
induc
tolllik
receptor
tlr
trigger
instrument
induc
autoimmun
multipl
sclerosi
ms
selfantigen
myelinoligodendrocyt
glycoprotein
mog
may
induc
neuron
demyelin
experiment
autoimmun
encephalomyel
eae
combin
adjuv
activ
tlr
determin
whether
alter
glycosyl
mog
disrupt
homeostat
control
derang
clrtlr
balanc
glycosyl
profil
nativ
mog
human
marmoset
investig
common
marmoset
provid
us
uniqu
preclin
model
due
high
clinic
patholog
immunolog
similar
ms
studi
demonstr
mog
may
express
glycan
target
clr
dc
clr
inde
differenti
express
healthi
diseas
human
marmoset
ms
brain
invitro
human
dc
studi
evalu
mechan
glycosyl
mog
exhibit
suppress
suppress
glycosyl
mog
develop
antimog
autoimmun
form
basi
futur
therapi
aim
toler
induct
ms
poster
session
eaetherapi
sphingosin
receptor
modul
amelior
experiment
autoimmun
encephalomyel
eae
ii
effect
myelin
oligodendrocyt
glycoproteininduc
eae
mice
n
seki
h
kataoka
ohtsuki
n
sato
fukunari
b
k
chiba
research
laboratori
iii
b
discoveri
technolog
laboratori
mitsubishi
pharma
corpor
yokohama
japan
sequest
circul
lymphocyt
secondari
lymphoid
tissu
thymu
longterm
downregul
sphingosin
receptor
type
highli
effect
myelin
proteolipid
protein
plp
induc
experiment
autoimmun
encephalomyel
eae
sjlj
mice
studi
evalu
therapeut
effect
myelin
oligodendrocyt
glycoprotein
mog
induc
eae
mice
method
eae
femal
mice
induc
immun
mog
presenc
freund
complet
adjuv
result
eae
develop
day
immun
mog
mice
eaeestablish
mice
use
day
mog
immun
eaeassoci
symptom
maintain
administr
period
control
group
consist
plpinduc
eae
sjlj
mice
moginduc
eae
significantli
inhibit
administ
therapeut
mgkg
oral
infiltr
cell
markedli
cell
spinal
cord
control
eae
mice
group
area
demyelin
infiltr
cell
cell
spinal
cord
decreas
compar
control
elev
mrna
level
spinal
cord
significantli
inhibit
group
addit
sinc
elev
mrna
observ
spinal
cord
eae
mice
analyz
level
mrna
group
conclus
result
suggest
show
therapeut
effect
moginduc
eae
mice
inhibit
cell
infiltr
dominantli
sphingosin
receptor
modul
amelior
experiment
autoimmun
encephalomyel
eae
effect
myelin
proteolipid
proteininduc
eae
sjlj
mice
h
kataoka
k
sugahara
k
shimano
maeda
koyama
b
fukunari
b
k
chiba
research
laboratori
iii
b
discoveri
technolog
laboratori
mitsubishi
pharma
corpor
yokohama
japan
introduct
new
class
immunomodul
effect
phosphoryl
sequest
circul
lymphocyt
secondari
lymphoid
tissu
thymu
longterm
downregul
sphingosin
receptor
type
exert
immunosuppress
activ
variou
allograft
autoimmun
diseas
model
studi
evalu
effect
myelin
proteolipid
protein
plp
induc
experiment
autoimmun
encephalomyel
eae
mice
method
eae
femal
sjlj
mice
induc
immun
plp
freund
complet
adjuv
clinic
score
eae
assess
period
result
eae
develop
day
plp
immun
relaps
week
primari
eae
control
group
develop
plpinduc
eae
almost
complet
prevent
infiltr
cell
spinal
cord
decreas
prophylact
treatment
mgkg
oral
mgkg
intraperiton
given
establish
eae
relaps
eae
markedli
inhibit
compar
area
demyelin
infiltr
cell
decreas
spinal
cord
eae
mice
conclus
result
indic
exhibit
prophylact
also
therapeut
effect
plpinduc
eae
sjlj
effect
eae
appear
due
reduct
infiltr
myelin
antigenspecif
cell
inflamm
site
role
brain
implic
multipl
sclerosi
receptor
particular
express
tcell
respons
tcell
egress
lymphat
tissu
bind
tcell
caus
receptor
intern
turn
prevent
traffick
tcell
blood
cn
reduc
accumul
harm
tcell
cn
multipl
sclerosi
patient
phase
ii
studi
clearli
shown
protect
effect
multipl
sclerosi
intriguingli
five
also
differenti
express
four
major
cell
type
brain
name
neuron
oligodendrocyt
astrocyt
microglia
littl
known
role
brain
studi
use
activ
indic
receptor
may
modul
four
cell
type
readili
cross
bloodbrain
barrier
therefor
suggest
work
beyond
immun
system
play
addit
protect
role
cn
cell
multipl
sclerosi
present
data
effect
nervou
system
use
vitro
cell
cultur
assay
well
preliminari
experi
direct
brain
administr
dose
caus
peripher
lymphocyt
deplet
differ
stage
relaps
remit
experiment
autoimmun
encephalomyel
eae
da
rat
superagonist
peptideinduc
cell
toler
treatment
multipl
sclerosi
kazuyuki
kawamura
meik
hueben
christoph
self
b
robert
weissert
c
thoma
g
forsthub
univers
texa
san
antonio
san
antonio
usa
b
provid
pharmaceut
inc
north
brunswick
nj
usa
c
herti
institut
clinic
brain
research
germani
specif
object
attent
focus
cell
specif
highaffin
mhcbind
myelin
epitop
ms
patient
mbp
clinic
trial
target
cell
show
limit
success
recent
studi
show
myelinreact
cell
ms
patient
primarili
highavid
cell
specif
lowaffin
mhcbind
epitop
found
lowaffin
bind
mbp
peptid
domin
epitop
transgen
mice
studi
mice
suggest
cell
specif
lowaffin
mbp
delet
analogu
peptid
enhanc
bindingaffin
mhc
superagonist
therefor
investig
whether
superagonist
peptid
design
mbp
treatment
ms
method
superagonist
peptid
analogu
mbp
gener
bound
sever
logfold
better
mhc
nativ
peptid
potenti
delet
mbp
cell
examin
vitro
result
design
superagonist
peptid
much
stimulatori
nativ
mbp
mbp
cell
cell
stimul
superagonist
peptid
posit
stain
annexinv
h
activ
indic
induct
apoptosi
conclus
superagonist
peptid
analogu
may
feasibl
therapeut
approach
delet
encephalitogen
cell
specif
lowaffin
hladrbind
peptid
epicutan
induc
toler
inhibit
experiment
autoimmun
encephalomyleti
depart
human
development
biolog
jagiellonian
univers
colleg
medicin
ul
kopernika
poland
multipl
sclerosi
ms
autoimmun
disord
central
nervou
system
cn
limit
treatment
modal
evalu
efficaci
epicutan
ec
toler
induct
prevent
cn
autoimmun
util
anim
model
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
induc
immun
myelin
basic
protein
mbp
show
applic
mbp
skin
prior
induct
eae
protect
mice
develop
diseas
addit
ec
applic
mbp
first
sign
eae
also
result
suppress
diseas
therapeut
effect
transfer
recipi
lymph
node
cell
mice
treat
epicutan
tolerogen
regulatori
cell
found
antigen
nonspecif
suppress
eae
also
occur
antigen
ova
tnp
appli
ec
skininduc
regulatori
cell
belong
popul
lymphocyt
mechanist
basi
toler
found
product
cell
popul
data
demonstr
ecinduc
regulatori
cell
potent
inhibitor
antigenspecif
cell
respons
suggest
ec
toler
may
potenti
effect
treatment
autoimmun
disord
recombin
two
domain
major
histocompat
complex
mhc
molecul
consist
peptid
bind
domain
mhc
class
ii
potent
therapeut
activ
mice
experiment
autoimmun
encephalomyel
eae
follow
iv
inject
mhc
detect
serum
plasma
mice
min
short
halflif
suggest
cellular
adher
respons
remov
mhc
peripher
blood
inde
found
adher
preferenti
cell
surfac
b
cell
among
murin
peripher
blood
pb
spleen
sp
cell
neither
full
length
four
domain
recombin
mhc
class
ii
molecul
mhc
class
ii
tetram
detect
affin
pb
sp
cell
fac
detect
level
mhc
surfac
b
cell
decreas
h
incub
howev
label
mhc
continu
fluoresc
b
cell
overnight
incub
indic
mhc
endocytos
bind
cellular
intern
mhc
molecul
suggest
releas
acquisit
mhc
natur
chronic
process
possibl
support
identifi
transfer
mhc
surfac
b
cell
ex
vivo
cell
cultur
hypothes
bind
intern
mhc
cell
may
trigger
immunomodulatori
respons
peptid
bound
mhc
enhanc
regulatori
cell
function
via
epitop
specif
immunotherapi
lead
diseas
control
eae
r
billetta
omori
kaspar
n
ghahramani
brigham
c
meschter
p
lanza
albani
present
therapeut
approach
autoimmun
diseas
larg
reli
direct
translat
human
therapi
model
trigger
antigen
use
induct
anim
model
identifi
mechan
modul
inflamm
independ
diseasetrigg
antigen
autoimmun
base
recognit
cell
epitop
deriv
heat
shock
protein
hsp
therapeut
approach
aim
restor
cell
mediat
regulatori
mechan
impair
autoimmun
toler
proinflammatori
hsp
epitop
via
mucos
treatment
studi
aim
modul
adapt
treg
use
hspderiv
peptid
via
mucos
treatment
monotherapi
combin
therapi
eae
induct
lewi
rat
eae
induc
immun
myelin
basic
protein
mbp
data
show
mbpimmun
rat
eae
develop
suppress
clinic
mucos
administr
particular
hspderiv
peptid
find
regulatori
mechan
activ
involv
chang
cytokin
express
inflammatori
ifngamma
tnfalpha
regulatori
profil
addit
observ
upregul
express
cell
indic
restor
regulatori
pathway
histolog
data
consist
clinic
effect
immunolog
find
use
monoand
combin
therapi
data
suggest
exist
immun
regulatori
circuit
activ
antigen
unrel
induct
autoimmun
diseas
exist
regulatori
pathway
suggest
hsp
peptidesmedi
restor
treg
function
could
signific
therapeut
valu
treatment
multipl
sclerosi
nk
celldepend
toler
experiment
autoimmun
encephalomyel
induc
heat
shock
protein
complex
complex
isol
brain
health
mice
mice
eae
purifi
use
affin
chromatographi
atpor
adpagaros
column
respect
show
complex
isol
brain
mice
eae
prevent
develop
eae
clinic
patholog
administ
proteolipid
protein
plp
immun
anim
eae
suppress
lymphocyt
show
increas
cell
death
respons
plp
correl
elev
product
cocultur
spleen
cell
immun
mice
spleen
cell
untreat
eae
mice
addit
deplet
experi
show
nk
cell
reduc
reactiv
plp
transfer
nk
cell
immun
mice
recipi
sensit
eae
abolish
diseas
develop
conclus
demonstr
peptid
deriv
inflam
cn
bound
abl
induc
novel
regulatori
circuit
involv
nk
cell
inhibit
autoreact
cell
find
might
contribut
understand
hsp
immunoregulatori
function
autoimmun
diseas
neonat
neuroantigenspecif
immun
protect
eae
harald
h
hofstett
andra
kovalovski
carey
l
shive
paul
v
lehmann
thoma
g
forsthub
case
western
reserv
univers
depart
patholog
usa
univers
texa
san
antonio
depart
biolog
san
antonio
tx
usa
rational
neonat
immun
system
believ
bias
toward
immun
respons
consist
view
inject
neonat
mice
neuroantigen
induc
immun
protect
induct
experiment
autoimmun
encephalomyel
eae
studi
ask
whether
neuroantigenspecif
immun
could
induc
neonat
mice
outcom
would
autoimmun
diseas
method
neonat
sjl
mice
inject
myelin
antigen
cfa
cytokin
profil
induc
cell
respons
measur
elispot
assay
neonat
inject
anim
observ
eae
mice
reinject
myelin
antigen
adult
determin
protect
eae
result
result
show
inject
neonat
sjl
mice
cfa
result
vigor
antigenspecif
product
proinflammatori
cytokin
includ
ifng
cytokin
importantli
neonat
inject
mice
develop
eae
despit
abund
neuroantigeninduc
product
proinflammatori
cytokin
protect
induct
diseas
upon
reinject
neuroantigen
adult
conclus
data
show
development
window
exist
neonat
period
proinflammatori
autoreact
cell
pathogen
induc
data
suggest
could
due
tissuespecif
decreas
propens
differenti
toward
encephalitogen
h
cell
result
may
provid
rational
persist
autoreact
cell
healthi
individu
absenc
autoimmun
patholog
target
fcgammareceptor
treatment
eae
pellkof
hl
schaefer
b
breithaupt
c
huber
r
jacob
u
multipl
sclerosi
ms
chronic
inflammatori
presum
autoimmun
demyelin
diseas
central
nervou
system
particular
increas
evid
autoantibodi
product
blymphocyt
result
target
myelin
sheath
complement
system
well
fcreceptor
carri
cell
may
play
import
role
immunopathogenesi
demyelin
research
focus
immunemodulatori
potenti
antagonist
agonist
fcreceptor
influenc
onset
diseas
cours
wide
accept
anim
model
ms
experiment
autoimmun
encephalomyel
eae
anim
model
diseas
induc
immun
heterolog
myelin
oligodendrocyt
glycoprotein
mog
therefor
administ
solubl
fcreceptor
fcr
diminish
interact
low
affin
fcr
immun
complex
addit
antibodi
given
target
inhibitori
lead
crosslink
oppos
activatori
result
inhibit
immun
respons
fcr
carri
cell
studi
investig
potenti
effect
solubl
fcr
antibodi
diseas
cours
eae
treatment
fcr
onset
clinic
symptom
result
faster
recoveri
signific
reduct
sever
eae
symptom
histopatholog
examin
reveal
treatment
solubl
fcr
well
antibodi
strongli
reduc
amount
infiltr
cell
especi
number
activ
macrophag
spinal
cord
associ
reduct
demyelin
patch
axon
damag
mice
receiv
solubl
fcr
also
show
decreas
level
pathogen
antibodi
activ
bcell
result
support
hypothesi
solubl
fcr
well
effect
therapeut
approach
bcell
mediat
autoimmun
diseas
bcell
deplet
revers
eae
induc
mog
protein
exacerb
diseas
induc
encephalitogen
peptid
object
investig
mediat
bcell
deplet
experiment
autoimmun
encephalomyel
eae
background
bcell
myelinspecif
antibodi
ab
play
pathogen
role
cn
autoimmun
diseas
recent
studi
indic
b
cell
may
also
regulatori
function
evalu
mediat
bcell
deplet
eae
induc
either
mog
recombin
mous
mog
rmog
method
eae
induc
human
mice
deplet
bcell
eaeprevent
mice
receiv
weekli
ip
inject
start
day
prior
immun
reversalexperi
mice
random
treatment
onset
paralysi
cell
prolifer
cytokin
ab
product
mog
rmog
well
histopatholog
examin
perform
mice
result
mediat
bcell
deplet
benefici
effect
eae
prevent
revers
paralysi
rmoginduc
eae
bcell
deplet
mice
reveal
decreas
titer
antirmog
ab
contrast
bcell
deplet
prior
immun
exacerb
mog
eae
enhanc
cnsinfiltr
demyelin
decreas
number
infiltr
bcell
splenic
mog
specif
respons
shift
toward
proinflammatori
pronounc
decreas
product
conclus
bcell
deplet
differenti
effect
mogprotein
mogpeptid
induc
autoimmun
encephalomyel
benefici
effect
bcell
deplet
rmoginduc
eae
may
reflect
decreas
antigen
present
andor
reduc
titer
myelinspecif
ab
wherea
exacerb
mog
peptideinduc
eae
may
relat
reduct
bcell
regul
neuroprotect
neurogenesi
induc
peripher
imunomodulatori
treatment
experiment
autoimmun
encephalomyel
glatiram
acet
r
aharoni
r
eilam
r
arnon
immunolog
depart
weizmann
institut
scienc
rehovot
israel
autoimmun
inflammatori
process
involv
multipl
sclerosi
ms
experiment
autoimmun
encephalomyel
eae
therapeut
consequ
self
neurogenesi
neuroprotect
limit
fail
regener
function
neuron
compens
damag
demonstr
peripher
immunomodulatori
treatment
ms
eaeglatiram
acet
ga
enhanc
neurogenesi
gener
neuroprotect
cn
eae
inflict
mice
eae
induc
mog
peptid
transgen
mice
select
express
yfp
neuron
popul
mice
ga
inject
either
concurr
diseas
induct
clinic
sign
appear
neurotroph
factor
express
situ
manifest
eae
well
ga
treatment
analyz
immunohistochem
neuroprogenitor
prolifer
quantifi
express
immatur
neuron
marker
dcx
incorpor
vivo
prolifer
marker
brdu
eae
inflict
mice
neurotrophin
express
neuroprolifer
elev
follow
diseas
appear
subsequ
declin
naiv
mice
contrast
ga
treatment
variou
diseas
stage
led
elev
bdnf
reduct
neuronalaxon
damag
typic
neurodegen
diseas
cours
moreov
ga
augment
three
process
characterist
neurogenesi
name
neuroprogenitor
prolifer
migrat
differenti
neuroprogenitor
manifest
massiv
migrat
excit
dormant
migrat
pathway
injuri
site
brain
region
normal
undergo
neurogenesi
differenti
matur
neuron
phenotyp
endors
direct
linkag
immunomodul
neuroprotect
neurogenesi
situ
therapeut
consequ
cn
transcript
modul
immun
respons
agonist
amelior
eae
ar
gock
rz
hussain
l
ben
ae
lovettrack
mk
rack
depart
neurolog
center
immunolog
univers
texa
southwestern
medic
center
dalla
tx
usa
peroxisom
prolifer
activ
receptor
ppar
ligandactiv
transcript
factor
belong
nuclear
hormon
receptor
superfamili
rencent
ppar
shown
express
macrophag
dendrit
cell
cell
b
cell
play
role
inflammatori
respons
group
previous
shown
agonist
gemfibrozil
fenofibr
amelior
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
inhibit
promot
product
current
studi
character
abil
agonist
induc
immun
deviat
regul
inflamm
eae
found
splenocyt
treat
gemfibrozil
alter
tbet
express
use
sirna
specif
level
reduc
vivo
administr
inhibit
abil
gemfibrozil
amelior
eae
prevent
secret
suggest
agonist
mediat
effect
receptordepend
manner
found
directli
bind
regulatori
region
gene
chromatin
immunoprecipit
mice
suspect
eae
even
follow
gemfibrozil
treatment
mice
express
lower
level
control
tbet
express
also
found
alter
gemfibroziltr
mice
final
treatment
eae
mice
gemfibrozil
fenofibr
amelior
diseas
cours
significantli
data
suggest
agonist
mediat
antiinflammatori
effect
receptordepend
manner
could
potenti
use
treatment
immunemedi
diseas
ms
regul
product
prostaglandin
acut
chronicrelaps
rodent
model
multipl
sclerosi
ss
ayoub
r
ashrafi
eg
wood
c
bolton
queen
mari
univers
london
london
uk
prostaglandin
pg
import
pathophysiolog
mediat
involv
wide
varieti
process
particular
acut
chronic
inflammatori
reaction
pg
synthesi
involv
metabol
arachidon
acid
shortliv
molecul
action
cyclooxygenas
cox
enzym
recent
discov
isoform
releas
pge
contribut
initi
acut
inflamm
contrast
pgd
shown
aid
resolut
inflammatori
state
ayoub
et
al
current
studi
utilis
rodent
model
experiment
autoimmun
encephalomyel
eae
model
human
demyelin
diseas
multipl
sclerosi
investig
relationship
pge
pgd
initi
resolut
neuroinflamm
level
pge
central
nervou
tissu
rodent
eae
similar
normal
valu
howev
pge
concentr
increas
significantli
recoveri
phase
pgd
content
decreas
control
valu
develop
eae
return
normal
level
resolut
diseas
studi
describ
effect
specif
receptor
antagonist
express
cox
enzym
pg
product
particular
investig
provid
inform
ident
novel
pathway
involv
control
product
pg
model
eae
refer
ayoub
ss
bot
rm
goorha
colvillenash
pr
willoughbi
ballou
lr
acetominopheninduc
hypothermia
mice
mediat
prostaglandin
endoperoxid
synthas
genederiv
protein
proc
nat
acad
sci
recent
show
bifunct
compound
compris
nonsteroid
antiinflammatori
ibuprofen
cholinerg
upregul
ach
inhibitor
achei
pyridostigmin
moieti
amelior
experiment
autoimmun
encephalomyel
eae
presenc
cholinerg
upregul
moieti
increas
antiinflammatori
effect
consequ
studi
antiinflammatori
effect
acetylcholinesteras
inhibitor
achei
cn
inflamm
vivo
vitro
achei
suppress
lymphocyt
prolifer
proinflammatori
cytokin
product
extracellular
esteras
activ
antiinflammatori
activ
mediat
nicotin
acetylcholin
receptor
neuron
type
muscarin
receptor
opposit
effect
treatment
eae
antisens
oligodeoxynucleotid
target
ach
mrna
convent
achei
reduc
diseas
sever
cn
inflamm
experiment
result
suggest
achei
increas
concentr
extracellular
acetylcholin
ach
render
avail
interact
nicotin
receptor
express
lymphocyt
observ
point
novel
role
achei
may
relev
cn
inflammatori
diseas
eae
multipl
sclerosi
also
emphas
import
cholinerg
balanc
neurolog
disord
alzheim
diseas
myasthenia
gravi
drug
use
keyword
acetylcholinesteras
acetylcholinesteras
inhibitor
nicotin
receptor
cn
inflamm
experiment
autoimmun
encephalomyel
alzheim
diseas
multipl
sclerosi
ms
cellmedi
autoimmun
diseas
cn
lead
demyelin
axon
damag
neuron
loss
pathophysiolog
mechan
respons
develop
ms
anim
model
eae
well
defin
howev
increas
express
activ
calciumactiv
neural
proteas
calpain
may
play
role
thu
hypothes
treatment
calpain
inhibitor
attenu
immun
cell
infiltr
neurodegener
eae
spinal
cord
test
hypothesi
eae
induc
male
lewi
day
postea
induct
control
eae
rat
treat
calpain
inhibitor
sja
mgkg
vehicl
dmso
day
postea
induct
anim
sacrif
lumbar
spinal
cord
segment
collect
immunohistolabel
cellspecif
calpain
express
antimcalapin
antibodi
calpain
markedli
increas
macrophagemicroglia
cell
cell
eae
anim
compar
control
sinc
cell
test
posit
control
tissu
suspect
cell
mainli
infiltr
macrophag
resid
microglia
treatment
sja
block
calpain
express
migrat
cell
cn
neuron
neun
specif
calpain
express
neuron
death
tunel
axon
damag
denfp
also
upregul
acut
eae
spinal
cord
treatment
sja
block
neuron
calpain
express
neuron
death
axon
damag
compar
vehicletr
eae
rat
data
suggest
calpain
inhibit
attenu
immun
cell
infiltr
neurodegener
eae
may
offer
potenti
therapeut
benefit
ms
patient
constitut
express
form
complex
transcript
factor
client
protein
inhibitor
promot
dissoci
induc
heat
shock
respons
hsr
wherea
upon
dissoci
client
protein
degrad
cpd
includ
kinas
aktpkb
involv
tcell
activ
show
clinic
symptom
experiment
autoimmun
encephalomyel
eae
reduc
geldanamycin
natur
occur
inhibitor
howev
whether
involv
hsr
cpd
address
character
effect
novel
inhibitor
glial
tcell
activ
clinic
histolog
sign
eae
akt
activ
screen
synthet
inhibitor
identifi
sever
high
low
nm
efficaci
inhibit
astrocyt
express
tcell
ifng
product
geldanamycin
deriv
reduc
clinic
sign
mogea
given
earli
diseas
induc
recoveri
administ
ill
mice
late
administr
also
reduc
subsequ
axon
damag
vivo
treatment
reduc
tcell
activ
inhibit
reactiv
prime
tcell
vitro
howev
inhibitor
reduc
depend
activ
tcell
also
reduc
akt
inhibitor
inhibitor
induc
akt
degrad
effect
lessen
cell
express
constitut
activ
myrakt
inhibitor
could
block
induct
null
cell
result
demonstr
efficaci
novel
inhibitor
eae
suggest
induct
hsr
critic
effect
support
part
grant
conforma
therapeut
inflammationinduc
oxid
stress
lead
axon
degener
felt
major
determin
progress
neurolog
disabl
multipl
sclerosi
ms
watersolubl
deriv
fulleren
uniqu
class
allotrop
form
carbon
compound
potent
antioxid
properti
week
old
mice
immun
mog
peptid
cfa
follow
pertussi
toxin
diseas
character
attack
follow
progress
phase
chronic
clinic
impair
follow
first
attack
anim
distribut
differ
group
similar
diseas
cours
treat
intraperiton
either
fulleren
solut
vehicl
dmso
pb
everi
day
termin
experi
day
test
three
differ
fulleren
deriv
fulleren
core
found
treatment
initi
diseas
onset
reduc
clinic
progress
chronic
eae
nod
mice
treat
vs
control
p
fulleren
consist
carbon
fulleren
core
known
nmda
receptor
ligand
attach
treatment
also
reduc
axon
loss
demyelin
evalu
silver
luxol
fast
blue
stain
respect
white
matter
mice
treat
anim
also
show
reduct
infiltr
astrogliosi
compar
vehicletr
group
data
demonstr
neuroprotect
effect
treatment
fulleren
compound
combin
nmda
receptor
ligand
may
applic
treatment
progress
ms
neurodegen
diseas
chronic
therapeut
administr
natalizumab
reduc
clinic
sever
guinea
pig
experiment
autoimmun
encephalomyel
model
natalizumab
human
monoclon
antibodi
integrin
use
multipl
sclerosi
mechan
action
involv
block
bind
lymphocyteexpress
endotheli
therebi
inhibit
extravas
leukocyt
central
nervou
system
natalizumab
crossreact
guinea
pig
dose
longterm
day
guinea
pig
without
appar
illeffect
loss
potenc
group
earli
chronic
stage
eaeafflict
guinea
pig
day
postinduct
chronic
progress
begin
treat
subcutan
everi
day
mgkg
natalizumab
vehicl
natalizumab
induc
peripher
blood
lymphocytosi
eae
anim
mean
elev
rel
vehicl
eae
anim
natalizumab
induc
immedi
revers
clinic
score
enhanc
bodi
weight
gain
reduc
mortal
rel
vehicl
maintain
signific
clinic
protect
throughout
complet
studi
mean
paralyt
clinic
score
natalizumabtr
anim
respect
compar
vehicl
eae
clinic
score
clinic
improv
natalizumabtr
guinea
pig
parallel
histolog
spinal
cord
section
percentag
lesion
area
white
matter
lower
natalizumabtr
anim
vehicl
eae
anim
result
consist
human
clinic
data
demonstr
reduc
clinic
sever
relaps
rate
disabl
score
reduct
gadoliniumenhanc
lesion
mri
character
lesion
guinea
pig
model
investig
use
celltypespecif
antibodi
identifi
infiltr
cell
type
via
immunohistochemistri
fcreceptor
antagonist
effect
therapi
autoimmun
diseas
anim
model
fcreceptor
igg
play
crucial
role
antibodymedi
autoimmun
diseas
link
humor
cellular
immun
respons
therefor
investig
anim
model
whether
administr
solubl
fcreceptor
sfcr
antagonist
immun
complex
recognit
could
influenc
cours
autoantibodi
mediat
autoimmun
disord
vitro
investig
show
sfcr
bind
human
mice
pool
igg
inhibit
antibodi
mediat
phagocytosi
red
blood
cell
strong
antagonist
immun
complex
bind
bcell
final
murin
model
multipl
sclerosi
ms
idiopath
thrombocytopen
purpura
rheumatoid
arthriti
system
lupu
erythematod
treatment
sfcr
significantli
reduc
sever
symptom
therebi
demonstr
model
independ
approach
histopatholog
examin
spinal
cord
sfcr
treat
mice
experiment
autoimmun
encephalomyel
reveal
decreas
amount
infiltr
cell
especi
reduc
number
activ
macrophag
furthermor
treatment
result
decreas
demyelin
plaqu
axon
damag
mice
receiv
solubl
receptor
also
show
lower
level
pathogen
antibodi
less
activ
bcell
multipl
sclerosi
ms
major
chronic
autoimmun
patholog
central
nervou
system
member
matrix
metalloproteinas
mmp
famili
known
import
factor
involv
key
step
ms
howev
littl
known
role
ms
determin
extent
might
involv
patholog
administ
oral
inhibitor
prevent
regimen
mgkg
moginduc
chronic
mice
well
cur
regimen
mgkg
whole
spinal
cord
protractedremit
rat
experiment
autoimmun
encephalomyel
eae
model
anim
model
mimick
variou
aspect
ms
prevent
treatment
inhibitor
significantli
delay
diseas
onset
decreas
sever
clinic
sign
cours
patholog
suggest
involv
induct
well
follow
effector
phase
patholog
protractedremit
eae
model
mix
model
inflamm
earli
demyelin
oral
administr
start
clinic
score
decreas
sever
first
attack
follow
remit
phase
minim
dose
mgkg
effect
parallel
elimin
inflammatori
infiltr
demyelin
axon
damag
spinal
cord
treat
anim
result
support
potenti
role
develop
mslike
condit
strengthen
previou
find
ms
patient
vo
et
al
aim
studi
examin
effect
stimul
eae
anim
model
multipl
sclerosi
ms
upon
recognit
bacteri
lp
signal
induc
express
rang
proand
antiinflammatori
mediat
role
autoimmun
well
character
induc
chronic
eae
femal
mice
subcutan
immun
myelin
oligodendrocyt
glycoprotein
cfa
intraperiton
ip
administr
pertussi
toxin
day
mice
receiv
lp
pb
ip
day
sacrif
variou
timepoint
spleen
cell
cultur
without
antigen
assess
prolifer
cultur
supernat
assay
cytokin
level
cytometr
bead
array
elisa
spinal
cord
cellular
infiltr
character
flow
cytometri
eae
onset
significantli
delay
lp
treat
mice
compar
pb
treat
group
regardless
antigen
stimulu
vitro
monocytemacrophag
chemoattract
elev
splenocyt
cultur
supernat
lp
treat
mice
compar
pb
control
day
post
immun
pi
despit
significantli
greater
cell
prolifer
lp
treat
mice
day
pi
lower
inflammatori
infiltr
spinal
cord
mice
day
pi
compar
pb
treat
mice
conclud
stimul
delay
onset
chronic
eae
mechan
includ
inhibit
lymphomononuclear
cell
infiltr
cn
may
due
enhanc
chemotact
activ
peripher
immun
system
argatroban
direct
thrombin
inhibitor
suppress
sever
experiment
autoimmun
encephalomyel
experiment
autoimmun
encephalomyel
eae
inflammatori
demyelin
autoimmun
diseas
central
nervou
system
cn
provid
model
human
multipl
sclerosi
ms
numer
studi
prove
correl
coagulationfibrinolysi
system
pathogenesi
eae
examin
role
coagul
system
eae
use
argatroban
direct
inhibitor
thrombin
argatroban
treatment
significantli
suppress
clinic
manifest
eae
lewi
rat
mean
cumul
clinic
score
argatroban
treat
rat
salin
treat
control
score
p
plasma
thrombinantithrombin
complex
tat
valu
significantli
lower
argatroban
treat
rat
compar
salinetr
control
p
immunohistolog
perivascular
fibrin
deposit
reduc
lumbosacrococcyg
spinal
cord
guineapig
myelin
basic
protein
gpmbp
sensit
rat
treat
argatroban
rtpcr
reveal
cytokin
level
reduc
within
spinal
cord
argatroban
treat
rat
compar
control
rat
show
cell
migrat
suppress
inhibit
fibrin
deposit
result
suggest
activ
coagul
cascad
import
role
develop
eae
furthermor
data
suggest
fibrin
could
potenti
therapeut
target
ms
anticoagul
therapi
aim
select
inhibit
fibrin
deposit
might
safer
approach
exogen
administr
deriv
organ
vitamin
amelior
experiment
autoimmun
encephalomyel
lewi
rat
moriya
nakatsuji
okuno
sakoda
depart
neurolog
osaka
univers
graduat
school
medicin
suita
japan
vitamin
k
wide
use
manag
osteoporosi
japan
demonstr
hmgcoa
reductas
inhibitor
statin
benefici
effect
experiment
autoimmun
encephalomyel
eae
inhibit
geranylgeranylpyrophosph
ggpp
synthesi
play
key
role
effect
sinc
side
chain
common
structur
geranylgeranylpyrophosph
ggpp
could
expect
similar
effect
seen
statin
lewi
rat
activ
immun
myelin
basic
protein
mbp
rat
receiv
intraperiton
administr
clinic
score
evalu
daili
histolog
immunohistochem
western
blot
analys
spinal
cord
cultur
glial
cell
also
perform
clinic
sever
eae
significantli
amelior
prophylact
administr
histolog
analysi
reveal
inflammatori
cellular
infiltr
significantli
reduc
spinal
cord
rat
immunohistochem
western
blot
analys
reveal
express
mhc
class
ii
induc
nitric
oxid
synthas
ino
significantli
reduc
spinal
cord
rat
eae
inhibitori
effect
ino
express
glial
cell
also
observ
vitro
consid
wide
use
without
notic
untoward
effect
may
applic
patient
ms
background
tnfrelat
weak
induc
apoptosi
tweak
mediat
proinflammatori
effect
receptor
previous
show
contribut
lesion
develop
experiment
autoimmun
encephalomyel
eae
neutralis
tweak
amelior
cn
inflamm
eae
tweak
also
increas
releas
cn
resid
cell
object
reveal
mechan
promot
autoimmun
inflamm
method
neutralis
induc
vaccin
extracellular
domain
tweak
full
length
adopt
transfer
eae
atea
induc
sjl
mice
transfer
plpspecif
lymph
node
cell
lnc
mice
immunis
mogpeptid
induc
activ
eae
chemokin
releas
cultur
supernat
measur
elisa
result
atea
use
vaccin
either
donor
recipi
mice
show
primari
immun
respons
cell
encephalitogen
modul
howev
tcellrecipi
mice
result
signific
amelior
eaesign
suggest
bloodbrainbarri
potenti
site
action
vaccin
tweak
protect
andto
lesser
extent
mice
develop
eae
indic
effect
lesion
develop
partial
depend
final
data
present
show
influenc
migrat
mononuclear
cell
vitro
transwel
system
conclus
might
promot
lesion
develop
via
sever
mechan
tweakinduc
modul
proinflammatori
molecul
tweak
may
involv
tweak
alter
encephalitogen
cell
respons
nucleosid
analogu
effect
glial
respons
experiment
autoimmun
encephalomyel
previous
shown
combin
treatment
nucleosid
analogu
ribavirin
r
tiazofurin
inosin
monophosph
dehydrogenas
inhibitor
amelior
clinic
sign
histolog
lesion
eae
suscept
rat
given
prevent
aim
studi
investig
effect
combin
treatment
r
given
appear
first
eae
clinic
sign
microglia
astrocyt
respons
cell
target
tissu
also
particip
autoimmun
process
diseas
induc
dark
agouti
rat
rat
spinal
cord
homogen
acut
monophas
cours
ribavirin
tiazofurin
given
dosag
mgkgday
mgkg
everi
day
day
respect
control
group
immun
treat
salin
amelior
clinic
sign
faster
recoveri
shown
group
treat
combin
r
comparison
control
group
immunohistochem
analysi
spinal
cord
tissu
isol
day
combin
therapi
reveal
decreas
vimentin
posit
cell
microglia
compar
control
group
addit
morpholog
gfap
posit
glial
fibrillari
acid
protein
cell
microglia
indic
reactiv
type
cell
control
group
result
studi
reveal
r
modul
glial
respons
eae
protect
effect
given
onset
diseas
work
support
ministri
scienc
environment
protect
republ
serbia
serbia
montenegro
grant
multipl
neuroprotect
mechan
minocyclin
autoimmun
cn
inflamm
katharina
maier
doron
merkler
b
joachim
gerber
naimeh
taheri
antj
v
kuhnert
sarah
k
william
clemen
neusch
mathia
ricarda
diem
neurologisch
b
institut
neuropathologi
germani
axon
destruct
neuron
loss
occur
earli
multipl
sclerosi
autoimmun
inflammatori
cn
diseas
frequent
manifest
acut
optic
neuriti
avail
therapi
mainli
target
inflammatori
compon
diseas
fail
prevent
neurodegener
investig
effect
minocyclin
surviv
retin
ganglion
cell
rgc
neuron
form
axon
optic
nerv
use
rat
model
myelin
oligodendrocyt
glycoprotein
mog
induc
experiment
autoimmun
encephalomyel
optic
neuriti
model
diagnos
record
visual
evok
potenti
rgc
function
monitor
measur
electroretinogram
function
histopatholog
data
rgc
optic
nerv
reveal
neuron
axon
protect
minocyclin
treatment
start
day
immun
furthermor
demonstr
minocyclineinduc
neuroprotect
relat
direct
antagon
multipl
mechan
lead
neuron
cell
death
induct
antiapoptot
intracellular
signal
pathway
decreas
glutam
excitotox
observ
conclud
minocyclin
exert
neuroprotect
effect
independ
antiinflammatori
properti
hypothesi
confirm
noninflammatori
diseas
model
lead
degener
rgc
surgic
transect
optic
nerv
combin
immunotherapi
strategi
promot
myelin
repair
treatment
establish
eae
goal
current
project
investig
cellular
molecular
mechan
regul
process
demyelin
remyelin
cn
autoimmun
diseas
design
immunoregulatori
glial
regen
combinatori
therapi
treatment
establish
diseas
anim
model
ms
realtim
pcr
data
suggest
correl
myelin
gene
express
cn
distinct
phase
relapsingremit
experiment
autoimmun
encephalomyel
reae
compar
preclin
stage
observ
decreas
myelin
gene
express
acut
diseas
first
relaps
increas
notch
signal
molecul
express
reae
notch
inhibit
oligodendrocyt
differenti
myelin
develop
hypothes
limit
factor
remyelin
design
treatment
strategi
ongo
eae
combin
inhibit
block
notch
signal
addit
host
factor
fab
wellestablish
immunoregulatori
strategi
addit
design
test
myelin
repair
strategi
combin
immunoregulatori
techniqu
preliminari
analys
cell
respons
extent
lesion
repair
follow
combinatori
treatment
yield
promis
result
futur
ms
therapi
effect
antibodi
experiment
autoimmun
enceph
infiltr
leukocyt
cn
key
event
format
new
lesion
multipl
sclerosi
ms
molecul
involv
interact
leukocyt
endotheli
cell
repres
prime
candid
target
novel
therapeut
approach
previous
shown
tetraspanin
regul
integrin
involv
migrat
monocyt
across
blood
brain
barrier
vitro
ask
whether
inhibit
monocyt
migrat
vivo
use
antibodi
would
benefici
effect
neurolog
symptom
experiment
autoimmun
enceph
mice
immun
treat
two
differ
hamster
antimous
antibodi
isotyp
control
mab
vehicl
n
per
group
antibodi
inject
ip
per
inject
everi
day
week
start
day
post
immunis
result
show
clinic
symptom
reduc
mice
treat
mab
compar
vehicl
cumul
clinic
score
vs
p
interestingli
treatment
mab
effect
clinic
score
wherea
irrelev
mab
result
intermedi
score
result
provid
first
indic
target
vivo
benefici
effect
neurolog
outcom
eae
valid
result
addit
eae
model
studi
pathogenet
mechan
underli
treatment
effect
allogen
versu
syngen
bmt
prevent
eae
role
donor
chimer
donor
suscept
eae
alloreact
background
autolog
bone
marrow
transplant
autobmt
explor
novel
treatment
ms
case
report
exist
benefici
effect
allogen
bmt
allobmt
howev
unresolv
question
action
mechan
warrant
investig
anim
model
aim
studi
eae
incid
diseas
cours
murin
bmt
explor
role
donoreaesuscept
degre
donorchimer
posttranspl
alloreact
method
allogen
syngen
radiat
bm
chimera
prepar
use
balbc
eaeresist
eaesuscept
mice
allobmt
group
given
donortyp
leukocyt
infus
dli
increas
donorchimer
mog
eae
induc
day
follow
day
later
ex
vivo
mog
splenocyt
prolifer
assay
result
syngen
chimera
balbc
lowgrad
allogen
chimera
eae
prevent
resp
eae
prevent
resp
full
donor
chimer
dli
balbc
allogen
chimera
result
complet
prevent
eae
loss
mog
respons
highgrad
allogen
chimera
induc
irradi
neither
prevent
eae
loss
mog
specif
prolifer
seen
contrast
nonradi
highgrad
chimera
obtain
repetit
dli
strong
vivo
alloreact
result
complet
prevent
eae
loss
mog
specif
prolifer
conclus
transient
eaeprotect
effect
synbmt
probabl
relat
posttranspl
aspecif
immunosuppress
highgrad
donorchimer
eaenonsuscept
donor
confer
robust
eaeresist
indic
role
genet
suscept
howev
equal
strong
protect
obtain
use
eaesuscept
donor
nonirradi
model
dliinduc
chimer
use
suggest
role
alloreact
suppress
experiment
autoimmun
encephalomyel
transfer
lymphokineactiv
natur
killer
nk
cell
shigemi
nagayama
sachiko
miyak
takashi
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
japan
object
purpos
experi
explor
passiv
transfer
natur
killer
nk
cell
may
suppress
develop
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
method
eae
induc
mice
sensit
myelin
oligodendrocyt
glycoprotein
mog
nk
cell
isol
spleen
nonimmun
mice
activ
vitro
inocul
intraven
mogsensit
mice
indic
day
result
first
studi
whether
nk
cell
infiltr
within
lesion
central
nervou
system
cn
eae
mice
immunofluoresc
analysi
mononuclear
cell
isol
cn
mogsensit
mice
day
sensit
demonstr
presenc
nk
cell
cell
posit
correl
number
migrat
nk
cell
clinic
sever
eae
intraven
inject
vitro
nk
cell
nklak
cell
mogsensit
mice
day
sensit
clearli
suppress
clinic
sever
eae
order
clarifi
whether
passiv
transfer
nklak
cell
could
infiltr
cn
lesion
transfer
nklak
cell
green
mice
eaeposit
mice
found
nklak
cell
green
mice
could
migrat
cn
mice
develop
eae
conclus
find
show
transfer
nklak
cell
could
downregul
ongo
inflamm
cn
lesion
eae
expans
regulatori
cell
midkinedefici
mice
result
partial
resist
experiment
autoimmun
encephalomyel
novel
immunomodul
midkin
jinyan
wang
hideyuki
takeuchi
shiji
jin
jun
kawanokuchi
reiko
kuno
yoshifumi
sonob
izumi
yawata
yukiko
doi
jianfeng
liang
guiqin
zhang
tetsuya
mizuno
hisako
muramatsu
b
takashi
muramatsu
b
akio
suzumura
depart
neuroimmunolog
research
institut
environment
medicin
nagoya
univers
nagoya
japan
b
depart
biochemistri
graduat
school
medicin
nagoya
univers
nagoya
japan
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
inflammatori
demyelin
diseas
cn
regulatori
cell
treg
play
crucial
role
induct
peripher
toler
control
autoreact
cell
increas
evid
shown
treg
cell
play
key
role
neg
regul
pathogenesi
ms
howev
endogen
factor
mechan
control
peripher
gener
treg
cell
larg
unknown
midkin
mk
protein
member
heparinbind
growth
factor
reportedli
exert
pleiotrop
activ
cell
prolifer
migrat
angiogenesi
fibrinolysi
varieti
tissu
studi
show
mkdefici
mice
resist
induct
progress
eae
resist
close
associ
substanti
expans
treg
cell
peripher
lymph
node
mog
immun
compar
wild
mice
administr
mk
mk
defici
mice
significantli
abrog
resist
eae
suppress
expans
treg
cell
vivo
vitro
addit
frequenc
autoreact
cell
decreas
without
affect
popul
result
indic
mk
defici
result
expans
treg
cell
peripheri
control
activ
autoreact
first
demonstr
mk
defici
play
critic
immunomodulatori
role
develop
eae
target
mk
defici
may
effect
therapeut
strategi
autoimmun
diseas
includ
ms
previou
studi
shown
rpe
retin
pigment
epithelium
abl
express
mhc
class
ii
expos
inflammatori
cytokin
studi
determin
vitro
activ
irbp
interphotoreceptor
bind
protein
specif
cell
presenc
absenc
rpe
cell
factor
produc
nonactiv
activ
rpe
also
compar
effect
astrocyt
anoth
eye
immunocompet
cell
vitro
activ
uveitogen
cell
result
show
rpe
cell
inhibit
highdegreeactiv
irbpspecif
cell
enhanc
lowdegreeactiv
cell
differenti
astrocyt
inhibit
highand
lowactiv
degre
enhanc
lowdegreeactiv
cell
moreov
factor
produc
activ
rpe
enhanc
inhibit
cell
activ
factor
produc
activ
astrocyt
inhibit
cell
result
suggest
rpe
astrocyt
regulatori
effect
activ
cell
eye
least
part
regulatori
effect
mediat
factor
produc
differ
parenchym
cell
eye
may
distinct
regulatori
effect
autoreact
cell
therefor
studi
mechan
parenchym
cell
eye
regul
invad
autoreact
cell
provid
need
inform
therapeut
intervent
estrogen
induc
immunomodul
involv
dual
effect
antigen
present
cell
apc
regulatori
cell
treg
direct
effect
effector
cell
report
investig
effect
apc
treg
cell
function
found
treatment
vivo
strongli
reduc
recoveri
apc
periton
caviti
inhibit
abil
induc
inflammatori
cytokin
enhanc
secret
moreov
condit
bone
marrowderiv
dendrit
cell
bmdc
could
enhanc
treg
cell
activ
directli
inhibit
respond
cell
absenc
treg
cell
examin
whether
inhibitori
activ
bmdc
might
involv
costimul
recent
describ
pathway
pregnanc
markedli
enhanc
express
sever
type
apc
includ
macrophag
b
cell
especi
dendrit
cell
dc
similar
enhanc
express
eae
protect
enhanc
cell
also
mediat
estrogen
receptor
alpha
dc
macrophag
b
cell
base
antibodi
inhibit
studi
interact
ligand
especi
could
mediat
either
posit
neg
regulatori
signal
matur
immatur
dc
depend
respect
rel
high
low
ratio
cell
bmdc
novel
find
indic
immunomodul
mediat
part
potenti
bmdc
costimulatori
pathway
express
function
activ
muopioid
receptor
mor
myelomonocyt
cell
line
j
gabrilovac
breljak
b
outsid
nervou
system
opioid
receptor
also
found
cell
hematopoiet
origin
particip
modul
growth
differenti
function
activ
base
ligand
select
three
main
class
opioid
receptor
delta
mu
kappa
muopioid
receptor
mor
import
class
involv
analgesia
mediat
alkaloid
opiat
morphin
use
polyclon
antibodi
muopioid
receptor
fac
analysi
recent
report
membran
express
mor
subpopul
cell
extend
studi
examin
transcript
express
mor
use
rtpcr
function
mor
express
cell
examin
measur
ca
mobilis
trigger
select
mor
agonist
morphin
use
repres
agonist
alkaloid
peptid
structur
respect
presenc
mrna
mor
detect
cell
correspond
neuron
cell
line
morphin
trigger
ca
mobilis
cell
concentrationdepend
manner
ca
mobilis
reduc
select
mor
antagonist
betafunaltrexamin
suggest
mormedi
action
short
cell
immatur
myelomonocyt
line
express
mor
level
mrna
level
function
activ
protein
capabl
transmit
intracellular
signal
via
ca
upon
ligat
select
agonist
alkaloid
peptid
structur
gabrilovac
j
et
al
membran
express
delta
mu
kappa
opioid
receptor
cell
line
annual
meet
croatian
immunolog
societi
book
abstract
ed
rijeka
crosstalk
chemokin
opioid
vanilloid
receptor
chemokin
receptor
serv
bridg
immun
neural
system
neuropeptid
opioid
inhibit
chemokin
receptor
function
leukocyt
activ
gi
protein
calciumindepend
protein
kinas
c
convers
inflamm
chemokin
similarli
regul
neuron
sens
two
way
activ
chemokin
receptor
neuron
desensit
analges
receptor
concomitantli
enhanc
sensit
pain
receptor
via
protein
kinas
cdepend
phosphoryl
result
hyperalges
effect
present
cellular
biochem
vivo
evid
show
receptor
crosstalk
provid
import
pathway
neuroimmun
interact
molecular
structur
basi
receptor
mechan
interferonalpha
hypothalamicpituitaryadren
axi
hypothalamicpituitaryadren
hpa
axi
play
pivot
role
respond
immunolog
challeng
cytokin
modul
function
hpa
axi
interferonalpha
also
effect
mechan
thoroughli
character
result
remain
controversi
conflict
studi
explor
molecular
structur
basi
receptor
mechan
upon
hpa
axi
vivo
vitro
two
kind
mutant
obtain
use
analges
activ
antivir
activ
administr
mutant
ventricl
vivo
cultur
hypothalam
slice
cell
adren
cortic
slice
content
crh
acth
corticosteron
sampl
assay
respect
result
show
could
decreas
crh
acth
corticosteron
content
vivo
decreas
crh
content
stimul
corticosteron
secret
vitro
significantli
could
block
opioid
receptor
antagonist
naloxon
pretreat
direct
effect
acth
secret
cell
without
opioid
receptor
express
also
similar
effect
vivo
vitro
less
potenc
insensit
naloxon
first
highli
suggest
mayb
regul
hpa
axi
least
two
differ
receptor
mechan
one
opioid
receptor
molecular
structur
basi
opioid
domain
work
support
nation
natur
scienc
foundat
china
role
brain
transport
immunolog
induc
fatigu
model
chronic
fatigu
syndrom
depart
integr
physiolog
graduat
school
medic
scienc
kyushu
univers
fukuoka
japan
investig
brain
mechan
fatigu
immunolog
induc
fatigu
conduct
rat
intraperiton
ip
inject
synthet
doublestrand
rna
polyriboinosin
polyribocytidyl
acid
poli
c
ip
inject
poli
c
mgkg
decreas
daili
amount
spontan
run
wheel
activ
preinject
level
day
gradual
return
baselin
level
day
amount
mrna
measur
realtim
capillari
pcr
method
increas
hypothalam
nuclei
cortex
day
even
day
express
transport
report
induc
also
enhanc
brain
region
increas
day
vivo
brain
microdialysi
reveal
decreas
extracellular
concentr
prefront
cortex
poli
c
block
select
reuptak
inhibitor
fluoxetin
final
poli
cinduc
suppress
run
wheel
activ
significantli
attenu
receptor
agonist
dopamin
receptor
agonist
find
taken
togeth
suggest
brain
receptor
play
import
role
neuron
mechan
poli
cinduc
fatigu
refer
katafuchi
et
al
neurosci
katafuchi
et
al
eur
j
neurosci
induct
microgli
apoptosi
corticotropinreleas
hormon
potenti
regulatori
mechan
neuroinflamm
k
suk
j
ock
kim
j
lee
depart
pharmacolog
kyungpook
nation
univers
school
medicin
daegu
ksuk
knuackr
neuropeptid
shortchain
peptid
found
brain
tissu
function
neurotransmitt
other
function
hormon
neuropeptid
may
directli
indirectli
modul
glial
function
central
nervou
system
cn
current
studi
effect
variou
neuropeptid
viabil
inflammatori
activ
cultur
microglia
investig
vasoact
intestin
peptid
substanc
p
cholecystokinin
neuropeptid
affect
microgli
cell
viabil
corticotropinreleas
hormon
crh
induc
classic
apoptosi
mous
microglia
cultur
evidenc
nuclear
condens
fragment
tunel
stain
cleavag
poli
adpribos
polymeras
parp
protein
crh
howev
influenc
nitric
oxid
product
assess
griess
reaction
inflammatori
gene
express
assess
rtpcr
western
blot
analysi
includ
cytokin
chemokin
indic
crh
affect
inflammatori
activ
microglia
crhinduc
microgli
apoptosi
appear
involv
mitochondri
pathway
reactiv
oxygen
speci
base
mitochondri
membran
potenti
chang
activ
sensit
antioxid
taken
togeth
result
indic
stress
neuropeptid
crh
may
regul
neuroinflamm
induc
apoptosi
microglia
major
cellular
sourc
inflammatori
mediat
cn
keyword
apoptosi
microglia
inflamm
immunomodulatori
effect
som
mastrotto
c
casnici
c
lattuada
crotta
k
franco
p
marelli
antiprolif
effect
somatostatin
analog
som
capac
regul
cytokin
releas
evalu
human
peripher
blood
lymphocyt
hpbl
activ
phytohemoagglutinin
pha
pokewe
pwm
alloantigen
mlr
pbl
prolifer
measur
thymidin
uptak
result
significantli
inhibit
asid
stimulu
alloantigen
stimul
affect
presenc
som
mitogen
induc
prolifer
inhibit
alloantigen
induc
one
profil
cytokin
releas
evalu
mlr
supernat
elisa
test
start
h
till
five
day
cultur
ifn
gamma
releas
result
inhibit
presenc
som
could
see
signific
chang
releas
evalu
growth
inhibit
lymphocyt
studi
dna
distribut
hpbl
stimul
pha
pwm
presenc
propidium
iodur
incorpor
flow
cytometri
analysi
h
stimul
pha
pwm
presenc
som
cell
cycl
analysi
demonstr
modest
accumul
cell
sphase
phenomenon
analys
brdu
incorpor
h
signif
result
studi
cell
cycl
longer
puls
brdu
hand
evalu
antiprolif
effect
som
depend
either
apoptot
annexin
v
test
autophag
effect
immunofluoresc
test
regul
immun
cell
function
nonneuron
cholinerg
system
moriwaki
k
yoshikawa
fujii
k
kawashima
lymphocyt
express
compon
requir
constitut
independ
cholinerg
system
acetylcholin
ach
cholin
acetyltransferas
chat
acetylcholinesteras
ach
muscarin
nicotin
ach
receptor
machr
nachr
respect
stimul
machr
b
cell
caus
oscil
intracellular
ca
signal
upregul
cfo
gene
express
stimul
nachr
produc
rapid
transient
intracellular
ca
signal
investig
gene
express
cholinerg
compon
splenic
mononuclear
cell
mnl
bone
marrowderiv
dendrit
cell
bmdc
macrophag
mice
rest
condit
chat
gene
express
detect
brain
rtpcr
ach
gene
express
observ
sampl
cona
lp
stimul
chat
gene
express
detect
mnl
bmdc
respect
suggest
immunolog
stimul
induc
ach
synthesi
gene
machr
express
sampl
gene
subunit
nachr
express
sampl
express
detect
gene
gene
express
vari
among
sampl
gene
recent
discov
endogen
peptid
alloster
ligand
nachr
express
sampl
result
suggest
ach
play
intermediari
role
dialogu
among
lymphocyt
bmdc
macrophag
immun
respons
via
machrand
nachrmedi
pathway
autocrin
andor
paracrin
fashion
via
contact
cell
surfac
molecul
evid
suggest
inflamm
signific
contributor
patholog
number
neurodegen
diseas
state
regard
proinflammatori
cytokin
play
key
role
initi
immun
respons
within
central
nervou
system
cn
action
regul
vivo
receptor
antagonist
molecul
prevent
act
receptor
consequ
balanc
patholog
import
pharmacolog
strategi
tip
balanc
favour
may
therapeut
benefit
evid
emerg
suggest
neurotransmitt
noradrenalin
elicit
antiinflammatori
action
cn
consequ
may
play
endogen
neuroprotect
role
studi
report
noradrenalin
induc
product
secret
primari
rat
mix
glial
cell
without
alter
concentr
noradrenalineinduc
product
attenu
nonselect
antagonist
propranolol
also
select
adrenoceptor
antagonist
butoxamin
select
adrenoceptor
antagonist
metoprolol
furthermor
select
adrenoceptor
agonist
salbutamol
mimick
abil
noradrenalin
increas
product
taken
togeth
data
indic
adrenoceptor
mediat
abil
noradrenalin
increas
product
consist
abil
activ
campprotein
kinas
pathway
stabl
camp
analog
dibutryl
camp
mimick
pka
antagonist
rpcamp
block
abil
noradrenalin
increas
overal
data
demonstr
noradrenalin
neurotransmitt
antiinflammatori
therefor
potenti
neuroprotect
action
within
cn
author
acknowledg
grant
support
scienc
foundat
ireland
nicotin
control
cell
function
direct
interact
cn
lymphoid
tissu
innerv
sympathet
autonom
nerv
termin
role
innerv
immun
tissu
clear
chronic
exposur
nicotin
caus
immunosuppress
impair
cell
function
given
intracerebroventricularli
icv
rel
small
concentr
nicotin
affect
cell
respons
effect
significantli
influenc
adrenalectomi
indic
hpa
axi
play
major
role
nicotineinduc
immunosuppress
howev
immunosuppress
block
ganglion
blocker
indic
condit
effect
nicotin
regul
sympathet
autonom
nervou
system
san
peripher
administr
nicotin
concentr
seen
smoker
also
suppress
immun
system
suppress
partial
attenu
ganglion
blocker
inde
cell
express
howev
spite
near
total
homolog
neuron
cell
form
detect
level
ligandg
ca
channel
oper
essenti
second
messeng
cell
nicotin
modul
two
distinct
signal
pathway
nicotin
increas
ca
srclike
protein
tyrosin
kinas
lck
requir
function
integr
cell
receptor
nicotin
affect
activ
erk
independ
tcr
thu
nicotin
modul
cell
inflammatori
respons
sympathet
autonom
nervou
system
well
via
direct
interact
uniqu
thu
nicotin
control
adapt
inflammatori
respons
san
direct
interact
cell
via
two
distinct
signal
pathway
support
nida
investig
sensori
neurogen
compon
bleomycininduc
scleroderma
model
use
receptor
cgrp
knockout
mice
capsaicinsensit
transient
receptor
potenti
vanilloid
receptorexpress
sensori
nerv
termin
exert
effer
activ
besid
affer
function
nocicept
neuropeptid
releas
via
activ
influenc
inflammatori
process
studi
examin
role
receptor
calcitonin
generel
peptid
cgrp
bleomycininduc
scleroderma
use
transgen
mice
cutan
sclerosi
receptor
calcitonin
generel
peptid
knockout
cgrp
mice
wildtyp
wt
counterpart
induc
daili
sc
inject
bleomycin
throughout
day
control
group
treat
solvent
pb
excis
skin
sampl
investig
histolog
biochem
method
composit
cutan
sclerosi
score
calcul
basi
thicken
leukocyt
infiltr
amount
collagen
bundl
collagenspecif
aminoacid
hydroxyprolin
skin
patch
measur
spectrophotometri
quantit
realtim
rtpcr
assay
use
determin
type
collagenalpha
mrna
bleomycin
treatment
induc
mark
cutan
thicken
fibrosi
compar
pbstreat
group
composit
sclerosi
score
greater
greater
cgrp
mice
compar
respect
wt
group
similarli
amount
hydroxyprolin
increas
cgrp
anim
versu
wt
group
type
collagenalpha
mrna
content
significantli
higher
skin
bleomycintr
compar
trpv
mice
day
experi
result
suggest
activ
receptor
inflammatori
mediat
induc
releas
sensori
neuropeptid
exert
protect
action
fibrosi
grant
otka
wellcom
trust
immunolog
neurolog
role
haemopoiet
factor
medicin
alli
health
scienc
kitasato
univers
sagamihara
japan
c
institut
anim
reproduct
kasumigaura
japan
japan
red
cross
hospit
tokyo
japan
factor
origin
detect
condit
medium
clone
rat
thymic
myoid
cell
factor
commonli
induc
growth
differenti
monocyt
lineag
cell
periton
bone
marrow
thymu
brain
coloni
induc
two
factor
differ
morpholog
earli
stage
cultur
show
monocyt
cell
characterist
termin
stage
immunohistochem
studi
indic
major
produc
two
factor
neural
cell
brain
myoid
cell
thymu
suggest
biolog
role
monocyt
cell
stimulatori
activ
examin
biolog
role
immunolog
neurolog
role
purifi
factor
brain
cell
cultur
myoid
cell
hyperplast
thymu
mani
precursor
myoid
cell
detect
test
immunolog
neurostimulatori
role
found
two
factor
sustain
neuron
growth
stimul
microgli
cell
growth
furthermor
factor
stimul
bcell
respons
synerg
fashion
without
aid
tcell
factor
tcell
induc
immunoglobulin
class
switch
factor
also
appear
stimul
tcell
produc
bcell
activ
cytokin
lead
bcell
prolifer
result
suggest
two
new
haemopoiet
factor
play
import
role
monocyticmicrogli
cell
diversif
also
brain
physiolog
mani
immunolog
event
proinflammatori
cytokin
produc
peripheri
brain
respons
variou
immun
challeng
includ
autoimmun
diseas
well
follow
exposur
psycholog
stressor
sinc
human
autoimmun
diseas
chronic
stress
import
risk
factor
develop
major
depress
previou
work
implic
behavior
suppress
follow
acut
challeng
sought
examin
role
cytokin
mediat
depressivelik
symptom
induc
episod
experiment
autoimmun
encephalomyel
eae
well
follow
exposur
chronic
mild
stress
cm
establish
model
depress
rodent
first
demonstr
tempor
correl
elev
brain
develop
depressivelik
symptom
eae
cm
exposur
use
mice
delet
type
receptor
transgen
overexpress
receptor
antagonist
brain
well
pharmacolog
administr
demonstr
depressivelik
effect
exhibit
mice
eae
follow
exposur
cm
complet
abolish
blockad
signal
furthermor
show
behavior
effect
cmsinduc
elev
mediat
adrenocort
activ
via
suppress
hippocamp
neurogenesi
final
chronic
administr
via
osmot
minipump
mimick
depressivelik
behavior
effect
eae
cm
also
produc
adrenocort
activ
reduc
hippocamp
neurogenesi
find
indic
necessari
suffici
depress
associ
autoimmun
chronic
stress
condit
neural
correl
igemedi
allergi
although
mani
author
consid
direct
interact
allerg
reaction
behavior
chang
support
evid
elus
seri
studi
show
oral
nasal
ovalbumin
ova
challeng
allerg
mice
present
increas
fosexpress
paraventricular
nucleu
hypothalamu
pvn
central
nucleu
amygdala
cea
mice
food
allergi
display
higher
level
anxieti
increas
serum
corticosteron
level
allergyactiv
neuron
express
corticotropinreleas
hormon
pvn
cea
ovaallerg
mice
develop
avers
antigencontain
solut
also
avoid
dark
compart
previous
associ
nebul
ova
result
brain
fo
express
behavior
data
seem
compat
adapt
respons
remov
ige
either
antibodi
deplet
develop
oral
toler
preclud
everi
respons
analyz
csensit
fiber
destruct
neonat
capsaicin
inhibit
activ
pvn
cea
decreas
magnitud
food
avers
cromolyn
mast
cell
stabil
complet
block
fo
express
pvn
cea
preclud
develop
avers
dark
compart
associ
nebul
ova
employ
mice
develop
import
inflammatori
infiltr
follow
nasal
ova
challeng
found
inflammatori
cell
requir
site
challeng
order
trigger
neural
behavior
correl
murin
experiment
asthma
altogeth
build
solid
ground
understand
neuroimmun
interact
allerg
respons
may
contribut
comprehens
psycholog
disord
associ
allergi
induc
microgli
activ
acut
stress
grow
number
research
report
microgli
cell
contribut
progress
neurodegener
parkinson
alzheim
hiv
enceph
multipl
sclerosi
present
studi
demonstr
stressinduc
microgli
activ
brain
base
find
circul
level
elev
stress
hypothes
may
involv
microgli
activ
brain
test
hypothesi
administ
recombin
monitor
microgli
activ
h
administr
invivo
invitro
control
condit
well
ngg
intraperiton
administr
signific
microgli
activ
observ
ngg
intraperiton
administr
signific
microgli
activ
start
occur
clear
microgli
activ
observ
follow
administr
ngg
well
addit
ino
induc
microgli
cell
respons
administr
quantit
realtim
pcr
studi
reveal
administr
induc
ino
mrna
cultur
microgli
cell
line
dose
depend
manner
furthermor
null
mice
microgli
activ
reduc
brain
respons
h
period
stress
thu
present
studi
demonstr
circul
may
activ
microgli
cell
brain
suggest
stress
may
induc
microgli
activ
stressinduc
agerel
bia
function
natur
killer
cell
granulocyt
stress
reciproc
associ
steroid
hormon
sympathet
nerv
stressassoci
immun
respons
compar
young
week
old
week
mice
sinc
stress
suppress
convent
immun
system
ie
b
cell
invers
activ
primordi
immun
system
ie
extrathym
cell
nkt
cell
granulocyt
paramet
analys
restraint
stress
h
thymu
becam
atroph
function
age
agerel
increas
number
lymphocyt
seen
liver
although
number
lymphocyt
thymu
liver
decreas
magnitud
much
promin
thymu
determin
stressresist
lymphocyt
subset
twocolor
immunofluoresc
test
conduct
nkt
cell
found
cell
liver
young
mice
hand
infiltr
granulocyt
due
stress
promin
liver
old
mice
young
mice
liver
injuri
result
stress
promin
young
mice
agerel
bia
function
nkt
cell
granulocyt
seem
associ
differ
respons
catecholamin
high
old
mice
corticosteron
high
young
mice
stress
inde
inject
adrenalin
mainli
induc
infiltr
granulocyt
cortisol
activ
nkt
cell
result
suggest
exist
agerel
bia
function
nkt
cell
granulocyt
stress
bia
might
produc
differ
respons
sympathet
nerv
steroid
hormon
young
old
mice
salivari
cortisol
dhea
respons
psychosoci
stress
social
anxiou
individu
social
anxieti
disord
sad
common
type
anxieti
disord
kessler
et
al
suggest
life
time
preval
sad
often
interfer
academ
social
occup
function
sad
character
fear
neg
evalu
other
patient
feel
anxieti
much
social
evalu
situat
impair
psycholog
physiolog
state
present
studi
conduct
trier
social
stress
test
tsst
kirschbaum
et
al
produc
firm
evalu
situat
investig
salivari
cortisol
dehydroepiandrosteron
dhea
respons
social
anxiou
peopl
studi
approv
ethic
committe
waseda
univers
particip
male
student
divid
high
social
anxiou
sa
group
low
sa
group
score
short
fear
neg
evalu
scale
sfne
sasagawa
et
al
experi
inform
purpos
present
studi
sign
consent
form
experi
conduct
result
studi
signific
correl
found
auc
area
curv
cortisol
sfne
r
p
auc
cortisoldhea
ratio
sfne
r
p
analysi
show
dhea
high
sa
group
rose
greater
low
sa
group
hand
cortisol
high
sa
group
react
less
tsst
result
indic
endocrin
imbal
social
anxiou
peopl
social
stressor
imbal
might
affect
mainten
sad
apprais
control
acut
stressor
braincardiacimmun
associ
acut
stress
elicit
multipl
respons
autonom
endocrin
immun
system
cognit
apprais
thought
one
import
modul
stress
respons
investig
brain
substrat
crosstalk
homeostasi
system
accompani
cognit
apprais
acut
stressor
record
simultan
region
cerebr
blood
flow
rcbf
owat
positron
emiss
tomographi
cardiovascular
indic
heart
rate
hr
blood
pressur
bp
neuroendocrin
indic
concentr
epinephrin
norepinephrin
adrenocorticotrop
hormon
acth
blood
immun
indic
proport
subset
lymphocyt
nk
cell
helper
cell
cytotox
cell
b
cell
blood
male
subject
conduct
mental
arithmet
task
high
control
hc
low
control
lc
lc
task
caus
less
sens
control
subject
hc
task
signific
increas
rcbf
medial
later
orbitofront
cortex
ofc
medial
prefront
cortex
mpfc
observ
comparison
lc
minu
hc
task
importantli
signific
posit
correl
rcbf
hr
bp
nk
cell
found
commonli
later
ofc
lc
task
hc
task
present
result
show
first
time
ofc
might
one
pivot
region
topdown
regul
cardiovascular
immun
activ
accompani
cognit
apprais
acut
stressor
salivari
secretori
immunoglobulin
modul
induc
repetit
stress
task
mathemat
model
modul
nomura
recent
psychoneuroimmunolog
psychoendocrinolog
studi
reveal
human
immun
endocrin
secretori
substanc
chang
level
sensit
along
particip
subject
mental
stress
relax
howev
precis
modul
substanc
induc
mental
intervent
mechan
still
unknown
studi
one
major
secretori
immun
substanc
secretori
immunoglobulin
siga
assess
investig
normal
human
secretori
respons
induc
stress
task
deskwork
oper
focus
follow
two
point
precis
chang
salivari
siga
repetit
shortterm
stress
work
beak
procedur
mathemat
model
siga
modul
induc
procedur
result
experi
studi
indic
chang
siga
concentr
within
saliva
clearli
reflect
particip
subject
stress
level
certain
time
delay
depend
durat
stress
work
refer
result
experi
previou
siga
studi
propos
mathemat
model
siga
modul
base
logist
function
nonlinear
ordinari
differenti
equat
consist
first
order
exponenti
increas
term
second
order
nonlinear
decreas
term
word
possess
homeostat
properti
live
organ
result
simul
model
well
consist
siga
modul
profil
experi
final
introduc
blue
print
deskwork
stress
predict
system
construct
via
mathemat
model
oxid
detect
ultraweak
chemiluminesc
may
relat
neuralimmun
interact
acut
psycholog
stress
aim
stress
sens
neural
system
affect
immun
system
previou
studi
describ
elev
secretori
immunoglobulin
siga
level
saliva
increas
oxid
statu
expos
acut
psycholog
stress
human
saliva
contain
peroxidas
electron
donor
scn
ultraweak
chemiluminesc
ucl
base
mainli
electron
transfer
oxidationreduct
reaction
regist
oxid
reaction
order
investig
relationship
immun
function
oxid
stress
neural
reaction
effect
perform
anxieti
salivari
ucl
examin
valu
compar
salivari
siga
level
particip
method
particip
volunt
student
subject
perform
task
serial
asept
manipul
cell
cultur
task
examin
accuraci
speed
asept
manipul
evalu
result
practic
train
saliva
collect
min
immedi
min
min
perform
result
oneway
repeat
measur
anova
ucl
reveal
signific
differ
across
four
measur
occas
f
p
post
hoc
dunnett
test
clarifi
ucl
level
immedi
task
significantli
greater
compar
min
p
twoway
anova
repeat
measur
indic
ucl
siga
exhibit
chang
pattern
four
occas
f
p
conclus
ucl
count
volum
photon
gener
oxid
reaction
effect
monitor
lipid
peroxid
gener
suggest
oxid
may
occur
neuralimmun
interact
therapeut
effect
color
acut
psycholog
stress
kuniaki
takagi
nobuhiro
goi
yuko
hirai
hitoshi
harada
akira
ikari
kimitsugu
nakamura
mitsuo
hiramatsu
hirohito
tsuboi
reiko
horiki
takahiko
ono
naohid
kina
univers
shizuoka
shizuoka
japan
hamamatsu
photon
kk
hamamatsu
japan
univers
hamamatsu
hamamatsu
color
work
tokyo
japan
aim
thalassotherapi
use
variou
diseas
age
hippocr
howev
effect
factor
mechan
almost
unknown
studi
focus
attent
blue
color
sea
examin
influenc
color
acut
psycholog
stress
particip
method
particip
volunt
student
subject
divid
eight
group
blue
investig
color
effect
subject
four
group
worn
color
glass
kraepelin
test
acut
psycholog
stress
hand
subject
group
worn
color
glass
kraepelin
test
saliva
collect
subject
stage
stress
marker
measur
result
subject
worn
color
glass
test
salivari
iga
siga
ultraweak
chemiluminesc
ucl
subject
red
green
higher
group
blue
addit
subject
worn
color
glass
test
siga
ucl
subject
blue
green
significantli
lower
group
red
conclus
result
suppos
calm
recoveri
effect
acut
psycholog
stress
blue
high
motor
activ
rat
novel
environ
hr
compar
low
motor
activ
lr
rat
better
cancer
institut
oncolog
gliwic
branch
poland
hr
lr
rat
show
strong
correl
motil
psychostimul
selfadministr
differ
locomotor
activ
index
behavior
reactiv
stress
situat
aim
studi
ass
hr
lr
natur
killer
cell
cytotox
nkcc
sometim
signific
chang
concentr
function
activ
immun
paramet
observ
necessarili
lead
higher
incid
ill
also
assess
vivo
hr
lr
rat
suscept
solid
tumor
carcinogenesi
peripher
blood
natur
killer
cell
cytotox
nkcc
standard
h
cr
releas
assay
target
cell
e
cytotox
nk
lymphocyt
singl
cell
level
agaros
assay
chemic
induc
tumor
incid
tumor
growth
rate
measur
result
indic
signific
p
differ
nkcc
hr
n
lr
rat
e
vs
e
vs
e
vs
respect
evalu
singl
cell
lytic
abil
effector
cell
reveal
signific
effect
percentag
conjug
format
target
lysi
signific
differ
either
tumor
incid
tumor
growth
rate
also
result
suggest
hr
rat
higher
nkcc
may
necessarili
lead
diminish
incid
carcinogenesi
lr
rat
poss
effect
anticanc
mechan
effect
attract
favorit
person
innat
immun
system
everybodi
fall
love
thu
everybodi
know
attract
favorit
person
invok
posit
feel
often
make
us
energet
question
aris
whether
biolog
system
autonom
nervou
endocrin
immun
system
affect
posit
emot
investig
effect
attract
favorit
person
biolog
system
record
variou
paramet
name
mood
state
heart
rate
hr
skin
conduct
level
scl
serum
level
sever
hormon
endorphin
oxytocin
vasopressin
norepinephrin
epinephrin
cortisol
proport
cell
natur
killer
nk
cell
lymphocyt
simultan
subject
view
video
film
favorit
person
mood
state
assess
profil
mood
statu
pom
serum
level
sever
hormon
measur
enzymelink
immunosorb
assay
elisa
proport
cell
nk
cell
lymphocyt
measur
flowcytomet
result
accompani
selfreport
vigor
better
feel
scl
proport
nk
cell
significantli
increas
signific
chang
hr
serum
level
variou
hormon
well
proport
cell
lymphocyt
found
result
suggest
possibl
attract
favorit
person
may
role
activ
nk
cellrel
innat
immun
system
mean
activ
sclrelat
autonom
nervou
system
tempor
redistribut
nk
cell
subset
acut
psycholog
stressor
k
kimura
b
isowa
h
ohira
depart
psycholog
nagoya
univers
aichi
japan
b
japan
societi
promot
scienc
accumul
evid
indic
acut
psycholog
stressor
could
elicit
lymphocyt
redistribut
via
sympathet
nervou
activ
furthermor
also
known
tempor
variat
redistribut
differ
lymphocyt
subset
instanc
acut
stressor
natur
killer
cell
nk
cell
remark
increas
peripher
blood
helper
cell
slightli
decreas
show
chang
one
possibl
explan
distinct
variat
adhes
molecul
express
surfac
lymphocyt
recent
research
suggest
redistribut
nk
cell
occur
differenti
base
express
densiti
distinct
express
nk
cell
subset
correspond
function
differenti
name
high
immunomodulatori
function
low
cytotox
function
although
differenti
redistribut
subset
report
sever
studi
tempor
variat
subset
relationship
sympathet
nervou
activ
remain
unclear
thu
present
studi
conduct
examin
issu
acut
stressor
paradigm
ten
human
particip
perform
mental
arithmet
task
acut
stressor
blood
sampl
estim
cell
cell
epinephrin
norepinephrin
cortisol
taken
min
task
addit
blood
pressur
heart
rate
monitor
experi
result
nk
cell
show
remark
increment
acut
stressor
variat
indic
close
relationship
sympathet
nervou
activ
elev
blood
pressur
psychoeduc
intervent
perceiv
social
support
effect
natur
killer
cell
activ
among
elderli
rural
japan
background
rel
littl
research
show
strategi
chang
perceiv
social
support
improv
health
outcom
previou
intervent
studi
elderli
women
focus
give
enact
social
support
fail
improv
perceiv
social
support
conduct
psychoeduc
intervent
improv
attitudin
perceiv
social
support
among
gener
elderli
peopl
examin
effect
natur
killer
cell
activ
method
random
control
crossov
design
involv
particip
year
old
ninetyminut
intervent
conduct
weekli
five
success
week
intervent
consist
lectur
ill
prevent
relax
use
dohsa
therapi
psychoeduc
intervent
perceiv
social
support
particip
administ
questionnair
taken
blood
sampl
noon
control
diurnal
variat
four
time
baselin
preintervent
postintervent
follow
nk
cell
activ
measur
use
standard
releas
assay
result
signific
improv
perceiv
social
support
score
natur
killer
cell
activ
intervent
group
postintervent
period
follow
period
conclus
found
perceiv
social
support
score
could
increas
psychoeduc
intervent
also
suggest
chang
perceiv
social
support
causal
effect
immun
natur
killer
cell
activ
effect
cytokin
neurosteroid
neuron
cell
death
respons
naf
ariyuki
kagaya
minoru
takebayashi
shigeru
morinobu
shigeto
yamawaki
recent
progress
neurosci
show
variou
neurotransmitt
hormon
cytokin
play
essenti
role
neuron
cell
surviv
death
variou
kind
stress
elicit
cellular
respons
lead
cell
death
sodium
fluorid
naf
wellknown
chemic
stressor
recent
report
suggest
naf
induc
cell
death
studi
investig
effect
cytokin
neurosteroid
nafinduc
cell
death
cell
cultur
dmem
contain
fc
micropl
cell
maintain
without
sodium
fluorid
naf
andor
indic
drug
cell
treat
drug
incub
measur
cell
viabil
optic
densiti
nm
wavelength
measur
microtit
plate
reader
naf
induc
cell
death
dose
time
depend
manner
tnfalpha
lif
littl
effect
cell
surviv
dhea
dhea
effect
cell
surviv
compound
littl
effect
nafelicit
cell
death
howev
estradiol
significantli
inhibit
cell
death
induc
naf
result
suggest
estradiol
effect
protect
nafinduc
cell
death
cytokin
modul
neurotrophindepend
axon
outgrowth
dorsal
root
ganglia
dosedepend
effect
ifng
tnfa
inflamm
part
wound
heal
respons
mechan
lesion
peripher
nervou
system
howev
clear
whether
inflammatori
cytokin
exert
benefici
detriment
effect
neurotrophin
nt
depend
axon
outgrowth
dorsal
root
ganglia
drg
analyz
effect
nt
cytokin
neurit
outgrowth
murin
embryon
drg
vitro
drg
cultur
matrigel
ngf
nt
ngml
appli
alon
doubl
tripl
combin
ifng
tnfa
ngml
ad
differ
nt
combin
use
imag
analysi
system
neurit
outgrowth
zone
axon
densiti
determin
h
alon
combin
induc
moder
increas
axon
growth
ngf
ngfinclud
combin
substanti
increas
axon
growth
effect
increas
outgrowth
stimul
induc
outgrowth
ifng
stimul
neurit
extens
ntfree
control
well
presenc
ngf
ifng
also
stimul
axon
densiti
absenc
nt
presenc
tnfa
inhibit
ngf
ngf
ngfinduc
outgrowth
summari
nt
differenti
stimul
drg
axon
outgrowth
densiti
ntinduc
axon
growth
dosedepend
modul
cytokin
diazepam
effect
blood
neutrophil
activ
ehrlich
tumor
growth
introduct
benzodiazepin
diazepam
commonli
use
anxiolyt
effect
ie
action
high
affin
receptor
site
coupl
gaba
receptor
complex
diazepam
treatment
lead
increas
serum
corticosteron
level
correl
posit
immun
alter
laboratori
anim
object
analyz
diazepam
effect
innat
immun
resist
ehrlich
tumor
growth
method
result
swiss
male
mice
divid
two
group
anim
experiment
group
e
control
group
c
treat
per
oral
diazepam
mgkgday
control
solut
gday
day
respect
mice
group
receiv
ip
ehrlich
tumor
cell
blood
neutrophil
activ
tumor
growth
evalu
day
anim
treat
diazepam
present
decreas
basal
neutrophil
oxid
burst
c
e
increas
neutrophil
oxid
burst
vitro
induct
phorbolmiristateacet
c
e
well
zymosan
c
e
increas
neutrophil
intens
c
e
percent
zymosan
phagocytosi
c
e
increas
ehrlich
tumor
growth
evalu
total
number
tumor
cell
ascit
fluid
c
e
conclus
diazepam
chang
neutrophil
activ
measur
vitro
decreas
anim
resist
ehrlich
tumor
growth
grant
cnpq
fapesp
effect
atyp
antipsychot
drug
product
proinflammatori
cytokin
nitric
oxid
reactiv
oxygen
speci
activ
microglia
microglia
recent
regard
mediat
neuroinflamm
releas
proinflammatori
cytokin
nitric
oxid
reactiv
oxygen
speci
ro
microglia
thu
play
import
role
patholog
neurodegen
diseas
alzheim
diseas
ad
parkinson
diseas
pd
patholog
mechan
schizophrenia
remain
unclear
recent
neuroimag
studi
suggest
even
schizophrenia
may
kind
neurodegen
diseas
like
ad
pd
far
studi
relationship
microglia
schizophrenia
atyp
antipsychot
drug
apd
becom
standard
drug
treatment
schizophrenia
less
advers
effect
effect
neg
symptom
schizophrenia
thu
investig
effect
atyp
apd
product
proinflammatori
cytokin
nitric
oxid
ro
activ
microglia
also
tri
clarifi
molecular
mechan
underli
effect
compar
haloperidol
typic
convent
apd
sever
kind
atyp
apd
significantli
inhibit
product
proinflammatori
cytokin
tumour
necrosi
factor
nitric
oxid
lipopolysaccharid
lp
stimul
microglia
result
suggest
atyp
apd
may
benefici
effect
proinflammatori
condit
cn
may
play
crucial
role
patholog
schizophrenia
lithium
chlorid
modul
function
human
monocytederiv
dendrit
cell
almost
half
centuri
lithium
one
wide
use
medic
bipolar
depress
ill
although
therapeut
mechan
action
remain
obscur
accumul
preclin
clinic
evid
action
lithium
brain
suggest
lithium
affect
membran
transport
system
neurotransmitt
receptor
regul
second
messeng
system
protein
kinas
c
pkc
regul
gene
express
recent
studi
show
long
term
acut
treatment
cultur
cerebellar
granul
cell
licl
induc
concentrationdepend
decreas
proapoptot
bax
level
remark
increas
cytoprotect
protein
result
suggest
lithium
addit
use
treatment
bipolar
depress
ill
may
expand
use
improv
neurodegener
howev
regul
lithium
dendrit
cell
notwel
defin
dendrit
cell
dc
key
regul
immun
respons
involv
initi
mainten
innat
adapt
immun
respons
demonstr
lithium
chlorid
treatment
enhanc
human
monocytederiv
express
addit
lithium
chlorid
increas
cytokin
tnfa
product
howev
lithium
effect
cell
prolifer
assay
mix
lymphocyt
reaction
data
suggest
lithium
chlorid
might
modul
dc
function
via
phenotyp
cytokin
express
associ
polymorph
gene
autism
pervas
development
disord
last
decad
becam
evid
pervas
development
disord
pdd
gener
autist
disord
specif
associ
sever
immun
alter
autoimmun
process
particular
innat
immun
system
seem
activ
accompani
product
proinflammatori
cytokin
neuroinflammatori
process
virus
measl
environment
toxin
mercuri
known
stimul
innat
immun
implic
etiolog
autism
stimuli
may
interact
genet
variabl
increas
preval
famili
autoimmun
disord
parent
proband
pdd
proinflammatori
cytokin
may
particularli
relev
pdd
involv
emot
social
cognit
modul
induc
vaccin
toxin
mediat
immun
respons
mercuri
play
major
role
autoimmun
recent
variabl
number
tandem
repeat
polymorph
second
intron
receptor
antagonist
gene
found
associ
increas
risk
chronic
inflammatori
autoimmun
diseas
test
hypothesi
polymorph
associ
autism
current
examin
famili
proband
diagnos
adir
adosg
parent
use
familybas
associ
test
unphas
furthermor
assess
whether
associ
mediat
role
gene
specif
disturb
socialemot
cognit
paramet
result
may
implic
genet
alter
signal
autism
relationship
autoimmun
process
major
depress
disord
mdd
common
preval
men
women
recent
year
associ
immun
system
alter
mdd
report
basi
new
observ
therefor
decid
accur
assess
determin
exclud
relationship
immun
system
mdd
materi
method
patient
control
group
determin
tnf
fn
elisa
serum
immunoglobulin
serum
protein
marker
immun
system
cell
includ
cd
cd
cd
cd
result
studi
includ
patient
fm
mean
age
year
fifteen
number
control
cytokin
studi
observ
signific
differ
patient
control
group
patient
group
moder
grade
signific
relationship
ifn
p
control
group
relationship
posit
signific
p
studi
immunoglobulin
patient
normal
rang
amount
total
protein
patient
group
higher
normal
rang
number
nk
b
cell
normal
rang
discuss
patient
mdd
inhibitori
cytokin
increas
sever
grade
diseasetot
protein
patient
group
higher
normal
rang
immun
system
cell
immunoglobulin
normal
rang
relev
cytokin
chemokin
immun
mediat
immunomodulatori
strategi
patient
suffer
chronic
idiopath
pain
syndrom
first
studi
give
insight
wide
pattern
chemokin
cytokin
receptor
well
corticotropinreleas
factor
crf
substanc
p
sp
histamin
serum
cerebrospin
fluid
patient
suffer
uncontrol
chronic
idiopath
pain
syndrom
compar
control
patient
method
patient
suffer
idiopath
chronic
widespread
pain
syndrom
cwp
fibromyalgia
myofasci
pain
syndrom
case
addit
complex
region
pain
syndrom
refractori
convent
pain
treatment
strategi
control
underw
spinal
anaesthesia
minor
lower
extrem
surgeri
enrol
studi
serum
cerebrospin
fluid
concentr
mention
paramet
determin
use
highsensit
elisa
kit
technolog
result
patient
serum
sp
histamin
eotaxin
mig
significantli
elev
compar
control
cerebrospin
fluid
sp
crf
ifna
mig
significantli
higher
compar
control
gcsf
detect
cerebrospin
fluid
patient
none
control
howev
rant
gmcsf
groa
tnfa
gdnf
detect
sampl
differ
significantli
patient
control
serum
cerebrospin
fluid
conclus
find
indic
possibl
role
immunopatholog
mechan
develop
therapyrefractori
chronic
pain
result
support
immunomodulatori
strategi
manag
chronic
idiopath
pain
syndrom
increas
nk
activ
group
schizophren
patient
function
alter
immun
system
schizophren
patient
shown
differ
studi
import
nk
cell
activ
schizophrenia
due
role
immun
surveil
tumor
viral
cell
studi
aim
explain
low
incid
cancer
schizophren
patient
consist
find
emerg
major
inconsist
must
due
effect
variou
confound
factor
smoke
medic
etc
purpos
studi
evalu
nk
activ
schizophren
patient
elimin
effect
factor
studi
chosen
medicationfre
schizophren
patient
healthi
sex
age
smoke
statu
match
individu
nk
cell
activ
case
control
subject
measur
mtt
methylthiazoltetrazolium
test
statist
analysi
data
obtain
use
spss
nk
activ
patient
mean
mean
sd
nk
activ
mean
normal
subject
statist
analysi
show
signific
increas
nk
activ
schizophren
patient
compar
control
p
also
nk
activ
smoke
patient
significantli
lower
nonsmok
patient
p
demograph
factor
show
influenc
nk
activ
higher
activ
nk
cell
schizophren
patient
compar
control
popul
could
explain
low
incid
cancer
patient
decreas
effect
smoke
nk
activ
patient
could
one
respons
factor
inconsist
result
differ
studi
decad
relationship
immun
system
schizophrenia
attract
consider
research
psychoneuroimmunolog
pni
etiolog
hypothes
connect
propos
relationship
viral
infect
autoimmun
activ
tlymphocytemacrophag
studi
focus
compar
analysi
immun
function
drugfre
schizophren
patient
healthi
individu
match
sex
age
smoke
statu
analysi
prolifer
cell
respons
pha
phytohaemagglutinin
mitogen
measur
methylthiazoltetrazolium
test
mtt
serum
ana
antinuclearantibodi
level
aca
anticytoplasmicantibodi
presenc
circul
immun
complex
cic
concentr
measur
indirect
immunofluoresc
peg
precipit
test
respect
result
assay
analyz
spss
cell
prolifer
patient
mean
cell
prolifer
mean
normal
subject
statist
analysi
show
signific
decreas
cell
prolifer
schizophren
patient
compar
control
p
serum
ana
level
cic
concentr
significantli
differ
two
group
p
p
respect
aca
shown
present
case
group
p
result
could
evid
autoimmunevir
hypothesi
least
group
schizophren
patient
associ
promot
polymorph
schizophrenia
iranian
popul
sever
report
show
abnorm
cytokin
level
psychot
patient
indic
possibl
role
immun
respons
system
pathogenesi
schizophrenia
gene
map
chromosom
locu
associ
genet
suscept
schizophrenia
investig
role
schizophrenia
analys
associ
four
singl
nucleotid
polymorph
snp
locat
promot
c
risk
schizophrenia
patient
n
unrel
control
n
resid
citi
mashhad
iran
frequenc
ta
snp
allel
promot
snp
c
allel
also
significantli
increas
patient
compar
control
p
furthermor
compar
control
frequenc
allel
significantli
increas
patient
p
patient
posit
famili
histori
n
p
undifferenti
p
nondisorgan
p
nonresidu
p
subtyp
promot
aa
genotyp
significantli
increas
famili
histori
posit
patient
p
nondisorgan
group
similarli
frequenc
allel
significantli
increas
patient
posit
famili
histori
p
nondisorgan
subtyp
p
preliminari
haplotyp
analys
suggest
frequenc
promot
haplotyp
associ
high
product
increas
schizophrenia
result
suggest
promot
snp
may
associ
increas
risk
schizophrenia
studi
show
differ
genet
background
schizophrenia
subtyp
iranian
popul
chronic
exposur
vapor
gasolin
diesel
upregul
metallothionein
ii
express
olfactori
brain
mice
olfactori
system
often
use
excel
model
studi
widespread
aspect
neural
develop
neuronglia
interact
exposur
agent
whose
rout
entri
cn
might
bypass
bloodbrain
barrier
sinc
pathway
might
frequent
stimul
airborn
urban
pollut
result
chronic
diseas
studi
attempt
evalu
effect
intermitt
exposur
mice
gasolin
g
diesel
vapor
brain
lung
kidney
express
metallothionein
ii
mt
cysteinerich
protein
metal
bind
affin
might
provid
cytoprotect
action
form
stress
injuri
purpos
mice
hday
close
small
metabol
chamber
ventil
fresh
air
g
vapor
protocol
repeat
day
mt
express
detect
brain
lung
kidney
find
compar
data
obtain
unstress
mice
found
g
inhal
markedli
upregul
mt
express
ventricular
ependyma
astrocyt
particularli
hippocampu
project
stellat
pyramid
cell
later
olfactori
tract
perfor
path
high
cytoplasm
nuclear
mt
express
found
also
alveolar
epithelia
kidney
impli
protect
effect
mt
area
expos
toxic
agent
product
simultan
stress
toxic
agent
increas
cytotox
hepat
splenic
lymphat
cell
syngen
thymocyt
impli
autoreact
clone
cell
particip
process
tissu
repair
support
grant
croatian
ministri
scienc
modul
proinflammatori
neural
activityrel
gene
express
olfactori
bulb
mice
nasal
inhal
lowlevel
toluen
sohel
ahm
hidekazu
fujimaki
tintinwinshw
shoji
yamamoto
shinji
tsukahara
yoshika
kurokawa
daisuk
nakajima
sumio
goto
nation
institut
environment
studi
ibaraki
japan
sinc
induct
multipl
chemic
sensit
might
relat
volatil
organ
compound
hous
offic
specul
posit
relationship
immunolog
neurolog
alter
inhal
volatil
organ
compound
studi
effect
exposur
lowlevel
toluen
olfactori
system
neuroimmun
respons
male
mice
expos
filter
air
control
ppm
toluen
noseonli
exposur
chamber
min
per
day
day
mice
either
maintain
nonimmun
immun
condit
ovalbumin
ova
use
quantit
realtim
pcr
method
investig
olfactori
bulb
express
sever
gene
data
demonstr
signific
differ
mrnaexpress
proinflammatori
gene
ovaimmun
mice
expos
ppm
toluen
compar
filter
air
control
ppm
toluen
case
neural
activityrel
gene
observ
similar
pattern
glutamaterg
nmda
receptor
subunit
howev
observ
pattern
dopaminerg
receptor
subtyp
first
studi
show
vivo
modul
olfactori
bulb
express
proinflammatori
neural
activ
gene
mice
nasal
inhal
exposur
lowlevel
toluen
concert
antigen
stimul
influenc
emot
regul
immun
autonom
respons
cognit
psycholog
nagoya
univers
aichi
japan
emot
regul
techniqu
decreas
face
anxieti
follow
physiolog
respons
self
focus
attent
known
increas
anxieti
state
adapt
selffocu
decreas
anxieti
state
former
maladapt
selffocu
includ
conceptu
analyt
evalu
way
selffocu
later
adapt
focus
direct
intuit
experienti
awar
experi
moment
adapt
selffocu
manipul
known
one
factor
mind
mind
third
wave
cognit
behavior
therapi
develop
treat
rang
psycholog
disord
includ
depress
anxieti
fibromyalgia
function
mechan
mind
still
unknown
use
adapt
selffocu
manipul
techniqu
emot
regul
hypothes
adapt
selffocu
manipul
also
effect
decreas
autonom
immun
respons
cognit
theori
interact
emot
cognit
previou
find
demonstr
increas
anxieti
state
lead
shift
alloc
cognit
resourc
neg
stimulu
also
demonstr
influenc
cognit
affect
endocrin
system
anxieti
state
purpos
studi
demonstr
adapt
selffocu
manipul
attenu
anxieti
respons
immun
autonom
respons
cognit
neg
bia
magnet
stimul
left
temporoparietooccipit
tpo
cerebr
cortex
noninvas
treatment
suppress
ongo
human
ige
respons
found
magnet
stimul
left
right
tpo
cerebr
cortex
allerg
human
significantli
increas
blood
cell
b
cell
number
h
strongli
suppress
serum
ige
level
day
contrast
right
stimul
number
blood
cell
decreas
serum
ige
level
chang
previous
report
electr
stimul
rat
left
right
tpo
cortex
increas
cell
export
thymu
mediat
sympathet
pathway
upper
spinal
cord
result
increas
blood
cell
number
h
moshel
et
al
j
neuroimm
contrast
right
stimul
number
blood
cell
decreas
studi
abil
left
vs
right
electr
stimul
tpo
cortex
suppress
peak
hapten
specif
ige
respons
bpoklh
sensit
rat
mechan
involv
support
research
foundat
suni
multipl
sclerosi
ms
chronic
neurolog
diseas
affect
central
nervou
system
diseas
character
demyelin
axon
loss
caus
abnorm
immunolog
respons
result
accumul
neurolog
disabl
ms
consid
complex
diseas
genet
environment
factor
contribut
pathogenesi
studi
investig
genet
role
gene
ms
nine
singl
nucleotid
polymorph
snp
select
genotyp
base
ld
pattern
hapmap
get
even
distribut
marker
gene
swedish
ms
patient
swedish
healthi
control
genotyp
use
sequenom
method
three
snp
show
signific
pvalu
signific
level
haplotyp
associ
found
associ
snp
locat
within
ld
block
order
confirm
result
three
signific
marker
genotyp
independ
case
control
materi
consist
nordic
norway
denmark
finland
ms
patient
nordic
healthi
control
none
associ
swedish
casecontrol
materi
replic
nordic
materi
conclud
gene
major
genet
import
ms
nordic
popul
studi
indic
two
import
factor
perform
genet
associ
studi
complex
diseas
necess
larg
casecontrol
materi
access
independ
materi
confirm
initi
associ
chromosom
multipl
sclerosi
bonetti
previou
studi
suggest
role
allel
variat
chromosom
multipl
sclerosi
ms
suscept
object
studi
test
three
subregion
associ
ms
famili
use
transmiss
disequilibrium
test
marker
area
show
nomin
signific
associ
ms
marker
resid
suggest
linkag
peak
associ
ms
previou
italian
studi
anoth
associ
found
apo
haplotyp
support
also
separ
casecontrol
analysi
previou
suggest
defici
associ
replic
studi
result
show
two
subregion
chromosom
associ
ms
warrant
studi
implic
diseas
multipl
sclerosi
put
autoimmun
snp
associ
studi
patient
germani
hungari
poland
polymorph
gene
region
associ
suscept
autoimmun
diseas
aid
recent
describ
singl
nucleotid
polymorph
locat
untransl
region
shown
associ
grave
diseas
autoimmun
thyroid
autoimmun
diabet
aid
although
one
studi
show
associ
haplotyp
multipl
sclerosi
ms
studi
fail
demonstr
associ
also
conflict
data
regard
alleledepend
gene
express
conduct
associ
studi
includ
far
total
patient
hungari
poland
germani
control
person
although
genotyp
overrepres
among
ms
patient
associ
reach
statist
signific
conclud
influenc
ms
suscept
isif
allrath
small
might
restrict
subgroup
patient
present
analysi
mhc
stratif
correl
clinic
data
furthermor
analyz
genotypedepend
express
ico
cell
vitro
stimul
pro
antiinflammatori
cytokin
gene
polymorph
multipl
sclerosi
patient
role
inflammatori
antiinflammatori
cytokin
pathogenesi
multipl
sclerosi
ms
extens
studi
elev
level
observ
blood
csf
central
nervou
system
cn
lesion
ms
patient
activ
phase
increas
remiss
inact
phase
therefor
alter
cytokin
product
may
influenc
suscept
ms
alter
could
due
gene
polymorph
aim
present
studi
analyz
whether
associ
cytokin
gene
polymorph
suscept
ms
iranian
popul
studi
screen
genom
dna
sampl
clinic
definit
ms
patient
healthi
control
use
polymeras
chain
reactionsequencespecif
primer
pcrssp
cytokin
gene
polymorph
determin
g
g
c
c
c
g
codon
c
codon
g
c
intron
result
indic
ms
patient
significantli
show
higher
gg
tt
gg
tc
gc
genotyp
compar
control
studi
also
show
frequenc
genotyp
associ
low
product
increas
ms
patient
howev
find
suggest
could
genet
dysregul
product
cytokin
multipl
sclerosi
risk
diseas
increas
low
produc
new
develop
cultur
method
effici
support
growth
chamydia
pneumonia
pbmc
csf
sampl
patient
multipl
sclerosi
chlamydia
pneumonia
cpn
associ
variou
neurolog
disord
includ
multipl
sclerosi
ms
basi
pcr
find
question
still
open
concern
difficulti
cultiv
directli
demonstr
cpn
clinic
specimen
fresh
cf
pbmc
sampl
obtain
patient
neurolog
mri
abnorm
suggest
ms
specimen
inocul
cell
duplic
well
incub
co
part
grown
cell
investig
immunofluoresc
use
cpnmonoclon
antibodi
increas
cpn
inclus
rest
well
centrifug
incub
addit
centrifug
cultur
day
medium
refresh
h
cultur
supernat
underw
touchdown
npcr
assay
target
rrna
momp
hsp
gene
cpn
patient
cultur
posit
csf
npcr
neg
dna
directli
extract
wherea
posit
rna
momp
cultur
sampl
dna
extract
day
cultur
supernat
pbmc
npcr
posit
gene
higher
posit
rate
cultur
csf
dna
extract
cultur
supernat
day
perform
cultur
posit
one
pbmc
sampl
result
obtain
confirm
efficaci
cultur
system
suggest
presenc
viabil
cpn
combin
addit
centrifug
extens
cultur
time
pcr
improv
sensit
method
suggest
potenti
use
detect
cpn
serolog
profil
immun
respons
microb
ident
twin
discord
multipl
sclerosi
base
nationwid
seri
italian
twin
multipl
sclerosi
perform
cotwin
control
studi
pair
order
investig
caus
factor
ms
among
variabl
possibl
associ
ms
etiolog
positev
neg
associ
predisposit
concord
twin
mainli
link
infect
find
prompt
us
investig
quantit
serolog
profil
immun
respons
microb
put
involv
ms
etiolog
ident
twin
discord
ms
serum
antibodi
epsteinbarr
ebv
antigen
cmv
varicella
zoster
vz
red
measl
herp
simplex
virus
bordetella
pertussi
quantifi
twin
pair
discord
diseas
concord
pair
control
unaffect
twin
pair
serum
antibodi
titer
compar
affect
unaffect
twin
elev
affect
vs
unaffect
twin
signific
igg
antivca
ruml
vs
p
trend
found
elev
unaffect
vs
affect
twin
signific
antibodi
vzv
ruml
vs
p
differ
found
microb
final
concord
twin
pair
unaffect
twin
pair
show
compar
serolog
profil
find
support
role
infect
etiolog
ms
serolog
profil
discord
twin
show
differenc
reactiv
vzv
ebv
enhanc
immun
respons
ebv
affect
twin
keep
previou
work
sporad
patient
reactiv
oxygen
speci
ro
play
crucial
role
sever
process
underli
pathogenesi
multipl
sclerosi
ms
involv
transendotheli
monocyt
migrat
myelin
phagocytosi
breakdown
oligodendrocyt
damag
axon
degener
exposur
cell
high
level
ro
induc
oxid
stress
lead
activ
nuclear
transcript
factor
activ
transcript
factor
induc
express
antioxid
respons
element
regul
gene
gene
encod
endogen
enzym
regul
cellular
redox
statu
offer
protect
oxid
stress
inflamm
thu
express
protein
may
act
sensit
indic
oxid
stress
far
data
express
areregul
enzym
brain
ms
patient
lack
henc
investig
distribut
variou
endogen
antioxid
enzym
includ
heme
oxygenas
superoxid
dismutas
peroxiredoxin
catalas
nad
p
h
quinon
oxidoreductas
differ
ms
lesion
type
show
first
time
antioxid
enzym
highli
upregul
activ
demyelin
ms
lesion
particularli
hypertroph
astrocyt
myelinladen
macrophag
specul
increas
antioxid
enzym
express
may
reflect
endogen
defens
respons
may
compens
rosmedi
cellular
toxic
compound
activ
signal
pathway
via
express
detoxifi
enzym
may
potenti
therapeut
target
futur
treatment
strategi
ms
reduc
express
mhc
antigenprocess
machineri
molecul
margin
multipl
sclerosi
lesion
clue
antiinflammatori
countermechan
lesion
border
assum
multipl
sclerosi
ms
lesion
reactiv
infiltr
autoreact
lymphocyt
like
mediat
local
antigen
present
cell
apc
microgliamacrophag
antigen
present
requir
major
histocompat
mhc
antigenprocess
complex
interplay
sever
protein
belong
antigenprocess
machineri
apm
order
evaul
regul
apm
molecul
relat
ms
lesion
format
investig
express
variou
mhc
apm
molecul
human
brain
specimen
ms
patient
n
mean
immunohistochemistri
relat
mhc
class
ii
microglia
macroph
exhibit
higher
express
mch
apm
molecul
activ
earlyact
lateact
chronicact
inact
chronicinact
ms
lesion
interestingli
albeit
higher
frequenc
microglia
macrophag
border
activ
lesion
observ
express
numer
mhc
apm
compon
delta
low
molecular
weight
transport
associ
antigen
calnexin
calreticulin
fold
higher
lesion
centr
lesion
border
normal
appear
white
matter
nawm
contrast
chronicinact
ms
lesion
character
compar
amount
mhc
apm
express
lesion
border
centr
data
demonstr
microglia
cell
macrophag
capac
process
present
antigen
alik
profession
apc
reduc
express
mhc
apm
molecul
lesion
border
comparison
lesion
center
could
suggest
antiinflammatori
countermechan
circumv
broaden
mslesion
express
cultur
human
astrocyt
nonhypertroph
astrocyt
brain
multipl
sclerosi
junichi
satoh
hiroko
tabunoki
yusuk
nanri
b
takashi
yamamura
b
kunimasa
arima
c
hidehiko
konno
depart
bioinformat
meiji
pharmaceut
univers
b
depart
immunolog
ncnp
c
depart
neuropatholog
ncnp
tokyo
depart
neurolog
nishitaga
nation
hospit
sendai
japan
object
identifi
express
aquaporin
aqp
human
neural
cell
background
aqp
constitut
evolutionarili
conserv
famili
integr
membran
water
transport
channel
protein
target
antigen
nmoigg
opticospin
multipl
sclerosi
osm
although
mechan
underli
highli
select
lesion
distribut
osm
remain
unknown
method
express
studi
cell
cultur
brain
tissu
four
convent
ms
case
rtpcr
western
blot
immunochemistri
result
human
astrocyt
cultur
constitut
express
cell
surfac
protein
level
elev
astrocyt
exposur
ifng
tnfa
unaffect
cytokin
protein
level
posit
correl
gfap
ms
brain
homogen
vari
number
nonhypertroph
astrocyt
elabor
process
contact
blood
vessel
neither
macrophag
neuron
express
intens
ms
nonm
brain
conclus
express
predominantli
nonhypertroph
astrocyt
wide
distribut
whole
cn
suggest
redund
role
aqp
astrocyt
water
balanc
involv
undefin
region
factor
select
lesion
distribut
osm
invari
cell
accumul
multipl
sclerosi
cidp
lesion
contrast
defici
nkt
cell
zsolt
ill
b
takashi
yamamura
depart
immunolog
nation
institut
neurosci
tokyo
japan
b
depart
neurolog
univers
pec
hungari
defici
nkt
cell
describ
sever
autoimmun
diseas
observ
absenc
nkt
cell
multipl
sclerosi
ms
lesion
convent
cell
infiltr
ms
plaqu
select
defici
invari
nkt
cell
ms
prompt
us
examin
mucos
associ
invari
cell
mait
nervou
system
autoimmun
consid
propos
complementari
function
similar
express
mous
homologu
use
rtpcr
sscp
method
express
report
four
invari
tcr
chain
examin
ms
lesion
inflammatori
demyelin
lesion
peripher
nerv
chronic
inflammatori
demyelin
polyneuropathi
cidp
follow
rtpcr
primer
amplicon
electrophores
nondenatur
sscp
gel
dna
hybrid
biotinyl
intern
invari
junction
probe
data
indic
invari
mait
cell
infiltr
autoimmun
lesion
central
peripher
nervou
system
contrast
nkt
cell
found
cidp
lesion
invari
cell
could
identifi
besid
two
subset
lesion
addit
presenc
one
nkt
cell
subset
associ
express
autoimmun
demyelin
lesion
pn
propos
antiinflammatori
role
differenti
express
two
subset
ms
lesion
suggest
mait
cell
may
complement
nkt
cell
substitut
defici
invari
cell
ms
chemokin
gradient
play
role
lesion
expans
secondari
progress
multipl
sclerosi
secondari
progress
sp
multipl
sclerosi
ms
slowli
expand
demyelin
lesion
modest
inflammatori
cell
cuf
recent
evid
accumul
chemokin
play
import
role
leukocyt
recruit
inflammatori
site
also
recruit
brain
parenchym
cell
elucid
pathomechan
spm
term
glial
activ
investig
express
chemokin
receptor
demyelin
plaqu
immunohistochem
analysi
autopsi
brain
tissu
provid
uk
multipl
sclerosi
tissu
bank
reveal
numer
hypertroph
astrocyt
observ
rim
center
chronic
activ
lesion
microgliamacrophag
phagocytos
myelin
debri
also
found
lesion
border
contrast
cell
infiltr
minim
plaqu
characterist
abund
immunoreact
rim
lesion
ongo
demyelin
wherea
immunoreact
rel
weak
center
lesion
form
chemokin
gradient
doubl
immunofluorescens
stain
reveal
chemokin
receptor
express
hypertroph
astrocyt
chemokin
receptor
express
mhc
class
iiposit
microgliamacrophag
addit
matrix
report
one
final
effector
demyelin
predominantli
express
rim
plaqu
find
suggest
chemokin
express
astrocyt
play
import
role
microgliamacrophag
activ
expans
demyelin
lesion
spm
target
chemokin
spm
could
therefor
power
therapeut
approach
inhibit
lesion
expans
death
receptor
cn
role
decoy
b
cannella
gaupp
k
omari
cs
rain
albert
einstein
colleg
medicin
new
york
usa
mechan
myelin
oligodendrocyt
select
target
lesion
pathogenesi
multipl
sclerosi
ms
unknown
link
tumor
necrosi
factor
tnf
relat
damag
may
due
express
tnfrelat
deathinduc
surfac
receptor
present
studi
undertaken
investig
morpholog
biochem
techniqu
whether
death
receptor
four
receptor
tnfrelat
apoptosisinduc
ligand
trail
decoy
express
ms
lesion
whether
express
correl
diseas
activ
result
show
reactiv
dr
molecul
vari
among
microglia
astrocyt
oligodendrocyt
cn
tissu
studi
inflammatori
cell
activ
ms
lesion
dr
express
specif
ms
seen
differ
level
neurolog
diseas
ond
normal
cn
tissu
express
oligodendrocyt
cn
group
examin
function
implic
dr
express
human
oligodendrocyt
grown
vitro
expos
trail
apoptosi
measur
fac
use
tunel
techniqu
find
vivo
vitro
show
although
oligodendrocyt
ms
ond
normal
cn
express
display
apoptosi
treat
trail
vitro
neglig
evid
oligodendrocyt
apoptosi
around
ms
lesion
find
suggest
loss
oligodendrocyt
ms
probabl
result
nonapoptot
mechan
preserv
around
within
lesion
may
link
presenc
decoy
receptor
confoc
immunofluoresc
microscopi
optic
neuriti
john
w
rose
veda
l
tsoi
kenneth
e
hill
judith
warner
noel
g
carlson
object
optic
neuriti
demyelin
inflammatori
diseas
optic
nerv
may
occur
isol
diseas
relat
multipl
sclerosi
ms
initi
studi
evalu
immunopatholog
method
patholog
optic
nerv
obtain
autopsi
patient
clinic
recoveri
clinic
isol
normal
optic
nerv
tissu
probe
antibodi
patholog
antigen
includ
myelin
basic
protein
mbp
fragment
induc
form
nitric
oxid
synthas
ino
macrophag
marker
nitrotyrosin
cyclooxygenas
also
examin
myelin
basic
protein
mbp
oligodendrocyt
marker
cyclic
nucleotid
phosphodiesteras
cnpase
glial
fibrillari
acid
protein
gfap
result
affect
patholog
nerv
ino
macrophagesmicroglia
ino
astrocyt
nitrotyrosin
observ
ino
occasion
observ
unaffect
nerv
decreas
express
mbp
cnpase
seen
patholog
optic
nerv
along
evid
gliosi
ongo
myelin
degrad
indic
presenc
mbp
fragment
conclus
immunopatholog
clinic
isol
optic
neuriti
individu
resembl
observ
activ
ms
plaqu
despit
clinic
recoveri
evid
ongo
inflamm
demyelin
receptor
interact
regul
microglia
macrophag
multipl
sclerosi
nathali
kone
rm
hoek
huitinga
netherland
institut
neurosci
amsterdam
netherland
depart
experiment
immunolog
academ
medic
center
univers
amsterdam
amsterdam
netherland
membran
glycoprotein
highli
express
neuron
mice
shown
provid
inhibitori
signal
cell
myeloid
lineag
includ
macrophag
microglia
via
receptor
hoek
rm
et
al
scienc
activ
macrophag
microglia
thought
pivot
develop
inflammatori
lesion
central
nervou
system
patient
ms
hypothes
reduc
express
involv
activ
normal
quiescent
cell
therefor
first
studi
express
postmortem
frozen
brain
tissu
ms
patient
control
immunohistochemistri
secondli
use
laser
dissect
microscop
isol
well
defin
area
rim
centr
chronic
activ
chronic
inact
white
matter
ms
lesion
area
gene
express
profil
relat
molecul
involv
myeloid
cell
regul
determin
real
time
quantit
pcr
compar
normal
appear
white
matter
ms
patient
healthi
control
preliminari
result
show
upregul
rim
chronic
activ
lesion
wherea
rim
centr
chronic
inact
lesion
downregul
grant
dutch
foundat
ms
research
brain
tissu
netherland
brain
bank
glutam
excitotox
damag
demyelin
axon
glutam
excitotox
recent
implic
lesion
pathogenesi
multipl
sclerosi
ms
experiment
autoimmun
encephalomyel
eae
ampa
receptor
antagonist
shown
protect
oligodendrocyt
axon
eae
without
alter
inflammatori
respons
oligodendrocyt
axon
known
express
ampa
receptor
axon
damag
excitotox
believ
requir
presenc
oligodendrocyt
underhil
sm
soc
neurosci
abstr
sinc
axon
lost
chronic
demyelin
ms
lesion
examin
hypothesi
axon
vulner
glutam
excitotox
absenc
oligodendrocyt
cuprizon
toxic
model
util
weekold
mice
elimin
oligodendrocyt
myelin
cn
white
matter
tract
week
oral
cuprizon
administr
absenc
myelin
oligodendrocyt
corpu
callosum
confirm
luxol
fast
blue
anticnpas
stain
microstereotact
infus
glutam
receptor
agonist
ampa
control
vehicl
demyelin
corpu
callosum
result
substanti
axon
damag
assess
axonspecif
fluoresc
label
result
indic
ampa
toxic
axon
take
place
absenc
oligodendrocyt
myelin
extracellular
glutam
like
increas
chronic
ms
lesion
due
excess
glutam
product
andor
decreas
glutam
transport
express
thu
excitotox
damag
demyelin
axon
feasibl
scenario
excitotox
could
therefor
contribut
accumul
axon
loss
ms
lesion
may
thu
repres
target
neuroprotect
intervent
pitt
fellow
nation
ms
societi
usa
axon
sprout
adult
cn
elicit
longterm
increas
number
oligodendrocyt
length
myelin
fibr
remyelin
often
incomplet
absent
demyelin
cn
reason
attenu
repair
might
involv
inhibitori
factor
within
area
myelin
destruct
failur
demyelin
axon
support
myelin
oligodendrocyt
intrins
limit
capac
adult
oligodendrocyt
precursor
cell
matur
cn
fibr
axon
segment
lack
myelin
sheath
gener
experiment
induct
axon
sprout
investig
abil
axon
sprout
induc
myelin
respons
stratum
radiatum
lucidum
hippocamp
region
adult
murin
cn
region
pure
sprout
degener
use
transect
entorhinohippocamp
perfor
pathway
oligodendrocyt
specif
transgen
marker
demonstr
axon
sprout
result
signific
increas
number
oligodendrocyt
mark
myelin
respons
increas
length
myelin
fibr
scatter
prolifer
oligodendrocyt
precursor
cell
suggest
slow
recruit
myelin
cell
contrast
dentat
gyru
degener
occur
strong
cell
respons
subsequ
chang
oligodendrocyt
number
studi
demonstr
newli
sprout
axon
abl
elicit
myelin
respons
matur
cn
point
healthi
axon
mean
stimul
myelin
repair
demyelin
diseas
mediat
endoplasm
reticulum
stress
transgen
mous
model
multipl
sclerosi
background
complex
human
retroel
envelop
protein
upregul
cn
patient
ms
also
contribut
oligodendrocyt
death
demyelin
although
underli
pathogen
mechan
remain
unknown
method
develop
transgen
mous
line
select
express
cn
togeth
perform
analys
host
respons
brain
ms
nonm
patient
cultur
human
neural
cell
result
implant
corpu
callosum
transgen
mice
caus
neuroinflamm
neurobehavior
deficit
oligodendrocyt
injuri
also
activ
endoplasm
reticulum
er
stressrel
gene
bip
perk
oasi
ino
compar
wild
type
litterm
control
similar
find
er
stress
gene
ino
induct
observ
brain
ms
patient
induc
oasi
ino
express
astrocyt
conjunct
repress
transcript
factor
bind
promot
put
receptor
likewis
treatment
astrocyt
nitric
oxid
donor
also
suppress
astrocyt
dysfunct
result
er
stress
character
diminish
level
trophic
factor
particularli
inhibit
astrocyt
result
reduc
oligodendrocyt
viabil
mirror
reduc
express
brain
transgen
mice
ms
patient
compar
respect
control
discuss
mechan
oligodendrocyt
damag
demyelin
describ
herein
repres
novel
pathway
overexpress
human
endogen
retroel
protein
lead
astrocyt
dysfunct
advers
consequ
term
oligodendrocyt
viabil
function
rrmous
doubletransgen
sjlj
mous
model
spontan
relapsingremit
multipl
sclerosi
bernadett
gurumoorthi
krishnamoorthi
han
lassmann
hartmut
wekerl
andrea
holz
mpi
neurobiolog
martinsri
germani
institut
neurolog
univers
vienna
austria
first
gener
transgen
mice
tcr
specif
mog
peptid
context
ia
pair
tcr
gene
encephalitogen
cell
clone
inject
fertil
oocyt
fvb
origin
transgen
founder
backcross
sjlj
strain
seven
transgen
line
express
transgen
tcr
low
medium
high
frequenc
transgen
cell
respond
vigor
mog
vitro
produc
transfer
eae
upon
activ
tcr
mog
high
transgen
mice
line
cross
igh
mog
knockin
mice
igh
mog
express
h
chain
antimog
antibodi
doubl
transgen
mice
spontan
develop
eae
femal
male
within
month
age
tcr
mog
sjlj
mice
none
igh
mog
mice
develop
spontan
rreae
femal
male
eae
took
relapsingremit
cours
initi
bout
ataxia
weight
loss
follow
complet
recoveri
within
day
week
later
first
relaps
either
ataxia
classic
eae
relaps
left
neurolog
residua
inflammatori
lesion
domin
macrophag
cell
faith
reflect
natur
time
clinic
diseas
episod
locat
cellular
composit
lesion
hypomyelin
consequ
alter
mbp
gene
transcript
stefani
gaupp
glaucia
furtado
b
joseph
arezzo
sergio
lira
b
cedric
rain
albert
einstein
colleg
medicin
ny
usa
b
mt
sinai
medic
school
ny
usa
delay
immatur
myelin
note
number
transgen
model
transgen
question
control
myelinrel
promot
express
oligodendrocyt
studi
mice
overexpress
chemokin
involv
monocyt
recruit
chemokin
control
myelin
basic
protein
promot
produc
oligodendrocyt
notic
widespread
evid
hypomyelin
appar
throughout
cn
mice
four
month
age
pronounc
optic
nerv
subpial
zone
spinal
cord
area
oligodendrocyt
retain
immatur
phenotyp
structur
immunocytochem
vast
major
axon
nonmyelin
small
calib
remaind
thinli
myelin
astrocyt
process
invest
nake
axon
apart
occasion
monocyt
within
cn
breakdown
myelin
oligodendrocyt
patholog
promin
older
anim
deeper
white
matter
normal
myelin
interstiti
parenchyma
intens
gliotic
evid
apoptosi
oligodendrocyt
electrophysiolog
visual
evok
potenti
show
respons
delay
substanti
diminish
peak
amplitud
compar
agematch
wildtyp
litterm
data
present
protein
level
myelinationrel
gene
profil
development
pathway
associ
oligodendrocyt
matur
appar
arrest
find
underscor
need
care
analysi
cn
architectur
model
involv
transgen
express
glial
cell
support
part
nmss
ns
ns
ns
shown
tcell
major
popul
exhibit
clonal
alter
tcell
receptor
length
distribut
blood
multipl
sclerosi
ms
patient
aim
character
epitop
recogn
tcell
deriv
myelin
antigen
mbp
plp
mog
frequent
classi
mhc
patient
peptid
abl
bind
mhc
select
sequenc
analysi
antigen
synthesis
test
affin
correspond
mhc
recognit
peptid
ms
patient
normal
individu
ni
pbmc
test
ifng
elispot
among
ms
patient
exhibit
ifng
respons
follow
peptid
stimul
among
ni
test
similar
respons
signific
increas
frequenc
respond
cell
ms
patient
versu
ni
p
public
recognit
myelin
peptid
sinc
patient
privat
respons
pattern
identifi
new
epitop
myelin
protein
moreov
one
patient
show
serial
posit
respons
time
point
peptid
respond
new
peptid
follow
three
patient
test
posit
first
stimul
neg
second
correspond
relaps
collect
character
new
autoreact
peptid
ms
patient
higher
frequenc
respond
cell
blood
ni
ni
ms
patient
respond
variou
autoreact
peptid
respons
fluctuat
time
may
depend
diseas
state
calpain
activ
correl
cytokin
product
patient
multipl
sclerosi
ms
mk
guyton
imam
da
haqu
wr
tyor
sk
ray
nl
banik
medic
univers
south
carolina
charleston
sc
usa
multipl
sclerosi
ms
devast
cellmedi
autoimmun
diseas
cn
l
mechan
respons
cytokin
dysregul
seen
ms
unclear
howev
increas
express
activ
calpain
may
play
role
previou
studi
indic
increas
calpain
activ
correl
product
cytokin
interleukin
il
activ
peripher
blood
mononuclear
cell
pbmc
hypothes
calpain
expressionact
correl
cytokin
dysregul
activ
pbmc
relapsingremit
ms
patient
treatment
calpain
inhibitor
alter
cytokin
product
order
investig
role
calpain
cytokin
dysregul
pbmc
relapsingremit
ms
patient
agesexmatch
control
pretreat
h
calpain
inhibitor
calpeptin
vehicl
dmso
cell
activ
h
harvest
western
blot
analysi
calpain
express
activ
supernat
collect
determin
level
cytokin
preliminari
data
indic
calpain
express
activ
significantli
p
increas
activ
unactiv
pbmc
remiss
relaps
patient
versu
control
product
significantli
increas
relaps
patient
level
higher
remiss
patient
interestingli
pretreat
pbmc
calpeptin
result
decreas
cytokin
level
data
suggest
calpain
play
import
role
product
cytokin
patient
ms
support
nihnind
dendrit
cell
dc
potent
antigenpres
cell
critic
onset
immun
respons
gener
infect
bacteria
virus
implic
autoimmun
diseas
pathogenesi
inde
multipl
sclerosi
ms
relaps
frequent
associ
infect
instanc
bacteri
hypothesi
studi
establish
whether
dc
bacteriainfect
ms
patient
modifi
autoreact
cell
pattern
activ
thu
trigger
diseas
exacerb
hladr
bright
dc
separ
peripher
blood
exacerb
link
bacteri
infect
relaps
without
infect
dc
antigenpres
capac
assess
mbp
mog
specif
autolog
cell
clone
tcc
tcc
stimul
dc
infect
ms
patient
show
maxim
prolifer
induc
secret
time
less
concentr
incub
dc
isol
uninfect
individu
interestingli
tcc
incub
dc
infect
ms
patient
secret
even
absenc
exogen
antigen
activ
pattern
correl
increas
cell
surviv
dc
infect
ms
patient
secret
show
higher
express
myeloid
differenti
factor
well
molecul
compar
dc
uninfect
individu
overal
result
consist
concept
bacteri
infect
dc
play
critic
role
ms
relaps
induct
bdnf
product
immun
cell
patient
relaps
remit
multipl
sclerosi
reduc
respons
stimul
neuroimmunolog
laboratori
depart
neurolog
tel
aviv
souraski
medic
center
sackler
medic
school
tel
aviv
univers
tel
aviv
israel
studi
product
bdnf
pbmc
immun
regul
neuron
protect
untreat
patient
relaps
remit
ms
rrm
healthi
control
hc
cell
incub
sever
condit
monoclon
antibodi
mab
bdnf
supernat
measur
elisa
supernat
differ
condit
pbmc
ad
neuroblastoma
cell
line
starv
condit
order
studi
neuroprotect
potenti
measur
neuron
cell
count
neurit
count
length
cellular
analysi
bdnf
product
done
flow
cytometri
pbmc
rrm
patient
secret
lower
bdnf
pgml
compar
hc
pg
ml
p
monocyt
found
domin
bdnf
produc
compar
cell
b
cell
stimul
pbmc
hc
either
anti
mab
anti
mab
lp
enhanc
bdnf
secret
pgml
p
pgml
p
pgml
p
respect
anti
mab
stimul
enhanc
secret
pgml
vs
pgml
condit
p
supernat
pbmc
cultur
anti
lp
induc
protect
effect
neuroblastoma
cell
line
supernat
anti
stimul
pbmc
induc
cell
death
bdnf
secret
pbmc
rrm
patient
fail
upregul
summari
lower
bdnf
product
immun
cell
rrm
relat
dysregul
bdnf
via
may
contribut
neuron
damag
rrm
activ
cell
lyse
human
oligodendrocyt
vitro
exact
mechan
lysi
unknown
mani
way
cell
could
exert
cytotox
investig
possibl
might
particip
antibodydepend
cell
cytotox
adcc
via
express
receptor
iii
investig
cell
deriv
ms
patient
abl
caus
specif
injuri
target
cell
via
adcc
establish
vitro
experiment
system
use
human
monoclon
antibodi
rituximab
bridg
antibodi
b
lymphoma
cell
line
target
cytotox
measur
multipl
paramet
flow
cytometri
result
show
effector
target
ratio
e
adcctyp
specif
cytotox
cell
raji
cell
line
significantli
increas
presenc
rituximab
p
find
suggest
cell
via
fc
receptor
bind
could
lyse
potenti
target
antibodi
myelin
protein
increas
ms
serum
spinal
fluid
rais
possibl
cell
bind
antibodi
could
becom
effect
target
killer
oligodendrocyt
human
glial
cell
express
ligand
trigger
immun
cytotox
implic
multipl
sclerosi
immun
cell
gamma
delta
cell
identifi
lesion
within
central
nervou
system
cn
inflammatori
diseas
multipl
sclerosi
ms
suggest
activ
involv
oligodendrocyteneuron
injuri
human
nk
cell
cell
gamma
delta
cell
express
stimul
costimul
receptor
recogn
multipl
ligand
ligand
usual
express
stresseddamag
cell
aberrantli
express
target
autoimmun
inflammatori
diseas
celiac
diseas
rheumatoid
arthriti
contribut
enhanc
cytotox
immun
effector
local
sought
determin
whether
ligand
express
human
cn
cell
ligand
detect
primari
cultur
human
adult
oligodendrocyt
fetal
astrocyt
proinflammatori
cytokin
increas
express
astrocyt
suggest
inflammatori
condit
ligand
could
upregul
vitro
kill
assay
use
activ
human
gamma
delta
cell
nk
cell
effector
demonstr
oligodendrocyt
astrocyt
suscept
injuri
sinc
blockad
consist
reduc
extent
death
immunohistochem
analys
suggest
ligand
select
detect
ms
lesion
absent
normal
appear
white
matter
result
impli
recognit
ligand
oligodendrocyt
astrocyt
bear
immun
effector
could
contribut
cytotox
respons
especi
inflammatori
condit
occur
ms
reduc
interferontyp
induc
activ
interferon
type
receptor
express
peripher
blood
mononuclear
cell
interferonna
relaps
remit
multipl
sclerosi
patient
cs
constantinescu
fahey
ra
robin
multipl
sclerosi
ms
inflammatori
demyelin
diseas
central
nervou
system
characteris
clinic
neurolog
deficit
often
relaps
remit
type
interferon
ifn
compris
ifnbeta
ifnalpha
immunomodulatori
effect
benefici
relapsingremit
rr
ms
ifnbeta
ifnalpha
bind
receptor
activ
signal
pathway
includ
phosphoryl
signal
transduct
molecul
object
studi
compar
ifn
activ
patient
ms
treatment
ifn
normal
control
assess
activ
intracellular
stain
phosphospecif
antibodi
flow
cytometri
investig
activ
ifnbeta
alpha
patient
rr
ms
age
sex
match
healthi
control
found
activ
significantli
reduc
rrm
patient
compar
control
ifnbeta
capabl
induc
phosphoryl
ifnalpha
reduc
compar
control
determin
mechan
reduc
activ
untreat
ms
quantifi
interferon
type
receptor
ifnar
express
peripher
blood
mononuclear
cell
ms
compar
control
flow
cytometri
use
antibodi
ifnar
quantit
revers
transcriptasepolymeras
chain
reaction
found
express
ifnar
reduc
rrm
patient
compar
control
studi
suggest
rrm
patient
may
reduc
ifntyp
respons
compar
control
sinc
shown
ifnbeta
induc
ifnar
ms
patient
shown
ifn
type
defici
may
explain
reduc
ifntyp
level
ms
current
studi
determin
whether
treatment
ifnbeta
enhanc
ifn
respons
support
ms
societi
uk
northern
ireland
detect
nkcell
put
regul
multipl
sclerosi
diseas
activ
pregnanc
object
multipl
sclerosi
ms
typic
amelior
pregnanc
deliveri
increas
relaps
rate
studi
conduct
better
understand
immunoregulatori
mechan
behind
phenomenon
method
prospect
studi
includ
clinic
radiolog
andor
immunolog
followup
mspatient
pregnanc
six
month
postpartum
period
group
healthi
pregnant
nonpregn
person
nonpregn
mspatient
studi
control
laboratori
investig
includ
measur
intracytoplasm
cytokin
product
peripher
blood
lymphocyt
subtyp
analysi
cell
b
cell
nk
cell
pregnanc
use
immunofluoresc
stain
fac
analysi
result
annual
relaps
rate
significantli
reduc
third
trimest
pregnanc
increas
deliveri
product
interferongamma
peripher
blood
mononuclear
cell
significantli
less
pregnanc
postpartum
period
result
increas
ratio
pregnanc
msgroup
control
group
ms
ratio
pregnanc
deliveri
diminish
msdiseas
activ
last
trimest
pregnanc
associ
expans
circul
bright
regulatori
nkcell
simultan
proport
circul
dim
nkcell
reduc
conclus
bright
nk
cell
known
effici
produc
cytokin
henc
observ
vivo
expans
bright
nk
cell
pregnanc
may
implic
potenti
role
bright
regulatori
nk
cell
control
autoimmun
pregnanc
ms
differenti
modul
immun
respons
multipl
sclerosi
viral
parasit
infect
j
correal
fiol
farez
epidemiolog
clinic
observ
suggest
viral
infect
may
introduc
bia
immun
respons
multipl
sclerosi
ms
patient
turn
trigger
diseas
exacerb
convers
strike
invers
correl
occur
parasit
infect
autoimmun
diseas
immun
respons
ms
patient
viral
infect
ms
patient
present
parasit
infect
studi
number
secret
cell
higher
pbmc
collect
exacerb
associ
viral
infect
stabl
diseas
exacerb
without
infect
parasit
infect
ms
patient
hand
mbpspecif
respons
show
signific
increas
decreas
secret
cell
compar
uninfect
ms
individu
addit
viral
antigen
ag
stimul
induc
maxim
myelinag
specif
cell
effector
respons
concentr
time
lower
nativ
ag
alon
moreov
mbpspecif
cell
clone
parasiteinfect
patient
character
cytokin
profil
similar
cell
subset
clone
frequenc
cell
substanti
increas
parasit
infect
ms
patient
compar
uninfect
viral
infect
ms
individu
overal
observ
suggest
wherea
viral
infect
increas
pbmc
respons
myelinag
caus
respons
increas
relaps
risk
parasit
infect
abl
induc
regulatori
cell
contrari
induc
remiss
diseas
pregnanc
natur
modul
diseas
activ
multipl
sclerosi
diseas
activ
relapsingremit
multipl
sclerosi
ms
significantli
modul
pregnanc
follow
clear
rebound
activ
deliveri
biolog
mechan
behind
phenomenon
larg
unknown
better
insight
natur
immun
endocrin
mechan
associ
clinic
suppress
diseas
ms
relev
futur
manag
diseas
rotterdam
studi
pregnanc
ms
aim
investig
immun
alter
observ
peripher
blood
investig
gene
express
differ
stage
pregnanc
blood
monocyt
purifi
use
mac
rna
extract
gene
express
probe
use
affymetrix
rnaarray
sampl
assess
longitudin
seri
time
point
per
patient
correct
multipl
test
gene
transcript
pilot
studi
gene
differenti
express
monocyt
fraction
pregnanc
compar
nonpregn
timepoint
major
gene
downregul
link
immun
function
chemokin
famili
member
proinflammatori
cytokin
lend
support
hypothesi
pregnanc
also
innat
respons
attenu
signific
find
confirm
taqmanpcr
protein
level
use
immunoassay
moreov
data
correl
serum
level
measur
elisa
well
clinic
diseas
activ
exacerb
deliveri
function
deficit
regulatori
cell
multipl
sclerosi
multipl
sclerosi
believ
cellmedi
autoimmun
disord
central
nervou
system
may
involv
impair
immun
regulatori
mechan
studi
examin
cell
isol
peripher
blood
ms
patient
healthi
individu
found
cell
number
cell
ms
slightli
higher
healthi
individu
treg
specif
gene
express
cell
deriv
ms
patient
significantli
lower
healthi
control
furthermor
cell
isol
ms
patient
less
inhibitori
effect
cell
activ
compar
cell
deriv
healthi
control
result
suggest
cell
ms
repres
mostli
vivo
activ
inflammatori
cell
lack
express
inhibitori
function
function
deficit
regulatori
cell
might
contribut
hyperact
cell
proinflammatori
potenti
ms
mobil
myeloid
progenitor
blood
multipl
sclerosi
patient
recent
data
indic
blood
monocyt
form
heterogen
cell
popul
compris
subset
progenitor
cell
express
surfac
molecul
found
haematopoiet
progenitor
haematopoiet
stem
cell
microglia
cell
endow
high
prolif
potenti
display
differenti
potenti
toward
macrophag
dendrit
cell
possibl
microglia
assess
behavior
bloodcircul
myeloid
cell
multipl
sclerosi
ms
patient
analyz
fac
peripher
blood
mononuclear
cell
pbmc
obtain
relapsingremit
ms
rrm
primari
progress
ms
ppm
healthi
control
subject
parallel
experi
perform
function
assay
cultur
pbmc
methylcellulos
supplement
macrophagecoloni
stimul
factor
percentag
cell
mhc
class
ii
cell
cell
unchang
ms
patient
compar
control
contrast
rrm
patient
rpm
patient
show
increas
percentag
myeloid
cell
rrm
patient
rpm
patient
control
p
student
test
increas
partli
due
specif
expans
cell
shown
doublestain
experi
accordingli
could
gener
larg
coloni
macrophag
least
cell
per
coloni
ms
patient
control
data
show
myeloid
progenitor
mobil
blood
ms
patient
migratori
behavior
fate
cell
neuroinflammatori
condit
current
assess
mice
secondari
progress
contrast
relapsingremit
multipl
sclerosi
patient
show
normal
regulatori
cell
function
express
present
studi
phenotyp
function
characterist
regulatori
cell
treg
isol
peripher
blood
patient
relapsingremit
rr
n
secondari
progress
sp
n
multipl
sclerosi
ms
investig
signific
quantit
abnorm
cell
rrand
spm
patient
detect
howev
mean
suppress
capac
treg
toward
induc
respond
cell
prolifer
found
significantli
lower
rrm
patient
compar
treg
spm
patient
suppress
ms
deriv
treg
correl
diseas
durat
age
indic
treg
function
affect
earli
phase
diseas
process
treg
spm
patient
show
normal
level
mrna
contrast
treg
rrm
patient
reduc
express
recent
develop
cfse
base
assay
compar
myelin
specif
respons
cell
treg
deplet
cell
ie
cell
cell
respons
myelin
basic
protein
mbp
myelin
oligodendrocyt
glycoprotein
mog
increas
treg
deplet
cell
healthi
control
current
use
indirect
approach
analyz
treg
suppress
myelin
cell
reactiv
ms
patient
taken
togeth
data
first
demonstr
differ
function
express
cell
patient
rrand
spm
addit
treg
appear
control
myelin
specif
cell
respons
healthi
subject
enhanc
level
antimyelin
antibodi
multipl
sclerosi
patient
assess
flow
cytometri
antibodi
thought
contribut
cn
inflamm
demyelin
subgroup
multipl
sclerosi
ms
patient
antibodi
direct
number
myelin
protein
measur
serum
multipl
sclerosi
ms
patient
singl
antigen
associ
exclus
ms
studi
anim
model
suggest
antibodi
demyelin
capac
direct
nativ
conform
posttransl
modifi
epitop
current
method
detect
antimyelin
antibodi
often
allow
recognit
epitop
recombin
denatur
protein
use
antigen
develop
reproduc
flow
cytometrybas
assay
detect
serum
antibodi
bind
human
whole
myelin
allow
detect
antibodi
bind
conform
posttransl
modifi
epitop
use
assay
antimyelin
antibodi
measur
serum
ms
patient
healthi
donor
hd
group
level
antimyelin
igm
level
ms
slightli
higher
hd
p
mannwhitney
addit
ms
patient
show
highli
signific
increas
antimyelin
igg
p
mannwhitney
analysi
individu
ms
patient
reveal
approxim
ms
patient
show
enhanc
antimyelin
igg
level
compar
hd
enhanc
antimyelin
igm
igg
level
found
clinic
subgroup
ms
patient
rr
sp
pp
antimyelin
antibodi
level
correl
diseas
sever
edss
mfsc
summari
myelin
flow
cytometri
assay
detect
increas
level
antimyelin
antibodi
subpopul
ms
indic
assay
may
provid
valuabl
biomark
identifi
patient
antibodymedi
inflamm
proteom
analisi
autoantibodi
reactiv
neural
antigen
sera
cerebrospin
fluid
multipl
sclerosi
patient
sever
protein
central
nervou
system
cn
investig
potenti
target
antibodydepend
immun
respons
multipl
sclerosi
ms
spite
effort
precis
ident
ms
autoantigen
clearli
defin
yet
studi
investig
employ
recombin
antigen
andor
relev
peptid
preselect
target
present
studi
overcom
restrict
approach
use
larg
panel
nativ
protein
antigen
deriv
white
matter
homogen
human
healthi
cn
compar
igg
repertoir
sera
cerebrospin
fluid
csf
control
subject
ms
patient
immunoblot
resolut
result
analysi
seric
csf
igg
reactiv
show
altogeth
spot
among
spot
specif
recogn
ms
patient
particular
identifi
seric
igg
csf
igg
major
spot
recogn
correspond
sera
thu
indic
compartiment
autoimmun
respons
noteworthi
spot
detect
seric
igg
csf
igg
present
ms
case
absent
control
sera
conclus
techniqu
allow
us
increas
sensit
analysi
compar
studi
autoantibodi
reactiv
cn
antigen
techniqu
enabl
identif
spot
serum
csf
ms
patient
detect
control
character
mass
spectrometri
provid
import
inform
regard
target
antigen
involv
autoimmun
respons
ms
subgroup
autoreact
bcell
mediat
immun
respons
earli
fingerprint
neurolog
disord
associ
autoimmun
process
identifi
antigen
target
autoimmun
demyelin
disord
use
analysi
serum
selfigg
respons
associ
proteom
approach
serpa
differ
clinic
experiment
model
neurolog
disord
associ
autoimmun
respons
first
step
global
analysi
western
blot
serum
selfigg
respons
healthi
multipl
sclerosi
ms
human
brain
protein
antigen
allow
discrimin
pattern
obtain
ms
patient
healthi
subject
three
clinic
form
ms
cluster
discrimin
antigen
band
also
found
studi
sequenti
chang
progress
experiment
autoimmun
encephalomyel
eae
manipul
either
antiinflammatori
drug
enhanc
deplet
regulatori
cell
test
signific
chang
potent
hallmark
diseas
activ
serum
selfigg
respons
also
evalu
neuropsychiatr
system
lupu
erythematosu
npsle
clinic
isol
syndrom
patient
ci
earliest
clinic
event
ms
singular
selfigg
pattern
found
npsle
prospect
studi
shown
signific
number
patient
ci
present
autoreact
pattern
predict
develop
clinic
definit
ms
subsequ
proteom
approach
perform
character
molecular
target
involv
previous
note
organ
specif
autoimmun
diseas
ubiquit
protein
appear
major
discrimin
target
found
ms
eae
npsle
case
specif
brain
deriv
antigen
target
found
thu
serpa
provid
promis
approach
investig
self
candid
antigen
involv
either
regulatori
pathogen
process
autoimmun
disord
develop
new
diagnost
tool
antigen
microarray
identifi
uniqu
immun
repertoir
multipl
sclerosi
ms
use
antigen
microarray
studi
repertoir
serum
antibodi
relapsingremit
rr
secondari
progress
sp
primari
progress
pp
ms
antigen
microarray
consist
antigen
includ
cnsrelat
autoantigen
eg
mbp
mog
plp
lipid
gangliosid
galactocerebrosid
autoantigen
eg
insulin
gad
collagen
gbm
viral
pathogen
eg
ebv
herp
varicella
randomli
assign
sampl
learn
set
test
set
investig
natur
autoantibodi
serum
dilut
assay
two
independ
array
result
analyz
use
genespr
softwar
found
could
distinguish
rrm
spm
ppm
healthi
control
uniqu
antibodi
pattern
singl
antibodi
reactiv
antibodi
pattern
use
analyz
test
set
correctli
identifi
rrm
spm
ppm
pattern
observ
differ
found
neurolog
diseas
discrimin
pattern
antibodi
reactiv
demonstr
igg
inform
igm
howev
detail
analysi
antibodi
improv
sensit
discrimin
antibodi
identifi
primarili
target
cnsspecif
antigen
also
contain
antibodi
direct
kda
kda
heat
shock
protein
igm
antibodi
ebv
associ
rrm
spm
result
demonstr
uniqu
immun
repertoir
ms
could
use
biomark
diagnosi
evalu
ms
patient
potenti
identifi
healthi
individu
risk
ms
function
relev
autoantibodi
myelin
peopl
multipl
sclerosi
mani
studi
identifi
antibodi
myelin
axon
protein
glycolipid
peopl
multipl
sclerosi
ms
studi
found
increas
level
antibodi
specif
myelin
proteolipid
protein
plp
epitop
sera
peopl
ms
compar
healthi
control
patient
neurolog
diseas
ond
studi
primarili
use
enzymelink
immunosorb
assay
elisa
immunoblot
detect
antibodi
possibl
antibodi
identifi
may
particularli
relev
diseas
process
may
recogn
antigen
nativ
configur
like
necessari
antibodi
function
relev
ms
therefor
studi
whether
antibodi
patient
ms
recogn
antigen
nativ
conform
use
human
myelin
opson
assay
flow
cytometri
stabl
cell
line
express
human
myelin
protein
find
antibodi
peopl
ms
significantli
better
opson
myelin
antibodi
healthi
control
patient
ond
flow
cytometri
assay
stabl
cell
line
gener
express
either
plp
altern
splice
isoform
myelin
basic
protein
mbp
oligodendrocytespecif
protein
osp
attach
fluoresc
marker
cell
incub
serum
sampl
peopl
ms
control
fitclabel
antihuman
antibodi
ad
cell
read
flow
cytomet
studi
show
whether
myelinspecif
antibodi
found
peopl
ms
like
function
relev
diseas
antibodi
produc
clonal
expand
plasma
cell
cerebrospin
fluid
ms
patient
display
cn
autoreact
oligoclon
igg
product
clonal
expand
bplasma
cell
diagnost
hallmark
csf
ms
patient
increas
evid
support
role
autoantibodi
pathogenesi
demyelin
ms
lesion
antigen
specif
pathogen
relev
oligoclon
csf
igg
remain
larg
unknown
perform
singl
cell
rtpcr
express
immunoglobulin
gene
individu
facssort
csfplasma
cell
ms
patient
follow
sequenc
analysi
express
pair
heavi
h
light
l
chain
gene
clonal
expand
plasma
cell
whole
recombin
human
eukaryot
express
system
recombin
human
monoclon
test
western
blot
immunofluoresc
stain
brain
tissu
reactiv
cn
antigen
h
chain
variabl
region
ighv
gene
expand
plasma
cell
clone
csf
ms
patient
mostli
util
subfamili
gene
monoclon
recombin
antibodi
deriv
differ
patient
show
specif
reactiv
antigen
present
brain
tissu
summari
find
sign
antigen
driven
cnsautoreact
humor
immun
respons
cn
compart
patient
ms
remain
unclear
whether
autoantibodi
respons
part
primari
immun
respons
lead
secondari
immun
respons
result
tissu
destruct
ms
pathogen
relev
antibodi
respons
subject
investig
diagnost
valu
csf
autoantibodi
heterogen
nuclear
ribonucleoprotein
multipl
sclerosi
patient
object
aim
studi
draw
conclus
implic
antiheterogen
nuclear
ribonucleoprotein
hnrnp
andor
antibodi
ab
multipl
sclerosi
ms
human
tcell
lymphotrop
viru
type
htlvi
associ
myelopathytrop
spastic
paraparesi
hamtsp
method
use
recombin
hnrnp
protein
western
blot
conduct
detect
antihnrnp
ab
csf
sampl
fulli
mask
condit
result
enrol
case
neurolog
abnorm
test
csf
antihtlvi
ab
among
case
neg
antihtlvi
ab
incid
csf
antihnrnp
ab
highest
ms
n
significantli
differ
incid
neurodegen
diseas
n
p
meningoenceph
n
p
inflammatori
polyneuropathi
n
p
among
case
posit
antihtlvi
ab
incid
csf
antihnrnp
ab
far
lower
hamtsp
n
group
diseas
n
interpret
present
studi
confirm
previou
find
regard
signific
associ
csf
antihnrnp
ab
ms
fail
demonstr
diagnost
valu
csf
antihnrnp
ab
ham
tsp
csf
antihnrnp
ab
may
provid
clue
diagnosi
ms
object
helicobact
pylori
hp
infect
previous
report
relat
variou
diseas
neutrophil
activ
protein
hpnap
capabl
activ
neutrophil
monocyt
aim
studi
disclos
preval
hp
infect
immun
respons
hp
proinflammatori
protein
hpnap
japanes
patient
multipl
sclerosi
ms
method
investig
presenc
antihp
antihpnap
reactiv
serum
ms
patient
n
compar
healthi
control
n
ms
patient
clinic
classifi
two
subtyp
opticospin
type
osm
convent
type
cm
result
found
frequenc
hp
seroposit
significantli
lower
cm
patient
compar
osm
patient
healthi
control
p
p
respect
analyz
separ
year
birth
patient
born
hp
seroposit
rate
significantli
lower
cm
osm
patient
p
sever
visual
impair
fs
higher
significantli
common
hpseroposit
patient
seroneg
patient
total
ms
patient
p
edss
score
final
followup
differ
significantli
hp
seroposit
seroneg
group
antihpnap
antibodi
found
posit
patient
ms
osm
patient
posit
conclus
studi
indic
differ
hp
seroposit
antibodi
proinflammatori
protein
hpnap
osm
cm
japanes
although
studi
requir
observ
may
suggest
distinct
childhood
environ
suffer
condit
role
chronic
infect
aetiologypathogenesi
idiopath
parkinson
object
elucid
causal
systemat
explor
clinic
clue
call
widerang
laboratoryclin
expertis
method
simpl
reliabl
object
measur
facet
parkinson
underpin
statist
model
hypothesi
gener
efficaci
studi
result
date
proofofprincipl
infect
contribut
idiopath
parkinson
ip
provid
case
studi
interim
protocol
analys
efficaci
studi
contrast
effect
timecours
ip
facet
success
helicobact
pylori
hp
erad
vs
placebo
vs
failur
helicobact
malign
ip
appear
convert
benign
mark
deterior
accompani
failur
categoris
accord
presenceabs
overt
helicobact
infect
use
therapeut
tool
even
late
ip
cachexia
although
hp
infect
overt
minor
proband
predict
probabl
parkinsonian
label
depend
serum
immunoblot
hp
antibodi
profil
clinicallyrelev
gradient
discrimin
index
diseaseburden
progress
inde
begin
explor
ureabreathtest
neg
ip
find
molecular
evid
infect
gastric
biopsi
growth
routin
cultur
presum
due
low
organ
densiti
moreov
earli
experi
open
intervent
suggest
might
prove
benefici
cultureposit
case
conclus
point
direct
surrog
necessarili
uniqu
role
particular
infect
pathogenesi
ip
eradicationfailur
bolusreleas
antigen
kill
bacteria
could
aggrav
effect
ongo
infect
appar
import
helicobact
aetiologypathogenesi
ip
confin
overt
infect
antinogo
receptor
autoantibodi
serum
multipl
sclerosi
object
myelinassoci
neurit
outgrowth
inhibitor
nogoa
play
key
role
inhibit
axon
regener
axon
damag
begin
earli
stage
ms
respons
perman
neurolog
deficit
although
molecular
mechan
remain
unknown
aim
studi
preval
autoantibodi
nogoa
nogo
receptor
ngr
serum
ms
method
antibodi
identifi
serum
ms
patient
patient
nonm
neurolog
diseas
ond
healthi
control
hc
subject
western
blot
use
recombin
human
nogoaspecif
segment
na
share
segment
nogoa
b
nab
nonglycosyl
form
ngr
glycosyl
ngr
ngrfc
myelin
oligodendrocyt
glycoprotein
mog
result
none
show
igg
antibodi
na
nab
contrast
ms
ond
hc
subject
exhibit
igg
ms
ond
hc
show
antimog
igg
none
hc
ms
ond
show
antinonglycosyl
ngr
igg
furthermor
ms
ond
hc
show
antingrfc
igg
conclus
igg
autoantibodi
ngr
mog
often
detect
serum
ms
control
serv
msspecif
marker
measur
cerebrospin
fluid
csf
serum
level
activ
matrix
tissu
inhibitor
activ
assay
system
elisa
respect
relapsingremit
rr
multipl
sclerosi
ms
patient
group
accord
clinic
magnet
reson
imag
mri
evid
diseas
activ
patient
inflammatori
neurolog
disord
oind
patient
noninflammatori
neurolog
disord
nind
statist
analysi
perform
mannwhitney
bonferroni
posthoc
correct
spearman
rank
correl
coeffici
test
csf
serum
activ
ratio
higher
ms
nind
p
p
respect
mri
inact
mri
activ
ms
patient
p
p
respect
wherea
csf
activ
ratio
elev
ms
oind
p
intrathec
synthesi
activ
greater
ms
oind
nind
p
mri
inact
mri
activ
ms
patient
p
addit
posit
correl
r
p
found
serum
activ
ratio
ms
diseas
durat
overal
result
suggest
shift
balanc
toward
proteolyt
activ
could
relev
tissu
repair
subset
ms
patient
mri
inact
diseas
seem
indic
serum
activ
ratio
may
repres
potenti
surrog
biomark
monitor
ms
diseas
durat
cell
surfac
adhes
molecul
cytokin
profil
blood
csf
primari
progress
multipl
sclerosi
object
evalu
whether
express
adhes
molecul
am
cytokin
blood
csf
could
use
marker
diseas
activ
primari
progress
multipl
sclerosi
ppm
method
express
am
level
cytokin
patient
ppm
compar
spm
control
correl
volum
focal
atroph
chang
brain
magnet
reson
imag
mri
result
express
late
activ
antigen
lymphocyt
function
associ
antigen
intercellular
adhes
blood
csf
higher
ppm
control
comparison
ppm
spm
show
higher
level
blood
csf
ppm
level
vascular
adhes
molecul
higher
blood
differ
level
cytokin
serum
csf
ppm
spm
control
evid
intrathec
synthesi
found
ppm
express
csf
ppm
correl
total
volum
cerebr
lesion
number
diffus
brain
lesion
mri
amount
csf
correl
number
spinal
lesion
conclus
upregul
express
am
blood
csf
evid
intrathec
synthesi
ppm
indic
import
inflammatori
chang
pathogenesi
ppm
suggest
use
molecul
marker
diseas
activ
ms
subtyp
regul
monocyt
express
multipl
sclerosi
use
treat
relaps
multipl
sclerosi
ms
respons
treatment
differ
among
patient
suggest
differ
sensit
gc
due
induct
gc
wonder
might
valuabl
marker
predict
glucocorticoid
respons
result
indic
induc
regul
vitro
well
vivo
final
vitro
induc
gc
correl
posit
clinic
respons
gc
suggest
possibl
prognost
marker
gc
sensit
level
serum
igm
antibodi
refold
recombin
human
mog
predict
respons
corticosteroid
treatment
acut
multipl
sclerosi
relaps
background
antimyelinoligodendrocyteglycoprotein
mog
antibodi
ab
discuss
biolog
marker
multipl
sclerosi
ms
patient
highdos
methylprednisolon
hdmp
iv
therapi
establish
treatment
acut
relaps
mspatient
howev
scant
inform
impact
corticosteroid
treatment
auto
antibodi
avail
object
establish
elisa
test
system
detect
serum
igg
igm
ab
direct
refold
recombin
human
mog
prospect
investig
whether
acut
relaps
subsequ
hdmp
therapi
impact
serum
antimog
ab
mspatient
whether
antimog
ab
level
might
predict
respons
hdmp
therapi
method
anti
refold
recombin
human
mog
elisa
evalu
mspatient
healthi
control
hc
mspatient
prospect
enrol
serum
sampl
analyz
remiss
relaps
acut
relaps
hdmp
treatment
week
hdmp
therapi
result
antimog
igg
sensit
specif
p
antimog
igm
sensit
specif
p
antibodi
level
significantli
increas
mspatient
compar
hc
hdmp
treatment
significantli
reduc
antimog
igg
p
total
igg
p
antimog
igm
total
igm
ab
level
patient
complet
remiss
acut
relaps
signific
increas
antimog
igm
ab
level
baselin
acut
relaps
valu
conclus
find
prospect
studi
could
import
futur
decis
patient
acut
relaps
especi
decis
regard
either
dosingdur
hdmp
escal
therapi
demonstr
multipl
sclerosi
ms
deregul
program
cell
death
pcd
play
key
role
induc
maintain
autoreact
immun
phenomenon
lead
demyelin
lesion
present
studi
investig
pcd
myelin
basic
protein
mbp
specif
lymphocyt
relapsingremit
rr
ms
patient
acut
am
stabl
ms
sm
healthi
control
hc
analyz
flow
cytometri
apoptot
prolifer
cell
percentag
rt
pcr
express
differ
anti
flip
xiap
pro
bid
apoptot
gene
sort
cell
stimul
mbp
peptid
differ
analyz
tstudent
mannwhitney
test
percentag
apoptot
mbp
specif
cell
decreas
am
compar
sm
p
hc
p
higher
prolifer
index
mbp
specif
cell
found
am
hc
compar
sm
p
higher
express
even
thought
statist
signific
anti
pro
apoptot
gene
shown
rrm
compar
hc
howev
signific
increas
anti
apoptot
gene
flip
xiap
observ
mbpspecif
sort
am
compar
hc
data
obtain
evid
specif
activ
immun
system
mbp
patient
am
hc
increas
pcd
hc
switch
mbp
specif
cell
immun
respons
am
decreas
apoptot
mbp
specif
cell
seem
involv
immun
mediat
destruct
myelin
sheath
differ
tradd
express
indic
array
analysi
discrimin
ms
diseas
subtyp
relapsingremit
rr
primari
progress
pp
ms
differ
clinic
cours
like
also
underli
pathomechan
studi
aim
identifi
biomark
associ
subtyp
ms
use
cdna
array
analysi
blood
mononuclear
cell
pbmc
initi
approach
array
analysi
perform
use
pool
rna
deriv
pbmc
patient
stabl
rrm
ppm
immunomodulatori
treatment
use
realtim
rtpcr
differenti
express
candid
gene
quantifi
individu
ms
patient
two
independ
patient
cohort
contain
subgroup
ppm
b
ppm
gene
express
array
analysi
identifi
gene
differenti
upregul
rrm
ppm
sever
candid
gene
reanalys
individu
quantit
rtpcr
death
domain
contain
protein
tradd
involv
tumor
necrosi
factor
receptor
tnfr
superfamili
signal
consist
express
higher
level
ppm
patient
compar
rrm
healthi
control
result
confirm
two
independ
cohort
high
express
tradd
protein
associ
infiltr
detect
spinal
cord
ms
patient
result
western
blot
threecolour
fac
analysi
tradd
differ
pbmc
popul
present
array
analysi
use
screen
approach
pool
ms
patient
sampl
identifi
differenti
express
gene
tradd
member
tnfr
superfamili
one
candid
gene
may
serv
biomark
discrimin
ppm
rrm
patient
suggest
distinct
pathogen
process
ms
subtyp
invers
associ
csf
level
solubl
hlag
fa
molecul
ms
patient
evid
mri
diseas
activ
studi
elisa
techniqu
cerebrospin
fluid
csf
level
classic
solubl
hlai
shlai
nonclass
solubl
hlag
shlag
solubl
fa
sfa
molecul
relapsingremit
rr
multipl
sclerosi
ms
patient
categor
accord
clinic
magnet
reson
imag
mri
evid
diseas
activ
patient
inflammatori
neurolog
disord
oind
patient
noninflammatori
neurolog
disord
nind
statist
analysi
perform
mannwhitney
bonferroni
posthoc
correct
spearman
rank
correl
coeffici
test
csf
level
shlag
higher
ms
oind
nind
p
p
respect
mri
inact
mri
activ
ms
patient
p
csf
shlai
concentr
elev
ms
nind
p
oind
nind
p
mri
activ
mri
inact
ms
patient
p
csf
level
sfa
lower
ms
oind
nind
p
p
respect
mri
inact
mri
activ
ms
patient
p
ms
patient
evid
mri
activ
trend
toward
neg
correl
found
csf
concentr
shlag
shlai
csf
level
shlag
sfa
result
seem
indic
csf
shlaishlag
balanc
could
modul
ms
activ
opposit
direct
suggest
potenti
immunoregulatori
role
shlag
control
ms
diseas
activ
fasmedi
apoptosi
vivo
macrophag
activ
imag
inflammatori
brain
lesion
multipl
sclerosi
use
mri
mitsunori
kanagaki
vincent
dousset
bruno
brochet
klau
g
petri
object
multipl
sclerosi
ms
activ
microglia
bloodborn
macrophag
play
pivot
role
inflammatori
process
caus
myelin
axon
loss
present
new
mr
imag
modal
monitor
vivo
macrophag
brain
infiltr
ms
rat
model
experiment
autoimmun
encephalomyel
eae
ultrasmal
superparamagnet
iron
oxid
uspio
nanoparticl
method
uspio
intraven
given
eae
rat
ms
patient
acut
attack
mriuspio
perform
h
later
mr
scanner
human
rat
comparison
gadolinium
gd
mri
marker
bloodbrain
barrier
permeabl
eae
rat
evalu
histolog
underli
physiopatholog
immunomark
result
acut
eae
uspio
enhanc
lesion
detect
gd
enhanc
uspio
proven
local
tissu
macrophag
ms
patient
lesion
show
uspio
uptak
gadolinium
enhanc
two
patient
present
lesion
enhanc
uspio
neg
gd
remain
lesion
detect
gd
j
neuroradiol
press
acut
relaps
eae
mriuspio
allow
monitor
efficaci
immunomodulatori
therapi
mult
scler
predict
alreadi
clinic
eae
onset
histopatholog
handicap
sever
neuroimag
press
conclus
uspio
appli
safe
inflammatori
human
diseas
acut
ms
uspio
gd
provid
complementari
inform
brain
lesion
mriuspio
promis
tool
monitor
vivo
dynam
macrophag
activ
modul
upon
therapeut
morphometri
corpu
callosum
earli
marker
brain
atrophi
patient
probabl
multipl
sclerosi
shmuel
miron
reshef
yael
nissan
anat
achiron
background
modern
neuroimag
techniqu
provid
inform
brain
structur
multipl
sclerosi
ms
possibl
studi
axon
loss
known
occur
earli
stage
diseas
irrevers
axon
loss
associ
brain
atrophi
overtim
lead
clinic
disabl
object
investig
whether
chang
area
corpu
callosum
cc
detect
earli
patient
probabl
ms
method
brain
mri
perform
subject
femal
male
clinic
isol
demyelin
event
suggest
ms
probabl
ms
healthi
subject
match
age
gender
serv
control
midsagitt
brain
mr
imag
use
measur
cc
total
area
subregion
anterior
middl
posterior
result
area
ccn
patient
probabl
ms
differ
significantli
healthi
subject
match
age
sex
howev
total
area
ccn
probabl
ms
group
significantli
diminish
mm
baselin
mm
one
year
p
decreas
mainli
attribut
middl
region
cc
diminish
mm
baselin
mm
one
year
p
conclus
measur
cc
area
subregion
reliabl
tool
detect
earli
chang
cc
find
demonstr
structur
chang
detect
even
patient
probabl
ms
thu
support
role
earli
treatment
even
patient
probabl
ms
dna
microarray
analysi
identifi
ligand
chemokin
earli
ifnrespons
gene
peripher
blood
lymphocyt
junichi
satoh
b
yusuk
nanri
wakiro
sato
takashi
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
b
depart
bioinformat
meiji
pharmaceut
univers
tokyo
japan
object
identifi
systemat
interferonbeta
ifnb
respons
gene
peripher
blood
mononuclear
cell
pbmc
background
ifnb
reduc
frequenc
relaps
number
new
mri
lesion
rrm
howev
proport
patient
discontinu
treatment
due
variou
advers
effect
emerg
earli
phase
treatment
biomark
predict
detriment
respons
ifnb
avail
method
total
rna
pbmc
incub
ngml
rhifnb
vitro
process
cdna
microarray
realtim
rtpcr
analysi
result
among
total
gene
ifnb
elev
express
reduc
gene
h
upregul
gene
categor
convent
ifnrespons
marker
compon
ifnsign
pathway
chemokin
cytokin
regul
apoptosi
dna
damag
heat
shock
protein
ifnb
markedli
upregul
ligand
chemokin
activ
effector
cell
ligand
chemokin
effect
monocyt
wherea
downregul
ligand
chemokin
activ
neutrophil
eleven
gene
includ
elev
rrm
patient
ifnb
treatment
month
conclus
ifnb
elev
immedi
express
chemokin
relev
earli
advers
effect
ms
gene
express
pattern
identifi
shortterm
rebif
treatment
effect
multipl
sclerosi
achiron
b
snir
magalashvili
feldman
p
soni
gurevich
multipl
sclerosi
center
sheba
medic
center
telhashom
ramatgan
israel
b
sackler
school
medicin
telaviv
univers
telaviv
israel
introduct
rebif
one
lead
immunomodulatori
drug
treatment
relapsingremit
multipl
sclerosi
rrm
howev
despit
well
document
efficaci
remain
unclear
mechan
involv
rebif
treatment
alter
clinic
cours
diseas
method
experi
use
cdna
affymetrix
microarray
analyz
peripher
blood
sampl
rrm
patient
month
initi
rebif
treatment
data
analysi
perform
use
ttest
tnom
threshold
number
misclassif
infotest
inform
gene
mig
defin
pvalu
statist
test
result
rebif
treatment
result
mig
ms
pathogenesisrel
effect
rebif
includ
adhes
inflamm
apoptosi
rebifinduc
adhes
effect
character
downregul
integrin
gene
like
itga
addit
selp
genetranscript
mediat
cell
adhes
directli
affect
adhes
activ
tcell
vascular
endothelium
suppress
antiinflammatori
effect
rebif
mainli
relat
suppress
inflammatorypathway
involv
overexpress
inhibit
tollip
involv
activ
induc
proapoptot
pathway
includ
upregul
apoptot
inductor
like
caspas
activ
like
antiapoptot
gene
like
snca
downregul
conclus
shortterm
rebif
treatment
result
immunomodulatori
effect
relat
antiadhes
effect
involv
integrin
famili
gene
suppress
inflamm
stimul
apoptosi
import
control
rrm
diseas
activ
attain
rna
express
signatur
peripher
blood
cell
interferon
beta
im
treat
multipl
sclerosi
ms
patient
time
systemat
timecours
gene
express
studi
focus
autoimmun
diseas
ms
effect
therapeut
intervent
aim
detect
surrog
marker
drugrel
molecular
candid
human
pbmc
infer
mechan
action
affili
effectspathway
appli
compound
discern
rnasignatur
deriv
non
respond
treatment
therapi
patient
ms
proven
efficaci
appear
suboptim
term
therapi
respond
rate
larg
scale
analysi
gene
transcript
time
provid
unpreced
view
complex
studi
diseas
gener
huge
data
set
shall
serv
molecular
group
classif
employ
affymetrix
set
gene
perform
ongo
full
genom
studi
monitor
patient
receiv
im
weekli
period
month
sampl
collect
directli
process
first
treatment
week
week
year
drawn
correspond
date
systemat
transcriptom
analys
supervis
learn
literaturemin
tool
realiz
compar
time
point
gene
show
increas
decreas
express
level
minimum
patient
ifnmodul
immun
responserel
identifi
host
defens
inflammatori
respons
may
also
alter
stabil
coordin
cell
compon
gene
implic
protein
lipid
metabol
cell
adhes
signal
cytoskelet
arrang
ubiquitin
pathway
differenti
express
set
gene
could
import
ancillari
diagnost
tool
longitudin
gene
express
profil
pbmc
multipl
sclerosi
ms
patient
receiv
therapi
koczan
r
goertsch
p
hj
thiesen
uk
zettl
b
institut
immunolog
univers
rostock
rostock
germani
b
clinic
neurolog
univers
rostock
rostock
germani
systemat
timedepend
comprehens
gene
express
analysi
treat
ms
patient
provid
ration
basi
optim
novel
therapeut
strategi
aim
modul
diseas
cours
appli
timecours
microarray
experi
find
new
prognost
diagnost
marker
peripher
blood
cell
therapeut
intervent
open
great
perspect
regard
respons
patient
subclassif
ethic
impact
accept
costintens
treatment
use
affymetrix
set
approxim
gene
perform
full
genom
studi
monitor
patient
period
year
sampl
taken
first
treatment
h
week
month
transcript
pass
detect
threshold
statist
algorithm
ma
use
analysi
order
distinguish
molecular
subgroup
treat
patient
base
gener
rnaprofil
clinic
paramet
linear
correl
model
supervis
learn
algorithm
appli
bootstrap
method
literaturemin
tool
appli
dynam
express
chang
individu
rna
profil
could
ascertain
compar
pretreat
express
level
gene
show
differenti
express
time
point
introduct
profil
result
interact
explor
softwar
gener
valuabl
candid
improv
understand
mechan
action
high
proport
ifnregul
gene
presenc
shortterm
molecular
indic
consist
induc
patient
support
valid
select
candid
gene
immedi
detect
long
last
differenti
express
gene
could
help
prospect
purpos
acut
steadi
state
effect
interferonbeta
multipl
sclerosi
evalu
gene
express
profil
treatment
multipl
sclerosi
ms
interferon
ifn
beta
modifi
immun
cell
activ
cytokin
secret
adhes
molecul
chemokin
receptor
express
matrix
metalloproteinas
recent
found
acut
immunolog
effect
treatment
ifnbeta
ie
within
h
drug
inject
differ
effect
seen
steadi
state
ie
h
drug
inject
use
affymetrix
genechip
focu
array
differ
gene
display
studi
chang
gene
express
patient
treat
intramuscularli
weekli
blood
sampl
studi
mrna
express
purifi
mononuclear
cell
mnc
drawn
first
inject
h
first
inject
three
month
treatment
new
blood
sampl
obtain
inject
ifnbeta
inject
ifnbeta
first
inject
ifnbeta
express
gene
differ
significantli
baselin
valu
p
bonferroni
correct
among
upregul
gene
induc
least
twofold
among
downregul
gene
least
reduc
gene
express
baselin
differ
significantli
three
month
treatment
ifnbeta
inject
ifnbeta
result
slightli
less
pronounc
chang
gene
express
signific
differ
gene
express
profil
treatment
ifnbeta
result
acut
chang
major
persist
chang
blood
mnc
mrna
express
vitro
inhibit
human
regulatori
lymphocyt
function
activ
autocrineparacrin
dopaminerg
pathway
impair
lymphocyt
treg
function
might
contribut
break
immun
toler
patient
multipl
sclerosi
investig
vitro
abil
interferon
affect
human
treg
function
defin
product
treg
isol
healthi
donor
blood
immunomagnet
sort
cultur
mrna
protein
measur
rtpcr
elisa
respect
incub
iuml
significantli
reduc
treg
mrna
protein
level
mrna
protein
mrna
protein
p
vs
control
case
recent
report
induc
releas
endogen
catecholamin
human
lymphocyt
first
measur
catecholamin
unstimul
treg
hplced
found
elev
intracellular
level
compar
activ
lymphocyt
therefor
test
whether
effect
could
antagon
select
antagonist
dopaminerg
adrenerg
receptor
receptor
antagonist
complet
revers
effect
first
report
show
direct
effect
human
treg
function
effect
involv
activ
receptor
pathway
like
autocrineparacrin
action
endogen
dopamin
releas
treg
view
role
treg
regul
immun
respons
health
diseas
studi
urgent
need
assess
clinic
signific
find
introduct
interferon
rebif
effect
treatment
known
reduc
diseas
activ
progress
patient
relapsingremit
multipl
sclerosi
rrm
use
microarray
geneexpress
analysi
recent
identifi
gene
character
rebif
treatment
effect
rrm
object
analysi
rebifinduc
regulatori
pathway
order
elucid
hierarchi
biolog
function
associ
treatment
effect
rrm
method
use
integr
model
classifi
gene
within
rebif
signatur
group
accord
chromosom
locat
intrachromosom
group
gene
reconstruct
regulatori
pathway
use
bayesian
network
identifi
regul
gene
next
identifi
common
motif
transcript
factor
promot
region
regul
gene
result
analysi
result
intrachromosom
regulatori
pathway
regul
regul
gene
analysi
motif
promot
region
regulatori
gene
identifi
transcript
factor
ad
inform
identif
interact
biolog
pathway
induc
rebif
rrm
interest
exampl
previous
unknown
mechan
identifi
overexpress
zinc
finger
ccch
type
domain
contain
gene
found
directli
regul
caspas
recruit
domain
famili
member
gene
play
signific
role
apoptosi
suggest
regul
rebif
induc
gene
indirectli
enhanc
apoptosi
conclus
use
integr
approach
gene
express
analysi
identifi
rebif
induc
regulatori
pathway
rrm
express
brainderiv
neurotroph
factor
human
lymphocyt
object
investig
effect
interferon
ifn
rebif
express
brainderiv
neurotroph
factor
bdnf
neurotroph
factor
human
lymphocyt
background
neurodegener
correl
progress
disabl
multipl
sclerosi
ms
reduc
progress
sustain
disabl
ms
suggest
neuroprotect
properti
bdnf
neurotroph
factor
capabl
promot
neural
cell
surviv
may
contribut
neuroprotect
immun
ms
designmethod
vitro
analys
mitogenactiv
peripher
blood
lymphocyt
pbl
obtain
untreat
ms
patient
healthi
donor
treat
prolif
activ
compar
secret
transcript
bdnf
assess
standard
elisa
realtim
pcr
result
prolif
activ
mitogenactiv
pbl
inhibit
dosedepend
manner
contrast
induc
bdnf
express
activ
nonactiv
pbl
highest
bdnf
level
induc
concentr
wherea
higher
lower
concentr
induc
lower
bdnf
level
bdnf
mrna
level
neurotroph
factor
proand
antiinflammatori
cytokin
current
investig
addit
ex
vivo
analys
serum
level
mrna
level
bdnf
assess
blood
obtain
untreat
rebiftr
ms
patient
conclus
result
support
hypothesi
may
promot
neuroprotect
induct
bdnf
express
modif
high
regulatori
cell
express
mrna
multipl
sclerosi
shimizu
ota
k
kawahata
k
ohara
k
ohashi
iwata
depart
neurolog
tokyo
women
medic
univers
school
medicin
tokyo
japan
tokyo
univers
scienc
tokyo
japan
univers
tokyo
graduat
school
medicin
tokyo
japan
background
regulatori
cell
suppress
autoreact
potent
regulatori
properti
especi
high
regulatori
cell
treg
anerg
antigen
stimul
activ
downregul
activ
recent
transcript
factor
gene
implic
key
element
balanc
immun
respons
express
tr
cell
present
studi
investig
whether
interferon
ifn
affect
induc
high
treg
cell
express
method
studi
frequenc
high
treg
cell
flow
cytometri
analysi
level
express
quantit
realtim
pcr
peripher
mononuclear
cell
pbmc
healthi
subject
multipl
sclerosi
ms
patient
treat
result
frequenc
high
treg
cell
level
mrna
express
pbmc
show
differ
healthi
subject
ms
patient
remiss
phase
mean
percentag
frequenc
high
treg
cell
ms
patient
year
treatment
slightli
higher
treatment
statist
signific
also
increas
express
observ
ms
patient
month
treatment
fold
increas
show
significantli
differ
compar
treatment
p
conclus
result
demonstr
might
play
role
control
autoreact
cell
increas
treg
cell
also
relev
treatment
ms
effect
express
circul
cell
multipl
sclerosi
patient
background
multipl
sclerosi
ms
autoimmun
diseas
whose
pathogenesi
cell
play
import
role
recent
becom
clear
treatment
effect
amelior
relapsingremit
multipl
sclerosi
rrm
treatment
efficaci
multipl
sclerosi
potenti
attribut
immun
regulatori
properti
drug
method
compar
express
chemokin
receptor
chemokin
receptor
cell
deriv
ms
patient
deriv
healthi
control
also
investig
chemokin
receptor
express
ms
patient
undergo
therapi
express
chemokin
receptor
assess
baselin
longitudin
period
month
start
treatment
rrm
patient
group
respond
nonrespond
accord
clinic
respons
therapi
result
percentag
cell
patient
ms
significantli
elev
compar
healthi
control
treatment
reduc
percentag
cell
respond
nonrespond
first
month
month
treatment
percentag
cell
respond
still
reduc
howev
nonrespond
return
level
baselin
conclus
percentag
cell
would
marker
immunolog
activ
ms
patient
correct
imbal
benefici
effect
treatment
patient
multipl
sclerosi
associ
transient
increas
serum
level
respons
inject
object
elucid
whether
untoward
effect
treatment
headach
skin
reaction
assess
easili
bedsid
background
patient
may
relationship
serum
cytokin
level
addit
investig
could
predict
respond
treatment
analys
method
twentyf
patient
multipl
sclerosi
ms
therapi
enrol
chronolog
blood
sampl
perform
h
inject
bodi
temperatur
headach
arthralgia
size
skin
reaction
inject
site
monitor
first
week
serum
level
measur
enzymelink
immunosorb
assay
elisa
interact
chang
cytokin
level
variabl
includ
headach
arthralgia
fever
size
skin
reaction
age
edss
score
initi
therapi
oneyear
treatment
relaps
rate
treatment
type
ms
analyz
result
transient
increas
serum
level
respons
administr
correl
headach
arthralgia
less
relaps
rate
prior
therapi
milder
disabl
assess
edss
score
initi
treatment
less
progress
disabl
treatment
conclus
may
help
assess
serum
level
point
h
administr
predict
efficaci
therapi
analysi
neutralis
antibodi
newli
emerg
multipl
sclerosi
initi
treatment
benefit
studi
neutralis
antibodi
nab
develop
current
immunomodulatori
treatment
multipl
sclerosi
controversi
exist
clinic
relev
benefit
studi
assess
safeti
toler
efficaci
interferon
patient
clinic
isol
syndrom
patient
randomis
n
placebo
n
treat
month
clinic
definit
ms
cdm
diagnos
nab
measur
use
mxa
assay
sampl
taken
baselin
everi
month
thereaft
end
studi
eo
nab
titr
consid
posit
impact
nab
time
cdm
evalu
proport
hazard
regress
patient
least
one
postbaselin
nab
sampl
addit
analys
impact
nab
perform
focuss
patient
longer
exposur
ie
patient
eo
day
day
day
respect
percentag
nabposit
patient
visit
month
month
rang
revers
nabneg
statu
observ
nabposit
patient
signific
effect
presenc
nab
time
cdm
analys
perform
hazard
ratio
nabposit
versu
nabneg
patient
patient
patient
eo
day
day
day
conclus
month
studi
effect
nab
time
cdm
detect
qualit
differ
neutral
antibodi
differ
interferon
beta
prepar
f
deisenhamm
c
gneiss
reindl
berger
interferon
beta
ifnb
first
line
therapi
multipl
sclerosi
ms
three
differ
type
ifnb
avail
im
sc
applic
three
prepar
differ
potenti
induc
neutral
antibodi
nab
relat
differ
dose
rout
applic
recognit
epitop
one
factor
treat
patient
show
significantli
higher
median
bind
titer
ntermin
end
treat
patient
vs
anoth
factor
affin
show
significantli
higher
affin
valu
treat
patient
compar
patient
vs
valu
obtain
titrat
antigenantibodi
bind
use
increas
concentr
sodium
isothiocyan
potenc
bind
antibodi
bab
neutral
ifnb
also
differ
among
differ
prepar
twelv
bab
posit
patient
treat
im
also
nab
posit
compar
sc
treat
patient
p
biochem
characterist
contribut
differ
abil
ifnb
prepar
induc
nab
differ
dynam
nab
develop
consequ
treatment
decis
therapi
monitor
discuss
well
potenti
strategi
overcom
nab
develop
revers
nab
neg
multipl
sclerosi
ms
oligodendrocyt
injuri
believ
caus
aberr
immun
respons
initi
autoreact
cell
increas
evid
indic
inflammatori
respons
central
nervou
system
exclus
detriment
may
also
exert
protect
effect
protect
effect
potenti
mediat
local
secret
neurotroph
factor
immun
cell
previous
report
cell
monocyt
produc
leukemia
inhibitori
factor
lif
member
neuropoiet
famili
neurotroph
factor
vitro
inflammatori
ms
lesion
present
studi
report
reduc
lif
product
cell
relaps
remit
ms
patient
compar
secondari
progress
ms
patient
healthi
control
furthermor
immunomodulatori
agent
leptin
simvastatin
studi
potenti
alter
secret
lif
cytokin
cell
monocyt
low
dose
simvastatin
leptin
enhanc
lif
secret
cell
rrm
patient
healthi
control
demonstr
lif
influenc
viabil
prolifer
cytokin
secret
cell
togeth
data
provid
new
inform
regul
lif
secret
immun
cell
insight
complex
regul
neurotroph
factor
lif
may
prove
use
treatment
ms
identif
select
diseas
relat
autoreact
cell
earli
multipl
sclerosi
patient
specif
tcell
vaccin
cell
sensit
myelin
epitop
believ
play
role
pathogenesi
ms
one
experiment
approach
treat
ms
term
cell
vaccin
tcv
involv
patient
immun
attenu
autoreact
tcell
line
respons
myelin
antigen
distinguish
diseaserel
autoreact
lineag
normal
cell
lineag
reactiv
myelin
autoantigen
cultur
essenti
vaccin
prepar
tcell
line
also
gener
healthi
subject
use
microarray
analys
identifi
uniqu
autoimmun
gene
express
fingerprint
mogrespons
cell
line
overexpress
vegf
lifeguard
imprint
absent
myelinrespons
tcell
line
healthi
subject
overexpress
suggest
resist
ms
autoreact
line
apoptosi
thu
protract
cell
exposur
antigen
line
select
commonli
use
day
day
time
normal
human
cell
undergo
apoptosi
ms
cell
line
gener
oligoclon
tcr
isoform
produc
cell
bear
determin
stimul
mog
respons
healthi
subject
cell
line
proinflammatori
treat
cell
express
higher
level
vegf
gene
mimick
autoimmun
fingerprint
autoimmun
fingerprintbear
line
insensit
addit
cytokin
stimul
pm
patient
line
express
autoimmun
fingerprint
stimul
sever
mbpreactiv
line
deriv
pm
bear
healthi
cell
featur
fingerprint
enabl
distinguish
diseaserel
healthi
lineag
within
ms
pm
individu
enabl
better
line
select
tcv
cell
line
reactiv
synthet
myelin
peptid
gener
peripher
blood
probabl
multipl
sclerosi
patient
pm
within
three
month
first
demyelin
attack
attenu
autoreact
cell
line
serv
cell
vaccin
patient
analyz
immunoscop
tcr
profil
line
cell
line
oligoclon
composit
tcr
famili
isoform
test
identifi
present
high
frequenc
tcell
line
patient
examin
occur
cell
line
patient
examin
also
occur
higher
frequenc
respect
noteworthi
combin
found
test
line
combin
line
despit
appar
degener
natur
autoreact
tcr
appear
common
denomin
myelin
antigen
stimul
pbmc
pm
patient
tetanu
toxin
epitop
stimul
autoreact
popul
find
indic
exist
cluster
pm
patient
occur
repetit
combin
cluster
evid
tcell
line
gener
respons
variou
myelin
antigen
within
given
patient
irrespect
natur
specif
antigen
tcell
vaccin
ms
csfderiv
activ
tcell
result
placebocontrol
trial
activ
antimyelin
tcell
accumul
cerebrospin
fluid
csf
ms
patient
indic
cell
may
repres
sourc
diseaserel
cell
previou
pilot
trial
cell
vaccin
tcv
activ
cell
deriv
csf
demonstr
safeti
feasibl
immun
effect
ms
patient
doubleblind
placebocontrol
trial
perform
earli
relapsingremit
ms
patient
studi
effect
tcv
diseas
activ
measur
magnet
reson
imag
mri
twentynin
ms
patient
demonstr
mri
activ
preentri
period
month
random
activ
tcv
n
placebo
n
group
three
immunis
irradi
csf
vaccin
million
cell
placebo
administ
subcutan
interv
month
patient
monitor
month
final
immunis
mri
activ
everi
month
clinic
score
immun
respons
vaccin
well
toler
toxic
advers
effect
report
antimyelin
cell
respons
reduc
tcv
ms
patient
mean
number
activ
mri
lesion
volum
activ
mri
lesion
lesion
reduc
treat
group
placebo
group
differ
howev
statist
signific
mean
edss
score
remain
stabl
group
patient
high
immun
respons
vaccin
cell
show
trend
improv
mri
clinic
respons
tcv
despit
lack
statist
signific
differ
due
low
patient
number
studi
demonstr
safeti
feasibl
tcv
ms
patient
suggest
possibl
therapeut
effect
tcv
may
promin
patient
show
high
immun
respons
vaccin
immunoadsorpt
plasma
pheresi
therapi
treatment
refractori
attack
multipl
sclerosi
ohashi
k
ota
b
shimizu
k
ohara
c
takeuchi
iwata
tokyo
women
medic
univers
tokyo
japan
b
tokyo
univers
scienc
tokyo
japan
effect
immunoadsorpt
plasma
pheresi
iapp
therapi
treat
acut
exacerb
multipl
sclerosi
ms
well
evalu
thu
accumul
therapeut
experi
diseas
import
addit
iapp
recent
report
prevent
efficaci
ad
establish
prevent
therapi
report
ms
patient
acut
subacut
exacerb
patient
unrespons
intraven
methyl
prednisolon
ivmp
therapi
intraven
immunoglobulin
therapi
show
improv
iapp
therapi
iapp
therapi
well
toler
effect
patient
acut
exacerb
pregnanc
three
ms
patient
show
frequent
exacerb
even
introduct
interferon
therapi
relaps
undergo
period
iapp
therapi
aim
prevent
relaps
advers
event
iapp
therapi
includ
deep
venou
thrombosi
cathet
infect
anaphylact
symptom
conclud
iapp
therapi
therapeut
option
especi
patient
fulmin
attack
opticospin
form
rel
safe
applic
patient
acut
exacerb
pregnanc
iapp
therapi
could
evalu
option
prevent
relapsingremit
ms
near
futur
ivig
decreas
matrix
product
tissu
inhibitor
pbmc
multipl
sclerosi
patient
k
okada
tsuji
depart
neurolog
univers
occup
environment
health
kitakyushu
japan
object
determin
whether
ivig
decreas
matrix
metalloproteinas
mmp
product
peripher
blood
mononuclear
cell
pbmc
multipl
sclerosi
ms
patient
method
pbmc
prepar
relaps
remit
ms
patient
n
administ
corticosteroid
within
day
never
introduc
healthi
control
n
pbmc
incub
without
lipopolysaccharid
lp
h
ivig
mgml
ad
h
moreov
studi
neutral
effect
ivig
pbmc
incub
lp
h
ivig
mgml
ad
h
tissu
inhibitor
metalloproteinas
timp
supernat
measur
use
elisa
statist
analysi
perform
use
mannwhitney
u
test
result
significantli
higher
ms
group
control
group
condit
without
lp
although
upregul
lp
two
group
signific
differ
two
group
ratio
significantli
higher
ms
group
control
group
ivig
decreas
dose
depend
two
group
ivig
decreas
ratio
dose
depend
two
group
suppress
effect
ivig
product
neutral
effect
conclus
result
demonstr
product
upregul
ms
suppress
ivig
chang
serum
cytokin
treatment
iapp
multipl
sclerosi
ohji
tomioka
r
mitsui
yoshida
n
iguchi
takahama
ohnuki
nomura
k
saitama
medic
center
depart
neurolog
saitama
medic
univers
saitama
japan
purpos
immuno
adsorpt
plasma
pheresi
iapp
recent
becom
avail
treatment
ms
howev
mechan
iapp
still
unclear
studi
measur
serum
cytokin
investig
mechan
immunomodul
effect
iapp
materi
method
iapp
carri
patient
ms
activ
stage
could
enough
clinic
improv
steroid
therapi
adsorpt
column
use
asahi
kasei
medic
co
ltd
serum
cytokin
ifngamm
determin
use
bead
array
method
bd
bioscienc
co
outflow
inflow
iapp
circul
outflow
circul
treatment
result
studi
chang
cytokin
outflow
inflow
treatment
decreas
inflow
compar
outflow
also
outflow
circul
iapp
increas
iapp
case
conclus
adsorpt
column
remov
variou
cytokin
nonspecif
iapp
ms
stimul
product
mainli
cytokin
made
immunost
shift
balanc
consequ
reactiv
immunomodul
effect
might
occur
natalizumab
effect
immun
cell
respons
multipl
sclerosi
object
studi
vivo
biolog
effect
natalizumab
immun
cell
phenotyp
function
ms
patient
background
natalizumab
hold
promis
effect
therapi
ms
emerg
case
pml
creat
imper
better
defin
mechan
underli
benefici
well
advers
drug
effect
develop
simpl
assay
measur
effect
could
prove
use
immun
monitor
patient
emerg
therapi
method
blood
obtain
serial
monthli
natalizumab
infus
track
function
express
migratori
capac
immun
cell
impact
infus
activ
threshold
immun
cell
evalu
result
preinfus
express
differ
across
immun
cell
subset
natalizumab
significantli
albeit
partial
diminish
express
circul
immun
cell
treatment
significantli
decreas
migratori
capac
immun
cell
correl
well
chang
express
effect
singl
dose
satur
persist
monthli
doseinterv
infus
effect
vari
across
patient
remark
stabl
within
individu
patient
multipl
infus
treatment
significantli
modul
prolif
respons
immun
cell
interpret
provid
first
proofofconcept
vivo
natalizumab
diminish
migratori
capac
human
immun
cell
prospect
studi
show
effect
therapi
like
differ
distinct
immun
cell
subset
ii
sustain
current
dose
interv
iii
uniqu
profil
individu
patient
iv
includ
modul
activ
threshold
immun
cell
monitor
paramet
could
relev
ongo
safeti
efficaci
consider
object
assess
safeti
immun
modul
dna
plasmid
express
fulllength
human
mbp
ms
patient
method
conduct
patient
random
doubleblind
placebocontrol
trial
relaps
ms
patient
within
trial
measur
sever
immun
paramet
includ
cfse
base
antigenspecif
cell
prolifer
intracellular
cytokin
product
pbmc
result
thirti
patient
random
date
twenti
patient
dose
cohort
mg
mg
complet
treatment
treatmentrel
advers
event
ae
mildmoder
placebo
arm
data
cfse
assay
four
patient
two
center
ran
assay
first
two
cohort
demonstr
antigenspecif
reduct
mbp
reactiv
cell
week
treatment
three
first
patient
prolifer
reactiv
posit
cell
decreas
second
patient
prolifer
reactiv
posit
cell
decreas
third
patient
prolifer
whole
mbp
reactiv
posit
cell
decreas
three
patient
prolifer
tetanu
toxoid
decreas
point
antigen
specif
follow
treatment
fourth
patient
chang
either
whole
mbp
tetanu
prolif
respons
conclus
data
indic
safe
may
suppress
immun
respons
antigenspecif
manner
background
antitumor
necrosi
factor
therapi
includ
infliximab
treatment
rheumat
diseas
associ
rare
case
new
exacerb
neuroinflammatori
disord
multipl
sclerosi
optic
neuriti
multipl
sclerosi
therapi
may
increas
diseas
activ
evid
increas
peripher
cell
reactiv
measur
enhanc
product
therapi
rheumatoid
arthriti
may
potenti
provok
neuroinflamm
sinc
system
administr
demonstr
exacerb
multipl
sclerosi
therefor
hypothes
case
clinic
neuroinflammatori
disord
observ
therapi
rheumat
diseas
repres
extrem
end
commonli
occur
minor
intrathec
immun
activ
case
give
overt
neurolog
dysfunct
object
method
test
hypothesi
determin
express
mrna
cerebrospin
fluid
cell
peripher
blood
mononuclear
cell
level
nitric
oxid
oxid
product
cerebrospin
fluid
serum
cerebrospin
fluid
cell
count
igg
indic
ten
patient
polyarthr
infliximab
treatment
result
signific
sign
intrathec
immun
activ
record
system
compart
induct
express
infliximab
treatment
demonstr
conclus
intrathec
immun
activ
measur
employ
assay
infliximab
therapi
common
phenomenon
therebi
refut
initi
hypothesi
find
increas
system
express
demonstr
system
proinflammatori
compon
part
divers
effect
therapi
statin
inhibit
neuron
cell
injuri
promot
activ
lymphocyt
background
cellcel
contact
interact
play
major
role
promot
neuron
cell
injuri
neuroinflammatori
diseas
activ
lymphocyt
caus
injuri
cell
contactdepend
non
antigenrestrict
manner
hypothes
statin
could
offer
neuroprotect
regul
tcell
activ
cellcel
contactdepend
interact
matrix
metalloproteinas
mmp
express
method
statinand
controltr
peripher
blood
lymphocyt
cocultur
two
neuron
one
astrocyt
cell
line
function
antibodi
direct
hladr
hlaabc
attenu
tcell
activ
puls
cell
present
target
cell
neuron
also
incub
differ
proinflammatori
cytokin
chemokin
cell
function
assess
mtt
assay
microscopi
elisa
fac
zymographi
result
neuron
highli
suscept
cytotox
caus
activ
cell
neuron
cell
viabil
restor
cell
pretreat
statin
revers
mevalon
also
prepuls
tcell
activ
antibodi
hladr
hlaabc
proinflammatori
cytokin
chemokin
promot
neuron
apoptosi
observ
decreas
statintr
cultur
cell
apoptosi
specif
neuron
cell
line
astrocyt
cell
line
show
similar
behaviour
conclus
treatment
statin
regul
cell
activ
marker
mediat
neuron
insult
cell
death
neuron
reconfirm
immunoreact
neuron
detect
nucleosom
cultur
medium
thu
statin
may
promot
neuroprotect
properti
neuroinflammatori
disord
multipl
sclerosi
lymphocyt
homeostasi
regulatori
cell
multipl
sclerosi
hallmark
autoimmun
diseas
multipl
sclerosi
ms
breakdown
selftoler
natur
occur
regulatori
cell
treg
preferenti
express
high
level
transcript
factor
forkhead
box
critic
mainten
peripher
toler
prevent
autoimmun
diseas
ms
patient
treg
number
normal
function
impair
compar
healthi
control
treat
cohort
patient
ms
use
monoclon
antibodi
induc
profound
prolong
cell
lymphopaenia
first
month
treatment
fivefold
increas
serum
cytokin
promot
homeostat
prolifer
overrepresent
cell
express
high
level
deplet
cell
pool
sought
determin
whether
truli
treg
use
function
assay
involv
fluoresc
dye
carboxi
fluoroscein
diacet
succinimidyl
ester
cfse
report
induc
transient
express
high
level
cell
howev
cell
suppressor
cell
function
investig
role
genesi
hi
cell
spike
healthi
control
human
peripher
blood
mononuclear
cell
pbmc
increas
concentr
recombin
human
result
increas
percentag
cell
express
high
level
determin
flow
cytometri
lymphopaen
patient
appear
link
homeostat
mechan
drive
lymphocyt
reconstitut
enrich
put
regulatori
tcell
neurotrophin
secret
lymphodeplet
multipl
sclerosi
multipl
sclerosi
ms
chronic
neurolog
disord
thought
driven
autoreact
lymphocyt
result
acut
inflammatori
axon
transact
focal
demyelin
oligodendrocyt
destruct
subsequ
chronic
axon
loss
therapeut
monoclon
antibodi
induc
prolong
lymphopaenia
treatment
patient
earli
aggress
relapsingremit
ms
result
reduct
relaps
rate
sustain
improv
fix
disabl
assess
expand
disabl
sever
score
report
efficaci
unparallel
trial
ms
therapi
earli
improv
may
repres
abrog
inflammationassoci
conduct
block
fail
explain
sustain
improv
seen
hypothesis
growth
factor
secret
context
immun
reconstitut
treatment
may
promot
neuron
surviv
repair
elisa
enzymelink
immunosorb
assay
use
determin
concentr
neurotrophin
peripher
blood
mononuclear
cell
pbmc
cultur
supernat
preand
postcampath
treatment
result
show
patient
pbmc
secret
neurotroph
factor
treatment
found
increas
ciliari
neurotroph
factor
cntf
substanc
recent
shown
enhanc
myelin
format
even
greater
elev
brain
deriv
neurotroph
factor
bdnf
dramat
reduct
insulinlik
growth
secret
explor
function
signific
observ
use
well
establish
vitro
model
neuron
deriv
rat
embryon
cortic
cultur
expos
pbmc
condit
media
untreat
ms
patient
greater
proport
matur
fewer
memori
b
cell
compar
healthi
control
one
month
profound
lymphopenia
three
month
total
number
b
cell
recov
cell
number
remain
deplet
even
twelv
month
post
treatment
within
b
cell
popul
matur
cell
remain
domin
cell
type
memori
cell
decreas
contrast
rel
domin
memori
cell
deplet
cell
pool
one
month
treatment
proport
transit
type
b
cell
recent
bone
marrow
emigr
increas
dramat
suggest
princip
respons
reconstitut
also
one
month
serum
b
cell
activ
factor
baff
increas
significantli
month
three
level
drop
observ
switch
matur
b
cell
phenotyp
agreement
publish
work
show
import
baff
b
cell
matur
surviv
howev
ex
vivo
neutralis
baff
alter
b
cell
prolifer
patient
differenti
express
gitr
gene
regulatori
cell
corticosteroid
treatment
relaps
interferon
treat
multipl
sclerosi
patient
regulatori
tr
cell
seem
play
crucial
role
mainten
immunolog
selftoler
autoimmun
diseas
multipl
sclerosi
ms
recent
experiment
data
shown
forkhead
box
highli
express
tr
cell
respons
function
cytotox
lymphocyt
antigen
constitut
express
tr
cell
respons
costimul
tr
cell
direct
suppress
effector
cell
glucocorticoid
induc
tnfrsf
gitr
upregul
tr
cell
trigger
lead
either
apoptosi
prolifer
tr
cell
studi
measur
mrna
protein
level
gitr
tr
cell
interferon
treat
relapsingremit
multipl
sclerosi
patient
corticosteroid
treatment
patient
examin
accord
expand
disabl
statu
score
edss
relaps
fresh
whole
blood
obtain
ms
patient
cell
isol
pbmc
total
rna
extract
quantif
gitr
mrna
level
perform
realtim
pcr
quantif
protein
level
perform
western
blot
follow
densitometri
patient
test
antibodi
mediat
neutral
activ
interferonbeta
molecul
result
indic
clear
trend
corticosteroid
treatment
result
upregul
gitr
molecul
opposit
express
profil
shown
downregul
immunomodulatori
therapi
low
dose
azathioprin
revers
partial
significantli
visual
neurolog
deficit
progress
multipl
sclerosi
object
determin
effect
addit
low
dose
azathioprin
immunomodulatori
therapi
progress
demyelin
diseas
method
azathioprin
mg
daili
ad
immunomodulatori
therapi
patient
progress
multipl
sclerosi
progress
demyelin
optic
neuropathi
patient
observ
twenti
four
forti
eight
month
result
partial
signific
revers
deficit
cognit
visual
acuiti
colour
vision
balanc
strength
sensat
micturit
follow
addit
low
dose
azathioprin
immunomodulatori
therapi
patient
revers
visual
acuiti
signific
p
revers
colour
vision
p
vision
patient
progress
demyelin
optic
neuropathi
five
year
improv
commenc
combin
therapi
deterior
either
immunomodul
azathioprin
withdrawn
improv
combin
reinstitut
effect
combin
therapi
upon
visual
acuiti
signific
p
effect
colour
vision
p
maintain
two
half
year
conclus
addit
low
dose
azathioprin
immunomodulatori
therapi
may
amelior
visual
neurolog
deficit
progress
multipl
sclerosi
therapi
institut
earli
phase
may
diminish
progress
lessen
disabl
visual
acuiti
ishihara
score
may
robust
vivo
therapeut
marker
long
term
advers
consequ
therapi
remain
determin
larg
scale
randomis
control
studi
need
doubl
edg
sword
treat
autoimmun
insight
therapeut
lymphocyt
deplet
treatment
multipl
sclerosi
two
consequ
treatment
multipl
sclerosi
lymphocyt
deplet
monoclon
antibodi
observ
prolong
cell
lymphopaenia
emerg
novel
autoimmun
diseas
shown
coincid
period
lymphopaenia
induc
prolifer
lip
anim
model
autoimmun
diseas
employ
lip
induc
suscept
diseas
suggest
homeostat
prolifer
inher
result
loss
self
toler
treatment
multipl
sclerosi
offer
uniqu
opportun
studi
phenomenon
human
conduct
survey
autoimmun
diseas
aris
treatment
multipl
sclerosi
institut
autoreact
lymphocyt
prior
follow
treatment
measur
challeng
carboxi
fluoroscein
diacet
succinimidyl
ester
label
pbmc
put
autoantigen
myelin
basic
protein
thyroid
stimul
hormon
receptor
extracellular
domain
report
incid
autoimmun
treatment
incid
greatest
patient
receiv
singl
puls
group
also
older
advanc
multipl
sclerosi
varieti
autoimmun
condit
identifi
includ
organ
specif
haematolog
system
autoimmun
preval
thyroid
autoimmun
diseas
eightfold
increas
autoreact
lymphocyt
emerg
lip
resid
within
cell
compart
demonstr
hypothesis
may
least
part
respons
emerg
autoimmun
patient
undergo
lymphocyt
deplet
treatment
multipl
sclerosi
simvastatin
affect
microglia
cell
motil
statin
treatment
propos
new
potenti
therapi
multipl
sclerosi
ms
inflammatori
demyelin
diseas
central
nervou
system
although
antiinflammatori
properti
studi
extens
effect
statin
brain
cell
howev
poorli
investig
therefor
evalu
effect
simvastatin
treatment
migratori
capac
brain
microgli
cell
key
element
pathogenesi
ms
use
fac
analysi
show
exposur
human
murin
primari
microgli
cell
simvastatin
reduc
cell
surfac
express
chemokin
receptor
addit
simvastatin
treatment
specif
abolish
chemokineinduc
microgli
cell
motil
determin
chemotaxi
assay
furthermor
use
cytoskeleton
stain
structur
electron
microscopi
show
simvastatin
treatment
microglia
alter
actin
cytoskeleton
distribut
lead
chang
intracellular
vesicl
data
clearli
show
simvastatin
inhibit
sever
immunolog
relev
featur
microglia
may
provid
rational
statin
treatment
ms
support
dutch
ms
research
foundat
grant
ms
background
object
patient
multipl
sclerosi
ms
year
old
accord
mcdonald
diagnost
criteria
ms
criteria
would
best
appli
patient
year
age
special
care
must
taken
make
diagnosi
ms
younger
older
although
case
lateonset
ms
report
clinic
charact
lateonset
ms
still
unknown
therefor
evalu
characterist
lateonset
ms
hospit
method
thirti
patient
ms
admit
hospit
april
march
late
onset
defin
onset
year
old
found
three
patient
year
old
one
woman
two
men
clinic
cours
mri
find
patient
evalu
result
three
patient
lateonset
ms
underw
relaps
remiss
site
lesion
optic
nerv
spinal
cord
one
patient
cerebrum
spinal
cord
two
patient
symptom
temporarili
improv
steroid
therapi
two
patient
lateonset
ms
poor
prognosi
one
patient
subcutan
administr
interferon
effect
prevent
relaps
year
conclus
charact
lateonset
ms
similar
japanes
ordinari
type
opticospin
form
interferon
therapi
may
provid
good
prognosi
lateonset
ms
questionnair
expedi
dna
microarray
analysi
differenti
diagnosi
multipl
sclerosi
predict
therapeut
respons
interferonbeta
yusuk
nanri
junichi
satoh
wakiro
sato
takashi
yamamura
depart
immunolog
nation
institut
neurosci
ncnp
kodaira
tokyo
japan
object
method
accur
diagnosi
multipl
sclerosi
ms
often
hamper
difficulti
differenti
diagnosi
neurolog
diseas
mimick
ms
syndrom
sj
diseas
gene
express
profil
peripher
blood
cell
dna
microarray
recent
found
ms
classifi
four
distinct
subgroup
differ
therapeut
respons
interferonbeta
ifnb
separ
healthi
control
subject
satoh
et
al
neurobiol
di
j
neuroimmunol
press
determin
expedi
dna
microarray
analysi
support
differenti
diagnosi
ms
predict
ifnb
respons
clinic
practic
questionnair
fax
certifi
neurologist
hospit
japan
result
answer
rate
great
number
neurologist
experienc
difficulti
discrimin
ms
tumor
cerebrovascular
accid
case
requir
patholog
diagnosi
respect
nine
neurologist
suggest
difficulti
differenti
diagnosi
ms
sj
approxim
half
ifnbtreat
ms
patient
show
satisfact
treatment
patient
group
poor
respond
compos
dropout
due
induct
sever
relaps
advers
effect
great
major
neurologist
show
favor
answer
expedi
dna
microarray
analysi
predict
ifnb
respons
conclus
even
certifi
neurologist
accur
diagnosi
ms
often
difficult
potenti
power
gene
express
profil
peripher
blood
cell
make
neurologist
expedi
dna
microarray
technolog
differenti
diagnosi
ms
predict
therapeut
respons
ifnb
coincid
multipl
sclerosi
autoimmun
diseas
background
multipl
sclerosi
ms
could
associ
autoimmun
diseas
ad
aim
studi
quantifi
coincid
ms
ad
character
ms
ad
patient
method
data
patient
definit
diagnosi
ms
women
men
age
year
rang
year
diseas
durat
year
defin
poser
criteria
retrospect
analys
benign
relapsingremit
secondari
progress
primari
progress
ms
two
group
ms
without
ad
compar
disabl
statu
assess
expand
disabl
statu
scale
edss
result
median
edssvalu
rang
patient
ms
ad
frequent
ad
autoimmun
thyroid
uveiti
rheumatoid
arthriti
ulcer
coliti
coeliac
diseas
asthma
bronchial
psoriasi
vulgari
spondyloarthr
one
patient
autoimmun
thyroid
rheumatoid
arthriti
ad
preced
ms
diagnosi
interferon
beta
therapi
case
found
signific
differ
age
edss
ms
group
without
ad
conclus
result
show
similar
find
report
neurolog
disabl
significantli
influenc
coincid
ms
ad
autoimmun
thyroid
show
strongest
coexist
ms
may
reflect
high
preval
common
popul
two
case
biopsyproven
tumefact
multipl
sclerosi
yoshii
iizuka
masuda
r
ujii
hamada
j
sakai
f
depart
neurolog
school
medicin
kitasato
univers
sagamihara
japan
object
report
two
case
steroidresist
tumefact
multipl
sclerosi
ms
improv
combin
therapi
includ
repeat
steroid
puls
intraven
immunoglobulin
ivig
plasma
exchang
pe
method
case
report
result
first
case
woman
present
convuls
seizur
follow
onset
headach
fever
brain
mri
show
multipl
enhanc
brain
tumor
underw
brain
biopsi
show
abund
accumul
lipidladen
macrophag
perivascular
lymphocyt
compat
acut
ms
improv
follow
steroid
puls
therapi
clinic
symptom
brain
mri
find
gradual
becam
stabil
repeat
combin
therapi
consist
steroid
puls
ivig
follow
interferon
beta
second
case
man
present
gradual
progress
memori
loss
admit
anoth
hospit
diagnosi
brain
tumor
underw
open
brain
biopsi
show
malign
given
diagnosi
ms
receiv
steroid
puls
therapi
without
benefici
effect
also
receiv
steroid
puls
therapi
follow
ivig
second
hospit
progress
relentlessli
becam
bedridden
transfer
hospit
brain
mri
show
enhanc
massiv
tumor
involv
corpu
callosum
initi
receiv
ivig
steroid
puls
therapi
septic
state
underw
pe
follow
interferon
beta
neurolog
deficit
remain
unchang
activ
ms
mri
markedli
decreas
conclus
patient
tumefact
ms
treat
intens
repeat
combin
therapi
may
effect
began
earlystag
ms
case
report
patient
tumefact
demyelin
lesion
masquerad
brain
tumor
prasat
neurolog
institut
bangkok
thailand
object
tumefact
demyelin
lesion
quit
rare
clinic
practic
patient
clinic
manifest
imag
simul
brain
tumor
surgic
biopsi
usual
perform
differenti
two
condit
would
like
present
case
diseas
method
case
report
thai
young
man
present
progress
left
hemiparesi
right
side
dull
headach
past
two
month
magnet
reson
imag
surgic
biopsi
done
demonstr
patholog
result
mri
reveal
hyposign
weightedhypersign
weight
fluidattenu
invers
recoveri
flair
right
frontopariet
white
matter
area
gadolinium
enhanc
lesion
complet
ring
also
anoth
lesion
left
parietooccipit
area
lesser
size
enhanc
magnet
reson
spectroscopi
mr
shown
drop
nacetyl
aspart
naa
peak
modest
increas
cholin
cho
phosphocreatin
cr
ratio
compat
demyelin
diseas
histopatholog
demonstr
foami
macrophag
perivascular
lymphocyt
infiltr
promin
reactiv
astrocyt
special
stain
reveal
markedli
loss
myelin
myelin
debri
patient
diagnos
tumefact
demyelin
lesion
clinic
statu
improv
high
dose
steroid
administr
conclus
patient
present
progress
neurolog
deficit
mass
like
lesion
neuroimag
addit
tumor
glioma
variant
form
demyelin
diseas
tumefact
demyelin
lesion
differenti
diagnosi
biopsi
alway
done
discrimin
two
condit
differ
treatment
prognosi
three
case
relaps
multipl
sclerosi
present
nausea
vomit
h
fukaura
takahashi
terayama
neurolog
iwat
medic
univers
morioka
japan
two
male
one
femal
patient
multipl
sclerosi
ms
admit
hospit
nausea
vomit
upper
gastroenterolog
examin
show
abnorm
magnet
reson
imag
show
high
signal
intens
area
dorsal
portion
medulla
gddtpa
enhanc
weight
imag
treatment
intraven
methylprednisolon
sodium
nausea
vomit
improv
lesion
involv
dorsal
motor
nucleu
vagu
nucleu
ambigu
autonom
nuclei
medullari
reticular
format
usual
associ
vomit
upper
gut
motil
disturb
specul
nausea
vomit
may
autonom
origin
immunolog
featur
also
report
believ
case
repres
unusu
manifest
ms
depress
score
multipl
sclerosi
patient
ohara
k
ota
k
shimizu
ohashi
iwata
depart
neurolog
tokyo
women
medic
univers
school
medicin
tokyo
japan
tokyo
univers
scienc
tokyo
japan
background
patient
multipl
sclerosi
ms
psychic
symptom
depress
observ
one
frequent
psychic
symptom
ms
howev
mani
paper
research
psycholog
intervent
ms
publish
form
definit
conclus
method
use
beck
depress
inventori
second
edit
investig
ms
depress
ms
patient
male
femal
relaps
remit
type
secondari
progress
type
clinic
isol
syndrom
averag
age
compar
categor
examin
respect
age
depress
score
edss
morbid
period
receiv
interferon
beta
therapi
total
frequenc
relaps
frequenc
relaps
last
year
result
signific
differ
depress
score
edss
number
cerebr
lesion
total
frequenc
relaps
frequenc
relaps
last
year
among
patient
high
edss
conclus
depress
score
ms
patient
associ
clinic
examin
studi
may
suggest
depress
constitut
diseas
character
cell
receptor
repertoir
neuromyel
optica
cell
activ
upregul
compar
multipl
sclerosi
warabi
b
k
yagi
h
hayashi
matsumoto
b
tokyo
metropolitan
neurolog
hospit
tokyo
japan
b
tokyo
metropolitan
institut
neurosci
tokyo
japan
character
cell
immun
neuromyel
optica
nmo
examin
cell
receptor
tcr
repertoir
nmo
patient
complementaritydetermin
region
spectratyp
compar
result
multipl
sclerosi
ms
patient
healthi
subject
patient
nmo
ms
patient
healthi
subject
peripher
blood
lymphocyt
pbl
isol
written
consent
obtain
subject
studi
approv
institut
review
board
rna
extract
pbl
cdna
synthes
amplifi
use
primer
pair
tcr
determin
spectratyp
nmo
ms
patient
larger
number
clonal
expand
gene
healthi
subject
moreov
nmo
patient
significantli
larger
number
expand
ms
patient
detail
analysi
reveal
significantli
activ
nmo
result
reflect
uniqu
pathophysiolog
nmo
distinguish
ms
furthermor
longitudin
examin
tcr
repertoir
demonstr
number
clonal
expand
nmo
correl
kurtzk
expand
disabl
statu
scale
edss
although
activ
pattern
tcr
repertoir
relapsingremit
ms
rrm
similar
nmo
secondari
progress
ms
spm
patient
longer
diseas
durat
higher
edss
score
consist
smaller
number
clonal
expand
rrm
patient
detail
tcr
investig
provid
use
inform
evalu
clinic
immunolog
statu
nmo
ms
develop
effect
immunotherapi
brain
mri
find
japanes
ms
patient
nmoigg
nakashima
k
fujihara
miyazawa
misu
itoyama
magnet
reson
imag
mri
investig
japanes
multipl
sclerosi
ms
patient
nmoigg
specif
serum
marker
neuromyel
optica
nmo
among
ms
patient
nmoigg
patient
brain
mri
lesion
patient
longitudin
extens
lesion
spinal
cord
mri
patient
without
longitudin
extens
spinal
cord
lesion
howev
extens
spinal
cord
atrophi
indic
histori
extens
cord
lesion
among
patient
brain
mri
lesion
optic
neuriti
transvers
myeliti
clinic
symptom
patient
episod
optic
neuriti
histori
cognit
dysfunct
hemiparesi
cerebellar
ataxia
brain
mri
diffus
white
matter
lesion
juxtacort
lesion
callos
lesion
periventricular
lesion
longitudin
extens
lesion
along
pyramid
tract
commonli
observ
cerebellar
hemispher
lesion
seen
one
patient
develop
cerebellar
ataxia
hypothalam
lesion
seen
anoth
patient
show
hyperprolactinemia
relaps
visual
disturb
caviti
format
observ
none
patient
although
brain
mri
lesion
seen
patient
nmoigg
resembl
classic
form
ms
shape
typic
ovoid
lesion
openr
enhanc
observ
patient
nmoigg
longitudin
extens
lesion
along
pyramid
tract
seem
specif
patient
nmoigg
brain
lesion
rare
patient
nmoigg
radiolog
featur
lesion
rather
atyp
ms
larg
cystic
cerebr
lesion
multipl
sclerosi
patient
discontinu
report
two
case
takahashi
nakashima
misu
shiga
k
fujihara
itoyama
depart
neurolog
tohoku
univers
school
medicin
sendai
japan
interferon
ifn
establish
diseasemodifi
therapi
multipl
sclerosi
ms
howev
follow
cours
discontinu
fulli
known
report
two
patient
develop
larg
cystic
cerebr
lesion
discontinu
although
pathogenet
mechan
develop
cystic
cerebr
lesion
remain
unknown
case
suggest
discontinu
might
link
develop
cystic
lesion
order
overslip
lesion
discontinu
check
brain
mri
regularli
cerebr
symptom
notic
regardless
sever
analysi
opticospin
convent
form
multipl
sclerosi
neuromyel
optica
taiwan
jen
jen
su
chih
chao
yang
multipl
sclerosi
ms
inflammatori
demyelin
diseas
unknown
etiolog
increas
evid
suggest
heterogen
accord
clinic
cours
ms
describ
relapsingremit
type
rrm
secondari
progress
type
spm
primari
progress
type
ppm
hand
concern
site
involv
two
ms
subtyp
japan
separ
opticospin
ms
osm
clinic
estim
main
lesion
confin
optic
nerv
spinal
cord
convent
ms
cm
show
dissemin
lesion
central
nervou
system
cn
includ
cerebrum
cerebellum
brainstem
neuromyel
optica
nmo
inflammatori
demyelin
diseas
select
affect
optic
nerv
spinal
cord
typic
nmo
wors
outcom
ms
frequent
earli
relaps
specif
igg
nmo
describ
nmo
asian
opticspin
form
ms
detect
classic
western
form
ms
whether
osm
nmo
still
mani
debat
discuss
taiwan
increas
number
multipl
sclerosi
mani
patient
present
optic
nerv
spinal
cord
involv
less
brain
involv
tri
evalu
patient
multipl
sclerosi
admit
one
primari
medic
center
taiwan
classifi
osm
convent
ms
cm
nmo
analyz
whether
differ
clinic
cours
prognosi
neuroimag
studi
tri
correl
relationship
osm
nmo
taiwan
neuromyel
optica
nmo
devic
diseas
disord
demyelin
diseas
spectrum
involv
mainli
optic
nerv
spinal
cord
within
central
nervou
system
cn
recent
abnorm
humor
immun
system
shown
case
nmo
antibodi
aim
look
nmo
igg
turkish
case
devic
diseas
comparison
case
classic
multipl
sclerosi
ms
healthi
control
hc
serum
sampl
patient
devic
diseas
case
ms
hc
assess
use
indirect
immunofluoresc
kit
contain
monkey
cerebrum
cerebellum
intestinum
cell
section
assess
blind
clinic
diagnosi
patient
devic
diseas
show
stain
around
vessel
pial
surfac
cerebrum
cerebellum
section
hand
none
ms
case
hc
show
stain
posit
devic
show
strong
bind
among
sever
clinic
involv
hand
among
case
devic
diseas
neg
sever
diseas
milder
form
diseas
howev
differ
reach
statist
signific
rel
small
cohort
patient
suggest
presenc
nmo
igg
might
associ
diseas
cours
sever
relationship
assess
larger
seri
acut
dissemin
encephalomyel
japan
populationbas
studi
pediatr
patient
gener
hospit
omuta
japan
e
univers
occup
environment
health
kitakyushu
japan
f
kurum
univers
kurum
japan
g
kitakyushu
citi
yahata
hospit
kitakyushu
japan
h
aso
iizuka
hospit
iizuka
japan
nippon
steel
yawata
memori
hospit
kitakyushu
japan
j
kyushu
rosai
hospit
kitakyushu
japan
acut
dissemin
encephalomyel
adem
recent
studi
sever
countri
due
develop
wide
spread
imag
technolog
epidemiolog
studi
adem
undertaken
especi
asian
countri
conduct
multicentr
studi
childhood
adem
acut
transvers
myeliti
atm
multipl
sclerosi
ms
epidemiolog
approach
fukuoka
prefectur
southern
japan
almost
million
peopl
live
identifi
patient
dissemin
demyelin
central
nervou
system
adem
tm
ms
estim
incid
adem
median
age
onset
year
malefemal
ratio
median
age
onset
year
ms
significantli
higher
adem
nineteen
patient
adem
experienc
febril
ill
within
one
month
onset
prodrom
symptom
adem
fever
observ
patient
initi
symptom
includ
disturb
conscious
motor
symptom
seizur
laboratori
studi
reveal
pleocytosi
protein
elev
cerebrospin
fluid
administr
highdos
methylprednisolon
effect
neurolog
sequela
mild
motor
disturb
occur
compar
previou
report
adem
countri
onset
age
sex
ratio
japan
similar
proport
fever
seizur
higher
might
distinct
clinic
featur
adem
asian
countri
intraneur
cell
experiment
autoimmun
neuriti
fujioka
kudeken
kiyozuka
iwasaki
kurihara
rostami
b
toho
univers
tokyo
japan
b
thoma
jefferson
univers
philadelphia
usa
investig
infiltr
cell
peripher
nervou
system
autoimmun
neuriti
fac
analysi
infiltr
lymphocyt
quantit
pcr
intraneur
express
tcr
mrna
cauda
equina
ce
femal
lewi
rat
experiment
autoimmun
neuriti
ean
sequenti
studi
total
rna
extract
ce
sampl
four
seven
day
postimmun
dpi
n
complementari
dna
analyz
quantit
pcr
tcr
hous
keep
gene
dehydrogenas
gapdh
express
valu
tcr
mrna
product
express
ratio
valu
gapdh
pcr
product
rat
fac
analysi
mononuclear
cell
recov
homogen
ce
sampl
dpi
n
stain
antirat
tcrpe
monoclon
antibodi
rat
develop
ean
dpi
peak
dpi
recov
tcr
mrna
neglig
dpi
increas
dpi
transient
start
increas
dpi
reach
peak
dpi
recov
basal
level
dpi
fac
analysi
reveal
cell
popul
among
total
cell
ce
alway
higher
organ
peripher
blood
lymph
node
spleen
rat
data
suggest
two
wave
cell
infiltr
one
might
proinflammatori
might
antiinflammatori
tumor
necrosi
factoralpha
induc
nitric
oxid
synthas
ino
involv
inflammatori
process
guillain
syndrom
anim
model
experiment
autoimmun
neuriti
ean
investig
presenc
ino
peripher
nervou
system
ean
differ
stage
diseas
spinal
root
adjac
lumbar
intumesc
cauda
equina
sensit
ganglia
sciatic
nerv
obtain
inducedean
lewi
rat
process
doubl
ino
fluoresc
immunohistochemistri
larg
oval
cell
smaller
round
ino
cell
evidenc
experiment
group
includ
control
group
show
cell
around
ganglia
perineurium
slight
differ
among
group
onset
clinic
sign
ino
cell
found
blood
vessel
cauda
equina
sciatic
nerv
acut
phase
increas
amount
cell
around
vessel
inflammatori
infiltr
ganglia
cauda
equina
spinal
root
peak
stage
ino
cell
region
sciatic
nerv
wide
distribut
around
numer
infiltr
recoveri
stage
ino
cell
still
found
cauda
equina
sciatic
nerv
vessel
resolut
stage
evidenc
evolut
ean
clinic
sign
may
relat
inosimmunoreact
cell
differ
nervou
region
probabl
cell
stimul
produc
ino
simultan
reach
peripher
nervou
microenviron
support
cape
fapesp
express
experiment
autoimmun
neuriti
express
relat
molecul
endotheli
nitric
oxid
synthas
eno
analyz
sciatic
nerv
lewi
rat
experiment
autoimmun
neuriti
ean
western
blot
analysi
show
significantli
increas
sciatic
nerv
ean
upon
initi
cell
infiltr
earli
peak
stage
day
postimmun
pi
declin
thereaft
pattern
eno
express
cours
ean
larg
match
immunohistochemistri
show
ean
lesion
intens
immunostain
seen
macrophag
well
intens
vascular
endotheli
cell
schwann
cell
constitut
express
normal
sciatic
nerv
consequ
postul
express
increas
sciatic
nerv
ean
possibl
mediat
either
molecular
traffick
nitric
oxid
gener
partli
activ
eno
vascular
endotheli
cell
schwann
cell
well
inflammatori
macrophag
ean
cellular
apoptosi
inflammatori
cell
function
role
ean
discuss
regul
gene
immun
systemassoci
molecul
schwann
cell
sc
cyclic
adenosin
monophosph
camp
vitro
rp
lisak
b
bealmear
ja
benjamin
b
yao
land
depart
neurolog
wayn
state
univers
detroit
usa
center
molecular
medicin
genet
wayn
state
univers
detroit
usa
part
ongo
studi
interact
cytokin
sc
studi
effect
camp
gene
regul
earli
h
intermedi
h
time
point
incub
sc
vitro
high
concentr
simul
mani
aspect
axolemm
effect
sc
neonat
rat
sc
incub
l
mm
h
rna
extract
sc
analyz
affymetrix
microarray
gene
chip
chip
contain
gene
regul
express
compar
unstimul
sc
set
high
stringenc
p
found
chang
express
mani
gene
includ
sever
origin
associ
immun
system
h
observ
upregul
gene
tumor
necrosi
factor
tnf
induc
protein
cytokineinduc
neutrophil
transform
growth
factor
tgf
binduc
transcript
regul
note
gene
tgfbinduc
transcript
h
upregul
gene
hypoxia
induc
factor
hif
la
respons
hifla
tgfbinduc
transcript
regul
note
gene
igg
fc
bind
protein
tnfrsf
member
receptor
tweak
integrinb
integrinbbind
protein
endotheli
monocyteactiv
polypeptid
thu
sc
differenti
associ
chang
express
gene
immun
system
associ
molecul
may
import
sc
differenti
interact
sc
immun
system
igg
antibodi
highli
posit
mri
show
brain
abnorm
abnorm
eeg
find
note
conclus
common
anteced
infect
well
common
autoantibodi
larg
studi
gave
conclus
evid
condit
close
relat
form
continu
spectrum
brain
abnorm
detect
fs
although
frequenc
lower
bbe
bbe
could
posit
cn
subtyp
fs
associ
conscious
disturb
bedsid
prognost
score
system
syndrom
r
van
koningsveld
e
w
steyerberg
b
p
van
doorn
c
b
c
jacob
c
depart
neurolog
b
public
health
c
immunolog
erasmu
medic
center
rotterdam
netherland
object
syndrom
gb
immunemedi
polyneuropathi
highli
variabl
clinic
cours
outcom
predict
outcom
import
counsel
identifi
highrisk
group
guid
futur
trial
studi
bedsid
score
system
develop
valid
predict
earli
diseas
phase
long
term
prognosi
ie
inabl
walk
independ
six
month
method
deriv
set
includ
gb
patient
two
dutch
trial
one
dutch
pilot
studi
sixteen
potenti
prognost
factor
test
univari
score
system
develop
base
regress
coeffici
variabl
multivari
logist
regress
model
model
perform
quantifi
regard
discrimin
area
receiv
oper
curv
roc
calibr
graphic
intern
valid
perform
bootstrap
resampl
result
sever
factor
signific
prognost
valu
univari
analysi
key
predict
variabl
multivari
analysi
age
preced
diarrhoea
gb
disabl
grade
two
week
admiss
score
system
rang
includ
three
categori
age
two
diarrhoea
absentpres
five
gb
disabl
grade
two
week
predict
show
high
associ
observ
outcom
good
discrimin
abil
area
roc
score
system
current
valid
anoth
larg
set
gb
patient
conclus
score
system
base
three
simpl
bedsid
clinic
characterist
present
two
week
admiss
accur
predict
inabl
walk
independ
six
month
patient
gb
axon
syndrom
antigangliosid
antibodi
could
caus
peripher
motor
nerv
conduct
failur
earliest
patholog
chang
lengthen
node
ranvier
ventral
root
saltatori
conduct
along
myelin
axon
depend
accumul
voltageg
sodium
nav
channel
node
paranod
axogli
junction
flank
node
import
appropri
ion
channel
cluster
nav
channel
dysfunct
may
caus
initi
motor
nerv
conduct
block
axon
syndrom
prove
examin
nodal
lesion
anim
model
immun
gangliosid
rabbit
produc
igg
antibodi
develop
acut
limb
weak
monophas
cours
electron
micrograph
show
abnorm
lengthen
node
ventral
root
paralyz
rabbit
immunohistochem
studi
reveal
deposit
igg
compon
complement
membran
attack
complex
node
ventral
root
rabbit
acut
phase
ill
epitop
reveal
iggdeposit
lesion
number
affect
node
complement
deposit
reduc
recoveri
phase
cluster
nav
channel
spectrin
cytoskelet
protein
node
contactinassoci
protein
caspr
axon
compon
paranod
junction
alter
disappear
abnorm
lengthen
node
complement
deposit
antibodi
mediat
complementdepend
destruct
node
ranvier
disrupt
nav
channel
cluster
find
confirm
hypothesi
nav
channel
dysfunct
respons
initi
nerv
conduct
block
consequ
motor
weak
axon
syndrom
higher
sensit
detect
antimyelin
associ
glycoprotein
mag
igm
autoantibodi
use
antigen
purifi
human
brain
materi
method
seventyf
sera
patient
suspect
autoimmun
neuropathi
sent
focu
diagnost
mag
igm
test
western
blot
human
mag
split
deidentifi
sent
blind
arup
laboratori
sera
assess
follow
igm
autoantibodi
arup
laboratori
antimyelin
indirect
fluoresc
antibodi
ifa
use
primat
peripher
nerv
antimag
western
blot
use
antigen
purifi
primat
antimag
enzym
immunoassay
eia
use
antigen
purifi
human
brain
paraglobosid
sgpg
eia
use
antigen
purifi
bovin
result
compar
mag
igm
result
obtain
focu
diagnost
western
blot
use
human
mag
follow
percent
agreement
sensit
specif
calcul
mag
igm
western
blot
primat
mag
mag
igm
eia
human
mag
respect
mag
western
blot
human
mag
posit
sera
neg
mag
western
blot
use
antigen
purifi
primat
nine
sera
also
posit
mag
eia
myelin
ifa
mag
western
blot
human
mag
neg
sera
posit
mag
eia
six
sera
also
gave
posit
result
sgpg
eia
conclus
assess
sera
patient
suspect
autoimmun
neuropathi
mag
igm
data
suggest
higher
sensit
method
use
human
mag
moreov
data
suggest
eia
may
sensit
western
blot
detect
igm
autoantibodi
human
mag
epidemiolog
chronic
inflammatori
demyelin
polyneuropathi
japan
chronic
inflammatori
demyelin
polyneuropathi
cidp
character
acquir
symmetr
motor
sensori
disturb
brought
immunemedi
segment
demyelin
peripher
nerv
although
epidemiolog
inform
alreadi
report
europ
oceania
littl
known
asia
aim
clarifi
crucial
preval
incid
rate
japan
perform
larg
epidemiolog
studi
throughout
japan
studi
cover
whole
japanes
popul
investig
number
cidp
patient
combin
sex
age
group
adult
juvenil
geograph
distribut
investig
preval
incid
number
patient
gener
univers
hospit
either
depart
neurolog
intern
medicin
pediatr
novemb
august
number
patient
report
hospit
depart
neurolog
randomli
extract
hospit
intern
medicin
pediatr
correspond
number
bed
number
japanes
patient
use
calcul
preval
incid
rate
follow
nation
censu
result
clarifi
annual
preval
rate
incid
rate
japan
similar
result
counti
addit
preval
incid
rate
almost
prefectur
throughout
japan
conclus
epidemiolog
cidp
show
univers
aspect
ethnic
distribut
also
geograph
distribut
worldwid
well
japan
chronic
inflammatori
demyelin
polyneuropathi
cidp
autoimmun
diseas
target
myelin
sheath
peripher
nerv
target
antigen
unknown
linkag
major
histocompat
mhc
locu
involv
protein
antigen
present
glycolipid
antigen
implic
autoimmun
neuropathi
investig
cidp
patient
dna
polymorph
member
gene
famili
involv
process
present
lipid
antigen
tcell
patient
igm
monoclon
gammopathi
mg
associ
neuropathi
also
investig
found
patient
cidp
n
twice
like
genotyp
normal
control
n
p
neg
associ
mg
neuropathi
n
also
observ
find
reach
statist
signific
p
associ
implic
immun
reactiv
lipid
antigen
pathogenesi
cidp
furthermor
gene
product
may
higher
affin
put
cidp
antigen
form
homozygos
may
result
higher
express
facilit
antigen
present
enhanc
suscept
diseas
point
pathway
potenti
target
therapeut
diagnost
criteria
nationwid
survey
crowfukas
syndrom
japan
previous
report
vegf
extrem
elev
crowfukas
syndrom
cf
key
molecul
pathogenesi
cf
accord
clinic
experiment
studi
propos
diagnost
criteria
cf
confirm
use
diagnost
criteria
conduct
japanes
nationwid
survey
cf
furthermor
investig
efficaci
variou
treatment
cf
estim
number
patient
detail
medic
questionnair
cf
patient
obtain
male
femal
mean
age
year
old
mean
durat
ill
year
suggest
improv
prognosi
syndrom
howev
mean
annual
frequenc
hospit
time
absenc
patient
show
complet
recoveri
indic
cf
still
intract
diseas
polyneuropathi
edema
skin
lesion
frequent
manifest
follow
organomegali
endocrin
abnorm
laboratori
examin
mprotein
high
serum
vegf
detect
patient
find
surprisingli
resembl
previou
japanes
nationwid
survey
conduct
nakanishi
differ
report
dispensieri
et
al
done
usa
accord
dispenzieri
diagnost
criteria
patient
correctli
diagnos
propos
diagnost
criteria
includ
serum
vegf
correctli
diagnos
cf
patient
treatment
peripher
blood
stem
cell
transplant
high
dose
chemotherapi
increas
respond
well
compar
convent
therapi
highli
concentr
vascular
endotheli
growth
factor
vegf
platelet
crowfukas
poem
syndrom
report
mark
differ
concentr
vascular
endotheli
growth
factor
vegf
serum
plasma
patient
crowfukas
syndrom
cf
serumplasma
vegf
level
four
cf
patient
pgml
respect
predict
cf
local
vegf
concentr
markedli
elev
aggreg
platelet
contain
excess
vegf
adhes
vascular
wall
result
excess
physiolog
activ
vegf
consid
deepli
involv
characterist
clinic
manifest
observ
cf
find
provid
import
inform
develop
effect
therapeut
trial
peripher
neuropathi
patient
multipl
sclerosi
background
multipl
sclerosi
ms
character
demyelin
central
nervou
system
studi
demonstr
involv
peripher
nerv
preval
peripher
neuropathi
ms
remain
controversi
aim
studi
perform
electrophysiolog
evalu
peripher
nervou
system
patient
ms
method
subject
patient
ms
male
femal
age
mean
motor
conduct
studi
median
ulnar
peron
tibial
nerv
well
sensori
conduct
median
ulnar
sural
nerv
evalu
result
electrophysiolog
evid
peripher
nervou
system
lesion
least
one
nerv
patient
low
compound
muscl
action
potenti
note
patient
low
sensori
nerv
action
potenti
note
patient
slow
motor
andor
sensori
conduct
veloc
prolong
distal
latenc
note
patient
two
patient
histori
syndrom
one
patient
diagnos
chronic
inflammatori
demyelin
polyradiculoneuropathi
well
ms
conclus
studi
demonstr
peripher
nerv
involv
patient
ms
investig
need
clarifi
immunolog
background
affect
central
nervou
system
peripher
nerv
object
investig
frequenc
mscidp
associ
correl
clinic
profil
method
consecut
patient
ms
patient
cidp
studi
result
clinic
evid
associ
two
disord
found
two
patient
ms
patient
cidp
patient
two
patient
ms
preced
cidp
year
activ
two
diseas
appear
parallel
nerv
conduct
studi
show
demyelin
intermedi
nerv
segment
without
involv
distal
nerv
termin
anoth
ms
patient
present
subclin
nerv
conduct
abnorm
suggest
intermedi
demyelin
conclus
frequenc
ms
cidp
associ
approxim
cidp
associ
ms
character
multifoc
demyelin
nerv
trunk
involv
distal
nerv
termin
myelin
compon
common
central
peripher
nervou
system
may
target
molecul
case
clinic
featur
neuropathi
high
titer
igm
antibodi
gangliosid
disialosyl
residu
igm
paraprotein
bind
gangliosid
disialosyl
residu
report
specif
associ
sensori
atax
neuropathi
among
sera
examin
antigangliosid
antibodi
titer
sera
high
igm
antibodi
titer
investig
clinic
featur
clinic
cours
respons
treatment
case
four
five
patient
igm
antibodi
gangliosid
sensori
atax
neuropathi
remain
one
patient
igm
high
titier
low
titer
sensorimotor
neuropathi
ataxia
patient
treat
either
intraven
immunoglobulin
ivig
corticosteroid
plasma
exchang
immunoadsorpt
immunosuppress
patient
respond
temporarili
treatment
two
patient
igm
mprotein
patient
malign
hematolog
diseas
treatment
hematolog
diseas
latter
patient
also
improv
neuropathi
import
reactiv
pathogenesi
sensori
atax
neuropathi
indic
sever
treatment
effect
effect
temporari
therapeut
effect
singl
administr
cyclophosphamid
rat
experiment
autoimmun
neuriti
preclin
model
autoimmun
peripher
neuropathi
high
dose
immunosuppress
therapi
use
treat
autoimmun
diseas
includ
autoimmun
peripher
neuropathi
agent
use
treat
case
syndrom
gb
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
multifoc
motor
neuropathi
mmn
resist
usual
treatment
plasma
exchang
pe
intraven
immunoglobulin
ivig
long
term
use
high
dose
immunosuppress
howev
limit
due
sever
side
effect
bone
marrow
suppress
hair
loss
upset
stomach
develop
hemorrhag
cystiti
order
assess
benefici
effect
short
term
treatment
lower
dose
alkyl
immunosuppress
drug
cyclophosphamid
cy
develop
preclin
model
gb
cidp
experiment
autoimmun
neuriti
ean
lewi
rat
singl
dose
cy
administ
anim
day
postimmun
data
obtain
experi
show
singl
low
dose
administr
cy
highli
effect
prevent
clinic
sign
ean
data
suggest
cy
deserv
consider
use
treatment
acut
chronic
autoimmun
peripher
neuropathi
particular
sinc
acut
phase
human
gb
usual
rang
week
possibl
one
singl
administr
drug
would
suffici
influenc
cours
diseas
thu
avoid
well
known
side
toxic
effect
provok
prolong
exposur
cy
intraven
immunoglobulin
therapi
miller
fisher
syndrom
background
evid
whether
intraven
immunoglobulin
ivig
benefici
effect
miller
fisher
syndrom
mf
patient
method
clinic
recoveri
review
consecut
seri
patient
mf
timecours
recoveri
compar
patient
treat
ivig
n
treat
plasmapheresi
pp
n
receiv
immun
modul
treatment
n
result
time
requir
start
amelior
extern
ophthalmoplegia
ataxia
slightli
shorter
ivig
group
ophthalmoplegia
median
day
p
ataxia
median
day
p
control
ophthalmoplegia
day
ataxia
day
group
time
requir
disappear
extern
ophthalmoplegia
ataxia
similar
ivig
control
pp
group
control
one
year
onset
patient
ophthalmoparesi
ataxia
irrespect
receiv
immunomodul
treatment
conclus
mf
ivig
slightli
hasten
amelior
ophthalmoplegia
affect
outcom
presum
good
natur
recoveri
variant
type
syndrom
vgb
patient
serum
miniatur
endplat
potenti
mepp
frequenc
increas
mfi
socal
like
effect
antigangliosid
antibodi
correl
clinic
symptom
mechan
mfi
specul
complement
depend
nerv
termin
destruct
autoantibodi
autoantibodi
complement
make
membran
attack
complex
creat
lot
pore
nerv
termin
membran
first
ca
inflow
concentr
gain
increas
mepp
frequenc
thereaft
much
ca
concentr
gain
injur
nerv
termin
result
disappear
mepp
end
abl
confirm
process
mous
diaphragm
tri
immunoglobulin
ig
prednisolon
psl
treatment
vitro
model
chose
vgb
patient
whose
serum
high
mfi
antigangliosid
antibodi
prepar
c
mous
diaphragm
prepar
bath
patient
serum
cc
record
mepp
use
convent
grass
microelectrod
techniqu
ad
immunoglobulin
ig
prednisolon
psl
patient
serum
complet
suppress
mfi
use
mgml
ig
mm
psl
mgml
ig
complet
suppress
mfi
mepp
frequenc
increas
suppress
mm
psl
appear
mepp
lost
fiber
suppress
one
mgml
ig
mm
psl
influenc
patient
serum
action
although
ig
effect
standard
clinic
dosag
use
time
standard
clinic
dosag
necessari
make
psl
effect
confirm
synergist
effect
ig
psl
use
patient
serum
contain
mm
psl
mgml
ig
howev
complet
mfi
suppress
could
confirm
use
ig
psl
combin
therapi
vitro
model
kitasato
univers
sagamihara
japan
univers
tokyo
tokyo
japan
institut
anim
reproduct
kasumigaura
japan
japan
red
cross
hospial
tokyo
japan
national
hospit
organ
nagoya
med
center
nagoya
japan
previous
report
thymic
myoid
cell
possibl
stem
plural
sourc
myoid
cell
clone
produc
growth
factor
includ
haemopoiet
factor
haemopoiet
biglycan
besid
achr
factorproduc
cell
also
abundantli
detect
hyperplast
myasthen
thymi
hmgthymi
achr
cell
myogenin
cell
subset
suggest
achr
doubl
posit
cell
matur
myoid
cell
wherea
achr
singl
posit
cell
precursor
numer
increas
myoid
cell
occur
precursor
stage
follow
concurr
product
larg
amount
achr
growth
factor
may
affect
achr
specif
breakag
anerg
state
appear
use
hallmark
understand
immunolog
state
hmgthymi
howev
littl
known
mechan
develop
myoid
cell
produc
factor
although
recent
studi
skelet
muscl
develop
suggest
biglycan
decorin
factor
differenti
express
embryon
fetal
myoblast
present
report
use
differ
type
myoid
cell
clone
mice
rat
hyperplast
thymic
tissu
correl
regulatori
factor
growth
factor
product
found
hmgthymi
mark
immunostimulatori
role
purifi
hmgthymi
current
test
role
regulatori
factor
myoid
cell
immunostimulatori
product
better
understand
mg
head
aim
studi
investig
pathogenesi
characterist
musclespecif
tyrosin
kinas
musk
antibodi
experiment
autoimmun
myasthenia
gravi
eamg
rat
background
gener
seroneg
mg
patient
antibodi
ab
musk
clear
ab
caus
myasthen
symptom
investig
pathogenesi
musk
ab
use
rat
method
femal
lewi
rat
age
week
inocul
twice
multipl
intraderm
site
either
musk
protein
complet
freund
adjuv
cfa
bordetella
pertussi
coadjuv
control
solubl
mous
protein
purifi
result
weight
muskimmun
rat
lower
control
rat
titer
antibodi
musk
rais
markedli
compar
control
electrophysiolog
examin
use
diaphragm
neg
quantiti
achr
musk
endplat
limb
muscl
reduc
muskimmun
rat
compar
control
rat
morpholog
chang
achrdeclust
muscl
fiber
appear
muskimmun
rat
edl
white
muscl
soleu
red
muscl
conclus
result
suggest
antimusk
antibodi
muskimmun
rat
may
downregul
musk
achr
lead
morpholog
chang
motor
endplat
investig
draw
conclus
whether
musk
ab
may
pathogen
thymic
theme
acetylcholinesteras
splice
variant
myasthenia
gravi
adi
gilboageffen
paul
lacost
lilach
soreq
geraldin
clairac
frederiqu
truffault
iftach
shake
hermona
soreq
sonia
berrihaknin
hebrew
univers
jerusalem
israel
cnr
leplessi
robinson
pari
franc
myasthenia
gravi
mg
autoimmun
diseas
mediat
antibodi
toward
nicotin
acetylcholin
receptor
thymic
abnorm
hyperplasia
thymoma
found
mg
patient
report
modifi
acetylcholinesteras
ach
gene
express
properti
involv
thymic
patholog
microarray
analysi
demonstr
attenu
gener
decreas
gene
express
characterist
adult
human
thymu
patient
mginduc
thymic
hyperplasia
accompani
reduc
express
dna
replicationassoci
transcript
reduc
level
synapt
ach
mrna
thymic
extract
mg
patient
present
elev
amount
reduc
hydrolyt
activ
mginduc
acher
variant
compar
adult
control
accompani
transloc
acher
signal
protein
kinas
cytoplasm
membraneassoci
fraction
explor
possibl
causal
associ
modifi
ach
splice
pattern
thymic
composit
function
employ
upregul
specif
thymic
ach
variant
tgr
mice
overexpress
human
h
acher
tg
mice
overexpress
membraneassoci
h
ach
variant
show
smaller
thymic
medulla
strainmatch
fvbn
control
suggest
differenti
imbal
intriguingli
tg
mice
display
smaller
thymu
weight
high
matur
cell
fraction
higher
rate
spontan
apoptosi
compar
control
contrast
tgr
mice
show
heavier
thymus
select
enlarg
fraction
protect
cultur
thymocyt
apoptosi
togeth
overexpress
acher
variant
could
explain
higher
number
thymocyt
transgen
model
human
thymu
associ
myasthenia
gravi
thymu
sourc
bcell
surviv
factor
april
baffin
myasthenia
gravi
mathula
thangarajh
thoma
masterman
lar
helgeland
rot
malin
v
jonsson
geir
egil
eid
ritva
pirskanen
roland
jonsson
jan
hillert
ml
antimusk
subgroup
also
higher
level
compar
antimusk
subgroup
stimul
achr
vs
pgml
p
secret
level
prolif
respons
differ
diseas
subgroup
although
regulatori
cytokin
activ
detect
mg
spontan
differ
diseas
subgroup
accord
ab
implic
result
studi
support
brain
research
societi
bad
istanbul
univers
research
fund
autoreact
cell
mediat
nk
cell
degener
autoimmun
diseas
mechan
underli
nk
cell
degener
known
show
experiment
model
human
autoimmun
myasthenia
gravi
induc
selfantigen
acetylcholin
receptor
nk
cell
undergo
expans
initi
autoimmun
follow
signific
degener
concomit
establish
autoreact
cell
respons
nk
cell
degener
mediat
deriv
autoreact
cell
nk
cell
degener
may
signifi
transit
innat
immun
trigger
emerg
autoreact
cell
serv
mean
evolv
immun
system
control
excess
autoimmun
compar
analysi
two
differ
assay
detect
antimusk
antibodi
marino
f
scuderi
c
provenzano
evoli
b
e
bartoccioni
institut
gener
patholog
b
depart
neurosci
cathol
univers
rome
itali
antimusk
autoantibodi
associ
seroneg
myasthenia
gravi
snmg
antibodi
detect
mean
two
differ
techniqu
homemad
immunoblot
biotinyl
protein
assay
ibba
radioimmunoprecipit
assay
ipa
ibba
use
biotinlabel
membran
protein
cell
ipa
use
purifi
recombin
antigen
result
given
nmole
precipit
per
liter
serum
compar
home
made
ibba
commerci
ipa
rsr
limit
test
sera
healthi
blood
donor
snmg
patient
neurolog
patholog
antimusk
ab
detect
control
sera
assay
detect
snmg
patient
test
ipa
test
ibba
five
sera
test
ibba
ipa
one
serum
ibba
ipa
concord
two
test
compar
valu
sensit
specif
ibba
qualit
test
detect
sever
immunoreact
nativ
muscl
antigen
complex
easi
standard
routin
requir
support
cell
cultur
facil
ipa
quantit
test
employ
recombin
antigen
extracellular
fragment
aa
allow
titr
antimusk
antibodi
patient
sera
howev
requir
support
radioisotop
facil
opinion
ibba
use
research
purpos
identifi
new
antigen
ipa
provid
simpl
procedur
detect
antimusk
ab
clinic
routin
new
sandwich
elisa
method
detect
antibodi
nativ
form
ryanodin
receptor
purpos
studi
design
new
measur
method
detect
serum
autoantibodi
ryanodin
receptor
ryr
striat
muscl
new
method
sandwich
elisa
use
complex
antiryr
monoclon
antibodi
nativ
form
ryr
rabbit
striat
muscl
target
antigen
measur
titer
autoantibodi
ryr
serum
sampl
patient
myasthenia
gravi
mg
diseas
control
normal
subject
titer
exceed
averag
standard
deviat
normal
sampl
defin
posit
patient
mg
turn
posit
hand
sampl
diseas
normal
control
neg
posit
rate
significantli
high
age
thymomaassoci
patient
furthermor
tend
high
femal
patient
gener
mg
spite
detect
antibodi
ryr
sampl
without
antibodi
acetylcholin
receptor
correl
two
autoantibodi
result
suggest
new
method
use
detect
antiryr
antibodi
expect
method
recogn
pathophysiolog
condit
myasthen
patient
antibodi
elev
antibodi
specif
serum
marker
myasthenia
gravi
thymoma
measur
serum
level
variou
cytokin
antibodi
patient
myasthenia
gravi
mg
level
significantli
elev
mg
patient
thymoma
n
titer
antibodi
significantli
elev
mg
thymoma
also
test
antibodi
found
significantli
elev
mg
thymoma
thymoma
without
mg
signific
correl
autoantibodi
thymoma
mg
howev
correl
mg
lfh
mg
normal
thymu
thymoma
without
mg
titer
signific
correl
histopatholog
thymoma
accord
classif
furthermor
level
antibodi
antibodi
correl
serum
titer
antiacetylcholin
receptor
achr
antibodi
clinic
sever
ratio
tl
accumul
thymu
thymectomi
follow
prednisolon
administr
four
year
significantli
decreas
antiachr
antibodi
level
level
antibodi
antibodi
observ
suggest
autoantibodi
associ
immunopatholog
mg
thymoma
distinct
immunopatholog
compar
mg
long
term
effect
infrastern
mediastinoscop
thymectomi
myasthenia
gravi
background
endoscop
thymectomi
wide
perform
rel
low
invas
less
stress
patient
howev
long
term
effect
suffici
evalu
object
assess
long
term
effect
infrastern
mediastinoscop
thymectomi
imt
compar
transstern
thymectomi
tt
myasthenia
gravi
mg
patient
method
among
mg
patient
underw
thymectomi
institut
januari
decemb
patient
receiv
imt
receiv
tt
enrol
studi
qmg
score
antiacetylcholin
receptor
antibodi
antiachr
titer
evalu
year
surgeri
intracellular
cytokin
peripher
blood
posit
cell
analyz
flowcytometri
patient
underw
imt
ratio
calcul
result
year
qmg
score
reduc
p
imt
group
p
tt
group
antiachr
titer
reduc
p
imt
group
p
tt
group
ratio
increas
p
conclus
imt
effect
tt
consid
suitabl
mg
imt
seem
allevi
mg
symptom
correct
shift
effect
thymectomi
late
onset
nonthymomat
myasthenia
gravi
n
kawaguchi
kuwabara
nemoto
h
takahashi
fukutak
k
arimura
b
osam
b
hattori
depart
neurolog
chiba
univers
graduat
school
medicin
chiba
japan
b
third
depart
intern
medicin
kagoshima
univers
kagoshima
japan
object
investig
whether
thymectomi
benefici
nonthymomat
myasthenia
gravi
patient
mild
gener
weak
onset
age
year
patient
method
clinic
cours
outcom
compar
patient
receiv
thymectomi
without
result
end
followup
mean
year
onset
thymectom
group
show
greater
percentag
clinic
remiss
symptom
without
medic
versu
p
less
frequenc
presenc
gener
symptom
versu
p
conclus
thymectomi
appear
effect
late
onset
nonthymomat
patient
gener
myasthenia
gravi
excitationcontract
ec
coupl
impair
myasthenia
gravi
object
investig
whether
ec
coupl
muscl
impair
patient
gener
myasthenia
gravi
mg
method
total
patient
mg
studi
compound
muscl
action
potenti
cmap
abductor
pollici
brevi
movementrel
potenti
use
acceleromet
place
thumb
tip
record
median
nerv
stimul
wrist
ec
coupl
time
ecct
estim
latenc
differ
cmap
movementrel
respons
antibodi
ryanodin
receptor
ryr
muscl
specif
receptor
tyrosin
kinas
musk
well
acetylcholin
receptor
measur
immunoassay
result
compar
agematch
normal
control
n
mean
ecct
longer
patient
mg
p
ecct
signific
correl
clinic
sever
diseas
durat
antiryr
musk
antibodi
wherea
mean
ecct
shorter
patient
treat
receiv
treatment
p
conclus
mg
ec
coupl
appear
impair
possibl
contribut
addit
muscl
weak
may
facilit
ec
coupl
mg
patient
tacrolimu
treatment
elderli
patient
myasthenia
gravi
h
takahashi
n
kawaguchi
nemoto
hattori
depart
neurolog
graduat
school
medicin
chiba
univers
chiba
japan
background
tacrolimu
immunomodul
agent
wide
use
patient
myasthenia
gravi
mg
rheumatoid
arthriti
organ
transplant
japan
tacrolimu
effect
inhibit
antiacetylcholin
receptor
achr
antibodi
product
suppress
helper
b
cell
help
uptak
corticosteroid
nucleu
evalu
effect
advers
effect
tacrolimu
elderli
patient
mg
object
method
two
group
evalu
myasthenia
gravi
activ
daili
live
mgadl
score
dose
corticosteroid
use
comparison
initi
month
one
group
consist
corticosteroid
depend
patient
f
yearold
consist
patient
treat
without
corticosteroid
f
yearold
result
corticosteroid
depend
group
patient
present
clinic
improv
month
initi
tacrolimu
mgadl
score
decreas
point
point
antiachr
antibodi
decreas
group
could
reduc
amount
daili
corticosteroid
averag
dose
corticosteroid
decreas
mg
everi
day
mg
everi
day
group
treat
without
corticosteroid
patient
present
clinic
improv
month
initi
tacrolimu
averag
mgadl
score
decreas
point
point
averag
number
antiachr
antibodi
decreas
patient
show
deterior
glucos
toler
patient
present
occurr
malign
evalu
conclus
even
elderli
mg
patient
tacrolimu
could
use
choic
treatment
tacrolimu
treatment
sever
myasthenia
gravi
tacrolimu
macrolid
immunosuppress
wide
use
liver
transplant
tacrolimu
author
treatment
myasthenia
gravi
mg
japan
result
reduc
requir
steroid
use
tacrolimu
patient
sever
mg
experienc
mgrelat
crisi
episod
observ
patient
two
year
critic
attack
patient
treat
use
plasmapheresi
methylprednisolon
mpsl
puls
therapi
tacrolimu
start
gradual
taper
psl
four
patient
receiv
cours
treatment
initi
therapi
wherea
eight
patient
previous
undergon
treatment
without
tacrolimu
experienc
crisi
episod
sever
year
treatment
five
control
patient
treat
immunosuppress
tacrolimu
azathioprin
azp
mizoribin
two
patient
initi
treat
azp
chang
tacrolimu
crisi
patient
respons
evalu
base
mgadl
scale
antiacetylcholin
receptor
antiachr
antibodi
titer
serum
tacrolimu
level
tacrolimustr
patient
show
improv
mgadl
scale
requir
lower
corticosteroid
dose
parallel
increas
serum
tacrolimu
concentr
howev
antiachr
titer
decreas
significantli
result
suggest
tacrolimu
potent
tool
treatment
mg
even
sever
affect
patient
tacrolimu
least
effect
immunosuppress
show
side
effect
although
fail
prevent
relaps
due
fatigu
infect
treatment
late
onset
myasthenia
gravi
japan
takata
arai
k
yokoyama
mizuno
patient
myasthenia
gravi
mg
patient
billion
popul
recent
japan
chang
drastic
high
speed
age
societi
like
number
lateonset
mg
clinic
onset
year
age
increas
purpos
studi
investig
lateonset
japanes
mg
patient
hospit
compar
earlyonset
case
better
characterist
therapeut
total
lateonset
mg
patient
analyz
compar
earlyonset
mg
clinic
outcom
thymectomi
earlyand
lateonset
myasthenia
gravi
mg
correl
mg
sever
treatment
antiach
receptor
antibodi
examin
thymectomi
first
choic
lateonset
mg
without
thymoma
remiss
lateonset
mg
thymectomi
patient
rate
nonthymectom
mg
patient
seem
often
encount
difficult
case
make
therapeut
strategi
lateonset
mg
complic
diseas
involut
thymu
frequent
seen
presenc
muscl
autoantibodi
influenc
outcom
thymectomi
lateonset
mg
therefor
thymectomi
alway
consid
shortli
mg
onset
lateonset
patient
show
progress
sever
ossermann
type
ii
new
therapeut
approach
myasthenia
gravi
base
molecular
recognit
theori
use
km
mice
tm
araga
tahara
b
ishida
b
fujii
memori
hospit
kurayoshi
japan
b
kirin
breweri
co
ltd
yokohama
japan
myasthenia
gravi
mg
result
interfer
neurotransmiss
autoantibodi
nicotin
acetylcholin
receptor
achr
muscl
base
molecular
recognit
theori
complementari
peptid
epitop
mg
induc
antiidiotyp
antibodi
ab
protect
develop
experiment
autoimmun
mg
km
afford
opportun
test
idea
human
km
produc
induct
human
chromosom
contain
ig
heavi
chain
light
chain
loci
use
microcellmedi
chromosom
transfer
techniqu
express
high
level
human
ig
heavi
light
chain
absenc
mous
heavi
light
chain
mate
ig
knockout
mous
immun
complementari
peptid
amino
acid
residu
human
achr
follow
booster
immun
sensit
spleen
cell
fuse
cell
produc
monoclon
ab
mab
obtain
four
mab
recogn
idiotyp
ab
mg
anticomplementari
peptid
ab
use
km
could
provid
use
tool
treatment
mg
clinic
serolog
studi
myasthenia
gravi
wuhan
china
ocular
childhood
case
myasthenia
gravi
mg
rel
common
orient
caucasian
popul
comprehens
serolog
studi
patient
china
studi
unselect
case
mg
attend
tongji
hospit
wuhan
one
year
durat
diseas
rang
month
year
patient
newli
diagnos
male
femal
ratio
patient
children
year
patient
year
ocular
mg
defin
symptom
restrict
ocular
muscl
two
year
present
children
adult
overal
children
adult
posit
acetylcholin
receptor
achr
antibodi
patient
gener
mg
without
achr
antibodi
one
musk
antibodi
two
vgcc
antibodi
indic
probabl
lambert
eaton
myasthen
syndrom
thymoma
evid
mri
children
adult
despit
patient
receiv
prednison
obtain
full
clinic
remiss
although
improv
evid
result
demonstr
childhood
onset
ocular
mg
even
common
previou
report
pacif
countri
moreov
mani
patient
achr
antibodi
confirm
diagnosi
mg
comparison
chines
popul
elsewher
provid
inform
regard
whether
genet
environment
factor
influenc
develop
mg
children
studi
factor
respons
exacerb
childhoodonset
myasthenia
gravi
cell
receptor
express
repertoir
myasthenia
gravi
mg
cellregul
autoimmun
diseas
patholog
autoantibodi
respons
mount
acetylcholin
receptor
achr
suggest
activ
antigenspecif
nonspecif
activ
cell
may
caus
exacerb
mg
identifi
factor
respons
exacerb
examin
cell
receptor
tcr
express
repertoir
peripher
blood
nine
patient
childhoodonset
mg
four
patient
latent
gener
type
three
gener
type
two
ocular
type
mg
six
patient
examin
remiss
exacerb
tcr
repertoir
patient
analys
quantit
receptor
amplif
spectratyp
expans
cell
patient
observ
exacerb
regardless
hla
drdq
type
remiss
data
suggest
exacerb
antigennonspecif
cell
activ
superantigen
induc
bacteri
viral
infect
might
contribut
exacerb
mg
preval
musk
antibodi
posit
myasthenia
gravi
worldwid
myasthenia
gravi
usual
associ
antibodi
muscl
acetylcholin
receptor
achr
proport
patient
generalis
myasthenia
without
achr
antibodi
antibodi
instead
muscl
specif
kinas
musk
sinc
first
descript
hoch
et
al
musk
antibodi
report
variabl
proport
patient
myasthenia
gravi
europ
usa
japan
taiwan
assess
incid
muskmg
systemat
collect
sera
differ
countri
europ
asia
four
usa
center
three
canadian
center
sera
neg
achr
antibodi
posit
musk
antibodi
give
overal
posit
howev
posit
vari
sera
differ
countri
interestingli
within
northern
hemispher
musk
antibodi
posit
peak
equat
lowest
posit
found
norway
philippin
three
countri
southern
hemispher
particip
posit
vari
clinic
data
musk
antibodi
mg
patient
suggest
previous
describ
similar
differ
countri
promin
bulbar
involv
result
similar
incid
equival
latitud
europ
usa
asian
countri
suggest
form
myasthenia
may
associ
environment
agent
rather
genet
predisposit
vitro
vivo
character
subunitspecif
autoantibodi
myasthenia
gravi
patient
muscl
acetylcholin
receptor
achr
autoantigen
myasthenia
gravi
mg
studi
pathogen
antibodi
specif
individu
achr
subunit
purpos
success
express
solubl
extracellular
domain
ecd
human
achr
subunit
yeast
pichia
pastori
ecd
immobil
sepharos
bead
use
immunoadsorb
correspond
autoantibodi
plasma
sera
mg
patient
isol
autoantibodi
subunit
four
patient
test
abil
caus
achr
intern
degrad
antigen
modul
human
cell
line
found
subunit
specif
equal
effici
caus
achr
antigen
modul
test
abil
mg
sera
purifi
subunitspecif
antibodi
caus
experiment
autoimmun
mg
eamg
lewi
rat
two
patient
sera
high
antirat
achr
titer
initi
identifi
strongli
myasthenogen
administ
rat
antibodi
carri
antirat
achr
activ
similar
serum
volum
similarli
effect
caus
eamg
contrast
deplet
autoantibodi
serum
ineffici
caus
eamg
similar
rat
crossreact
antibodi
amount
pathogen
process
isol
larg
amount
autoantibodi
variou
subunit
ecd
sever
sera
crossreact
rat
achr
character
order
identifi
characterist
pathogen
antibodi
mg
phenotyp
analysi
lymphocyt
use
flow
cytometri
dermatomyos
without
interstiti
pneumonia
object
activ
lymphocyt
consid
play
key
role
pathogenesi
dermatomyos
dm
diseas
sometim
associ
interstiti
pneumonia
ip
lead
poor
prognosi
patient
find
clinic
marker
suggest
associ
ip
dm
investig
intracellular
cytokin
surfac
antigen
peripher
blood
lymphocyt
use
flow
cytometri
method
thirteen
patient
activ
dm
n
mean
age
yr
without
ip
n
mean
age
yr
enrol
studi
nine
healthi
subject
mean
age
yr
use
control
separ
mononuclear
cell
use
ficollhypaqu
method
perform
flow
cytometri
order
investig
intracellular
cytokin
surfac
antigen
particularli
activ
marker
lymphocyt
result
dm
patient
without
ip
show
signific
decreas
p
p
p
cell
signific
increas
ratio
p
compar
control
signific
differ
subpopul
dm
patient
without
ip
lymphocyt
significantli
decreas
dm
patient
ip
without
ip
p
conclus
helper
cytotox
cell
activ
peripher
blood
patient
activ
dm
lymphocyt
peripher
blood
may
key
marker
suggest
associ
ip
dm
evalu
serum
cytokin
death
receptor
level
polymyos
dermatomyos
studi
new
criteria
sugimoto
kano
mikata
b
tsuji
j
shimizu
depart
neurolog
univers
tokyo
graduat
school
medicin
tokyo
japan
b
depart
neurolog
shimoshizu
nation
hospit
yotsukaido
chiba
japan
background
reveal
polymyos
pm
rare
diseas
rel
overdiagnos
wide
use
bohan
criteria
differenti
dermatomyos
dm
pm
skin
chang
recent
new
criteria
pm
dm
propos
dalaka
base
clinic
patholog
find
object
compar
serum
level
cytokin
death
receptor
patient
pm
dm
diagnos
new
criteria
method
case
inflammatori
myopathi
case
definit
pm
case
definit
dm
met
criteria
propos
dalaka
serum
sampl
case
obtain
treatment
examin
suspens
array
system
luminex
serum
level
gmcsf
measur
result
dm
serum
level
significantli
increas
pm
although
serum
level
cytokin
stay
normal
control
level
serum
level
significantli
increas
conclus
first
time
approach
measur
serum
cytokin
death
receptor
new
diagnost
criteria
pm
dm
differ
serum
cytokin
profil
confirm
dm
system
diseas
pm
diseas
confin
skelet
muscl
new
criteria
result
suggest
solubl
tnf
receptor
may
regul
mediat
muscl
fiber
damag
dm
pm
role
autoantibodi
cproteininduc
experiment
polymyos
kuniko
kohyama
ilkwon
park
mie
nakajima
yoh
matsumoto
depart
molecular
neuropatholog
tokyo
metropolitan
institut
neurosci
tokyo
japan
present
studi
aim
clarifi
pathogenesi
polymyos
regard
celland
b
cellmedi
immun
immun
partial
purifi
skelet
myosin
induc
sever
experiment
autoimmun
myositi
eam
lewi
rat
howev
purifi
myosin
show
poor
myositogenis
cprotein
minor
compon
crude
myosin
fraction
strong
myositogenis
obtain
suffici
dose
protein
gener
four
recombin
cprotein
cover
entir
molecul
addit
synthes
twelv
overlap
peptid
identifi
epitop
b
cell
although
four
sc
fragment
induc
eam
show
strongest
myositigenis
immunopatholog
examin
reveal
main
featur
eam
infiltr
cell
macrophag
cell
infiltr
muscl
earli
stage
epitop
analysi
demonstr
cell
isol
rat
respond
antisera
reactiv
conform
epitop
molecul
although
report
pothogen
cell
main
effector
human
pm
immun
contain
cell
epitop
fail
induc
eam
hand
intramuscular
inject
mab
induc
mild
definit
inflamm
find
suggest
cell
activ
suffici
induc
eam
autoantibodi
play
import
role
develop
eam
also
gener
recombin
cardiac
cprotein
fragment
induc
experiment
autoimmun
myocard
eac
comparison
eam
eac
prolif
respons
cell
overlap
peptid
detect
wherea
antibodi
variou
peptid
gener
find
strongli
suggest
import
autoantibodi
gener
autoimmun
muscl
diseas
role
granulysin
muscl
fiber
injuri
polymyos
okada
h
nemoto
b
nishina
kurihara
b
morishita
ichikawa
gener
hospit
ichikawa
japan
b
toho
univers
tokyo
japan
granulysin
gln
cytolyt
molecul
coloc
perforin
cytolyt
cell
investig
role
gln
pathogenesi
polymyos
pm
rat
myoblast
cell
line
cultur
rpmi
fc
differenti
muscl
fiber
rpmi
hors
serum
recombin
r
gln
coincub
express
intracellularli
glnmediat
cytotox
evalu
mtt
assay
dna
fragment
also
evalu
tunel
assay
local
gln
biopsi
muscl
specimen
pm
dm
noninflammatori
muscl
diseas
studi
immunofluoresc
stain
rgln
induc
cytotox
dose
depend
manner
introduc
extracellularli
intracellular
express
rgln
also
damag
dna
fragment
observ
rgln
express
rgln
administ
extracellularli
immunofluoresc
stain
show
gln
molecul
cytosol
rgln
coincub
contrast
rgln
detect
jurkat
cytosol
rgln
induc
dna
fragment
biopsi
muscl
specimen
gln
local
posit
cell
adjac
muscl
fiber
gln
observ
insid
muscl
fiber
taken
togeth
gln
may
releas
cell
well
perforin
lead
muscl
fiber
damag
muscl
cell
uptak
gln
glnmediat
apoptosi
take
place
izumi
kawachi
keiko
tanaka
masatoyo
nishizawa
depart
neurolog
brain
research
institut
niigata
univers
therapeut
administr
interferon
ifn
provok
autoimmun
disord
sarcoidosi
moreov
evid
lead
differenti
dendrit
cell
dc
potent
antigenpres
cell
play
pivot
role
induct
immun
respons
studi
examin
whether
dc
play
import
role
pathogeni
inflammatori
muscl
disord
sarcoidosi
polymyos
pm
sera
sarcoidosi
contain
high
amount
interleukin
il
sera
pm
contain
moder
amount
comparison
neurolog
disord
ond
measur
elisa
skelet
muscl
sarcoidosi
contain
consider
amount
pm
ond
littl
elev
measur
real
time
rtpcr
notabl
numer
dclampposit
cell
specif
marker
matur
dc
accumul
epithelioid
granuloma
sarcoidosi
wherea
pm
ond
littl
dclampposit
cell
mean
immunohistochemistri
matur
dc
produc
close
proxim
posit
cell
result
defin
highli
special
matur
state
dc
could
lead
condit
regard
format
sarcoid
granuloma
sever
tlr
stimul
produc
high
amount
via
activ
plasmacytoid
dc
point
exist
natur
allianc
dc
develop
instrument
ensur
effici
connect
innat
adapt
immun
poster
session
paraneoplast
antibodymedi
diseas
one
antihuassoci
pn
evid
intrathec
ig
synthesi
control
includ
studi
associ
tumour
small
cell
lung
cancer
carcinoid
tumor
lung
breast
cancer
one
patient
tumour
detect
far
patient
present
symptom
compat
antiri
associ
pn
oligoclon
band
detect
isoelectr
focus
rispecif
affin
blot
use
assess
rispecif
band
serum
csf
result
csf
sampl
reactiv
igg
band
recombin
ri
antigen
found
one
patient
absenc
oligoclon
band
total
igg
csf
antirispecif
oligoclon
band
detect
sampl
indic
higher
sensit
rispecif
affin
blot
compar
affin
blot
antihuman
igg
antibodi
conclus
find
provid
argument
antirispecif
antibodi
produc
bcell
clone
central
nervou
system
patient
pnd
support
hypothesi
intrathec
immun
reaction
respons
antiri
associ
paraneoplast
neurolog
syndrom
autoantibodi
neurolog
paraneoplast
disord
object
neurolog
paraneoplast
disord
npd
uncommon
howev
diagnosi
import
maxim
likelihood
favor
oncolog
neurolog
outcom
increas
evid
pathogenesi
mani
npd
appear
immun
reaction
antigen
share
cancer
nervou
system
examin
autoantibodi
gephyrin
amphiphysin
voltageg
k
channel
vgkc
gad
patient
npd
method
seven
patient
stiffperson
syndrom
four
cerebel
ataxia
one
progress
encephalomyel
rigid
per
one
chorea
one
limbic
enceph
one
sensori
polyneuropathi
protein
extract
rat
brain
separ
sd
gel
electrophoresi
western
blot
analysi
perform
use
serum
sampl
patient
npd
human
igg
detect
ecl
method
immunohistochem
analysi
also
done
use
rat
brain
tissu
result
one
sp
patient
mediastin
cancer
reveal
antigephyrin
antibodi
one
patient
per
breast
cancer
reveal
autoantibodi
amphiphysin
one
patient
ataxia
small
cell
lung
cancer
reveal
autoantibodi
amphiphysin
two
patient
stiffperson
syndrom
reveal
anti
gad
antibodi
one
patient
chorea
lung
cancer
reveal
antivgkc
antibodi
conclus
autoantibodi
detect
six
patient
fifteen
identif
antibodi
serum
npd
patient
confirm
clinic
diagnosi
paraneoplast
syndrom
allow
earli
identif
underli
tumor
absenc
paraneoplast
antineuron
antibodi
sera
patient
motor
neuron
diseas
oliv
stich
barbara
kleer
sebastian
rauer
background
isol
motor
neuron
diseas
mnd
paraneoplast
syndrom
controversi
discuss
rare
case
suggest
concurr
cancer
mnd
previou
report
indic
motor
neuron
diseas
may
rare
paraneoplast
origin
howev
larg
cohort
patient
motor
neuron
diseas
never
screen
systemat
preval
paraneoplast
antineuron
antibodi
object
assess
frequenc
wellcharacteris
antineuron
antibodi
among
patient
motor
neuron
diseas
method
test
sera
cohort
patient
motor
neuron
diseas
presenc
paraneoplast
antineuron
antibodi
six
differ
elisa
employ
recombin
antigen
hud
yo
ri
amphiphysin
result
patient
high
titr
antineuron
antibodi
suggest
paraneoplast
origin
detect
patient
reveal
low
concentr
antineuron
antibodi
sera
confirm
test
immunoblot
well
analysi
intrathec
antineuron
antibodi
synthesi
case
neg
conclus
found
correl
motor
neuron
diseas
presenc
antineuron
antibodi
suggest
paraneoplast
etiolog
mnd
accord
data
studi
routin
analysi
antineuron
antibodi
typic
isol
motor
neuron
diseas
mandatori
recombin
immunoblot
detect
paraneoplast
antineuron
antibodi
specif
hud
yo
ri
amphiphysin
francesc
grau
christian
rasiah
sebastian
rauer
background
aetiolog
limbic
enceph
le
unclear
antivoltageg
potassium
channel
antibodi
vgkcab
recent
report
case
revers
le
vgkcabsassoci
le
potenti
treatabl
enceph
diagnos
serolog
test
object
assess
antivgkc
ab
preval
rate
le
patient
japan
radioimmunoassay
ialfadendrotoxin
adtx
also
evalu
electrophysiolog
influenc
antivgkc
antibodi
le
patient
method
sera
obtain
consecut
le
patient
consecut
acquir
neuromyotonia
nmt
posit
control
healthi
control
serum
vgkcab
titer
measur
radioimmunoassay
use
whole
rabbitbrain
homogen
iadtx
igg
purifi
hitrap
prote
hitrap
desalt
column
follow
electrophysiolog
studi
patchclamp
studi
effect
patient
igg
electr
properti
cultur
cell
igg
patient
control
day
k
current
record
cell
held
hold
potenti
mv
squar
puls
ms
durat
mv
mv
step
appli
interv
result
nine
twenti
le
patient
antivgkc
ab
differ
clinic
featur
antivgkc
ab
posit
neg
le
antivgkc
ab
nmt
suppress
potassium
cation
current
cell
meanwhil
ab
le
conclus
differ
clinic
present
antivgkc
associ
le
associ
le
antivgkc
ab
le
patient
suppress
potassium
cation
current
studi
necessari
potassium
channel
antibodi
specif
differ
neurolog
syndrom
antibodi
potassium
channel
specif
subtyp
detect
grow
number
patient
neurolog
diseas
patient
present
mostli
peripher
nerv
hyperexcit
neuromyotonia
muscl
cramp
fascicul
central
nervou
system
involv
limbic
enceph
memori
loss
seizur
combin
autonom
symptom
morvan
syndrom
addit
sleep
cardiac
gut
dysfunct
antibodi
detect
radioimmunoprecipit
idendrotoxin
label
vgkc
extract
mammalian
brain
tissu
titer
rang
pm
sinc
dendrotoxin
bind
vgkc
kv
clear
whether
patient
antibodi
bind
distinct
kv
subtyp
whether
antibodi
specif
correl
differ
clinic
syndrom
character
antibodi
bind
differ
part
nervou
system
compar
commerci
antibodi
variou
subtyp
found
igg
antibodi
patient
limbic
enceph
colocalis
antibodi
peripher
nerv
spinal
cord
cerebellum
hippocampu
wherea
antibodi
patient
neuromyotonia
mainli
colocalis
tissu
patient
antibodi
colocalis
addit
exclus
result
confirm
cell
line
express
individu
vgkc
subtyp
result
suggest
first
time
clinic
express
vgkcantibodi
associ
diseas
correl
antibodi
specif
vgkc
subtyp
inform
experiment
studi
set
cancer
system
autoimmun
diseas
accompani
autoantibodi
respons
nucleolar
protein
probabl
appear
autoantibodi
induc
uniqu
conform
tumor
cell
thu
demonstr
uniqu
conform
liver
tumor
like
result
ntermin
truncat
present
tumor
hepatocyt
form
sdsstabl
gbsensit
oligom
ulanet
db
et
al
pna
establish
structur
state
nucleophosmin
differ
human
tumor
cell
hela
ngp
hep
jurkat
osa
normal
mous
tissu
brain
lung
kidney
liver
sdsstabl
oligomer
form
nucleophosmin
observ
exclus
tumor
lysat
interestingli
number
sdsstabl
oligom
electrophoret
mobil
differ
examin
cell
also
defin
charact
ntermin
truncat
hela
cell
studi
support
russian
foundat
basic
research
project
serum
anticn
antibodi
common
chronic
hla
narcolepsycataplexi
introduct
hla
associ
find
suggest
sporad
narcolepsycataplexi
nc
may
autoimmunemedi
especi
hypocretindefici
patient
object
look
serum
cn
antibodi
nc
method
test
nc
f
age
durat
nc
yrang
sleep
disord
osd
f
age
healthi
f
age
immunohistochemistri
ihc
rat
brain
western
blot
wb
individu
test
neg
autoantibodi
includ
onconeur
ana
ds
dna
enaexcept
nc
thyroid
ab
hypothyroid
nc
osd
patient
test
within
diseaseonset
vgkc
ab
result
cn
ab
nc
ihc
wb
osd
ihc
wb
healthi
ihc
nc
serum
bind
weak
moder
nc
none
control
sera
bound
brainstem
neuron
ihc
kda
protein
wb
consist
pattern
within
group
within
nc
group
ab
posit
correl
time
syndrom
onset
serum
test
conclus
lowtitr
serum
cn
ab
common
chronic
nc
probabl
diseas
nonspecif
find
exclud
autoantibodi
pathogenesi
consid
design
futur
studi
ideal
antibodi
test
close
nc
onseta
diseasespecif
antibodi
respons
may
monophas
shortlast
antigliadin
antibodi
celiac
diseas
target
c
domain
synapsin
depart
neurolog
neurosci
weill
medic
colleg
cornel
univers
new
york
ny
usa
neurolog
deficit
includ
neuropathi
ataxia
among
commonli
associ
extraintestin
complic
gluten
sensit
although
littl
known
pathogenesi
mechan
autoimmun
result
molecular
mimicri
gliadin
nervou
system
autoantigen
suspect
previous
show
antigliadin
antibodi
celiac
diseas
bind
synapsin
neuron
phosphoprotein
involv
regul
neurotransmitt
releas
studi
sought
character
immun
crossreact
determin
epitop
synapsin
involv
interact
antigliadin
antibodi
antibodi
affinitypurifi
pool
sera
multipl
gliadinimmun
rabbit
column
chromatographi
reactiv
epitop
synapsin
map
assess
bind
purifi
antibodi
array
overlap
human
synapsin
iaib
peptid
synthes
cellulos
membran
design
peptid
offset
amino
acid
major
immunoreact
epitop
found
locat
c
domain
synapsin
correspond
section
protein
surfaceexpos
direct
away
plane
dimer
epitop
also
form
part
domain
shown
role
mediat
interact
synapsin
synapt
vesicl
penetr
lipid
membran
find
studi
suggest
synapt
uptak
antigliadin
antibodi
bind
synapsin
may
deleteri
effect
regul
neurotransmitt
releas
might
involv
pathogenesi
neurolog
manifest
gluten
sensit
manifest
cn
central
nervou
system
engag
variabl
rang
migrain
sever
psychot
condit
ms
multipl
sclerosi
like
syndrom
seen
case
sinc
sle
system
lupu
erythematosu
prototyp
b
cell
mediat
autoimmun
diseas
ms
regard
cell
mediat
interest
compar
neuroinflammatori
mechan
two
diseas
baff
bcell
activ
factor
april
proliferationinduc
agent
rel
recent
describ
protein
member
tnf
tumor
necrosi
factor
super
famili
import
b
cell
mediat
inflamm
method
npsle
patient
femal
particip
studi
neurolog
examin
cognit
test
mrt
magnet
reson
tomographi
perform
csf
cerebrospin
fluid
peripher
blood
collect
baff
april
protein
level
csf
blood
analyz
use
commerci
avail
elisa
kit
comparison
sampl
ms
patient
noninflammatori
neurolog
diseas
ond
biobank
use
result
found
mark
elev
level
april
csf
among
npsle
case
compar
ms
ond
blood
level
baff
increas
npsle
csf
signific
differ
group
could
detect
conclus
first
time
present
csf
level
baff
april
npsle
patient
result
indic
possibl
role
molecul
pathogenesi
npsle
magnuslaandersson
karolinskas
neurobehcet
diseas
associ
long
term
outcom
cytokin
mainli
innat
immun
secret
mononuclear
phagocyt
endotheli
cell
activ
astrocyt
one
major
function
stimul
neutrophil
report
cerebrospin
fluid
csf
increas
progress
neurobehcet
diseas
bd
aim
assess
relationship
csf
long
term
prognosi
neurobd
total
patient
male
bd
variou
form
neurolog
symptom
includ
primari
headach
disord
parenchym
neurobd
dural
sinu
thrombosi
stroke
serum
csf
level
assess
elisa
signific
differ
serum
level
mean
csf
level
pg
ml
group
headach
sinu
thrombosi
parenchym
neurobd
stroke
respect
p
level
increas
patient
examin
acut
attack
correl
csf
cell
count
total
protein
level
patient
independ
lea
year
compar
dead
depend
increas
level
found
second
group
howev
patient
elev
csf
cellprotein
level
acut
stage
also
significantli
higher
rate
long
term
disabl
p
although
elev
csf
level
seem
relat
long
term
disabl
still
csf
cellprotein
level
seem
good
marker
cheap
easi
perform
longitudin
studi
patient
neurosweet
diseas
present
recurr
encephalomening
kimura
sakurai
koumura
suzuki
tanaka
hozumi
inuzuka
depart
neurolog
geriatr
gifu
univers
graduat
school
medicin
gifu
japan
background
neurosweet
diseas
nsd
recent
report
sweet
diseas
central
nervou
system
cn
involv
character
multisystem
neutrophil
infiltr
skin
biopsi
histolog
show
dens
dermal
infiltr
neutrophil
sign
vascul
import
distinguish
nsd
diseas
addit
hla
neg
method
longitudin
analyz
clinic
laboratori
neuroimag
data
patient
nsd
one
year
result
patient
present
encephalomening
twice
one
year
histolog
skin
biopsi
obtain
erythemat
plaqu
left
upper
limb
compat
nsd
acut
phase
encephalomening
peripher
blood
neutrophil
creactiv
protein
level
increas
small
increas
protein
level
degre
pleocytosi
predomin
mononuclear
cell
observ
csf
investig
cytokin
level
csf
show
increas
level
acut
phase
hla
type
posit
neg
brain
mri
show
highsignalintens
lesion
brainstem
thalamu
caudat
nucleu
cerebr
subcortex
cerebr
cortex
acut
phase
system
glucocorticoid
effect
improv
neurolog
symptom
abnorm
mri
laboratori
find
howev
encephalomening
recur
glucocorticoid
therapi
discontinu
conclus
relationship
level
encephalomening
diseas
activ
nsd
found
import
develop
monitor
marker
diseas
activ
prophylact
therapi
collagen
tissu
diseas
cn
involv
purpos
vascul
central
nervou
system
cn
classifi
primari
angiiti
vascul
secondari
varieti
diseas
aim
studi
determin
characterist
patient
initi
present
cn
syndrom
diagnos
cn
involv
collagen
tissu
diseas
serial
examin
method
patient
femal
male
follow
januari
septemb
univers
hacettep
hospit
depart
neurolog
includ
demograph
featur
initi
complaint
durat
initi
complaint
final
diagnosi
laboratori
find
modal
imag
techniqu
varieti
diagnosi
differenti
respons
treatment
evalu
result
age
patient
rang
year
common
present
featur
convuls
hemiparesi
headach
shortest
durat
initi
complaint
diagnosi
month
longest
durat
year
patient
diagnos
sle
patient
sjogren
syndrom
patient
isol
cn
rheumatoid
arthriti
patient
probabl
cn
vascul
case
despit
year
detail
examin
autoantibodi
remain
undefin
long
time
maximum
year
cranial
spinal
magnet
reson
imag
mri
find
differ
characterist
demyelin
diseas
intens
immunosuppress
therapi
seem
effect
treatment
modal
conclus
insist
question
system
involv
mri
examin
import
diagnosi
patient
preliminari
diagnosi
demyelin
diseas
give
respons
immunomodulatori
therapi
one
think
cn
vascul
benign
recurr
encephalomening
possibl
neurosweet
diseas
k
hisanaga
iwasaki
itoyama
b
miyagi
nation
hospit
miyagi
japan
b
tohoku
univers
sendai
japan
sweet
diseas
multisystem
inflammatori
disord
character
pain
rais
erythemat
plaqu
asept
neutrophil
infiltr
variou
organ
skin
biopsi
reveal
deep
dermal
infiltr
matur
neutrophil
absenc
vascul
sweet
diseas
respond
system
corticosteroid
report
case
sweet
diseas
neurolog
manifest
neurosweet
diseas
nsd
propos
criteria
diagnosi
case
benign
frequent
recurr
enceph
mening
accompani
autopsi
verifiedsweet
erythemat
plaqu
without
behcet
mucocutan
lesion
classifi
probabl
nsd
criteria
neuronsweet
diseas
sex
age
year
affect
region
cn
involv
strong
human
leukocyt
associ
system
corticosteroid
highli
effect
neurolog
manifest
identifi
probabl
case
far
possibl
nsd
criteria
includ
enceph
mening
without
erythemat
plaqu
analysi
case
reveal
enceph
mening
also
gener
benign
especi
compar
rel
disord
neurobehcet
diseas
abnorm
mri
markedli
improv
case
treatment
system
corticosteroid
may
accept
tent
diagnos
case
benign
recurr
encephalomening
inadequ
diagnos
case
without
sweet
erythemat
plaqu
nsd
background
antitumor
necrosi
factor
therapi
includ
infliximab
treatment
rheumat
diseas
associ
rare
case
new
exacerb
neuroinflammatori
disord
multipl
sclerosi
optic
neuriti
multipl
sclerosi
therapi
may
increas
diseas
activ
evid
increas
peripher
cell
reactiv
measur
enhanc
product
therapi
rheumatoid
arthriti
may
potenti
provok
neuroinflamm
sinc
system
administr
demonstr
exacerb
multipl
sclerosi
therefor
hypothes
case
clinic
neuroinflammatori
disord
observ
therapi
rheumat
diseas
repres
extrem
end
commonli
occur
minor
intrathec
immun
activ
case
give
overt
neurolog
dysfunct
object
method
test
hypothesi
determin
express
mrna
cerebrospin
fluid
cell
peripher
blood
mononuclear
cell
level
nitric
oxid
oxid
product
cerebrospin
fluid
serum
cerebrospin
fluid
cell
count
igg
indic
ten
patient
polyarthr
infliximab
treatment
result
signific
sign
intrathec
immun
activ
record
system
compart
induct
express
infliximab
treatment
demonstr
conclus
intrathec
immun
activ
measur
employ
assay
infliximab
therapi
common
phenomenon
therebi
refut
initi
hypothesi
find
increas
system
express
demonstr
system
proinflammatori
compon
part
divers
effect
therapi
neuroinflammatori
reaction
link
pd
focus
reaction
one
hypothes
explain
signific
age
gender
male
domin
effect
neurodegen
process
pd
may
result
link
risk
factor
inflammatori
process
aim
studi
simultan
determin
striatal
tyrosin
hydroxylas
th
protein
concentr
cytokin
tnfa
ifng
tgfb
gene
express
young
age
month
old
male
femal
mice
h
day
post
tetrahydropiridin
mptp
intox
western
blot
analysi
shown
male
femal
decreas
level
th
observ
within
day
follow
intox
achiev
minim
level
timepoint
howev
earli
timepoint
male
show
greater
reduct
striatal
th
versu
femal
contrast
age
mice
young
male
femal
day
post
intox
notic
gradual
increas
th
concentr
rtpcr
analysi
reveal
increas
express
tnfa
ifng
gene
post
intox
faster
young
age
male
femal
age
young
male
observ
maxim
increas
tgfb
post
intox
contrast
young
age
femal
tgfb
elev
later
timepoint
mptp
caus
increas
striatum
male
femal
increas
significantli
higher
femal
observ
may
help
better
understand
age
gender
differ
exist
pd
regulatori
cell
show
higher
frequenc
age
individu
increas
suppress
activ
neurodegen
diseas
neurodegen
disord
like
alzheim
ad
parkinson
diseas
pd
neuroinflamm
establish
fact
role
inflamm
remain
obscur
howev
due
promis
immun
studi
anim
model
diseas
idea
evolv
benefici
autoimmun
respons
may
prevent
diseas
develop
even
though
idea
remain
proven
decid
analyz
regulatori
cell
treg
ad
pd
patient
work
hypothesi
higher
activ
number
treg
may
suppress
benefici
immun
respons
result
acceler
either
ad
pd
four
differ
group
analyz
ad
pd
patient
well
healthi
young
agedmatch
nondement
individu
find
indic
elderli
group
higher
treg
frequenc
compar
young
group
addit
observ
trend
increas
treg
activ
healthi
elderli
group
compar
young
group
develop
significantli
higher
treg
activ
ad
pd
patient
compar
elderli
healthi
donor
observ
treg
differ
alreadi
total
pool
peripher
treg
young
elderli
group
identifi
treg
immunecel
undergo
immunolog
senesc
take
account
chang
treg
function
increas
neurodegen
phenotyp
present
ad
pd
patient
data
support
hypothesi
exist
benefici
autoimmun
effector
mechan
patient
suppress
treg
consequ
special
interest
analyz
treg
specif
cnsrelev
antigen
ad
pd
parkinson
diseas
pd
progress
neurodegen
disord
unknown
etiolog
character
loss
nigrostriat
dopamin
da
neuron
accompani
da
defici
striatum
degen
process
observ
nigrostriat
system
lead
neuroinflammatori
respons
result
glial
activ
manifest
elev
inflammatori
mediat
includ
cytokin
nitric
oxid
present
studi
examin
ino
induc
nitric
oxid
synthas
protein
express
neurotransmitt
level
striatum
male
femal
mice
month
old
murin
model
pd
induc
mptp
ino
protein
express
assay
western
blot
method
rel
quick
rise
ino
express
group
young
old
male
mice
day
observ
young
femal
mice
day
old
day
increas
ino
express
detect
addit
use
hplc
method
examin
level
select
neurotransmitt
signific
decreas
da
level
observ
femal
within
day
male
within
day
follow
mptp
inject
correl
analysi
reveal
whole
studi
group
neg
correl
ino
protein
express
da
concentr
well
posit
correl
ino
protein
express
da
turnov
hvada
found
factor
analysi
allow
extract
independ
factor
repres
biochem
data
indic
central
neuroinflammatori
process
engag
increas
ino
express
simultan
decreas
da
concentr
find
indic
neuroinflammatori
aspect
murin
model
pd
throughout
lifespan
aim
studi
evalu
differ
cytokin
product
mononuclear
cell
pbmc
healthi
control
hc
ad
pd
patient
method
subject
compos
group
follow
ad
patient
clinic
diagnosi
accord
dm
ivr
nincdsadrda
patient
idiopath
pd
accord
london
brain
bank
criteria
hc
match
sex
age
none
patient
histori
infecti
immun
neurodegen
disord
pbmc
purifi
cultur
without
pha
rant
level
supernat
measur
commerci
avail
elisa
kit
statist
analysi
perform
use
wilcoxon
test
result
discuss
present
studi
suggest
rant
product
unstimul
pha
stimul
pbmc
pd
ad
significantli
differ
pbmc
hc
p
could
provid
new
insight
immunoregulatori
characterist
two
differ
neurodegen
diseas
use
pbmc
peripher
model
vitroex
vivo
may
help
studi
pathogenet
mechan
treatment
effect
pd
ad
amyloid
protein
level
match
csf
alzheim
diseas
ad
object
quantit
level
match
pair
cerebrospin
fluid
csf
plasma
patient
alzheim
diseas
ad
nonad
control
correl
data
age
apo
genotyp
background
investig
report
level
higher
csf
second
promin
speci
next
howev
level
measur
match
csf
ad
plasma
method
studi
includ
patient
women
men
probabl
ad
mean
age
year
women
men
elderli
nondement
control
year
level
measur
use
elisa
result
csf
level
similar
ad
control
significantli
lower
ad
control
p
plasma
level
group
similar
csf
level
higher
control
without
posit
correl
age
plasma
p
ad
group
strong
correl
csf
level
p
correl
level
csf
plasma
group
conclus
combin
speci
measur
csf
use
aid
diagnosi
ad
lack
relat
csf
plasma
speci
indic
sourc
synthesi
differ
inflamm
cn
increas
alzheim
diseas
relat
neurofibrillarytangl
burden
studi
experiment
autoimmun
encephalomyel
transgen
anim
model
neurofibrillarytangl
occurr
cell
substantia
nigra
patient
dementia
lewi
bodi
neuroinflamm
play
signific
role
neurodegen
diseas
involv
brainderiv
innat
immun
system
compon
microglia
complement
protein
seem
establish
last
two
decad
hand
signific
acquir
immun
system
cell
play
central
role
yet
unveil
even
hardli
investig
report
occurr
cell
substantia
nigra
sn
patient
dementia
lewi
bodi
dlb
sn
mani
dlb
patient
number
melanin
posit
cell
still
remain
activ
neurodegen
process
seen
even
time
death
immunohistochemistri
reveal
cell
control
present
blood
vessel
brain
parenchyma
sn
mani
dlb
patient
number
cell
relat
degre
system
inflamm
agon
stage
number
cell
hippocampu
patient
relationship
degre
alphasynuclein
accumul
evid
result
suggest
small
number
cell
enter
substantia
nigra
process
neurodegener
vigor
microglia
highli
activ
whether
cell
contribut
pathophysiolog
nigral
degener
issu
futur
investig
poster
session
ischemia
injuri
brain
tumor
focal
cerebr
ischaemia
neuron
death
absenc
inflammatori
respons
l
felton
water
v
h
perri
cn
inflamm
group
school
biolog
scienc
univers
southampton
southampton
uk
aim
studi
characteris
inflammatori
respons
novel
vivo
model
focal
cerebr
ischaemia
induc
intrastriat
inject
potent
vasoconstrictor
substanc
focal
cerebr
ischaemia
induc
rat
intrastriat
inject
pmol
inject
also
made
combin
recombin
ng
neuron
death
leucocyt
recruit
cytokin
express
measur
use
immunocytochemistri
taqman
pcr
mrna
elisa
protein
inject
gave
rise
localis
neuron
loss
lesion
volum
mm
minim
leucocyt
recruit
h
express
tumour
necrosi
transform
growth
either
low
undetect
express
antiinflammatori
mediat
receptor
antagonist
increas
mrna
protein
level
coinject
fail
modifi
lesion
volum
three
day
despit
induc
dosedepend
increas
neutrophil
recruit
confirm
focal
cerebr
ischaemia
induc
inject
give
rise
minim
inflammatori
respons
demonstr
contrast
previou
studi
show
exacerb
ischaem
excitotox
brain
injuri
cytokin
impact
cerebr
ischaemia
fund
bbsrc
nurin
ltd
hugh
et
al
j
neuropathol
exp
neurol
express
microglia
bloodborn
macrophag
focal
cerebr
ischemia
mice
abstract
known
play
central
role
ischemiainduc
brain
patholog
use
murin
model
focal
cerebr
ischemia
recent
shown
accumul
larg
number
mrnaexpress
immunoreact
cell
peripheri
infarct
might
reflect
induct
resid
microglia
recruit
bloodborn
produc
cell
presum
bloodborn
macrophag
combin
thereof
clausen
et
al
address
question
gener
green
flourescen
protein
gfp
bone
marrow
chimer
mice
focal
cerebr
ischemia
induc
perman
occlus
middl
cerebr
arteri
mca
cell
count
reveal
thousand
donoerderiv
gfp
cell
within
infarct
periinfarct
h
mca
occlus
cell
display
round
elong
morpholog
express
microglialmacrophag
antigen
time
observ
bone
marrowderiv
cell
transform
ramifi
microgliallik
cell
tripleimmunofluoresc
analysi
show
protein
locat
infiltr
small
proport
infiltr
bloodborn
macrophag
gfp
gfp
within
infarct
periinfarct
activ
resid
microglia
gfp
periinfarct
express
protein
h
perman
mca
occlus
time
activ
microglia
gfp
locat
peripheri
infarct
synthesis
protein
summari
data
show
perman
occlus
mca
mice
result
express
protein
segreg
subpopul
microglia
macrophag
role
surfact
protein
ischem
brain
injuri
inflamm
mice
surfact
protein
spd
member
collectin
famili
collagenlik
lectin
spd
endogen
modul
inflamm
bind
pathogen
microorgan
apoptot
cell
spd
present
circul
synthes
endotheli
cell
macrophag
proatherogen
effect
mice
investig
whether
spd
also
play
role
strokeinduc
infarct
secondari
ischemiainduc
inflammatori
respons
subject
spd
knockout
wildtyp
wt
mice
perman
occlus
middl
cerebr
arteri
pmcao
model
acut
infarct
result
breakdown
bloodbrain
barrier
predict
microglialmacrophagereact
comparison
mean
infarct
volum
h
surviv
reveal
distinct
knockout
wt
mice
quantit
pcr
show
ischemiainduc
upregul
mrna
level
tnf
howev
similar
knockout
wt
mice
immunohistochem
analysi
microglialmacrophag
show
activ
microglia
macrophag
infiltr
infarct
periinfarct
group
mice
data
suggest
spd
effect
ischemiainduc
brain
injuri
neuroinflamm
h
surgeri
studi
progress
mice
day
surviv
tell
system
local
produc
spd
affect
inflammatori
respons
protract
phase
follow
experiment
stroke
ischem
neuronderiv
condit
media
protect
ischem
brain
erk
relat
manner
cerebr
ischemiainduc
brain
inflamm
often
lead
brain
cell
death
function
deficit
stroke
patient
main
purpos
studi
evalu
antiinflammatori
action
condit
media
cm
ischem
neuron
cerebr
ischemia
studi
protect
effect
neuronderiv
cm
determin
vivo
vitro
cm
collect
neuron
cultur
depriv
glucos
oxygen
sera
vitro
ischemia
h
end
min
bilater
common
carotid
arteri
occlus
plu
unilater
middl
cerebr
arteri
occlus
ccaomcao
cm
inject
directli
ischem
brain
sd
rat
follow
h
reperfus
brain
infarct
size
determin
cmmediat
protect
ischem
microglia
astrocyt
neuron
also
determin
vitro
base
surviv
rate
phosphoryl
extracellular
signal
regul
kinas
erk
express
induc
nitric
oxid
synthas
ino
nitric
oxid
releas
cell
without
cm
result
show
cm
significantli
reduc
infarct
size
ischem
brain
increas
surviv
ischem
brain
cell
three
type
ischemiainduc
ino
express
releas
suppress
cm
ischem
microglia
astrocyt
neuron
contrari
erk
phosphoryl
increas
cm
three
cell
type
result
indic
ischemiainduc
brain
inflamm
cell
death
could
prevent
ischem
neuronderiv
cm
suggest
therapeut
valu
cm
futur
control
cerebr
ischemia
upregul
follow
transient
middl
cerebr
arteri
occlus
rat
express
modul
cytokin
astrocyt
endotheli
cell
cultur
cross
ak
haddock
g
stock
cj
allan
surr
j
bun
rad
buttl
dj
woodroof
mn
biomed
research
centr
sheffield
hallam
univers
howard
st
sheffield
uk
divis
genom
medicin
e
floor
medic
school
univers
sheffield
sheffield
uk
faculti
life
scienc
univers
manchest
michael
smith
build
manchest
uk
adamt
disintegrin
metalloproteinas
thrombospondin
motif
enzym
secret
metalloproteinas
bind
extracellular
matrix
ecm
substrat
includ
brain
ecm
compon
aggrecan
versican
brevican
also
exhibit
antiangiogen
activ
main
inhibitor
focal
cerebr
ischaemia
lead
neuron
damag
infiltr
ischaem
area
inflammatori
cell
present
studi
focal
cerebr
ischaemia
produc
temporari
occlus
middl
cerebr
arteri
mcao
rat
brain
tissu
obtain
h
h
day
mcao
mrna
protein
express
measur
mrna
level
increas
occlud
hemispher
compar
contralater
hemispher
mcao
anim
brain
tissu
shamoper
rat
h
post
mcao
accompani
increas
mrna
level
interleukin
il
receptor
antagonist
tumour
necrosi
factor
tnf
adamt
express
modul
tnf
primari
human
astrocyt
brain
endotheli
cell
cultur
increas
mcao
may
detriment
promot
ecm
breakdown
enabl
infiltr
inflammatori
cell
increas
express
may
also
inhibit
angiogenesi
contrast
benefici
effect
may
includ
promot
neurit
outgrowth
remov
inhibitori
ecm
molecul
ongo
work
examin
possibl
new
substrat
adamtss
effect
hypoxia
adamt
express
vitro
activ
vessel
glial
cell
rat
brain
chronic
cerebr
hypoperfus
hideaki
wakita
kaichi
yoshizaki
c
hidekazu
tomimoto
keikichi
takahashi
b
takeshi
tabira
depart
vascular
dementia
research
b
nation
institut
longev
scienc
nation
center
geriatr
gerontolog
obu
citi
japan
c
depart
neurolog
graduat
school
medicin
kyoto
univers
kyoto
japan
rarefact
white
matter
impair
memori
function
report
rat
chronic
cerebr
hypoperfus
use
model
investig
activ
vessel
glial
cell
white
matter
lesion
male
wistar
rat
subject
perman
occlus
bilater
common
carotid
arteri
activ
vessel
examin
immunohistochemistri
tumor
necrosi
factor
tnf
glial
activ
examin
immunohistochemistri
major
histocompat
complex
mhc
class
ii
antigen
glial
fibrillari
acid
protein
gfap
activ
vessel
glial
cell
assess
day
occlus
shamoper
anim
express
vessel
mhc
class
ii
antigen
express
microglia
gfap
immunoposit
astrocyt
distribut
predominantli
white
matter
occlus
number
vessel
immunoposit
increas
white
matter
includ
optic
tract
corpu
callosum
fiber
bundl
caudoputamen
number
mhc
class
ii
antigenposit
microglia
gfapposit
astrocyt
increas
preferenti
white
matter
chang
persist
even
day
occlus
rarefact
white
matter
observ
region
result
indic
persist
activ
vessel
glial
cell
may
play
role
pathogenesi
white
matter
rarefact
chronic
ischemia
suggest
involv
immunolog
inflammatori
pathomechan
cerebrovascular
white
matter
lesion
differenti
regul
prostaglandin
e
receptor
subtyp
rat
hippocampu
cerebr
ischemia
ischem
toler
investig
distribut
time
cours
express
two
subtyp
prostaglandin
e
pge
receptor
rat
model
cerebr
ischemia
ischem
toler
short
min
cerebr
ischemia
well
threeminut
ischemia
follow
second
lethal
ischemia
enhanc
express
receptor
pyramid
neuron
hippocampu
toleranceacquir
neuron
immunoreact
upregul
h
h
respect
immunoreact
promin
three
day
sustain
least
day
consist
result
immunoblot
experi
contrast
immunoreact
pge
receptor
increas
reactiv
glial
cell
vulner
hilar
region
rat
subject
lethal
ischemia
without
ischem
precondit
immunoreact
occur
microgli
cell
astrocyt
wherea
increas
immunoreact
occur
astrocyt
data
suggest
ischemia
induct
ischemiatoler
differ
regulatori
effect
express
receptor
pge
may
exert
uniqu
pathophysiolog
function
relat
delay
neuron
death
ischem
toler
induct
rat
hippocampu
via
specif
pge
receptor
research
support
grant
brain
research
center
centuri
frontier
research
program
fund
ministri
scienc
technolog
republ
korea
spatiotempor
express
osteopontin
rat
astroyct
microgli
cell
follow
transient
forebrain
ischemia
osteopontin
opn
adhes
glycoprotein
contain
peptid
sequenc
argglyasp
rgd
intim
associ
cellmedi
immun
recent
increas
bodi
evid
suggest
opn
may
play
defin
role
pathogenesi
acut
neuroinflamm
moreov
opn
induct
detect
set
macrophag
focal
global
forebrain
ischemia
suggest
opn
may
play
key
cytokin
tissu
repair
remodel
within
central
nervou
system
investig
use
semiquantit
rtpcr
analysi
situ
hybrid
histochemistri
immunohistochemistri
spatiotempor
express
opn
rat
hippocampu
follow
transient
forebrain
ischemia
ischemiainduc
opn
mrna
protein
express
appear
subset
microgli
cell
earli
reach
peak
postischemia
return
basal
level
howev
day
opn
express
hippocamp
region
reincreas
reactiv
astrogli
cell
sustain
express
opn
reactiv
astrocyt
postischemia
signific
result
compar
establish
paper
data
suggest
opn
may
play
key
role
chemotact
factor
astrocyt
microgli
cell
vivo
imag
phagocyt
cell
gain
interest
studi
variou
patholog
critic
involv
neurodegen
diseas
brain
tumor
stroke
present
first
mri
magnet
reson
imag
data
obtain
mice
focal
cerebr
ischemia
show
vivo
label
phagocyt
ultrasmal
superparamagnet
particl
iron
oxid
uspio
uspioenhanc
mri
kinet
analysi
unravel
inflammatori
respons
surround
ischem
lesion
well
contralater
hemispher
corpu
callosum
imag
data
correl
histochem
analysi
show
inflamm
remot
lesion
ingest
nanoparticul
microgliamacrophag
studi
show
mrtrack
phagocyt
cell
feasibl
mice
may
central
therapeut
implic
light
potenti
neurotox
activ
microglia
macrophag
central
nervou
system
cn
disord
tolllik
receptor
tlr
essenti
role
respons
microbi
agent
induct
inflammatori
respons
recent
report
indic
tlr
could
also
regul
inflammatori
immun
respons
endogen
stimuli
studi
suggest
inflamm
induc
endogen
stimul
caus
physic
injuri
mous
brain
use
stab
wound
method
use
stereotax
injector
dispos
syring
injur
brain
physic
glial
cell
wild
type
mous
brain
activ
stab
wound
result
immunostain
gfap
howev
knock
mous
activ
glia
regul
wild
type
result
shown
mrna
express
gfap
stab
wound
brain
induct
gene
decreas
brain
knock
mice
result
briefli
indic
role
mediat
inflammatori
respons
endogen
factor
mous
brain
investig
influenc
ontd
pattern
glial
differenti
ontd
induc
surgeri
use
hamburg
hamilton
stage
chick
embryo
spinal
cord
tissu
postop
day
pod
process
observ
astrocyt
radial
glial
microgli
differenti
glial
fibrillari
acid
protein
gfap
vimentin
ricinu
communi
agglutinini
rcai
stain
respect
four
embryo
assign
subgroup
pod
control
embryo
control
group
gfap
posit
shown
faintli
dorsal
midlin
embryon
day
e
correspond
pod
ventral
onethird
white
matter
e
whole
white
matter
e
embryo
ontd
show
earlier
stronger
gfap
posit
pod
especi
dorsal
surfac
adjac
gray
matter
control
group
vimentin
stain
demonstr
posit
reaction
midlin
posit
faint
radial
pattern
e
e
disappear
e
embryo
ontd
vimentin
posit
enhanc
persist
pod
find
promin
along
dorsal
surfac
ontd
differ
rcai
stain
found
control
ontd
group
result
reveal
ontd
promot
astrocyt
differenti
prolong
express
radial
glial
fiber
seem
reaction
damag
caus
exposur
spinal
cord
tissu
amniot
fluid
crosspresent
exogen
antigen
mous
microglia
donnou
c
beauvillain
u
jarri
p
jeannin
couez
microgli
cell
major
immunocompet
cell
function
sentinel
central
nervou
system
follow
injuri
nervou
parenchyma
rapidli
activ
abil
becom
compet
antigen
present
cell
sever
group
also
demonstr
abil
differenti
dendrit
cell
one
strike
properti
dendrit
cell
abil
crosspres
antigen
lymphocyt
thu
ask
mous
microgli
cell
abl
crosspres
antigen
compar
abil
microgli
cell
line
primari
adult
quiescent
microgli
cell
neonat
microglia
three
cell
type
abl
activ
antigen
specif
cell
line
variabl
effici
primari
microgli
cell
inde
less
effici
neonat
cell
interestingli
reflect
respect
activ
state
confirm
adult
quiescent
microglia
need
activ
stimulu
becom
fulli
compet
nevertheless
also
confirm
quiescent
microgli
cell
abl
take
process
present
antigen
mhc
class
molecul
situ
result
thu
open
new
perspect
treatment
cerebr
malign
new
glioma
express
antigen
regularli
describ
immunotherapi
tumor
intratumor
administr
capsaicin
jaquelin
beltran
amiya
ghosh
pramod
srivastava
sreyashi
basu
center
immunotherapi
cancer
infecti
diseas
univers
connecticut
school
medicin
farmington
ct
usa
red
chili
pepper
capsicum
frutescen
highli
consum
spice
throughout
world
princip
pungent
ingredi
phenol
capsaicin
cp
cp
caus
neurogen
inflamm
analges
antiinflammatori
activ
observ
dendrit
cell
dc
key
cell
type
immun
respons
receptor
cp
engag
receptor
power
immun
consequ
studi
demonstr
intratumor
administr
cp
preexist
tumor
result
retard
progress
inject
tumor
lead
signific
inhibit
growth
uninject
tumor
anim
treatment
cp
also
mediat
regress
advanc
preexist
solid
tumor
immun
cell
mediat
tumorspecif
result
reflect
immunolog
potenc
neurolog
ligand
modul
immun
respons
preexist
tumor
role
genesi
develop
oncogen
process
cellular
respons
dna
damag
play
import
role
tumorogenesi
poli
adpribos
synthesi
one
cellular
dna
damag
respons
poli
adpribos
polymeras
act
dna
damag
sensor
facilit
access
dna
repair
factor
site
new
function
protein
recent
shown
modul
function
protein
involv
tumorigen
process
base
studi
function
may
carri
genesi
develop
oncogen
process
specif
affect
glia
purpos
character
defici
would
affect
cellular
respons
specif
oncogen
event
null
astrocyt
show
lower
rate
prolifer
wildtyp
cell
maintain
differ
even
presenc
oncogen
insult
unexpectedli
glial
cell
differ
cell
type
neither
two
popul
show
featur
cellular
senesc
oncogen
stress
express
adprt
astrocyt
rescu
wildtyp
phenotyp
result
allow
us
conclud
absenc
seem
influenc
neg
way
cell
cycl
progress
especi
presenc
oncogen
event
thu
defici
prolif
disadvantag
certain
tumor
cell
investig
involv
novel
substrat
matrix
metalloproteinas
mmp
process
neurodegener
prion
diseas
express
cellular
local
associ
studi
brain
mous
model
prion
diseas
scrapi
human
creutzfeldtjakob
diseas
cjd
messeng
rna
protein
significantli
increas
scrapieaffect
brain
particularli
time
abnorm
prion
protein
prp
sc
began
accumul
brain
well
confirm
coimmunoprecipi
addit
found
bind
normal
prion
protein
prp
c
immunohistochem
mainli
immunostain
isolectinposit
cell
presum
activ
microglia
astrocyt
area
prp
sc
accumul
neuron
death
scrapi
infect
brain
well
human
brain
cjd
find
suggest
accord
activ
brain
phagocyt
human
cjd
mous
model
impli
increas
express
play
import
role
neurodegen
process
human
cjd
well
prion
diseas
model
defici
src
kinas
fgr
hck
lyn
impair
leukocyt
recruit
bacteri
kill
prevent
product
reactiv
oxygen
speci
ro
experiment
pneumococc
mening
src
famili
kinas
sfk
implic
regul
integrin
signal
phagocytosi
bacteri
mening
character
invas
neutrophil
product
cytokin
eg
caus
inflammatori
respons
caus
intracrani
complic
brain
edema
format
increas
intracrani
pressur
icp
studi
investig
role
sfk
fgr
hck
lyn
murin
model
pneumococc
mening
use
fgr
hck
lyn
tripl
knockout
mice
intracistern
inject
live
pneumococci
wildtyp
mice
caus
signific
increas
cerebrospinalfluid
csf
leukocyt
count
icp
h
infect
infect
fgr
hck
lyn
mice
csf
pleocytosi
significantli
attenu
wherea
increas
icp
pronounc
cerebr
express
gcsf
increas
infect
tripl
ko
mice
compar
infect
wildtyp
mice
lack
sfk
associ
wors
clinic
outcom
higher
mortal
rate
moreov
bacteri
titer
brain
blood
infect
fgr
hck
lyn
mice
higher
compar
infect
wildtyp
mice
indic
impair
host
defens
vitro
studi
reveal
fgr
hck
lyn
leukocyt
challeng
pneumococci
ro
product
complet
inhibit
wherea
bacteri
uptak
phagocytosi
affect
result
indic
sfk
fgr
hck
lyn
play
pivot
role
leukocyt
recruit
bacteri
clearanc
activ
ro
product
bacteri
mening
neurocysticercosi
intrathec
synthesi
igg
takayanagui
om
minelli
c
odashima
ns
depart
neurolog
faculti
medicin
preto
univers
paulo
preto
brazil
neurocysticercosi
ncc
seriou
public
health
problem
especi
develop
countri
aim
current
studi
assess
intrathec
synthesi
igg
patient
ncc
sixteen
patient
activ
form
ncc
select
compar
patient
control
group
includ
multipl
sclerosi
syndrom
asept
mening
ischem
cerebrovascular
disord
chronic
headach
without
pleocytosi
intrathec
synthesi
igg
studi
quantit
method
igg
index
tourtellott
formula
reiber
diagram
qualit
method
oligoclon
igg
band
serum
cerebrospin
fluid
ncc
group
intrathec
synthesi
igg
detect
patient
quantit
qualit
method
respect
control
group
exclud
patient
multipl
sclerosi
syndrom
intrathec
synthesi
igg
detect
patient
intrathec
synthesi
igg
ncc
patient
pattern
multipl
sclerosi
patient
intrathec
synthesi
igg
associ
variabl
indic
inflammatori
process
patient
activ
form
ncc
studi
requir
investig
possibl
intrathec
synthesi
igg
differ
evolutionari
stage
ncc
gener
mutant
theiler
murin
encephalomyel
viru
tmev
caus
demyelin
brain
suscept
mice
okuwa
takanomaruyama
k
asakura
h
murayama
b
ohara
depart
microbiolog
kanazawa
medic
univers
ishikawa
japan
b
divis
patholog
sendai
citi
hospit
sendai
japan
da
strain
tmev
caus
demyelin
viru
persist
spinal
cord
mice
chronic
phase
infect
thought
excel
anim
model
multipl
sclerosi
ms
howev
ms
lesion
extens
develop
spinal
cord
also
brain
studi
use
sitedirect
mutagenesi
tri
gener
da
mutant
viru
develop
demyelin
brain
leader
protein
l
nonstructur
locat
nterminu
polyprotein
use
sitedirect
mutagenesi
gener
mutant
viru
serin
amino
acid
posit
within
l
substitut
prolin
dal
pro
find
induc
dal
pro
virolog
patholog
compar
induc
wild
type
da
dal
pro
titer
brain
higher
da
day
postinocul
pi
although
infect
cell
inflammatori
cell
promin
detect
dal
pro
inocul
mice
day
pi
observ
dainocul
mice
addit
demyelin
observ
corpu
callosum
day
pi
inflammatori
reaction
demyelin
observ
spinal
cord
dal
pro
dainocul
mice
sever
dal
pro
inocul
mice
viru
possess
kb
fragment
background
induc
high
rate
spongiform
neurodegener
within
week
studi
use
cultur
glial
cell
suggest
kb
fragment
influenc
express
env
protein
furthermor
neuropathogen
chimera
despit
low
viral
replic
brain
exhibit
stronger
express
env
protein
compar
nonneuropathogen
virus
result
suggest
level
express
env
protein
brain
relat
neuropathogen
role
antibodi
sfvinduc
remyelin
f
mokhtrianr
immunolog
research
depart
medicin
microbiolog
immunolog
suni
downstat
maimonid
medic
center
usa
sfv
envelop
rna
viru
replic
brain
induc
autoimmunemedi
demyelin
one
week
clearanc
viru
follow
complet
remyelin
day
one
import
anim
model
ms
previous
shown
demyelin
sfvinfect
may
depend
antibodi
respons
myelin
peptid
mimic
viral
epitop
recent
studi
suggest
strong
role
human
peripher
blood
tcell
receptor
tcr
cell
humor
immun
provid
b
cell
help
antibodi
product
role
tcr
cell
sfvinduc
myelin
injuri
repair
investig
wildtyp
wt
tcr
knockout
ko
mice
clinic
ko
mice
show
sever
ill
wt
mice
flow
cytometr
analysi
mononuclear
cell
brain
show
tcell
reach
peak
decreas
pi
wt
mice
sfvinfect
ko
mice
clear
viru
earli
wt
mice
inflamm
sustain
wt
mice
although
demyelin
compar
group
ko
mice
exhibit
usual
complet
remyelin
seen
wt
mice
day
pi
tcr
ko
mice
made
significantli
lower
antibodi
respons
wt
mice
show
remyelin
viral
clearanc
wt
mice
studi
indic
cell
helper
cell
product
anti
membraneassoci
epitop
sfv
antibodi
astrocyt
immunoreact
murin
encephalitozoonosi
e
f
bondan
lallo
univers
paulista
paulo
brazil
encephalitozoonosi
increasingli
import
opportunist
protozoan
infect
immunocompromis
individu
studi
aim
examin
astrocyt
respons
use
glial
fibrillari
acid
protein
gfap
vimentin
vim
immunostain
experiment
encephalitozoon
cuniculi
infect
central
nervou
system
cn
immunosuppress
mice
known
although
vim
express
progress
disappear
astrocyt
birth
reactiv
astrocyt
may
soon
recov
capac
express
protein
follow
injuri
adult
balbc
mice
divid
group
imic
immunosuppress
cyclophosphamid
mgkg
twice
week
intraperiton
routeip
experiment
period
inocul
e
cuniculi
ip
iiimmunocompet
mice
inocul
e
cuniculi
iiinoninfect
nonimmunosuppress
mice
infect
anim
kill
day
postinocul
tissu
sampl
collect
process
light
microscopi
investig
gramchromotrop
hematoxylineosin
stain
techniqu
perform
well
gfap
vim
immunohistochem
stain
avidinbiotin
method
infect
mice
present
multifoc
granuloma
organ
proport
granuloma
higher
group
lymphocyt
diffus
nonsuppur
menongoencephalomyel
observ
spore
seen
microgranuloma
increas
astrocyt
gfap
immunostain
note
reexpress
vim
found
reactiv
astrocyt
surround
granuloma
astocyt
respons
intens
group
group
ii
vim
express
seen
astrocyt
group
iii
parasit
easili
identifi
gramchromotrop
stain
section
e
cuniculi
infect
develop
intens
astrocyt
reaction
cn
especi
immunosuppress
anim
object
evalu
effect
highdos
methylprednisolon
therapi
patient
htlviassoci
myelopathi
ham
measur
cerebrospin
fluid
csf
neopterin
concentr
marker
reflect
degre
inflamm
central
nervou
system
method
five
ham
patient
treat
highdos
methylprednisolon
mgday
iv
three
day
csf
peripher
blood
collect
treatment
csf
neopterin
level
determin
high
perform
liquid
chromatographi
peripher
blood
mononuclear
cell
pbmc
separ
peripher
blood
densiti
gradient
method
amount
htlvi
provir
dna
quantifi
realtim
pcr
clinic
symptom
evalu
use
osam
motor
disabl
score
urinari
disturb
score
result
csf
neopterin
concentr
patient
high
mean
valu
pmolml
exceed
normal
valu
pmol
ml
csf
neopterin
level
reduc
highdos
methylprednisolon
therapi
mean
valu
pmolml
treatment
also
reduc
mean
htlvi
provir
load
copi
per
pbmc
four
five
patient
show
clinic
improv
treatment
conclus
highdos
methylprednisolon
therapi
use
patient
ham
csf
neopterin
level
valuabl
marker
evalu
efficaci
treatment
depart
microbiolog
immunolog
center
molecular
virolog
neuroimmunolog
institut
molecular
medicin
infecti
diseas
drexel
univers
colleg
medicin
philadelphia
pa
usa
myelopathytrop
spastic
paraparesi
ham
tsp
character
gener
intens
cytotox
cell
ctl
respons
larg
number
ctl
direct
oncoprotein
tax
previou
studi
suggest
tax
may
avail
immun
recognit
dendrit
cell
dc
effici
antigen
present
cell
popul
studi
shown
purifi
tax
protein
effici
bound
local
cell
membran
monocytederiv
dendrit
cell
mddc
intern
within
hour
uptak
tax
induc
express
dc
activ
marker
mhc
class
ii
costimulatori
molecul
well
dc
matur
marker
tax
also
promot
product
major
immunedirect
cytokin
proinflammatori
chemokin
rant
drive
immun
respons
observ
also
confirm
gene
level
microarray
analys
inhibitor
abrog
taxinduc
secret
cytokineschemokin
indic
role
signal
taxmedi
immun
respons
final
tax
enhanc
allogen
antigenspecif
cell
prolifer
capabl
mddc
result
indic
extracellular
tax
may
select
target
mddc
taken
cell
like
special
pathway
promot
matur
antigenpres
function
drive
immun
respons
viral
load
determin
extent
qualiti
b
cell
respons
hiv
infect
central
nervou
system
sabin
cepok
gloria
von
geldern
thorsten
nolt
verena
grummel
rajneesh
srivastava
hanspet
hartung
ortwin
adam
gabriel
arendt
bernhard
hemmer
depart
neurolog
heinrich
heineunivers
moorenstr
duesseldorf
germani
depart
virolog
heinrich
heineunivers
moorenstr
duesseldorf
germani
central
nervou
system
cn
involv
common
human
immunodefici
viru
hiv
infect
cn
constitut
immunolog
protect
compart
neurolog
progress
possibl
independ
system
viral
burden
hiv
cn
infect
intrathec
ig
synthesi
pleocytosi
frequent
observ
analys
humor
immun
respons
csf
blood
hiv
patient
patient
hiv
infect
differ
stage
diseas
includ
studi
analyz
b
cell
repertoir
fourcolour
flow
cytometri
determin
viral
load
csf
blood
patient
b
cell
subset
hiv
compar
patient
inflammatori
noninflammatori
neurolog
diseas
number
b
cell
plasmablast
significantli
elev
csf
hiv
patient
compar
control
group
csf
b
cell
plasmablast
number
higher
untreat
clinic
asymptomat
hiv
infect
patient
symptomat
aid
patient
determin
viru
load
compart
reveal
csf
pleocytosi
correl
csf
viru
titer
serum
viru
titer
csf
blood
strong
correl
percentag
plasmablast
hi
viru
load
observ
extent
intrathec
product
igg
also
correl
csf
viral
load
percentag
plasmablast
find
demonstr
profound
earli
b
cell
respons
hiv
cn
given
strong
correl
hi
viral
load
occurr
plasmablast
cell
seem
central
humor
immun
respons
hiv
cn
andor
immun
activ
macrophag
regul
astrocyt
product
h
peng
n
whitney
n
erdmann
ghorpad
j
zheng
laboratori
neurotoxicolog
center
neurovirolog
neurodegen
disord
depart
pharmacologyexperiment
neurosci
depart
pathologymicrobiolog
univers
nebraska
medic
center
omaha
ne
usa
stromal
cellderiv
factor
alpha
receptor
play
import
role
pathogenesi
dementia
howev
underli
mechan
regul
product
unknown
report
investig
role
macrophag
import
cell
type
pathogenesi
mediat
product
astrocyt
data
demonstr
astrocyt
major
cell
popul
express
brain
immun
activ
andor
monocytederivedmacrophag
mdm
condit
media
mcm
induc
substanti
increas
product
human
astrocyt
elev
product
astrocyt
correspond
concomit
upregul
infectedactiv
macrophag
moreov
mcminduc
astrocyt
product
abrog
receptor
antagonist
sirna
treatment
human
mdm
observ
provid
evid
andactiv
macrophag
play
critic
role
product
astrocyt
may
contribut
mediat
cn
regul
traffick
monocyt
blood
brain
barrier
bbb
one
pathway
human
immunodefici
viru
type
dissemin
central
nervou
system
cn
studi
suggest
inflamm
within
bone
marrow
compart
may
respons
increas
migrat
monocyt
cn
thu
contribut
patholog
event
associ
dementia
hivd
interestingli
progenitor
cell
within
bone
marrow
refractil
infect
becom
suscept
differenti
bone
marrow
progenitor
cell
line
select
model
studi
infect
differenti
process
hematopoiet
progenitor
cell
proinflammatori
cytokin
shown
effect
bone
marrow
progenitor
cell
prolifer
varieti
cytokin
known
role
hematopoiesi
gmcsf
mcsf
inflamm
tnfalpha
studi
abil
induc
differenti
effect
consider
dramat
cytokin
use
result
upregul
preserv
express
potenti
provid
window
opportun
infect
downregul
modestli
upregul
indic
differenti
activ
respect
moreov
transient
stabl
transfect
analysi
demonstr
ltr
activ
significantli
increas
follow
treatment
cell
tnfalpha
result
indic
progenitor
cell
differenti
potenti
increas
cours
diseas
evalu
possibl
role
predict
factor
neurolog
complic
statist
analyz
result
seventysix
patient
male
sexual
contact
common
mode
transmiss
heterosexu
domin
sexual
prefer
noncompli
art
associ
higher
incid
neurolog
complic
p
chisquar
test
among
variabl
investig
serum
sodium
level
time
diagnosi
hiv
infect
found
correl
develop
neurolog
complic
p
mannwhitney
u
test
statist
signific
declin
tcell
count
observ
associ
neurolog
complic
p
p
respect
conclus
uninhibit
hiv
replic
caus
hyponatremia
result
dysfunct
reninangiotensin
system
neurolog
complic
known
develop
commonli
patient
uncontrol
infect
first
studi
establish
link
hyponatremia
neurolog
complic
drug
abus
act
cofactor
human
immunodefici
viru
infect
progress
associ
neuron
dysfunct
effect
cocain
express
chemokin
receptor
mechan
cocain
regul
receptor
yet
determin
normal
human
astrocyt
nha
recent
evid
indic
cocain
activ
mitogenactiv
protein
kinas
map
kinas
induc
cellular
chang
hypothes
cocain
alter
signal
transduct
pathway
astrocyt
lead
neuron
dysfunct
infect
subject
treatment
nha
cocain
increas
express
extracellular
signal
relat
kinas
erk
determin
quantit
pcr
western
blot
analys
furthermor
cocaineinduc
phosphoryl
erk
occur
dose
time
depend
manner
min
maximum
respons
occur
chang
total
erk
level
occur
exposur
nha
pd
inhibitor
erk
prior
cocain
treatment
prevent
upregul
induc
cocain
alon
result
suggest
cocaineinduc
modul
neuroimmun
pathogenesi
infect
may
mediat
via
dysregul
mapk
may
help
develop
novel
therapeut
strategi
prevent
cocain
induc
neuron
dysfunct
antiretrovir
toxic
neuropathi
lentiviru
infect
impair
brainderiv
neurotroph
factor
product
mitochondri
injuri
background
antiretrovir
toxic
neuropathi
atn
common
form
peripher
neuropathi
patient
infect
although
pathogenesi
unclear
herein
develop
model
atn
induc
didanosin
ddi
follow
infect
close
relat
lentiviru
felin
immunodefici
viru
fiv
method
treatment
ddi
fivinfect
anim
dorsal
root
ganglia
drg
cultur
investig
neuron
nerv
morpholog
neurobehavior
test
viral
load
mitochondri
neurotroph
factor
gene
express
result
fiv
ddi
caus
titer
concentrationdepend
drg
neuron
injuri
vitro
respect
evid
addit
neurotox
effect
depend
neuron
paramet
vivo
fiv
infect
show
delay
latenc
noxiou
stimulu
exacerb
ddi
treatment
fivinfect
drg
neuron
highli
vulner
ddi
toxic
epiderm
densiti
sural
nerv
end
reduc
fiv
infect
especi
ddi
treatment
ddi
diminish
viru
replic
drg
fivinfect
anim
although
suppress
viral
replic
sera
anim
ddi
decreas
mitochondri
cytochrom
c
oxidas
unit
ii
express
drg
fivinfect
anim
also
felin
lymphocyt
brainderiv
neurotroph
factor
bdnf
express
downregul
ddi
schwann
cell
drg
follow
fiv
infect
conclus
ddi
treatment
result
atn
associ
mitochondri
injuri
reduc
bdnf
product
schwann
cell
henc
bdnf
reduct
may
serv
potenti
target
atn
therapi
futur
involv
gutassoci
lymphoid
tissu
tse
agent
neuroinvas
intestin
bridget
r
glaysher
neil
mabbott
institut
anim
health
ogston
build
west
main
road
edinburgh
unit
kingdom
neilmabbott
bbsrcacuk
transmiss
spongiform
encephalopathi
tse
prion
diseas
neurodegen
diseas
affect
human
anim
natur
tse
infect
usual
acquir
peripher
exposur
eg
ingest
via
skin
lesion
follow
exposur
infect
usual
accumul
lymphoid
tissu
spread
brain
shown
follicular
dendrit
cell
fdc
resid
lymphoid
follicl
import
site
tse
agent
accumul
lymphoid
tissu
inde
tse
pathogenesi
critic
depend
fdc
absenc
tse
agent
accumul
lymphoid
tissu
block
diseas
suscept
significantli
reduc
tse
agent
accumul
fdc
infect
spread
along
peripher
nerv
central
nervou
system
process
term
neuroinvas
howev
known
lymphoid
tissu
tse
agent
neuroinvas
actual
occur
exampl
follow
oral
inocul
prp
sc
accumul
first
fdc
peyer
patch
gutassoci
lymphoid
tissu
subsequ
spread
nondrain
lymph
node
spleen
whether
effici
neuroinvas
occur
directli
follow
accumul
upon
fdc
first
encount
within
drain
lymphoid
tissu
eg
peyer
patch
follow
oral
inocul
requir
dissemin
fdc
network
within
multipl
lymphoid
tissu
known
use
mice
defici
variou
combin
gutassoci
lymphoid
tissu
investig
contribut
tissu
tse
agent
neuroinvas
intestin
follow
oral
exposur
identif
cell
tissu
mechan
involv
tse
agent
neuroinvas
may
identifi
import
process
therapeut
intervent
direct
therapi
resist
localisationrel
epilepsi
patient
categoris
tle
hs
n
tle
hs
n
extratempor
epilepsi
n
base
ictal
eletroclin
characterist
high
resolut
mri
patient
suspect
cd
gluten
sensit
underw
duoden
biopsi
result
seven
patient
gluten
sensit
patient
tle
hs
wherea
none
patient
without
hs
gluten
sensit
p
duoden
biopsi
three
patient
histolog
evid
cd
four
inflammatori
chang
consist
earli
develop
cd
without
villou
atrophi
four
patient
gluten
sensit
evid
dual
patholog
hs
anoth
brain
lesion
wherea
none
rest
patient
p
conclus
present
studi
demonstr
previous
unrecogn
associ
gluten
sensit
tle
hippocamp
sclerosi
associ
robust
well
characteris
group
patient
thu
gluten
sensit
ad
list
potenti
mechan
lead
intract
epilepsi
hs
type
diabet
mellitu
central
nervou
system
demyelin
possibl
associ
hacettep
univers
school
medicin
depart
neurolog
ankara
turkey
object
autoimmun
diseas
heterogen
group
disord
lead
disrupt
bodi
tissu
immun
system
recent
epidemiolog
studi
shown
increas
risk
acquir
new
autoimmun
diseas
subject
one
autoimmun
diseas
multiphas
demyelin
autoimmun
syndrom
ms
occur
concurr
autoimmun
diseas
includ
autoimmun
thyroid
diseas
autoimmun
gastriti
addison
diseas
rheumatoid
arthriti
pemphigu
vulgari
scleroderma
differ
popul
increas
preval
multipl
sclerosi
adult
type
diabet
firstdegre
rel
report
methodresult
present
three
patient
type
diabet
mellitu
develop
central
nervou
system
demyelin
diseas
followup
patient
discuss
common
special
clinic
genet
cranial
magnet
reson
imag
find
myelopathi
syndrom
report
case
activ
littl
evid
phagocytosi
observ
contrast
previou
evid
microgli
activ
neurodegen
disord
harm
suggest
microgli
activ
repres
twoedg
sword
harm
potenti
benefici
effect
effect
cell
sensit
injur
motoneuron
follow
facial
nerv
axotomi
adult
mous
recent
studi
suggest
cell
attenu
level
motoneuron
degener
follow
facial
nerv
axotomi
adult
mice
import
featur
cell
abil
becom
sensit
specif
antigen
reexposur
antigen
produc
robust
cell
respons
hypothes
cell
prior
exposur
motoneuron
injuri
would
show
increas
respons
subsequ
motoneuron
injuri
sensit
cell
would
enhanc
neuron
surviv
mice
receiv
sham
surgeri
sensit
mice
receiv
axotomi
facial
nerv
group
receiv
experiment
axotomi
contralater
nerv
week
later
neuroimmun
respons
quantifi
experiment
axotom
facial
motor
nucleu
fmn
number
cell
microglia
express
major
histocompat
complex
ii
microgli
phagocyt
cluster
effect
cell
sensit
motoneuron
viabil
follow
injuri
determin
count
number
surviv
motoneuron
measur
crosssect
area
motoneuron
repres
section
throughout
fmn
number
cell
greater
injur
fmn
sensit
mice
follow
experiment
axotomi
compar
control
enhanc
cell
respons
accompani
improv
motoneuron
surviv
data
suggest
cell
sensit
occur
respons
neuron
injuri
increas
respons
cell
suffici
promot
motoneuron
surviv
research
requir
determin
whether
cell
alter
function
statu
neuron
follow
injuri
nitric
oxid
exposur
divert
neural
stem
cell
fate
neurogenesi
toward
astrogliogenesi
aim
studi
effect
nitric
oxid
differenti
pattern
adult
neural
stem
cell
nsc
introduct
central
nervou
system
cn
regul
prolifer
neural
stemprogenitor
cell
develop
adulthood
neuroinflammatori
condit
trauma
product
correl
diseas
activ
method
expos
adult
nsc
cultur
femal
dark
agouti
rat
nodonor
detanono
ate
effect
differenti
assess
immunolabel
cell
neuron
tuj
oligodendrocyt
astrocyt
gfap
lineag
marker
western
blot
realtim
rtpcr
use
quantifi
express
gene
known
activ
earli
stage
neurogenesi
result
exposur
neurogenesi
downregul
correspond
decreas
express
proneur
gene
decreas
abil
gener
neuron
also
found
transmit
progeni
cell
exposur
instead
benefici
astrogli
differenti
confirm
increas
activ
signal
transduct
pathway
conclus
result
clinic
implic
diseas
like
multipl
sclerosi
trauma
neuroregener
impair
glial
scar
format
age
injuryrel
molecular
profil
subgranular
zone
sgz
mice
contribut
hippocamp
injuryinduc
neurogenesi
hippocamp
dentat
gyru
contain
neural
progenitor
continu
prolifer
differenti
glia
neuron
activ
mainten
cell
popul
declin
age
may
contribut
decreas
repair
plastic
environ
prolif
zone
modul
neurogenesi
critic
factor
yet
identifi
mice
day
year
old
sgz
hippocampu
isol
laser
captur
microdissect
rna
amplifi
hybrid
affymetrix
whole
mous
genom
genechip
molecular
profil
differ
function
age
genesest
show
differenti
alter
express
sgz
examin
follow
injuri
induc
hippocamp
toxic
trimethyltin
level
genesest
alter
differenti
respons
injuri
occur
function
age
pathway
map
molecular
profil
neurogen
environ
includ
pathway
tradd
immatur
brain
pathway
brain
pathway
differ
seen
injur
brain
level
neurogenesi
induc
tmt
identifi
brdu
neun
immunostain
suggest
greater
respons
mous
compar
respons
age
relat
chang
sgz
molecular
profil
may
contribut
neurogenesi
follow
injuri
character
age
relat
differ
neurogen
environ
identifi
novel
signal
factor
promot
repair
adult
brain
support
intramur
research
program
niehsnih
neural
differenti
potenti
mesenchym
stem
cell
deriv
bone
marrow
fat
spleen
thymu
mesenchym
stem
cell
msc
multipot
element
capac
differenti
vitro
sever
cell
lineag
conflict
result
report
regard
neural
differenti
potenti
evalu
neural
differenti
potenti
human
msc
deriv
bm
fat
spleen
thymu
vitro
cocultur
glial
cell
msc
deriv
healthi
human
donor
schwann
cell
cultur
human
benign
schwannoma
accord
standard
protocol
msc
display
neural
morpholog
phenotyp
h
specif
differenti
protocol
differenti
cell
express
neuron
glial
marker
neun
psancam
gfap
galc
differenti
transient
msc
return
previous
demonstr
human
mesenchym
cell
msc
inhibit
b
cell
prolifer
arrest
phase
cell
cycl
effect
associ
induct
apoptosi
percentag
apoptot
lymphocyt
upon
antigen
receptor
activ
presenc
msc
neglig
thu
sought
studi
effect
msc
cell
b
cell
undergo
apoptosi
differ
stimuli
msc
rescu
b
cell
death
cultur
serum
free
condit
similar
effect
observ
human
isol
thymocyt
rescu
spontan
apoptosi
msc
also
decreas
percentag
annexin
v
posit
cell
upon
induct
activ
induc
cell
death
aicd
upon
aicd
trigger
presenc
msc
observ
decreas
express
fa
fasl
granzym
b
total
caspas
cell
msc
also
decreas
antifa
induc
apoptosi
jurkat
tcell
studi
effect
msc
b
cell
apoptosi
isol
normal
germin
center
gc
b
cell
subset
undergo
spontan
apoptosi
secondari
lymphoid
organ
revert
vitro
ligat
msc
rescu
gc
b
cell
spontan
apoptosi
effici
compar
find
relev
use
msc
multipl
sclerosi
autoimmun
diseas
suggest
msc
immunosuppress
effect
lymphocyt
prolifer
support
surviv
quiescent
state
protect
apoptosi
tempor
express
integrin
chemokin
receptor
adult
neuron
stem
cell
partial
analysi
intracellular
signal
pathway
r
zilkhafalb
n
kaushanski
bennun
depart
immunolog
weizmann
institut
scienc
rehovot
israel
therapeut
potenti
adult
neuron
stem
cell
adultnsc
suggest
sever
model
central
nervou
system
cn
insult
intraven
inject
adultnsc
migrat
home
area
damag
cn
therefor
investig
express
rtpcr
integrin
chemokin
receptor
invitro
differenti
adultnsc
potenti
involv
adhes
migrat
adultnsc
home
insult
area
brain
analysi
sever
member
integrin
ccr
cxcr
chemokin
receptor
show
adultnsc
express
rel
high
basal
level
significantli
upregul
upon
induct
differenti
constitut
express
albeit
low
level
upregul
upon
adultnsc
differenti
express
undifferenti
adultnsc
significantli
induc
upon
differenti
analysi
intracellular
signal
pathway
activ
ligand
integrin
particular
laminin
suggest
involv
erk
pathway
upstream
signal
mediat
fyn
contrast
activ
ligand
respect
reduc
erk
phosphoryl
increas
phosphoryl
result
suggest
involv
erk
signal
pathway
adultnsc
activ
ligand
integrin
test
signal
pathway
activ
chemoattract
elev
express
chemoattract
demonstr
area
inflamm
cn
identif
signal
pathway
involv
innat
immun
respons
human
embryon
stem
cell
univers
california
irvin
california
usa
develop
spinal
cord
motoneuron
oligodendrocyt
produc
ventral
ventricular
zone
call
pmn
domain
basic
helixloophelix
bhlh
transcript
factor
essenti
gener
motoneuron
oligodendrocyt
spinal
cord
null
mice
motoneuron
oligodendrocyt
complet
disappear
besid
previou
lineag
analysi
experi
use
mice
suggest
progenitor
pmn
domain
gener
motoneuron
oligodendrocyt
astrocyt
progenitor
expect
possibl
candid
transplant
therapi
demyelin
diseas
multipl
sclerosi
spinal
cord
injuri
howev
previou
lineag
analysi
system
includ
problem
clear
whether
anoth
celltyp
produc
pmn
domain
clinic
applic
progenitor
import
reveal
whether
motoneuron
oligodendrocyt
cell
type
cell
produc
pmn
domain
elucid
accur
lineag
progenitor
perform
lineagetrac
experi
use
tamoxifeninduc
crerecombinas
insert
locu
studi
demonstr
motoneuron
oligodendrocyt
deriv
progenitor
pmn
domain
also
found
subset
astrocyt
ependym
cell
also
produc
pmn
domain
system
aid
elucid
molecular
mechan
cell
specif
lineag
preexist
immun
inhibit
express
transgen
muscl
cell
immun
compet
anim
host
immun
respons
one
critic
factor
success
gene
therapi
addit
immun
vial
vector
mutant
host
also
develop
immun
respons
transgen
product
nonimmunogen
normal
anim
method
fifteen
adult
femal
balbc
mice
divid
three
group
immun
intraderm
first
group
receiv
e
coli
betagalactosidas
second
group
receiv
plasmid
encod
betagalactosidas
pcblacz
last
five
mice
receiv
pb
anim
immun
four
time
seven
day
last
immun
receiv
intramuscular
inject
pcblacz
result
elisa
titer
antigalactosidas
show
anim
treat
protein
develop
predomin
immun
mice
receiv
dna
preferenti
respons
mean
number
muscl
cell
express
betagalactosidas
much
less
anim
immun
protein
dna
compar
littl
mate
discuss
gene
deliveri
muscl
potenti
therapi
protein
defici
hemophilia
patient
may
ever
receiv
protein
therapi
year
applic
gene
therapi
may
need
repeat
gene
therapi
keep
longterm
express
transgen
studi
demonstr
preexist
immun
either
predomin
inhibit
transgen
express
muscl
cell
intrasplen
electrotransf
encod
plasmid
dna
effici
inhibit
rat
experiment
allerg
encephalomyel
seonghyun
ho
hwangja
lee
dongsik
kim
jaegyun
jeong
sujeong
kim
seung
shin
yu
sunyoung
kim
jongmook
kim
